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Abstract 
Genital infection with Chlamydia trachomatis (‘chlamydia’) is the most 
commonly diagnosed sexually transmitted infection in England. Chlamydia is 
often asymptomatic and can lead to serious complications, especially in women. 
Chlamydia screening offers one approach to controlling chlamydia and its 
consequences. In England, chlamydia screening is offered opportunistically to 
sexually-active under-25 year-olds through the National Chlamydia Screening 
Programme, which was introduced in 2003 and nationally implemented by 
2008. 
Evaluating the real-world impact of chlamydia screening against its aims of 
interrupting transmission and reducing the prevalence of infection presents a 
considerable challenge, in part due to the absence of a robust outcome 
measure. 
The research presented in this thesis sought to address this challenge. Four 
approaches to outcome measurement were investigated:  
 Analysis of trends in percentage testing positive for chlamydia among 15-24 
year-olds accessing chlamydia testing using surveillance data; 
 Pilot of a postal survey of 17-18 year-old women to measure population 
prevalence; 
 Analysis of chlamydia prevalence among 16-24 year-old participants in the 
second and third National Surveys of Sexual Attitudes and Lifestyles 
(Natsal-2: 1999-2000; Natsal-3: 2010-12); 
 Application of a novel antibody assay to stored sera from 16-44 year-old 
participants in the Health Survey for England (HSE) between 1994 and 2012 
to measure prevalence of antibodies in serum as a marker of previous C. 
trachomatis infection. 
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In summary, no definitive evidence was found in these or other published 
analyses to suggest that chlamydia screening, as delivered in practice, has led 
to a reduction in the incidence or prevalence of chlamydia infection among 
young adults in England up to 2012. Possible reasons for the absence of such 
evidence are discussed in light of findings presented in the thesis. 
The strengths and limitations of these approaches to outcome measurement 
are discussed, and recommendations regarding the future evaluation and 
delivery of chlamydia control programmes are presented.  
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Glossary of terms 
Chlamydia trachomatis; 
C. trachomatis;  
chlamydia 
This thesis follows the convention for microbial 
nomenclature set out by Low et al.8 Chlamydia trachomatis 
(abbreviated to C. trachomatis) is used to describe the 
organism. ‘Chlamydia’ is the name of the condition, and is 
used to describe genital infection with C. trachomatis.   
Percentage testing 
positive 
The percentage of tests for current infection with C. 
trachomatis that return a positive result. Percentage testing 
positive is distinct from chlamydia prevalence, as the tests 
are not necessarily drawn from a representative sample of 
the general population. 
Prevalence  The percentage of a defined population who have 
chlamydia at a given point in time. 
C. trachomatis 
antibody/ Pgp3 
seropositive 
The percentage of sera tested where C. trachomatis or 
Pgp3 antibodies are detected. 
 
C. trachomatis 
antibody/ Pgp3 
seroprevalence 
The percentage of a defined population who test positive 
for C. trachomatis or Pgp3 antibodies in serum. 
 
Incidence  The rate at which chlamydia infections occur in a defined 
population during a specified period. 
Cumulative incidence  The probability of having been infected with chlamydia by a 
given point (i.e. by a given age or number of years after first 
sex). 
Diagnosis rate The number of diagnoses per 100,000 population 
(generally applied to 15 to 24 year-olds) 
Coverage The number of chlamydia tests divided by the population 
(expressed as a percentage of a given age group)  
Opportunistic 
screening 
Screening offered to people at the time of attending 
healthcare or other specified venues. Not register-based. 
Register-based 
screening 
Screening offered systematically via active invitation of the 
eligible population in a given age/demographic group.  
Sexually-experienced Reports at least one sexual partner by the time of 
measurement/interview. 
Lifetime sexual 
partners 
Number of sexual partners by the time of 
measurement/interview. 
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Table of abbreviations 
AC2 Aptima-Combo 2 assay (Hologic Gen-Probe) 
AOR Adjusted odds ratio 
CDC Centers for Disease Prevention and Control 
CI Confidence interval 
ClaSS Chlamydia Screening Studies 
CMO Chief Medical Officer 
CSI Chlamydia Screening Implementation project 
CSO Chlamydia screening office 
DFA Direct fluorescent antibody assay 
ECDC European Centre for Disease Prevention and Control 
EIA Enzyme immunoassay 
ELISA Enzyme-linked immunosorbent assay  
EU/EEA European Union/European Economic Area 
GP General practice 
GUM Genitourinary medicine 
GUMAMM Genitourinary medicine access monthly monitoring 
GUMCAD Genitourinary medicine clinic activity dataset 
HIV Human immunodeficiency virus 
HSE Health Survey for England 
HPA Health Protection Agency 
HPV Human papillomavirus 
IgG Immunoglubulin G 
IMD Index of Multiple Deprivation 
IPP Infertility Prevention Program 
LCx Ligase chain reaction assay (Abbott Diagnostics) 
LGV Lymphogranuloma venereum 
LSOA Lower super output area 
MSM Men who have sex with men 
MSW Men who have sex with women 
NAAT Nucleic acid amplification test 
NAO National Audit Office 
Natsal-2 2nd National Survey of Sexual Attitudes and Lifestyles 
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NCSP National Chlamydia Screening Programme 
NHANES National Health and Nutrition Examination Survey 
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1 Introduction 
Genital infection with Chlamydia trachomatis (‘chlamydia’) is the most 
commonly diagnosed bacterial sexually transmitted infection (STI) in England.9 
Most chlamydia infections are asymptomatic10,11 and infection can lead to 
serious reproductive sequelae in women.12-15 In England, the National 
Chlamydia Screening Programme (NCSP) recommends that sexually active 
under-25 year-olds are screened for chlamydia annually and on change of 
sexual partner with the aim of reducing transmission and preventing future 
complications. The programme was introduced in England in 2003 and 
nationally implemented by 2008.  
As set out in the following chapter, chlamydia screening is expected to lead to a 
reduction in the incidence and prevalence of infection. However, the 
effectiveness of screening in practice has not yet been shown and evidence 
from previous research is inconclusive. When the NCSP was established no 
strategy was put in place to monitor the impact of screening on health-related 
outcomes. The impact of chlamydia screening to date on either the incidence or 
prevalence of chlamydia is unknown. 
One of the major challenges in evaluating the impact of chlamydia screening is 
the availability of a robust and valid outcome measure. As the majority of 
infections with C. trachomatis are asymptomatic, true incidence of chlamydia 
(i.e. the rate at which chlamydia infections occur in a defined population during 
a specified period) cannot be directly measured without incredibly intensive 
studies of large samples with frequent and repeated chlamydia testing. Such an 
approach is not feasible for evaluating the impact of chlamydia screening at a 
17 
national level over a long time period. Instead, the research presented in this 
thesis focusses on three outcome measures: the prevalence of chlamydia 
among the general population (hereafter termed ‘prevalence’); the percentage 
testing positive for chlamydia among people accessing testing; and the 
prevalence of C. trachomatis antibodies detected in serum (hereafter termed ‘C. 
trachomatis antibody seroprevalence’) as a measure of the percentage of the 
population who have had at least one C. trachomatis infection by a given age 
(hereafter termed ‘age-specific cumulative incidence’).  
1.1 Aims 
The aims of this PhD are: 
1. to identify and appraise outcome measures, and methods of their 
measurement, for the purpose of evaluating the impact of opportunistic 
chlamydia screening on the incidence and prevalence of infection (or related 
measures); and 
2. using the outcome measures and methods identified in (1), to examine 
whether widespread opportunistic chlamydia screening, as it has been delivered 
in practice, has led to a reduction in the incidence or prevalence of chlamydia 
among young adults in England up to 2012 that would otherwise have been 
seen in the absence of opportunistic chlamydia screening.   
The findings from this research can contribute to public health policy by 
producing recommendations on methods to evaluate the impact of chlamydia 
screening and on the future development of chlamydia control policies in 
England. 
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1.2 Structure of the thesis 
This thesis is based on original analyses of nationally-collected surveillance 
data, a pilot of a chlamydia prevalence survey involving primary data collection, 
original analyses of data from the second and third National Surveys of Sexual 
Attitudes and Lifestyles (Natsal), and the application of a novel C. trachomatis 
antibody test to stored sera from the Health Survey for England (HSE).  
Chapter 2 sets out the background and rationale for the research. It includes an 
overview of chlamydia and chlamydia screening, describes limitations of the 
evidence base for the effectiveness of chlamydia screening and sets out the 
challenges of evaluating the impact of chlamydia screening on the incidence 
and prevalence of infection. Key features of how chlamydia screening has been 
implemented in practice in England are presented.  
Chapter 3 presents a review of the literature around methods of measuring a) 
the prevalence of chlamydia in the general population, b) changes over time in 
the percentage testing positive for chlamydia among people accessing testing 
and c) C. trachomatis antibody seroprevalence as a marker of age-specific 
cumulative incidence. The key methodological issues around selection bias and 
confounding are highlighted and discussed.  
Chapter 4 uses nationally-collated surveillance data from women and men 
tested for chlamydia to explore the use of trends in percentage testing positive 
for chlamydia as a proxy for changes in chlamydia prevalence in the general 
population over time. 
Chapter 5 describes the design and implementation of a pilot survey to measure 
prevalence of chlamydia among 17 to 18 year-old women. 
19 
Chapter 6 presents analyses of data from the second and third National 
Surveys of Sexual Attitudes and Lifestyles, conducted in 1999-2000 (Natsal-2) 
and 2010-12 (Natsal-3). Age-specific prevalence of C. trachomatis detected in 
urine is compared between Natsal-2 and Natsal-3. Differences between the 
design of the surveys and context in which they were carried out are examined 
to assess changes in chlamydia prevalence in the decade between the surveys. 
Chapter 7 uses data from Natsal-3 and presents a detailed analysis of the 
epidemiology of prevalent C. trachomatis infection in relation to reported testing 
to explore the extent to which opportunistic chlamydia screening up to 2012 was 
reaching groups at risk of chlamydia. 
Chapter 8 presents a C. trachomatis antibody seroprevalence survey using a 
novel assay to investigate change in age-specific cumulative incidence over 
time during a period of increasing chlamydia screening.  
Chapter 9 brings together the findings from the previous chapters to summarise 
the strengths and weaknesses of each method and to examine whether there is 
any evidence for there having been a decrease in chlamydia prevalence or age-
specific cumulative incidence since the implementation of the NCSP, up to 
2012. This chapter summarises the contribution made by this research by 
discussing the implications for future monitoring and evaluation, for chlamydia 
control strategies and for future research. 
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2 Background 
In this chapter I present an overview of the epidemiology and clinical impacts of 
genital infection with C. trachomatis and the putative role of chlamydia screening in 
its control. I discuss the limitations in available evidence for the effectiveness of 
chlamydia screening with particular reference to its impact on the incidence and 
prevalence of infection, thereby setting out the rationale for the thesis. I also provide 
a summary of how chlamydia screening has been implemented in practice in England 
over the last decade.  
2.1 What is chlamydia? 
C. trachomatis is a bacterium, belonging to the genus Chlamydia. Serotypes A-
C cause ocular infections; L1, L2, L3 and L2b are responsible for 
lymphogranuloma venereum (LGV) and serotypes D to K cause urogenital tract 
infections,16 which are the focus of this thesis. Genital infection with C. 
trachomatis (hereafter termed ‘chlamydia’) is the most commonly diagnosed STI 
in the UK and elsewhere.9,17 Untreated chlamydia can persist for several 
months or years18, and can cause a range of complications (see section 2.1.1). 
The acute symptoms of chlamydia infection include pain and abnormal 
discharge,19 but a large proportion of people who are infected with C. 
trachomatis remain asymptomatic.10,11,20 
Highly sensitive and specific nucleic acid amplification tests (NAATs) that detect 
the presence of C. trachomatis are available in most diagnostic laboratories in 
England, and can be performed on non-invasive samples (urine in men, self-
taken vulvovaginal swabs or urine for women).19 Chlamydia testing can 
therefore be offered in a range of clinical and non-clinical settings. Once 
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detected, chlamydia is easily treated with antibiotics.19 Systemic and local 
antibodies to C. trachomatis can be detected in those with a current or previous 
chlamydia infection.21,22  
The prevalence of chlamydia is highest among young adults. In the third 
National Survey of Sexual Attitudes and Lifestyles (Natsal-3, carried out in 
2010-12), the prevalence of C. trachomatis (detected in urine) in the sexually-
active adult British general population was 1.5% (95% confidence interval [CI] 
1.1%-2.0%) among women and 1.1% (95%CI 0.7%-1.6%) among men aged 16 
to 44 years old; prevalence among 16 to 24 year-olds was 3.1% (95%CI 2.2%-
4.3%) in women and 2.3% (95%CI 1.5%-3.4%) in men.23 
2.1.1 Sequelae and natural history of infection 
Although largely asymptomatic, chlamydia presents a serious public health 
problem, as genital infection with C. trachomatis can cause several severe 
complications which are associated with losses of quality of life24-26 and incur 
substantial healthcare costs.27-30 In women, infection with C. trachomatis can 
ascend the genital and reproductive tract and lead to pelvic inflammatory 
disease (PID), a spectrum of clinical disorders involving inflammation of the 
uterus, fallopian tubes, ovaries, or adjacent peritoneum. PID can resolve without 
any damage caused to the reproductive tract. However, PID can lead to 
scarring and fibrosis in the pelvic organs, which in turn can lead to serious long-
term reproductive consequences including tubal factor infertility and ectopic 
pregnancy.11,15,31-34 The scarring and fibrosis of pelvic organs occur as a result 
of the immunological processes involved in response to chlamydia infection, 
although the exact biological mechanism(s) by which genital chlamydia 
infections cause tissue damage are not fully understood.35 In men, chlamydia 
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can cause epididymitis (swelling of one of the tubes in the testicles).11 Babies 
born to mothers with chlamydia infection are at risk of neonatal conjunctivitis 
and pneumonia.11,36,37 
There are considerable uncertainties concerning the natural history of 
chlamydia.38 However available data suggest that in the region of 10% to 15% 
of untreated genital infections with C. trachomatis result in diagnosed clinical 
PID;14,38,39 10% to 15% of these cases may then lead to tubal factor infertility.38 
Progression rates from chlamydia to other outcomes are less well understood.38 
In an economic evaluation of chlamydia screening in England, it was estimated 
that 7.6% of women with symptomatic PID would progress to ectopic 
pregnancy; 14.8% of babies born to mothers with chlamydia would develop 
neonatal conjunctivitis, 7% would develop neonatal pneumonia and 2% of men 
with asymptomatic chlamydia would develop epididymitis.28 
More recently, chlamydia has been suggested as a possible cause of adverse 
birth outcomes including pre-eclampsia, spontaneous preterm birth or 
stillbirth,40-42 although study findings vary and further work is needed to fully 
understand this relationship.43 Chlamydia may also increase the risk of disease 
arising from other sexually transmitted pathogens, through facilitation of human 
immunodeficiency virus (HIV) transmission44 and increasing the persistence of 
high-risk human papillomavirus (HPV).45,46 
Genital infection with C. trachomatis confers, at best, only partial immunity to 
subsequent infection.47 Therefore re-infections are possible either from 
untreated or new sexual partners. Re-infection with chlamydia is common and 
those who test positive for chlamydia are at greater risk of testing positive at 
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subsequent tests than those who test negative. Studies have found that around 
10% to 15% of young adults diagnosed with chlamydia also test positive at their 
next test48-57 and that the percentage testing positive at a repeat test is around 
two to three times higher in those with an initial positive than in those with an 
initial negative test.48-55 Repeat diagnoses may be due to re-infection due to 
incomplete treatment of sexual partner(s), re-infection due to continuing risk 
behaviour (i.e. unprotected sex with new or existing partners) or detection of a 
persistent infection due to incomplete or ineffective treatment. The extent to 
which treatment affects the development of protective immunity is unclear.47,58,59 
2.2 What is chlamydia screening? 
One way of trying to control chlamydia and reduce the adverse consequences 
associated with infection is to screen people for current chlamydia infection. 
Screening is a process of identifying apparently healthy people who may be at 
increased risk of a disease or condition. They can then be offered information, 
further tests and appropriate treatment to reduce their risk and/or any 
complications arising from the disease or condition.60 In the case of chlamydia 
screening, people diagnosed with chlamydia following asymptomatic testing can 
be offered treatment and advised that their sexual partners should also be 
screened and treated (hereafter termed ‘partner notification’).  
Criteria for determining whether a disease or condition is a suitable target for 
screening were originally set out by Wilson and Junger in 1968.61 These criteria 
remain the basis of definitions of screening, although they have been adapted 
and developed to be more applicable to modern public health practice, 
emerging technologies and to emphasise the need for evidence of 
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effectiveness, evaluation and quality assurance in any screening 
programme.60,62-64 In summary, in order for a disease or condition to be 
considered a suitable target for screening, it should present an important public 
health problem, have a recognisable latent or early symptomatic stage and its 
natural history including development from early/latent period to active disease 
should be understood. There should be a precise and acceptable test and an 
accepted and effective treatment. The cost of screening should be 
economically-balanced in relation to medical expenditure as a whole and the 
benefits of screening should outweigh the harms.60-64 
Chlamydia presents a potential target for screening as a significant public health 
problem, especially among young people, as it is the most commonly diagnosed 
STI in the UK and as untreated chlamydia infections can have serious long term 
consequences. Accurate and acceptable65 tests are available and safe and 
effective antibiotics to treat chlamydia infection are available and included in 
clinical guidelines.19 As the majority of chlamydia infections are asymptomatic, 
chlamydia screening should result in the diagnosis and treatment of infections 
that would otherwise go undiagnosed, or be detected later in the course of 
infection, thereby reducing the average duration of infection.  
By reducing the duration of infection, chlamydia screening is expected to reduce 
an individual’s risk of developing complications such as PID, ectopic pregnancy 
or tubal factor infertility.39,66 The potential for chlamydia screening to interrupt 
the development of tubal pathology has been shown in four randomised 
controlled trials (RCT) that have investigated the effectiveness of a single offer 
of a chlamydia screen on the risk of developing PID within one year (Figure 
2-1). A recent meta-analysis of these studies reported the pooled risk ratio of 
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all-cause PID after one year of follow-up for women invited to have a chlamydia 
screen to be 0.64 (95%CI 0.45-0.90). Uptake of screening in the intervention 
arm varied between 29% and 100% and the reduction in the risk of PID was 
greater in studies with higher rates of uptake of chlamydia screening.2  
Figure 2-1: Reduced risk of pelvic inflammatory disease (PID) within one year 
associated with a single offer of a chlamydia screen among women: results of 
four randomised controlled trials 
Adapted from European Centre for Disease Control and Prevention Report
2
 
 
 
Study Year 
Effect estimate 
(95%CI) 
 
Scholes
1
 1996 0.43 (0.21-0.90) 
 
Ostergaard
67
 2000 0.49 (0.23-1.07) 
Oakeshott
39
 2010 0.65 (0.34-1.24) 
Andersen
68
 2011 0.89 (0.56-1.42) 
   
Overall (I-squared = 11.7%, p = 0.334) 0.65 (0.47-0.91) 
    
    Risk ratio 
    
Favours screening               Favours control 
In contrast to other screening programmes such as screening for breast cancer 
or for cervical cancer, screening for chlamydia, as an infectious disease, 
includes a strong element of infection control through treatment of the infected 
individual and their sexual partner(s). Chlamydia screening is therefore 
expected to confer benefits at a population level by interrupting transmission, 
thereby reducing the incidence of infection. The logical basis for this can be 
seen using the epidemiological concept of the ‘basic reproductive number’, 
denoted as R0. R0 is defined as the average number of secondary infections 
caused by an infected person in a totally susceptible population. For STI, R0 is 
dependent on three parameters, such that R0=βcD, where β denotes the 
average probability that an infected individual will infect a susceptible partner 
over the duration of their relationship; c denotes the average number of new 
0.25 0.5 2 4 1 
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partners acquired per unit of time; and D the average duration of infection.69 
When R0 is greater than one, infection will spread through a population and the 
larger the value of R0, the more quickly the infection will spread. Chlamydia 
screening, which is expected to reduce the average duration of infection (D), 
should therefore reduce R0 and hence the incidence of infection.
70 Chlamydia 
screening is also expected to lead to a fall in the prevalence of chlamydia, given 
the relationship prevalence=incidence x duration.71  
2.2.1 The National Chlamydia Screening Programme (NCSP) in England 
Although the validity of some of the earlier RCTs of chlamydia screening and 
PID was later questioned (see section 2.3), the landmark trial by Scholes et al in 
1996 and subsequent trial by Ostergaard et al in 2000 provided strong evidence 
in the late 1990s and early 2000s in support of chlamydia screening, having 
reported a significant reduction of ~50% in PID among those invited to screen 
compared to the control arm.1,67 Observational data from Sweden and the USA 
were also considered to support the argument for chlamydia screening.72 
Increases in testing in women in Sweden had been found to correlate with a fall 
in the number of diagnoses made73 and in the US, a before and after study 
found the percentage testing positive among women attending family planning 
clinics in Wisconsin to be lower after the implementation of a selective 
screening policy.74  
In 1998, the Chief Medical Officer (CMO) in England commissioned an Expert 
Advisory Group to review the case for chlamydia screening, the report of which 
concluded that:  
“Action is required to reduce the prevalence and morbidity associated 
with chlamydial infection. The sequelae of chlamydial infection are 
27 
severe and can have lifelong implications. There is evidence that the 
effective management of chlamydial infection will result in 
considerable health benefit.”75 
And that, 
“The evidence supports  opportunistic screening of sexually active 
women aged under 25.”75 
Following this report and two pilots of chlamydia screening in 1999,75-77 the 
Department of Health in England announced the planned roll-out of a national 
screening programme for chlamydia in targeted groups (women attending 
genitourinary medicine (GUM) clinics, seeking termination of pregnancy or 
having their first cervical smear) from 2002, with a broader national programme 
to follow.76 The National Chlamydia Screening Programme (NCSP) was 
implemented on a phased roll-out basis in 2003, with national implementation 
by March 2008. The NCSP remains in place to this date and recommends that 
sexually active women and men aged under 25 are tested annually and on 
change of sexual partner, with the aim of reducing the incidence and prevalence 
of chlamydia and its consequences.78 Although the original recommendation 
from the CMO’s Expert Advisory Group referred to asymptomatic screening in 
women, the NCSP included recommendations for opportunistic screening in 
men from the start of the programme. Men were included to highlight the role of 
both sexes in controlling onward transmission and in preventing reproductive 
complications in women and to increase both sexes’ ability to take responsibility 
for their sexual health.79 
The delivery of chlamydia screening in England is described in detail in section 
2.5. Briefly, chlamydia screening is offered to under-25 year-olds when they 
attend a range of clinical and non-clinical venues. This approach differs to 
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register-based screening programmes, where the eligible population are 
actively invited and recalled on a regular basis. The NCSP is therefore defined 
as an opportunistic screening programme and is referred to as such throughout 
this thesis to distinguish this approach from register-based screening. 
The expected impact of opportunistic chlamydia screening on the prevalence of 
chlamydia was explored using a mathematical model developed by the then 
Health Protection Agency (HPA)i in 2006.80,81 Turner et al modelled scenarios 
based on offering chlamydia screening to women only or women and men, 
attending general practice (GP) settings. The model explored the impact of 
different assumptions including: the age group screened; the proportion of 
people who accepted screening; different rates of partner notification; the 
proportion of the eligible population who attended GP settings and the interval 
between offers of screening. The results from three of the modelled screening 
strategies, using the base case assumptions of the model are shown in Figure 
2-2. The model results suggested that opportunistic chlamydia screening of 
women or women and men aged <25 years could at least halve the prevalence 
of chlamydia within ten years, providing that the healthcare settings offered 
screening to the entire eligible population when they attend, that 50% of those 
offered screening accept the invitation and that 20% of partners were treated.81 
As seen in Figure 2-2, decreases in chlamydia prevalence in women aged 16 to 
19 and 20 to 24 were predicted within the first few years of implementation of 
chlamydia screening, with more gradual declines seen in later years. These 
findings again supported the expectation that chlamydia screening could have a 
beneficial impact on population health. 
                                                             
 
i
 The HPA was incorporated into Public Health England (PHE) in April 2013. 
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Figure 2-2: Age specific impact of three screening strategies in those aged under 
25 on chlamydia prevalence in women using the base case parameter set. 
Reproduced with kind permission from Sexually Transmitted Infections from Turner et al 2006.
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Age-specific impact of screening strategies in those aged less than 25 years on chlamydia 
prevalence in women using the base case parameter set. The different figures show different 
screening strategies: A (offer annual screen to women); B (offer annual screen to women and if 
changed their partner in the past 6 months) and C (offer annual screen to women and men). 
Time (years) shows years from implementation of hypothetical screening scenarios. 
 
 
 
 
 
Several countries in Europe, North America and Australasia recommend 
asymptomatic testing for chlamydia among groups considered to have a higher 
risk of chlamydia. This includes young people (e.g. aged <25), men who have 
sex with men (MSM), pregnant women, and women undergoing abortion.82 
Scotland and Wales do not have an organised screening programme, but 
guidelines recommend opportunistic testing for chlamydia among young 
adults82, with a focus on those at high risk of infection, including individuals 
attending GUM clinics, those who have been previously diagnosed with 
chlamydia, or those who have a partner who has been diagnosed with 
chlamydia, and those with two or more sexual partners in the last year.83 In the 
US, the United States Preventive Services Task Force (USPSTF) and the 
Centers for Disease Prevention and Control (CDC) recommend testing in 
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asymptomatic young women and older women at increased risk.84 However 
England is the only country with an organised – albeit opportunistic - chlamydia 
screening programme.82 ii  
2.3 Questioning the evidence base for the effectiveness of chlamydia 
screening 
As set out above, there is a strong logical basis for chlamydia screening and 
evidence from RCTs and mathematical modelling support the notion that 
chlamydia screening can benefit population health. However, the evidence base 
relating to the effectiveness of chlamydia screening is subject to some important 
limitations and has come under scrutiny in recent years. 
While evidence from the available RCTs and observational data was used to 
support chlamydia screening in the early 2000s, from around 2006, the validity 
of evidence on the effectiveness of chlamydia screening began to be 
questioned in the public health literature.77,85,86 It is now thought that HIV 
prevention messages in the late 1980s and early 1990s led to a reduction in 
sexual risk behaviour, which in turn reduced STI transmission during this period. 
It is therefore likely that the role of chlamydia screening in observational studies 
had been over-emphasised.86 Re-appraisal of the early RCTs by Scholes et al 
and Ostergaard et al highlighted some important methodological issues.85 In the 
Scholes study, more effort was made to invite women in the screening group to 
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 As defined by criteria set out by the European Centre for Disease Prevention and Control 
(ECDC), who define an organised screening programme as one “that offers regular chlamydia 
screening to asymptomatic individuals in a well-defined target population. People found to be 
infected are managed according to guidelines for treatment and partner notification services. 
[The country also has] primary prevention activities”
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take part, and they were followed up more rigorously than controls.1,85 In the 
Ostergaard study, participants were randomised before they had consented to 
take part, almost half of the participants did not provide information at follow up, 
and assessment of whether someone had PID or not at follow up was not 
blinded.67,85 Thus the effect of chlamydia screening may have been over- or 
underestimated in these studies. 
Furthermore, more recent studies found smaller and non statistically-significant 
effect sizes. Oakeshott et al reported a 35% reduction in risk of PID at one year 
(risk ratio [RR] 0.65, 95%CI 0.34-1.24)39 and Andersen et al reported an 11% 
reduction (RR 0.89, 95%CI 0.56-1.42). The meaning of these smaller effect 
sizes is subject to some uncertainty. In the well-conducted study by Oakeshott 
et al, around one fifth of women in both the intervention and control arms were 
tested outside of the study between the time of enrolment and follow up39 and 
9% of women in the Andersen et al study were tested in the first three months 
of the study.68 This would have biased both studies towards a smaller effect 
size. Andersen et al used prescription information to measure cases of PID in 
community settings.68 This means it is likely that a lot of cases of PID will have 
been missed,68,87 which adds further uncertainty to the findings from this study. 
However, the magnitude of the effect seen in these two studies was 
substantially smaller than that reported in the two earlier RCTs by Scholes and 
Ostergaard that found ~50% reduction in risk of PID within one year of 
screening.  
The effectiveness of chlamydia screening was further called into question with 
the publication of a cluster RCT of register-based chlamydia screening in the 
Netherlands in 2010. In the Chlamydia Screening Implementation (CSI) 
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project,88  16 to 29 year-old women and men living in three areas of the 
Netherlands were offered chlamydia screening annually for three years. Postal 
invitations were used to offer screening. Those who accepted used an internet 
site to request a home sampling kit, which was then posted to a laboratory for 
testing. The study was conducted with stepped-wedge implementation, with 
those in the first phase being sent three yearly invitations, and the final group 
participating only in the final round of screening. The study found no statistically 
significant reduction in the percentage testing positive for chlamydia among 
those tested or in estimated prevalence and no difference between areas that 
had participated in all three rounds of screening versus those in the comparison 
group who had been offered screening only once. This study had lower uptake 
than expected (16% in round one, decreasing to 10% in round three), which 
may have limited the impact of screening on transmission. However, the 
potential for chlamydia screening to reduce the incidence or prevalence of 
infection had yet to be demonstrated in practice.  
The implications of the findings from these RCTs for the expected impact of 
chlamydia screening on population health in England are unclear. There are 
some important differences between the study interventions or populations 
which limit the generalisability of findings from the RCTs. None of the RCTs of 
chlamydia screening and PID investigated the impact of repeated offers of 
chlamydia screening and there are differences in the age groups, genders, and 
risk groups targeted. While the RCT in the Netherlands did investigate the 
impact of three rounds of annual offers of screening, the intervention was 
delivered using a registry to send invitations, which differs to the opportunistic 
approach in England and uptake of screening in the Netherlands was not 
comparable to that in England.88 
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At the outset of the NCSP, surveillance systems were established to collect 
data on numbers of tests and diagnoses among the target population tested 
through the NCSP (see Chapter 4). However, no system was established to 
monitor the health outcomes of the programme in terms of the incidence or 
prevalence of chlamydia or the incidence of chlamydia-related sequelae. No 
baseline survey of chlamydia prevalence was carried out at the start of the 
NCSP and there was no clear strategy as to how the programme would be 
shown to have delivered (or not) against its expected objectives.89  
Thus ten years after widespread opportunistic chlamydia screening among 
young adults had been recommended in England,75 there remained uncertainty 
about the expected or actual impact of the NCSP on population health. This 
uncertainty in the evidence base for chlamydia screening as it had been 
delivered in practice in England was epitomised in a National Audit Office 
(NAO) review of chlamydia screening among young people,89 which was carried 
out in 2009, six years after the introduction of the NCSP. The NAO concluded 
that:  
“A good understanding of two key aspects of chlamydia – the 
prevalence of the infection in the general population of young adults, 
and the probability of chlamydia leading to severe health 
complications – are crucial to any assessment of the Programme’s 
impact and its cost-effectiveness. The scientific evidence in both 
these areas is limited and the interpretation of the existing data is 
subject to debate. Some of the studies which have been carried out 
since the Programme’s launch have not strengthened the case for 
testing.” 89  
The research presented in this thesis was undertaken in response to this 
evidence gap.   
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2.4 How should chlamydia screening be evaluated? 
There is a large body of literature on methods of evaluating public health and 
other policy interventions.90-97 One of the key pieces of work in this area in the 
UK in recent years has been the publication and development of the Medical 
Research Council Framework on the Development and Evaluation of Complex 
Public Health Interventions.94 The research presented in this thesis was not 
carried out within a specific theoretical evaluation framework. However, there 
are several key features of the literature on evaluation that are of particular 
relevance. Specifically: the choice of outcome measures, the role of non-
experimental evaluation and the importance of process evaluation, each of 
which is dealt with in more detail below.  
2.4.1 Choice of outcome measure 
Choosing a suitable outcome measure is crucial to impact evaluation of public 
health interventions. The choice of outcome measure should be guided by a 
theoretical understanding of the expected impact of an intervention. All public 
health programmes will (either implicitly or explicitly) be underpinned by a 
theory of change, which can direct the evaluator to the target outcomes of 
interest.90,98 
As set out above, chlamydia screening is expected to have an impact on a 
number of health outcomes, specifically on the incidence and prevalence of 
chlamydia infection and the incidence of chlamydia-related complications such 
as PID and ectopic pregnancy. However achieving robust measures of these 
outcomes is a major challenge.  
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As chlamydia is largely asymptomatic, case reports per year do not equate to 
the annual incidence of infection. Nonetheless, measurement of the incidence 
of chlamydia infection has been attempted. For example, Lamontagne et al in 
their 2007 study of women attending GP, GUM and family planning clinics 
attempted to measure incidence of infection by inviting women to be tested for 
chlamydia and then re-tested either six (for those who originally tested negative) 
or three (for those who originally tested positive) months later. While the authors 
reported incidence rates per person year calculated on the basis of infections 
measured at follow-up, they could not take account of infections that had been 
acquired and cleared in between measurements.51 Direct measurement of the 
true incidence of chlamydia is not possible without incredibly intensive studies 
of large samples with frequent and repeated chlamydia testing. Such an 
approach is not feasible for impact evaluation of chlamydia screening at a 
national level over a long time period, and is not, therefore, explored any further 
in this thesis.  
The prevalence of infection presents another obvious target outcome measure. 
As described above, chlamydia screening is expected to reduce the prevalence 
of infection both by reducing the average duration of infection and by 
interrupting transmission. However, as described further in the next chapter, 
measures of chlamydia prevalence in the general population are hard to 
achieve. The percentage testing positive for chlamydia among people 
accessing testing or screening will not equate directly to population prevalence 
if the population accessing testing is not representative of the general 
population. Measures of population prevalence from surveys require robust 
sampling frames and ways of protecting against or dealing with non-response. 
This thesis explores the use of percentage testing positive (Chapter 4) and 
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population prevalence measured in cross-sectional surveys (Chapters 5 to 7) as 
outcome measures for the evaluation of screening.  
Measuring C. trachomatis antibodies in serum has been proposed as an 
alternative approach for evaluating the impact of chlamydia screening.99  The 
presence of antibodies to C. trachomatis in serum indicate that someone has 
been previously infected, even if they have been treated, or the infection has 
cleared on its own. The use of antibody seroprevalence as an outcome 
measure for evaluating chlamydia control programmes is promising for a 
number of reasons. Firstly, using stored or retrospectively collected blood 
samples that have been collected for a purpose other than chlamydia testing 
may avoid the bias associated with data from populations who are seeking or 
accepting chlamydia testing. Secondly, chlamydia antibodies persist and thus 
provide a longer-term marker of age-specific cumulative incidence.100 Thirdly, 
as age-specific cumulative incidence will by definition be higher than the 
prevalence, smaller sample sizes should be needed to monitor change over 
time. The use of C. trachomatis antibody seroprevalence as a marker of age-
specific cumulative incidence is the subject of Chapter 8. 
Chlamydia-related outcomes such as rates of PID, ectopic pregnancy and tubal 
factor infertility are all also potential outcome measures for evaluation. As with 
infection-related measures, the use of these conditions as outcome measures is 
problematic as they are difficult to measure consistently across sites and over 
time,101,102 they all have causes other than chlamydia38 and infection doesn’t 
necessarily lead result in these adverse outcomes. Ethical considerations of 
allowing a diagnosed infection to remain untreated also make it challenging to 
establish the incidence of complications following untreated compared to 
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treated infections.2 Ectopic pregnancy and tubal factor infertility are rare 
outcomes that may be diagnosed a considerable time after infection, thus 
studies aimed at measuring these complications would require large sample 
sizes and long follow up times.  Investigation of the impact of screening on 
sequelae, while warranted, is therefore beyond the remit of this thesis. Similarly, 
the thesis does not include an economic evaluation, since an understanding of 
the costs, benefits and harms of screening warrant detailed investigation in their 
own right and is beyond the scope of this thesis. 
2.4.2 The role of non-experimental approaches to evaluation 
Another important consideration in evaluation is how to establish causal 
associations between any change in an outcome measure of interest and the 
intervention under evaluation. RCTs are considered the gold standard of 
evidence for investigating causal associations on specified outcomes among a 
defined population.103 However the role of RCTs in the evaluation of public 
health interventions has received considerable attention in recent years,96,104,105 
and they are not feasible or desirable in all circumstances. As set out by Bonell 
and colleagues in their summary of a multi-disciplinary symposium held in 2006, 
interventions that have already been delivered across an entire area are not 
conducive to RCT methodology as it is not possible to establish a control 
group.103,106 This is the case with chlamydia screening in England, as the NCSP 
has been operational across all areas of England since 2008. Thus estimating 
the effect of chlamydia screening in England via a RCT would not now be 
feasible without withdrawing existing service provision in order to establish a 
true control group. 
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Parts of the chlamydia screening pathway would be amenable to RCT 
methodology, for example comparing screening intervals, and the effectiveness 
of interventions to increase or target uptake in certain groups.107 However the 
overall question of whether the NCSP has had a beneficial effect on population 
health, can no longer be answered through an RCT in England. Alternative, 
non-experimental approaches are therefore required. In this thesis I use several 
novel approaches to outcome measurement and identify the strengths and 
weaknesses of each. I then draw together the findings from these different 
approaches to evaluate what they, together, can tell us about whether 
chlamydia screening has reduced either the incidence or prevalence of 
chlamydia among young adults up to 2012.  
There are other approaches to evaluating the impact of chlamydia screening on 
incidence and prevalence that could have been explored. Mathematical models 
of C. trachomatis transmission can help understand the potential impact of 
chlamydia screening.108 The ability of such models to recreate actual 
transmission events over time is limited by the available data on chlamydia 
prevalence at baseline, tests, diagnoses, sexual behaviours and transmission 
dynamics over the last decade which are required for parameterisation and 
fitting, all of which are subject to considerable gaps109 or uncertainty.108 
Mathematical modelling may be complementary to evaluation based on 
empirical outcome measurement by exploring the potential impact of screening 
frequency or target populations. However, this approach was beyond the remit 
of this thesis.  
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2.4.3 The importance of process evaluation 
The importance of process evaluation has received more attention in the public 
health literature in recent years, in recognition of the multifactorial aetiology of 
many public health problems and of the multiple components of interventions.110 
Post-implementation process evaluation of an intervention  includes a 
description of what was actually delivered, the interaction between the 
intervention and the people targeted and an appreciation of the context in which 
an intervention was implemented, in order to understand whether what was 
done would be expected to have had an impact given the theoretical 
understanding of mechanisms of action.90,111 
The potential impact of chlamydia screening on incidence and prevalence will 
vary according to uptake of testing in different populations, the rates of 
treatment and testing and the index case and their sexual partner(s). In order to 
move beyond the generic question of ‘does chlamydia screening work’, we 
therefore need to understand what is meant by ‘chlamydia screening’ in the 
specific evaluation context. Section 2.5 below therefore describes how 
chlamydia screening has been delivered in practice in England via the NCSP 
since its implementation, thus providing the context in which the impact of 
chlamydia screening will be evaluated. Additionally, the analysis presented in 
Chapter 7 examines whether chlamydia testing and screening reported in 2010-
12 was reaching 16 to 24 year-olds at risk of prevalent infection, thus exploring 
whether chlamydia screening has been implemented in such a way that we 
would expect there to have been an impact on transmission. 
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2.5 How has chlamydia screening been implemented in practice in 
England? 
Figure 2-3 shows some of the key milestones and developments in the 
implementation of chlamydia screening in England. The way in which the NCSP 
has been implemented and delivered has changed substantially since the start 
of the programme in 2003. This variation has been driven by several factors, 
including local approaches to commissioning and service provision;112 
technological developments;113 the development and constant review of 
national guidance on screening;114 changes in the political and economic 
context in which screening is delivered and the re-organisation of health and 
public health services.115 Some of the main features of chlamydia screening as 
delivered in practice, and changes in the implementation of chlamydia 
screening over time are described below. 
Figure 2-3:  Timeline showing implementation of chlamydia screening 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Adapted from National Audit Office Report
89
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The NCSP recommends that sexually-active under 25 year-old women and men 
are tested for chlamydia annually and on change of sexual partner (Figure 2-4). 
Chlamydia screening in England is offered opportunistically to under-25 year-
old women and men when they attend a range of settings. These include 
specialist sexual health services (GUM clinics, sexual and reproductive health 
services, and abortion services) where young adults may be attending for 
sexual health-related reasons. Screening is also offered in non-specialist, 
clinical settings such as GPs and pharmacies. The availability of testing in non-
clinical settings varies by area, but includes testing offered in schools, colleges 
and universities, and in bars, pubs and clubs. In several areas it is also possible 
to order home sampling kits online, where samples are taken at home and then 
returned back to a laboratory for testing.113 The relative contribution to tests and 
diagnoses made by each of these settings, and the percentage testing positive 
in each, varies. This is explored in more detail in Chapter 4.  
Young adults who test positive for chlamydia should be provided with timely 
antibiotic treatment. Azithromycin (1g) and doxycycline (100mg twice a day for 7 
days) are both recommended as first-line treatments.19 In the first full year of the 
NCSP (2008-09), 88% of people who tested positive through the programmeiii 
were recorded as having received treatment.89 The proportion of cases that has 
been treated with azithromycin versus doxycycline or whether this has changed 
over time is unknown, although anecdotal evidence suggests 1g azithromycin is 
more widely used for asymptomatic genital infections with C. trachomatis as 
compliance with treatment is considered more likely (personal communication, 
Paula Baraitser).  
                                                             
 
iii
 Not including GUM clinics 
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Figure 2-4: Schematic showing the chlamydia screening pathway according to 
National Chlamydia Screening Programme recommendations 
 
 
Partner notification is the process of informing and treating sexual partners of 
individuals who have been diagnosed with STIs. Partner notification is an 
essential element of chlamydia control and confers benefit by reducing risk of 
re-infection and its adverse consequences in the original patient, preventing 
onward transmission of infection by infected sexual partner(s), and reducing risk 
of complications in infected sexual partner(s).116,117 For asymptomatic 
chlamydia infection, an arbitrary period of six months (or to date of most recent 
sexual partner, whichever is longest) is used as a cut-off to determine which 
sexual partners should be followed up as contacts. Achieving high partner 
notification rates is notoriously challenging, and rates vary substantially by 
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clinic.118 Up to 2012,iv the NCSP monitored partner notification performance 
against a standard of 0.4 partners treated per index case in a large city and 0.6 
elsewhere89. In 2008-09 almost three-quarters of areas delivering chlamydia 
screening did not meet these standards.89  Although rates of treatment and of 
partner notification are both subject to underreporting, the available data 
described above suggest that the screening pathway has not always been 
delivered in an optimal fashion, leaving infected individuals at risk of persistent 
or repeat infections.  
The frequency of screening and timing of testing in relation to time since 
infection are also likely to affect the impact of chlamydia screening. The NCSP 
recommends that young adults are tested annually and on change of sexual 
partner, as young adults continue to be at risk of new and repeat infections after 
having been tested.51 The proportion of young adults who get tested every year 
or upon change of sexual partner is unknown, as routinely collected data do not 
include a unique personal identifier, and to date this has not been investigated 
in national surveys. Given the frequency of chlamydia re-infections (section 
2.1.1), following an evidence review and consultation with professionals and 
young people, the NCSP amended their case management guidelines in 2013 
to recommend that those who test positive for chlamydia should be advised to 
re-test around 3 months after completing treatment.119 An analysis of 
surveillance data from 2010 by Woodhall et al found the incidence rate of re-
testing to be 18.4 and 26.1 per 100 person years in 15 to 24 year-olds testing 
                                                             
 
iv
 National monitoring of treatment and partner notification for tests carried out as part of the 
NCSP was discontinued in 2012, as central data collection was deemed to place an 
unnecessary burden on local areas at a time when chlamydia screening offices were being 
integrated into sexual health services. Local areas are advised to monitor treatment and partner 
notification rates locally. 
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via the NCSP and in GUM clinics respectively.120 Rates of re-testing before this 
period are not known.  
2.5.1 Changes in performance management, public health indicators 
and standards 
From the time when the NCSP had been nationally implemented in 2008, local 
areas were monitored against national targets for chlamydia screening 
coverage, defined as the proportion of the population tested each year. These 
‘vital signs’ indicators were set by the Department of Health for 2008-09 to 
2010-11 (Figure 2-3). The target for local areas increased from 17% of all 15 to 
24 year-olds tested per year in 2008/09 to 35% in 2010/11 (tests performed in 
GUM clinics did not initially contribute towards this target, although were latterly 
included).89 The introduction and implementation of these targets led to a step 
change in the number of tests and diagnoses reported in each year (Figure 2-5 ; 
Figure 2-6). In Natsal-3 (carried out in 2010-12) 57.1% of 16 to 24 year-old 
women and 37.3% of men living in England who reported at least one sexual 
partner over their lifetime reported having been tested for chlamydia in the last 
year.23 
After 2011, following a change of government, the national target for screening 
coverage was removed. Chlamydia control remained a public health priority, 
and an indicator relating to chlamydia screening was included in the 2013 to 
2016 Public Health Outcomes Framework for England.121 Since 2013, the 
Department of Health has recommended that local areas aim to achieve a 
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diagnosis ratev (defined as the number of chlamydia diagnoses per head of the 
15 to 24 year-old population) of 2,300 per 100,000 or higher. The change in 
focus from coverage to a diagnosis rate indicator for programme monitoring was 
partly because the coverage target had driven high volumes of testing in 
relatively low risk populations resulting. The diagnosis rate indicator was 
considered a more appropriate measure of programme performance as treating 
infections is thought to reduce subsequent ill health and as a higher diagnostic 
rate would be expected to lead to greater reductions in chlamydia 
prevalence.121 As with the use of a coverage target there are some potential 
limitations of using a diagnosis rate to monitor programme performance. 
Diagnosis rate will depend on volumes of testing, who is being tested as well as 
the underlying prevalence in each area. It is therefore feasible that areas with 
high underlying prevalence in the population may be able to achieve the 
specified diagnosis rate of 2,300/100,000 more easily than those who have a 
low underlying prevalence of infection. In areas of particularly high or low 
prevalence this may create a perverse incentive where screening activity 
required to reach a specified diagnosis rate would be inverse to sexual health 
need. There is no evidence at present to support local geographical variation of 
population prevalence, so the extent to which diagnosis rate may operate as a 
perverse incentive is unclear. However local authorities are encouraged to 
consider local needs across sexual health when commissioning services to 
rather than consider this as a fixed target.121 
                                                             
 
v
 The name of this indicator changed in 2014, and is now referred to as the ‘detection rate’. For 
the purposes of consistency, ‘diagnosis rate’ is used throughout this thesis. 
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Since 2010, the NCSP has also encouraged the integration of chlamydia 
screening services into sexual health services for young adults.122 In addition to 
continued provision in specialist GUM clinics, local areas are advised to focus 
on provision in general practice, community sexual and reproductive health 
services, pharmacies, termination of pregnancy clinics. Individuals tested in 
these services tend to have a moderate to high risk of chlamydia.20,123,124 These 
settings present sustainable options for screening in services that can address 
other aspects of sexual health including contraception and other STI testing and 
interventions.124 
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Figure 2-5: Number of test reported among 15-24 year-olds in NCSP and other 
non-GUM settings, 2000 to 2012 
Women Men 
  
GUM: genitourinary medicine. NCSP: National Chlamydia Screening Programme. 
*Tests reported from non-NCSP, non-GUM clinics were reported from April 2008 onwards only. 
Tests were not reported by age group in GUM clinics until 2009 so are not included. Tests 
reported of unknown age have been re-allocated according to year- and gender-specific 
distributions. 
 
Figure 2-6: Number of diagnoses reported among 15-24 year-olds in all settings 
(GUM clinics, NCSP and other) 2000 to 2012a 
Women Men 
  
GUM: genitourinary medicine. NCSP: National Chlamydia Screening Programme. 
a
Diagnoses reported from non-NCSP, non-GUM clinics were collected from 2008 onwards. 
Diagnoses reported of unknown age have been re-allocated according to year- and gender-
specific distributions.  
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2.5.2 Changes in the context of chlamydia screening delivery 
As shown in Figure 2-5 and Figure 2-6 chlamydia testing of young adults has 
increased substantially in England over the last decade. In evaluating the role of 
chlamydia screening on changes in prevalence over this period, the role of 
other interventions should also be considered. Along with increases driven by 
the national scale-up of the NCSP increases in testing occurred in GUM clinics 
as a result of improved access to sexual health services125-127 and increased 
availability of diagnostic testing using non-invasive samples (urine or 
vulvovaginal swabs).128  
Following the introduction of waiting time targets for patients attending a GUM 
clinic in 2004,76,129,130 the proportion of GUM attenders who were seen within 48 
hours increased from 38% in May 2004 to 87% in February 2009 (Figure 2-7). 
Reduced waiting times were achieved, to some extent, through increased 
capacity and the expansion of the role of primary care in sexual health service 
provision.130 Numbers of chlamydia tests and diagnoses reported in GUM 
clinics increased from at least 2004 onwards (when data on tests in GUM clinics 
are first available), which likely indicates increased attendance as well as 
increased testing among attenders over this period. Findings from Natsal-2 and 
Natsal-3 demonstrate an increase in attendances at GUM clinics over this 
period: the percentage of 16 to 44 year-old women with at least one lifetime 
sexual partner who reported attendance at a GUM clinic in the past 5 years 
increased from 7% (95%CI 6%-8%) in Natsal-2 (carried out in 2000) to 21% in 
Natsal-3 (95%CI 20%-23%); and among men reported attendance increased 
from 8% (95%CI 7%-9%) to 20% (95%CI 18%-21%)23. This increase was seen 
across all age groups, but most notably among 16 to 24 year-olds.  
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Figure 2-7: Proportion of genitourinary medicine (GUM) clinic attendees seen 
within 48 hours 
Between May 2004 and August 2007, data were collected as part of the HPA GUM Waiting 
times audit, which was performed quarterly and based on questionnaire provided to attendees 
in a 1 week period
125
. From 2009 onwards, data are derived from the 48 Hour Genitourinary 
Medicine Access Monthly Monitoring (GUMAMM) dataset
131
. Data were reported on a monthly 
basis, but the corresponding months are presented here for comparison purposes. Data were 
not collected between November 2007 and December 2009. Data collection was discontinued 
after 2011. 
 
 
2.6 Summary  
In summary, chlamydia presents an important public health problem in England. 
The implementation of the NCSP and increased access to sexual health 
services led to substantial increases in chlamydia testing in the decade up to 
2012, with sustained rates of diagnoses among 15 to 24 year-olds since 2008. 
The way in which screening has been delivered has changed considerably 
during the course of the programe. Despite this moving target, there is a need 
to evaluate the impact of chlamydia screening - as it has been delivered in 
practice - against its objectives of reducing the incidence and prevalence of 
infection. However at the outset of the NCSP there was no system established 
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to do this and obtaining robust measures of incidence, prevalence or related 
measures is challenging.  
In the next chapter the challenge of outcome measurement is addressed in 
more detail through a review of the relevant literature.  
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3 Review of the literature 
In the previous chapter I summarised the evidence and theoretical basis for a 
chlamydia screening programme. I set out the need and rationale for evaluating the 
impact of the NCSP on outcomes relating to the incidence and prevalence of infection. 
In this chapter I provide a summary of studies that have estimated chlamydia 
prevalence among general population samples or that have estimated changes over 
time in either chlamydia prevalence, percentage testing positive or antibody 
seroprevalence as a marker of age-specific cumulative incidence. Methodological 
considerations arising from these studies are discussed, which provide the basis by 
which the methods of outcome measurement presented in chapters 4 to 8 are 
appraised.  
3.1 Methods 
3.1.1 Chlamydia prevalence studies using population-based sampling 
methods 
Studies of chlamydia prevalence measured among general population samples 
were identified as part of a systematic review of chlamydia prevalence studies, 
which was carried out as part of a collaborative project on chlamydia control in 
Europe2,  the full methodology and results of which have been reported 
(Appendix 4).3  
Cross-sectional surveys that used population-based sampling and tested genital 
specimens from adult participants for C. trachomatis were eligible for inclusion. 
Population-based sampling was defined as studies that used a sampling frame 
and method that are potentially representative of the resident population of a 
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particular area. This includes surveys based on household sampling and/or 
population registers and GP registers (although the limitations of GP registers 
are discussed in section 3.2.2.2 below). Studies of populations attending clinical 
settings who were tested for chlamydia as part of routine clinical care were 
identified but not included.  
The review focussed on studies of adults living in European Union 
(EU)/European Economic Area (EEA) Member States. Studies from other high-
income countries (as defined by the Organisation for Economic Cooperation 
and Development) were also eligible for inclusion. Electronic databases (Ovid 
Medline, EMBASE, Popline and The Cochrane Library) were searched from 
January 1990 to 17 October 2011. Search strategies included terms for 
‘chlamydia infection’ and ‘prevalence’ and names of the eligible countries. The 
titles and abstracts were screened by two reviewers (Redmond, Alexander-
Kissling) and assessed against the predefined inclusion criteria. Two reviewers 
(Redmond and Woodhall or Redmond and Alexander-Kissling) extracted data 
independently in duplicate onto standardised data collection forms, compared 
the extracted data for each paper and resolved differences where necessary. 
Discrepancies were adjudicated by a third reviewer (Low). Study characteristics, 
numbers eligible, numbers tested and with C. trachomatis detected and 
estimated prevalence and 95% confidence intervals were extracted from each 
paper. Chlamydia prevalence estimates were compiled by sex, age group, 
country (EU/EEA or non EU-EEA), whether the study was conducted at a 
national or sub-national level and whether prevalence was estimated among the 
total population or limited to those who reported at least one sexual partner by 
the time of the survey (hereafter termed ‘sexually-experienced’). Chlamydia 
prevalence and 95% confidence intervals were estimated using the number of 
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positive tests divided by the number of people tested unless stratified sampling 
methods were used in which case the estimates presented in the papers were 
used.3  
The results of Natsal-3 were published after completion of the systematic review 
and therefore fell outside of the review’s eligibility criteria. Results from Natsal-3 
are included in the text and table below, but not in the meta-analyses. The 
systematic review also incorporated a meta-analysis to pool chlamydia 
prevalence estimates where appropriate and a meta-regression to examine the 
association between estimated chlamydia prevalence in <25 year-old women 
and men and the calculated response rate.3 These aspects of the review were 
carried out by other investigators, but results of these analyses are presented 
below for completeness.  
3.1.2 Reviews of trends in outcome measures of interest 
The reviews of literature presented in this chapter relating to: a) repeated, 
cross-sectional estimates of chlamydia prevalence using population-based 
sampling, b) trends in percentage testing positive using clinical/routinely-
collected data and c) trends in C. trachomatis antibody seroprevalence, were 
not carried out as systematic reviews. For these reviews, electronic databases 
(including Ovid Medline, EMBASE) were searched using terms for chlamydia 
infection, prevalence, percentage testing positive and seroprevalence for 
papers up to November 2012. For the review of studies reporting trends in C. 
trachomatis antibody seroprevalence studies published up to the end of 
February 2014 were also included due to important contributions to the 
literature being published after the initial review had been carried out.132 Studies 
of C. trachomatis antibody seroprevalence were included if they aimed to 
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investigate the burden of genital infection with C. trachomatis; studies aimed at 
monitoring C. trachomatis associated with ocular infections are not reported.  
3.2 Systematic review of chlamydia prevalence studies using 
population-based sampling methods: Results 
The search strategy identified a total of 1,003 reports. A total of 91 publications, 
describing 39 studies of chlamydia prevalence in the general population (25 
EU/EEA, 14 non-EU/EEA) were included.3 Table 3-1 presents a summary of 
included studies. Point estimates of chlamydia prevalence in these studies 
ranged from 0.2% to 8.0% in women and 0.4% to 6.9% in men. Five studies 
(not including Natsal-3) reported chlamydia prevalence in nationally-
representative samples of sexually-experienced adults aged <26 years (Figure 
3-1). The pooled estimate of chlamydia prevalence in these studies was 4.3% 
(95%CI 3.6%-5.0%) among women and 3.6% (95%CI 2.8%-4.4%) in men. Point 
estimates of prevalence ranged from 3.0%133 to 5.3%134 in women and 2.4%135 
to 7.3%134 in men. Further details of the studies carried out in the UK are 
provided below. 
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Table 3-1a: Summary of characteristics of studies included in systematic review 
of chlamydia prevalence, studies with national coverage 
Adapted from Redmond SM, Kissling KA, Woodhall SC et al.
3
 The red shaded area indicates 
Natsal-3 survey, findings of which were not included in the original systematic review. 
 
Country, 
year 
Sex, 
age 
(years) 
Prevalence 
estimated in 
whole study 
Sample, 
sexually 
experienced 
only or both 
Number invited for 
testing 
(response rate 
overall, %) 
Study name (acronym), if known; purpose 
of study, setting and sampling strategy 
EU/EEA Countries 
Croatia 
2011
134
 
W&M, 
18–25    
S-E 1005 participants. 861 
sexually experienced. 
280 provided urine 
sample (women 
37.5%, men 27.9%) 
Cross-sectional survey of sexual behaviour and STI 
prevalence. Nationally representative sample from all 21 
counties in Croatia, with multi-stage probability sampling. 
France 
2010
135
 
W&M, 
18–44 
S-E 4957 eligible by age 
and sexual 
experience (women 
54.4%, men 49.3%) 
Sexual behaviour survey (subsample of Contexte de la 
Sexualité en France study, NatChla). Random subsample of 
sexually experienced people from a national population-
based survey on sexual behaviour with two-phase stratified 
sampling. Urine testing kit only sent to women if no swab 
returned after 1 month. 
Germany 
2012
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W&M, 
12–17 
Both 5755 in this age group 
(women and men 14–
17 years 63%) 
General health survey (Kinder und 
Jugendgesundheitsstudie, KiGGS). Two-stage stratified 
cluster sampling, nationally representative sample of 0–17 
year-olds. Only tested samples from participants in this age 
group. 
Netherlands 
2005
137
 
W&M, 
15–29 
Both 20791 (women 
47.0%, men 33.0%) 
Cross-sectional survey to estimate chlamydia prevalence 
and screening feasibility (CT PILOT). Stratified probability 
sample of randomly selected men and women in 4 regions of 
the Netherlands according to population density. Regions not 
sampled at random. 
Slovenia 
2004
138
 
W&M, 
18–49 
Both 2616 invited (women 
60.0%, men 50.9%) 
Sexual behaviour study. Stratified two stage probability 
sample of the general population of Slovenia in this age 
group. All participants invited to provide specimen for 
chlamydia testing. 
Britain 
2001
133
 
W&M, 
18–44 
S-E 5026 invited to give 
urine sample (women 
71.1%, men 68.7%)
a
 
Sexual behaviour study (National Survey of Sexual Attitudes 
and Lifestyles, Natsal-2), conducted 1999-2001. Random 
sample of sexually experienced people taking part in a 
stratified probability sample of people aged 16–44 years 
resident in Britain (total 11 161 interviewed).  
Britain 2012 W&M, 
16-44 
S-E
 b
 8047 eligible 
participants invited to 
provide a urine 
sample, 4828 (W 
59.7%, M 60.4%)
c
 
Sexual behaviour study (National Survey of Sexual Attitudes 
and Lifestyles, Natsal-3), conducted 2010-12. Random 
sample of sexually experienced people taking part in a 
stratified probability sample of people aged 16–74 years 
resident in Britain (total 15 162 interviewed). 
Non-EU/EEA countries, including high-income OECD countries 
USA 
2002a
139
 
M,  
18–19, 
22–26 
WSS 1995 survey: data 
from 470 aged 18–19, 
and 995 aged 22–26 
who were aged 15– 
19 in 1988 survey 
(insufficient data to 
calculate) 
National Surveys of Adolescent Males (NSAM). Sexual 
health survey. Nationally representative sample of never-
married, noninstitutionalised men aged 15–19 (1995 survey), 
and aged 22–26 (aged 15–19 in 1988 survey but re-
interviewed in 1995). Oversampling of black and Hispanic 
youths. 
USA 
2004
140
 
W&M, 
18–26 
Both Wave III: 14322 
(women and men 
84%) 
Cohort study (US National Longitudinal Study of Adolescent 
Health, Add Health). Nationally representative sample of 
young people in the USA. Total in first survey, Wave I: 
18924. 
USA 
2012
141
 
W&M, 
14–39 
WSS 20836 selected 17190 
interviewed (women 
80.4%, 2007–2008, 
men 74.5%, 2007–
2008) 
d
 
General health survey (US National Health and Nutrition 
Examination Surveys, NHANES). Stratified multistage 
probability cluster sampling. Data from five 2-year survey 
cycles. 
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Table 3-1b: Summary of characteristics of studies included in systematic review 
of chlamydia prevalence, sub-national studies 
Adapted from Redmond SM, Kissling KA, Woodhall SC et al.
3
  
 
Country, 
year 
Sex, 
age 
in 
years 
Prevalence 
estimated in 
whole study 
Sample 
(WSS), 
sexually 
experienced 
only (S-E) 
Number invited for 
testing 
(response rate 
overall, %) 
Study name (acronym), if known; purpose 
of study, setting and sampling strategy 
EU/EEA Countries 
Denmark 
1998
142
 
W&M, 
mean 
18.0 
women, 
18.2 
men 
S-E 2603 women 928 
eligible (women 
33.3%) 1733 men 442 
eligible (men 24.8%) 
RCT of home sampling versus usual care. Random sample 
(half) of all high schools in Aarhus County. All students 
invited. Eligible if sexually experienced. (Only data from 
home sampling group included). 
Denmark 
1999
143
 
W, 20–
29 
WSS 16345 eligible 11088 
in cohort (women 
67.8%) 
Cohort study about risk factors for cervical cancer. Random 
sample of women born in Denmark, in catchment area of 
Righospitalet, Copenhagen taking part in a cohort study, who 
had cervical swab sample taken by gynaecologist. 
Denmark 
2001
144
 
M, 17–
32 
Both 2500 (men 53.8%) Cross-sectional survey to estimate chlamydia prevalence. All 
men in Northern Jutland, Aarhus or Copenhagen counties 
liable for military service and seen by a medical board. 
Denmark 
2002
145
 
W&M, 
21–23 
S-E 4000 women (women 
32.5% group 1, 
Response rates from 
online results for 
26.3% group 2) 5000 
men (men 25.9% 
group 1, 15.4% group 
2) 
RCT on effectiveness of outreach screening strategies. 
Simple random sample from all residents of Aarhus County 
in this age group. Group 1 received sampling kit, group 2 
had to request kit by post. 
Estonia 
2008
146
 
W&M, 
18–35 
WSS 1398 reachable 
(women 48%, men 
32%) 
Cross-sectional survey to estimate chlamydia prevalence. 
Stratified random sample of residents of Tartu county. 
Netherlands 
2000
147
 
W&M, 
15–40 
WSS 5714 women (women 
50.8%) 5791 men 
(men 33.0%) 
Cross-sectional survey to estimate chlamydia prevalence 
and screening feasibility. Simple random sample of patients 
on the lists of 16 general practices in Amsterdam. 
Netherlands 
2010
137
 
W&M, 
16–29 
S-E 140058 Amsterdam 
(women 22.4%, men 
10.8%) 107806 
Rotterdam (women 
19.6%, men 10.5%) 
Cluster controlled trial of chlamydia screening effectiveness 
(Chlamydia Screening Implementation, CSI). All 16–29 year-
old residents of Amsterdam, Rotterdam, parts of South 
Limburg. Sexually active people invited to request test kit. 
South Limburg excluded because eligibility depended on 
response to questionnaire assessing risk of chlamydia. 
Norway 
2005
148
 
W&M, 
18–29 
WSS 646 reached (women 
43.8%, men 25%) 
Cross-sectional survey to estimate chlamydia prevalence. All 
patients on the list of a group practice in Oslo. 
Norway 
2012
149
 
W&M, 
18–25 
S-E 10000 invited 1670 
returned sample 
(women 18.9%, men 
11.9%) 
Cross-sectional survey to estimate chlamydia prevalence. 
Simple random sample of 10,000 people in this age group 
living in Rogaland county using unique personal identification 
number. 
Spain 
2007
150
  
W, 15–
44 
S-E 1821 invited 916 
reached or accepted 
(women 66.1%) 
Cross-sectional multinational HPV prevalence survey. 
Random age stratified sample of the adult female general 
population from census list of 4 urban communities in 
metropolitan Barcelona. 
Sweden 
1992
151
 
W, 15–
34 
S-E 543 reached and 
were sexually 
experienced women 
(68.9%)  
Cross-sectional survey to estimate chlamydia prevalence. All 
women in this age group in a primary health care area in 
Nättraby invited, only sexually experienced screened. 
Sweden 
1995
152
 
W, 19, 
21, 23, 
25 
WSS 816 reached 611 
participated (68.3% 
women) 
Cross-sectional survey to estimate chlamydia prevalence. All 
women of this age living in primary health care area of 
Ålidhem community centre in Umeå. 
Sweden 
2003
153
 
M, 22 WSS 1074 (men 35.6%) Cross-sectional survey to investigate feasibility of chlamydia 
screening. All males of this age living in Umeå. 
Sweden 
2004
154
 
W&M, 
20–24 
WSS 200 (women 65%, 
men 45%) 
Cross-sectional survey to estimate chlamydia prevalence 
and cost-effectiveness of home sampling. Simple random 
sample of 100 men and 100 women in this age group living 
in Umeå. 
Sweden 
2007
155
 
M,  
19–24 
WSS 1936 reached (men 
14.5%) 
Cross-sectional survey to estimate chlamydia prevalence. 
Sampling method unclear, 1000 men living in Uppsala 
county (from population register), and 1000 Uppsala 
university students (from student register database). 
United 
Kingdom 
2000a
156
 
M,  
18–35 
WSS 919 invited by post 
and reachable (men 
45.3%) 
Cross-sectional survey to estimate chlamydia prevalence 
and screening feasibility. Postal recruitment of all men aged 
18–24 and a random sample of men aged 25–35 in 4 
general practices in North West London. 
57 
United 
Kingdom 
2000b
157
 
W&M, 
18–35 
S-E 166 women reached 
(women 39%) 175 
men reached (men 
46%) 
Pilot study of acceptability of home sampling. Simple random 
sample of patients on the lists of 3 general practices in North 
West London and Avon. Urine samples from random 50% of 
women, vulval swabs from other 50%. 
United 
Kingdom 
2007
10
 
W&M, 
16–39 
WSS 14382 reached 
(women 37.6%, men 
27.9%) 
Cross-sectional survey to estimate chlamydia prevalence 
and screening feasibility (Chlamydia Screening Studies 
project, ClaSS). Random sample of general population in 
Birmingham and Bristol areas, selected from 27 general 
practice lists. 
United 
Kingdom 
2012
158
 
W&M, 
18–24 
WSS 29917 invited (women 
13.2%, men 9.8%) 
Cross-sectional survey investigating feasibility of postal 
screening invitations. All people in this age group registered 
with any GP in North East Essex Primary Care Trust. 
Non-EU/EEA countries, including high-income OECD countries 
Australia 
2003
159
 
W&M, 
15–40+ 
WSS 6431 eligible 2862 
participated (women 
and men 43.8%) 
General health survey. All people living in 26 rural 
indigenous Australian and Torres Strait Islander communities 
in northern Queensland taking part in Well Person’s Health 
Check. 
Australia 
2004
160
 
W&M, 
15–35 
WSS 2703 eligible listed 
1219 screened 
(women 50.7%, men 
39.3%) 
Cross-sectional survey to estimate chlamydia and 
gonorrhoea prevalence. Indigenous Australian people aged 
15–35 living in Alice Springs area 
Australia 
2006
161
 
W, 
18–35 
Both 1532 eligible 
households 979 
women interviewed 
657 gave urine 
sample (women 
42.9%) 
Cross-sectional survey to estimate chlamydia prevalence. 
Simple random sample from Melbourne residential telephone 
directory. 
Australia 
2008
162
 
W&M, 
14–40 
WSS ca. 1300 in 1996 
(insufficient data to 
calculate) 
Cross-sectional survey in STI control programme screening 
for chlamydia, gonorrhoea and syphilis. All resident 
indigenous Australians living in the Anangu Pitjantjatjara 
Yankunytjatjara Lands. 
Canada 
2002
163
 
W&M, 
15–39 
WSS 1075 women (women 
29.3%) 1130 men 
(men 16.2%) 
Chlamydia mass screening study. All adults from remote 
Inuit communities in Nunavik region. All sexually 
experienced or in this age group especially encouraged to 
take part. 
Canada 
2009
164
 
W&M, 
15–65 
WSS 224 estimated eligible 
(insufficient data to 
calculate) 181 
screened (80.8% for 
women and men) 
Chlamydia and gonorrhoea mass screening study. All men 
and women in this age group living in a rural Inuit community 
from Baffin Region, Nunavut. 
New 
Zealand 
2002
165
 
W&M, 
16+ 
S-E 1582 invited 1136 
consented 582 
sexually active 
(insufficient data to 
calculate) 
Cross-sectional survey to estimate chlamydia prevalence. 
Random sample of 50% of classes in all private and public 
high schools, Christchurch. Only sexually active had their 
samples tested. 
Switzerland 
2008
166
 
M, 
18–26 
Both 521 eligible and gave 
written consent 
(insufficient data to 
calculate) 
Cross-sectional survey to estimate chlamydia prevalence. All 
young Swiss men attending obligatory medical board before 
army recruitment (French speaking region only). 
USA 
2001
167
 
W,  
18–29 
S-E 2148 eligible 1439 
enrolled 1370 tested 
1314 sexually active 
(women 61.2%) 
Household survey of risk behaviour and chlamydia 
prevalence. All English- or Spanish speaking women in this 
age group in a random sample of low income housing blocks 
from the 1990 census (<10th percentile) in 3 counties in 
California. 
USA 2002
c
 
168
 
W&M, 
18–35 
WSS 1224 adults aged 18–
45 reached 728 age-
eligible for screening 
(women and men 
79.5%) 
Cross-sectional survey to estimate chlamydia and 
gonorrhoea prevalence. Stratified probability sampling of 
households in Baltimore; urine samples requested from 
those in study age group. 
USA 
2011
169
 
W&M, 
15–35 
Both 4998 eligible (women 
and men 42.7%) 
Cross-sectional survey to estimate STI prevalence 
(Monitoring STI Survey Program). Probability sample of 
Baltimore residents. 
EU/EEA, European Union or European Economic Area Member States; M, men; OECD, 
Organization for Economic Cooperation and Development; S-E: Sexually-experienced; STI, 
sexually transmitted infections; W: women; WSS: Whole study sample.  
a
Numbers from 
technical report Erens et al. 2001
4
. 
b
Specimens were collected from all 16 to 17 year-olds 
regardless of reported sexual activity; prevalence of chlamydia infection was estimated among 
sexually-experienced only  
c
Numbers from technical report Erens et al.
5
 
d
Response rates from 
online results for 2007–2008 www.cdc.gov/nchs/nhanes/response_rates_CPS.htm  
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Figure 3-1a: Forest plot, estimates of chlamydia prevalence in women ≤ 26 years 
in EU/EEA and other high-income countries 
Reproduced from Redmond SM, Kissling KA, Woodhall SC et al.
3
 For references, see Table 3-1 
above. 
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Figure 3-1b: Forest plot, estimates of chlamydia prevalence in men ≤ 26 years in 
EU/EEA and other high-income countries.  
Reproduced from Redmond SM, Kissling KA, Woodhall SC et al.
3
 For references, see Table 3-1 
above. 
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3.2.1 UK-based studies of chlamydia prevalence 
The National Surveys of Sexual Attitudes and Lifestyles (Natsal) are three, 
stratified probability sample surveys of the British general population (covering 
England, Scotland and Wales; Northern Ireland is not included). The first survey 
(Natsal-1) was conducted in 1990-1991170, Natsal-2 in 1999-2001171 and  
Natsal-3 in 2010-12172. In both Natsal-2 and Natsal-3, chlamydia prevalence 
was estimated among a subset of participants23. Natsal-2 and Natsal-3 are the 
only studies to have estimated population prevalence at a national level within 
the UKf. In both surveys a sample of households was identified using a national 
postcode list, and interviewers visited the selected homes to identify eligible 
participants and carry out face to face interviews. The response rate to the 
overall survey was 65% in Natsal-2 and 58% in Natsal-3.g Natsal-2 recruited 
11,161 men and women aged 16 to 44; Natsal-3 recruited 15,162 16 to 74 year-
olds. In Natsal-2, a sub-sample of sexually-experienced 18 to 44 year-olds in 
Natsal was also invited to provide a urine sample for chlamydia testing, 71% of 
whom (n=3,569) agreed. The prevalence of chlamydia among sexually-
experienced 18 to 44 year-olds was estimated to be 2.2% (95%CI 1.5% to 
3.2%) among men and 1.5% (95%CI 1.1% to 2.1%) among women. Among 18 
to 24 year-olds, chlamydia prevalence was 3.0% (95%CI 1.7%–5.0%) among 
women and 2.7% (95%CI 1.2%-5.8%) among men.133 In Natsal-3, as well as all 
sexually-experienced 18 to 24 year-olds and a subset of 18 to 44 year-olds, all 
                                                             
 
f
 The Natsal surveys were conducted in Britain (England, Scotland, Wales, not Northern 
Ireland). Studies in this review are labelled with the country of origin. UK is used to denote 
studies that were conducted in any of the countries of the UK.  
g
 As eligibility within households was not known for those households not contacted, these 
calculated response rates use an estimated denominator of eligibles using data from 
households that could be contacted.
4,5
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16 and 17 year-olds - regardless of reported sexual activity - were invited to 
provide a urine specimen for anonymous testing for C. trachomatis infection. 
The estimated chlamydia prevalence among sexually-experienced 16 to 24 
year-olds was 3.2% (95%CI 2.2%-4.6%) in women and 2.6% (95%CI 1.7%-
4.0%) in men.23 
The other UK-based study to have estimated chlamydia prevalence using 
population-based methods was conducted on a sub-national basis. Chlamydia 
prevalence was estimated for two areas of England (West Midlands and Avon) 
as part of the Chlamydia Screening Studies (ClaSS) project in 2001/02. Lists of 
16 to 39 year-old men and women registered with GPs were used to identify the 
eligible target population. Individuals were then randomly selected from these 
lists and sent a postal invitation to participate in chlamydia screening by 
providing a urine sample for chlamydia testing. A total of 35% of those who 
were successfully contacted agreed to a test. The estimated population 
prevalence was 3.6% in women (95%CI 3.1%-4.9%) and 2.8% among men 
(95%CI 2.2%-3.4%) aged 16 to 39. Prevalence was higher among 16 to 24 
year-olds (women 6.2%; 95%CI 5.2%-7.8%; men 5.1% 95%CI 4.0%-6.3%).10 
A small number of studies of population prevalence of chlamydia conducted at 
the national level have been conducted outside of the UK (Table 3-1; Figure 
3-1). The most established of these is the National Health and Nutrition 
Examination survey (NHANES) in the US. NHANES is a series of cross-
sectional surveys using a stratified, multistage probability cluster design to 
select a representative sample of the US civilian, non-institutionalised 
population. Interviews are conducted in the household, and biological samples 
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are collected at mobile examination units. Recruitment is continuous, and data 
are presented in two-yearly cycles.141 
3.2.2 Methodological issues in general population studies 
Selection bias is error that arises from procedures used to select subjects or 
from factors that influence study participation173. Bias occurs when members of 
the study population differ in an important way from those who are not included 
in the study, with respect to the outcome or outcomes of interest. Some types of 
selection bias are particularly relevant for studies of chlamydia prevalence and 
are explored in more detail below. 
3.2.2.1 Non-response bias 
In the absence of 100% response rates, non-response bias occurs when 
members of the study population differ in an important way from non-
participants. In the case of chlamydia prevalence surveys, non-response bias 
occurs when the prevalence of chlamydia is different among participants and 
non-participants174,175.  
The response rates in the prevalence surveys reported in section 3.2 ranged 
from 9.8%158 to 84%140. The standard view in survey research has been that 
high response rates (ranging from more than 50% to more than 85% 
participation) are required in order to reduce the risk of non-response bias. 
However the relationship between response rate and non-response bias is not 
straightforward, and several studies have shown that non-response bias is not 
directly correlated with the survey response rate. Thus Groves argues that 
“there is no minimum response rate below which survey estimates are 
necessarily subject to bias”174. The extent to which an estimate among 
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participants will be a biased estimator of the target population depends on 
whether the factors affecting the likelihood that an individual will participate in a 
survey are related to the outcome of interest. If the factors relating to 
participation are entirely unrelated to the outcome, then estimates will be 
unbiased174. While this is theoretically possible, this is unlikely to happen in 
practice. An individual’s propensity to participate is often related to their interest 
in the topic, or in this case risk of infection, and thus is likely to lead to a 
difference in the outcome measure between participants and non-
participants176.  
The studies among general population samples described in section 3.2 provide 
some important evidence to suggest that participation in surveys of chlamydia 
prevalence is indeed likely to depend on factors relating to risk of infection, 
including sociodemographic characteristics and sexual behaviours. In Natsal-2 
and Natsal-3, chlamydia testing was performed among a subsample of 
respondents to the main survey. In both surveys the probability of providing a 
urine sample was associated with demographic factors including gender, 
ethnicity, and social class, as well as sexual risk factors, including history of 
condomless intercourse, having had a same-sex partner or reporting anal sex. 
Some of this differential participation would have led to participants being more 
at risk of having a prevalent infection than non-participants (e.g. those reporting 
more sexual partners without a condom and reporting a previous STI diagnosis 
were more likely to participate) whereas other factors may have tended towards 
a bias in the opposite direction (e.g. respondents of non-white ethnicity were 
more likely to participate in the urine study than those of other ethnicities).177,178 
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As part of the CSI project in the Netherlands, findings from a survey of non-
respondents versus respondents found some evidence that demographic 
factors associated with increased risk of infection (young age, ethnic minority 
groups, living in areas with high community risk), were associated with a 
decreased likelihood of participation. Conversely, individual sexual behavioural 
risk factors for chlamydia (casual or multiple sexual partners or a recent STI 
diagnosis), were associated with an increased likelihood of participation in 
screening, thus demonstrating the complexity of the factors affecting 
participation.179,180 Uusküla et al used linked data from a healthcare utilisation 
database in Estonia to compare the characteristics of respondents and non-
respondents in their population-based survey of chlamydia prevalence. 
Individuals who had a STI or related diagnosis within the past 12 months were 
more likely to participate in the survey, suggesting those with an interest in the 
topic had a higher propensity to participate.181 The higher rates of infections 
seen in populations attending clinical settings for testing are consistent with this 
evidence, suggesting that individuals who seek or accept testing are likely to be, 
on average, at higher risk of infection.123,182 Further evidence of this is found in 
the meta-regression presented by Redmond et al in their systematic review of 
chlamydia prevalence studies, which found that surveys with lower response 
rates had higher estimates of chlamydia prevalence.3 However, as the surveys 
were carried out in different countries and at different times, the extent to which 
this association is due solely to different participation rates is unclear. 
Given the relationship between propensity to participate and risk of infection 
demonstrated above, the extent to which estimates are subject to non-response 
bias is likely to differ by study design. For example studies with a broad health 
focus (e.g. NHANEs), or those using stored samples collected for another 
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purpose, may be subject to different biases than those with a specific focus on 
sexual health (e.g. Natsal), as the decision to participate in the survey or 
provide a biological sample would be informed by considerations other than 
those that relate specifically to sexual risk behaviour. Similarly, those designed 
specifically as chlamydia screening interventions (e.g. CSI and ClaSS), are 
likely to be subject to selection biases, and may be more similar to study 
populations of individuals accepting testing in other clinical settings. Assessing 
the scale of bias in each case is, however, extremely difficult and the different 
methods (if any) used for assessing non-response bias make it infeasible to 
quantitatively compare bias between studies.  
 
Where the variables that predict participation are perfectly measured in both the 
target population and the survey population, non-response bias can 
theoretically be eliminated.174,183 However in practice, this is limited by the data 
available, and only minimal information is usually available from non-
participants. Where the studies reported above have tried to address non-
response, this has usually been limited to applying post-stratification weightings, 
to weight the sample population to a known distribution in the target population, 
for example age, gender and ethnicity.  While this approach can go some way 
to correcting for non-response bias, this assumes that the prevalence of 
chlamydia among participants and nonparticipants is the same within specified 
demographic subgroups. Weights that only allow for basic demographic 
characteristics are likely to be inadequate, as the studies where non-response 
has been investigated show that these factors do not fully capture the risk 
difference between participants and non-participants. A few studies have 
applied more detailed weights. In Natsal-2 and Natsal-3, as well as weighting 
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for age, sex and geographical distribution of the target population, additional 
weights were applied to allow for the differential response patterns to the 
request to provide a sample for chlamydia testing.5,133,177 However, even this 
approach is imperfect, as it does not allow for any self-selection in participating 
in the main Natsal-2 survey beyond age, sex and region.177 In order to estimate 
prevalence, rather than percentage testing positive using data from participants 
in the CSI project in the Netherlands, weights were applied to match the age, 
gender, ethnicity and a community-level risk score of the population of the 
regions where the study took place. Further weights were applied to allow for an 
estimated proportion of the population who were sexually experienced, and to 
adjust for the use of a risk score to determine eligibility in one of the three 
participating regions (South Limburg, where population prevalence was thought 
to be lower than in the other two, largely urban regions). No weights were 
applied to account for any other sexual behaviour differences.88 
3.2.2.2 Coverage bias 
Coverage bias is a form of selection bias that occurs when the sample from 
which a study population is selected is not representative of the target 
population, for which conclusions from the study are to be drawn.184 The 
availability of adequate sampling frames varies by country, and identifying a 
representative population can be difficult and can have a large impact on the 
cost of the study.  
The studies presented in section 3.2 above used a range of different sampling 
frames. Some studies were able to use a population registry, for example in 
Estonia, Uusküla et al selected a random sample of 18 to 35 year-olds living in 
Tartu from the national population registry in 2005/06. Forty percent of those 
67 
who were contacted participated, 86% of whom returned both a questionnaire 
and a sample for testing.146 In the Netherlands, the CSI project137 and the 
prevalence survey carried out before the implementation of the trial185 used 
municipal population registers to access addresses of the eligible population.  
However not all countries have reliable population registers available and 
alternative approaches have been used. For example, telephone directory 
listings have been used as a sampling frame in studies conducted in 
Australia161 and France.141 In Britain, in the absence of a readily-available 
population registry, Natsal-2 and Natsal-3 used the national Postcode Address 
File as the initial sampling frame, from which postcodes and subsequently 
addresses were selected. Interviewers at the household then assessed 
eligibility upon contact with the household.133 Where the eligibility criteria are 
relatively broad (e.g. adults), this approach will potentially be more efficient than 
where more restrictive criteria are applied (e.g. 15 to 24 year-old women), as 
fewer households would have to be contacted in order to identify one eligible 
person. 
One alternative sampling frame to population or household lists in England is to 
use GP registers, as used by the CLaSS survey.10 Almost all residents of 
England are registered with a GP. In 2011, an estimated 98% of 15 to 24 year-
old females were registered.h   However GP lists have substantial limitations. 
The names and addresses held on GP registers may be inaccurate due to 
                                                             
 
h
 Calculated using ONS mid-2011 population estimates, plus data from the NHS Information 
Centre Attribution Dataset of GP registered populations scaled to ONS population estimates, 
2011, assuming that 1 registration = 1 person. http://www.ic.nhs.uk/statistics-and-data-
collections/population-and-geography/gp-registered-populations/attribution-dataset-gp-
registered-populations-scaled-to-ons-population-estimates-2011  
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registrations that relate to deceased patients, duplicate records or patients who 
have either moved out of the area or moved within the area but not updated 
their contact details (so-called ‘ghost patients’). As part of the ClaSS study, 
intensive efforts were used to identify whether people actually received the 
postal invitation to screen. Individuals were classified as ‘ghosts’ if they were 
either confirmed as not resident at the address held by the practice or not 
contactable by any method. 26% of the invited 16 to 24 year-olds women were 
classed as ‘ghosts’10. While there has been a move in recent years to improve 
the accuracy of these lists,186 GP lists are still likely to be subject to 
inaccuracies.  
In summary, few nationally-representative studies in EU/EEA or other high 
income countries have estimated chlamydia prevalence, although prevalence 
has been estimated in Natsal-2 and Natsal-3 in Britain. Surveys are subject to 
non-response bias and coverage bias. Although weighting has been used to 
correct for this in some surveys, this potential for bias remains a challenge for 
achieving robust estimates of prevalence in the general population. These 
biases are relevant for single estimates of chlamydia prevalence but are also 
important to consider when using repeated measures, which is the subject of 
the next section. 
3.3 Repeated, cross sectional estimates of chlamydia prevalence in 
the general population 
One option for monitoring changes in chlamydia prevalence would be to have 
regular, repeated measurements of a random sample of the population. Only 
two published studies using repeated sampling among a general population 
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sample to measure chlamydia prevalence over time had been published at the 
time of carrying out this review.  
In the US, NHANES has measured chlamydia prevalence since 1999. The 
estimated prevalence among 14 to 39 year-olds declined from 2.6% to 1.6% 
between 1999/2000 and 2007/2008. However there was no statistically 
significant fall measured among 14 to 25 year-old women, the population 
targeted for annual screening in the US.141  
In the Netherlands, chlamydia prevalence was repeatedly estimated as part of 
the CSI project. As described in section 3.2.2.1, prevalence was derived from 
percentage testing positive using post-stratification weightings. No significant 
change was seen in either the overall percentage testing positive or estimated 
prevalence. A small decline was observed in one of the three regions (South 
Limburg), where the percentage testing positive declined from 5.1% to 3.1% 
and the estimated population prevalence declined from 3.2% to 1.8%.88 
While these two studies used general population sampling frames, they have 
some limitations.  
The sampling strategy of the NHANES survey means that different areas are 
sampled in each two year survey cycle. While this is based on probability 
sampling, and thus will be generally representative of the US population, 
prevalence estimates for diseases that are highly geographically clustered may 
be very sensitive to the chance selection of areas. For this reason, NHANES is 
no longer used for estimating the population prevalence of gonorrhoea, as 
selecting areas where a cluster of infections exists may lead to erroneous 
conclusions about the prevalence of infection in the general population.187 
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Chlamydia is more evenly distributed through the population,188 but it is feasible 
that the clustering of infection within sexual networks may make such estimates 
more prone to measurement error.  
In the CSI project in the Netherlands, participants had higher levels of sexual 
risk behaviour than the general population, and the proportion reporting sexual 
risk behaviours increased in each year (among those with available data on 
sexual behaviour).88 Therefore not only are prevalence estimates within each 
year likely to be overestimated, but the change between years is subject to 
confounding by the change in the participating population in each year. 
Specifically, the change over time is likely to be underestimated, as the sample 
includes an increasingly higher-risk population over time. 
The publication of findings from Natsal-3 in 2013, provided a third study which 
used repeated cross-sectional estimates of population prevalence. 
Comparisons between these two surveys are investigated in detail in Chapter 6. 
3.4 Trends in percentage testing positive for chlamydia using clinical 
and routinely-collected data 
Given that few studies have used repeated population-based measurement of 
prevalence, one potential alternative is to use data from populations accessing 
chlamydia testing to look at changes over time.  
Two systematic reviews have demonstrated the existence of numerous studies 
of populations attending clinical settings who were tested for chlamydia as part 
of routine clinical care.2,123 The percentage testing positive in these studies 
does not equate to the prevalence of chlamydia among the general population 
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as individuals seeking or accepting a chlamydia test will not be representative of 
the general population. This is clearly demonstrated in the systematic review by 
Adams et al, who found that estimates of percentage testing positive conducted 
in healthcare settings were higher than prevalence estimates conducted in 
population-based studies.123 This distinction can also be seen in a comparison 
of NCSP data from 2008 and findings from Natsal-2 by Riha et al, which found 
that the percentage testing positive among women and men aged 18 to 24 
years who were tested as part of the NCSP was higher than estimated 
population prevalence in Natsal-2 (8.5% versus 3.1% in women and 9.4% 
versus 2.9% in men).182  
While studies using data from populations accessing testing cannot provide 
estimates of population prevalence of chlamydia, they may have some utility as 
outcome measures of changes in the burden of chlamydia infections over time, 
albeit in subgroups of the population. 
Reports of trends in percentage testing positive for chlamydia using data from 
sexual health or family planning clinics have been published or included in 
routine surveillance reports for several countries, including the UK,189 the 
US,190-192 Australia,193-195 New Zealand,196 Finland,197 the Netherlands,198 
Sweden73 and Norway.199 In the US, trends have also been reported among 
men and women tested through the National Job Training Program (NJTP), 
representing a high-risk subgroup of socioeconomically-disadvantaged 16 to 24 
year-old men and women.200 In contrast to trends seen in England (section 
4.4.1), increasing trends in percentage testing positive for chlamydia have been 
seen since around 2000 in Denmark, Sweden and New Zealand.101 In Australia, 
increases in percentage testing positive have been observed in several 
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populations,193 although stable trends or decreases have been seen among 
men who have sex with men (MSM).194 In the US, test positivity in family 
planning clinics and among young people entering the NJTP has been 
increasing in the last decade.200 After adjusting for test technology and known 
changes in the test population however, either stable or declining trends were 
seen. Analyses at a sub-national level have shown increases in percentage 
testing positive during this period, even after adjustment.192 
3.4.1 Methodological issues in studies of trends in chlamydia 
prevalence or percentage testing positive 
3.4.1.1 Measured and unmeasured confounding 
Confounding occurs when the estimated effect of an exposure of interest is 
distorted, as it is mistaken for the effect of another exposure (or exposures). In 
order for this to happen, the confounder must be correlated with both the 
outcome and the exposure of interest, and must not be part of the causal 
pathway from the exposure of interest to the outcome of interest.173 Whether 
using repeated prevalence measures from population-based samples, or trends 
in percentage testing positive in populations accessing testing, estimates will be 
subject to confounding if there are any changes in the characteristics of the 
population tested or the way that infection status is measured that are also 
associated with risk of infection.201 Where all confounders are perfectly 
measured, the main effect of time on chlamydia result can be measured by 
including confounders as covariates in multivariable models, or by carrying out 
stratified analyses. In practice, it is unlikely that all potential confounders can be 
measured, but it may be possible to reduce the impact of confounding on 
estimates of trends in infection over time.  
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3.4.2 Changes in demographics or sexual behaviour of those tested 
The potential for confounding was seen in the CSI project in the Netherlands.88 
Among those who completed the questions on sexual behavioural at the time of 
screening, reported levels of sexual risk behaviours were higher than the 
general population and increased with each round of screening invitation, while 
the overall uptake of screening in the study decreased with each round from 
16% in round one to 10% in round three.88 Even though the project used 
population-based sampling (i.e. invited the total eligible population) it is 
reasonable to expect that the true prevalence of infections would be lower than 
that estimated in the CSI project’s main findings and that the decline in 
prevalence would be steeper than was observed.88  
Depending on the specific context, it is easy to see how trends in the 
percentage testing positive among tested populations may be even more 
subject to changes in who is tested than in population-based studies.201 
Changes in national or local screening policies or rates of partner notification 
may lead to different populations being tested. Media campaigns may increase 
awareness of chlamydia, and lead to people either requesting a test or 
accepting the offer of a test that may not have done before. While several 
reports have been published that examine the trends in percentage testing 
positive, relatively few have made any attempts to control for potential 
confounding introduced by the observational nature of the data.  
In the US, Satterwhite et al examined trends in percentage testing positive in 
women tested in Infertility Prevention Program (IPP) family planning clinics191 
and antenatal settings.202 In both settings, trends in percentage testing positive 
were adjusted for test technology, age, ethnicity and region. No sexual 
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behaviour data were available. The analysis was performed using the clinic as 
the unit of analysis. The unadjusted trend in percentage testing positive in the 
IPP clinics showed 2% annual increase in percentage testing positive (odds 
ratio (OR) 1.02, 95%CI: 1.01 to 1.03).  After adjustment, the authors found that 
there was no change in percentage testing positive in women attending IPP FP 
clinics between 2004 and 2008 (adjusted odds ratio (AOR) 1.00, 95%CI: 0.99 to 
1.00) and a decline in percentage testing positive among women attending IPP 
prenatal clinics between 2004 and 2009 (AOR 0.93, 95%CI 0.92-0.95). While 
this method was able to control for unmeasured confounding arising from a 
changing distribution of clinics, it assumes that the populations attending each 
clinic are largely stable over time, within the demographic stratum. 
Fine et al explored trends in percentage testing positive among women 
attending IPP FP clinics in the Pacific Northwest region of the US between 1997 
and 2004.  Enhanced demographic and sexual behaviour data are collected at 
a regional level, and thus they were able to examine the trend in percentage 
testing positive adjusting for age, state, race/ethnicity, city size, test technology 
and several sexual behaviour variables. Adjusting for all these factors together 
had little effect on the measured trend in percentage testing positive, with both 
unadjusted and adjusted analyses showing a 5% increase per year in the odds 
of testing positive (AOR 1.05, 95%CI 1.03 to 1.05).192 
Two papers have examined adjusted trends in percentage testing positive in 
Australian settings. O’Rourke et al reported trends in percentage testing positive 
among women attending the Melbourne Sexual Health Centre, and Vodstrcil et 
al reported trends among men from the same setting. Among women, the self-
reported characteristics of attendees were found to be relatively stable over the 
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analysis period, with only minor changes observed, such as an increase in the 
proportion reporting 2 or more sexual partners in the previous 3 months from 
25% in 2003 to 30% in 2007.193 More substantial changes were observed 
among men who have sex with women (MSW), among whom the proportion 
reporting 2 or more sexual partners increased from 42% in 2002 to 53% in 
2009. Among men who have sex with men (MSM), the only notable change was 
the proportion reporting symptoms or contact with infection, which decreased 
from 39% in 2002 to 35% in 2009. Although these changes in the population 
tested were noted, adjusting for these characteristics made negligible difference 
to the measured trend in percentage testing positive, suggesting that the 
changes in the population were not sufficient to explain any of the trend in 
percentage testing positive over time. After adjusting for available risk factors, 
percentage testing positive was found to increase among women and MSW 
(women: AOR 1.12; 95%CI: 1.05-1.20; MSW: AOR 1.04, 95%CI: 1.01-1.07), but 
no change was found among MSM (AOR = 0.99, 95%CI: 0.93-1.06).194 
3.4.3 Changes in test technologies 
While relatively few studies have attempted to deal with potential changes in the 
demographic or behavioural characteristics of those tested, more have tried to 
address the impact of changes in test technologies. A change to a more 
sensitive test could result in an increase in percentage testing positive for 
chlamydia without a change in the prevalence of infection among the tested 
population, whereas a change to a more specific test could result in a decrease 
in the percentage testing positive, due to fewer false positive results. Changes 
in the test technology may also result in changes in the population tested. Less 
invasive sampling for both men and women may increase the likelihood of 
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someone either seeking a test, being offered a test, or accepting the offer of 
testing.  
Three studies aimed specifically at determining the change in percentage 
testing positive that can be attributed to the change in test were identified in this 
literature review. Burckhardt et al  used data from a GUM clinic in Scotland 
between 1992 and 2003, where the test used switched from culture to ligase 
chain reaction (LCR) in September 1998;203 Dicker et al examined data from 
two regions of the Infertility Prevention Program (IPP), and compared 
percentage testing positive in the calendar quarters immediately before and 
after changes from a DNA probe to LCR in one region (1996-1997) and from 
direct fluorescent antibody (DFA) to enzyme immunoassay (EIA) with 
confirmatory DFA in another (1993-1994);204 Gotz et al compared changes in 
percentage testing positive in laboratories that did and did not change their 
testing procedures in Sweden between 1996 and 1998, and 1998 and 1999.205 
In all cases, some, but not all of the increase in percentage testing positive was 
attributable to changes in the test used.  
Consistent with the expected increase in percentage testing positive with 
increasingly sensitive test technology, Satterwhite et al found that adjusting for 
test technology had a substantial impact on the observed trend in percentage 
testing positive among men and women tested in the National Job Training 
Program (NJTP) in the US. Comparison of unadjusted data showed an increase 
in percentage testing positive between 2003 and 2007 (OR 1.11, 95%CI: 1.10 – 
1.14), however after adjusting for test technology and other variables,  the 
adjusted trend showed an average 5% decline in percentage testing positive 
per year (AOR 0.95, 95%CI: 0.93-0.97).200 
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In summary, in considering trends in prevalence or percentage testing positive 
for chlamydia, if the population tested or test used varies over time then 
changes in the measured outcome may be wrongly attributed to a change in the 
amount of infection in the population over time. This has been demonstrated in 
studies in the US and Australia, but the impact of differences in the population 
accessing testing has not been explored in England. This is the subject of 
Chapter 4. 
3.5 Trends in C. trachomatis antibody seroprevalence as a marker of 
age-specific cumulative incidence 
Seroepidemiology has been widely used for the monitoring of vaccine-
preventable diseases where there is a clear correlation between previous 
vaccination and/or wild-type infection and detectable antibodies and to identify 
susceptible sections of the population.206,207 As the presence of C. trachomatis 
antibodies in serum provides a marker of previous infection, serological 
analyses have been used to establish the association between previous 
chlamydia infection and reproductive complications including PID, ectopic 
pregnancies and tubal factor infertility.208 However seroepidemiology has rarely 
been used to investigate trends in genital infection over time, or as a marker of 
control of genital chlamydia infections.99  
This is, in part due to the lack of a suitable assay. Until recently, serological 
testing for C. trachomatis-specific antibodies was problematic as several assays 
were subject to cross-reactivity with other chlamydiae species21,208 and 
sensitivity and specificity of commercially available assays was relatively poor.99 
In recent years, tests with higher specificity and which are not subject to cross-
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reaction have become available209 and present new opportunities for chlamydia 
seroepidemiology.  
At the outset of this PhD, three studies had reported on trends in antibodies to 
chlamydia using samples collected from pregnant women. In Japan, the 
percentages testing positive for C. trachomatis antibodies (hereafter ‘C. 
trachomatis antibody seropositive’) were compared between pregnant women in 
1987, 1992 and 1996/97 (n=275, 297 and 9,652 respectively). Women in the 
later sample were routinely screened at the time, whereas the earlier results 
were obtained by testing stored serum samples. The percentage C. trachomatis 
antibody seropositive was found to declinei in all age groups, for example from 
35% to 31% among women aged 20 to 24 years old.210 Two studies in Finland 
have reported trends in C. trachomatis antibody seroprevalence among 
pregnant women up to the age of 28, using stored serum from the Finnish 
Maternity Cohort serum bank.211,212 Both studies report a fall in antibody 
seroprevalence from around 1990 to the early 2000s. For example, 
seroprevalence among 23 to 28 year-olds decreased from 22% (95%CI 19%-
25%) in 1989-1991 to 12% (95%CI 10%-15%) in 1998 to 2000.212  
More recently, in the Netherlands, van Aar et al have reported results from a 
study using stored sera from participants in two nationally-representative 
surveys of the general population in 1995-1996 and 2006-2007. Sera were 
tested using the Medac quantitative CT IgG ELISA. There was no statistically 
significant evidence of a difference in seroprevalence between birth cohorts.132  
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 Statistical significance of the decline was not reported. 
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In England, two studies to date have investigated trends in percentage C. 
trachomatis antibody seropositive. Horner et al used residual sera submitted to 
laboratories in England for routine microbiological or biochemical 
investigations.213 A second study by the same group used residual sera from 
individuals tested for syphilis at two GUM clinics in England.214 In both studies, 
sera were tested using an “in-house” indirect immunoglobulin G (IgG) enzyme-
linked immunosorbent assay (ELISA) based on the Pgp3 antigen (hereafter 
‘indirect Pgp3 ELISA’, see section 8.3.2.1 for more details), which have 
demonstrates superior sensitivity to commercially-available assays such as that 
used in the studies in Japan, Finland and the Netherlands above.209 Reductions 
in percentage with Pgp3 antibodies detected in serum (‘Pgp3 seropositive’) 
among young women were observed in both studies, consistent with a decline 
in exposure to antibody inducing infection in the mid- to late-2000s, at a time 
when there was increasing uptake of chlamydia testing and treatment. In the 
first study using sera collected for routine testing in non-GUM settings, the age-
standardised seroprevalence among 17 to 24 year-old women decreased from 
20% (95% CI 17%–23%) to 15% (95%CI 12%–17%) in 2010 (p=0.0001).213 In 
the second study that used sera from women attending GUM services, the 
percentage Pgp3 seropositive among women <20 years old decreased from 
42% in 1998 to 30% in 2009.214  
Antibody seroprevalence surveys are potentially less subject to selection bias 
as they can use stored or retrospectively collected blood samples that have 
been collected for a purpose other than chlamydia testing. However the studies 
above remain subject to bias and confounding. Pregnant women may have a 
different risk of infection to the general population and seroprevalence trends 
may be subject to confounding from changes in age-specific characteristics of 
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women who become pregnant. The studies from the UK were based on clinic-
attending populations rather than nationally-representative samples and in both 
studies it is also possible that the population who contributed serum samples 
changed over time. Sera in the study by Horner et al were excluded if they were 
listed as coming from GUM clinics. However it is feasible that the accuracy of 
coding improved over time meaning that the proportion of sera from high-risk 
populations may have changed (personal communication, Kate Soldan). 
Patterns in access to clinics may have affected the population being tested for 
syphilis testing in the UK study from GUM clinics.214 
Along with general considerations of bias and confounding, seroprevalence 
studies are also subject to some specific limitations. The interpretation of age-
specific trends in seroprevalence is complicated by the fact that serum antibody 
levels are likely to depend on several factors including the time since infection, 
the duration and seriousness of infection as well as number of infections. Thus 
trends in seroprevalence can only provide an indicator of trends in exposure to 
antibody-inducing infection, and all tests will underestimate the number of 
people who have ever been infected. These limitations are discussed further in 
Chapter 8). 
3.6 Summary 
Studies in Europe and the US that have used population-based methods to 
estimate chlamydia prevalence at a national level among sexually-experienced 
under 26 year-olds report prevalence estimates of 3.0% to 5.3% in women and 
2.4% to 7.3% in men. Achieving robust measures of chlamydia prevalence is 
challenging due to the need for appropriate sampling frames with sufficient 
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information to adjust for non-response bias and changes in sampling or 
response over time.  
The percentage testing positive among samples from clinical populations or 
those accessing testing is typically higher than prevalence estimated in 
population-based studies as those who access testing will be at higher risk than 
the general population.  
In the absence of RCTs, interpreting trends over time in chlamydia-related 
outcome measures (chlamydia prevalence, the percentage testing positive, or 
antibody seroprevalence) is problematic due to changes in the population 
tested, changes in sexual behaviour and changes in tests. It is possible to 
control for confounding where all confounders are perfectly measured, but this 
is unlikely in practice. The confounding effect of changing test technology on 
trends in chlamydia infection has received some attention in the literature, but 
there have been relatively few studies that have attempted to control for 
potential confounding due to behavioural factors.  
In the next chapter, I describe an analysis of nationally-collated surveillance 
data, which was carried out to address the issue of confounding and investigate 
the potential use of these data for monitoring changes in chlamydia infection 
over time.  
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4 Trends in percentage testing positive for chlamydia 
using routinely-collected surveillance data 
As set out in the previous chapter, changes in the percentage testing positive for 
chlamydia among populations accessing testing may be due to changes in the 
population tested rather than a change in the underlying amount of infection in the 
population. Changes in percentages testing positive may also be due to changes in 
sexual behaviour rather than due to the effect of a chlamydia control intervention 
such as chlamydia screening. In this chapter, I investigate the use of surveillance data 
for the purposes of evaluating the impact of chlamydia screening. I explore the extent 
to which trends in percentage testing positive for chlamydia in England are affected 
by changes in the characteristics of the population tested and in turn whether these 
data provide any evidence of there having been a decline in chlamydia infections in 
the context of widespread chlamydia screening among under-25 year-olds.   
4.1 Background  
Public health surveillance involves the ongoing and systematic collection, 
analysis and interpretation of health-related data for the purposes of informing  
public health action, including planning and implementation of services or 
interventions and evaluation of public health practice.215,216 Infectious disease 
surveillance encompasses a spectrum of activities from collation of case reports 
to active, population-based surveillance that aims to capture the total picture of 
infection or disease within a population.216 These different approaches have 
different strengths and limitations. Systems based on case reports, even if 
augmented with additional demographic or clinical data, will often rely on 
routinely-collected information, the quality and completeness of which may vary 
depending on the setting and purpose for which it is collected. Data collected 
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from people who have accessed health services for testing or diagnosis of an 
infection will also be biased towards the health-seeking population. For 
asymptomatic infections such as chlamydia, this is particularly problematic. 
Systems based on more complete pictures of a population of interest that 
employ a sampling strategy to achieve a representative population of interest 
may avoid some of these problems but will often be much more resource-
intensive and may still be subject to bias depending on who participates or from 
whom data are available. 
During the course of the 2000s, a number of developments were made in STI 
surveillance in England. The KC60 data return, which reported aggregate data 
on STI diagnoses in GUM clinics with limited demographic data, was replaced 
in 2009 by the genitourinary medicine clinic activity dataset (GUMCAD). 
GUMCAD is a patient-level data return including all STI diagnoses made 
(including chlamydia) and services provided (including chlamydia tests) in STI 
clinics in England along with patient demographic information.6  
Alongside the implementation of the NCSP from 2003 onwards, data reporting 
systems were set up to collect information on chlamydia tests carried out 
through the programme. From 2003 to 2011, all chlamydia tests performed 
outside of GUM clinics as part of the NCSP were reported by service providers 
to the Health Protection Agency (HPA)j (hereafter termed ‘NCSP dataset’).217 
The NCSP dataset includes tests performed in a range of settings including GP, 
community sexual and reproductive health services, community pharmacies, 
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 The Health Protection Agency (HPA) was incorporated into Public Health England (PHE) from 
April 2013. 
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education and youth venues and tests accessed via the internet. From 2008 to 
2011, the HPA also collected aggregate data on tests among 15 to 24 year-olds 
performed outside of GUM settings, but not reported to the NCSP, via a 
quarterly return from testing laboratories (the Non-NCSP, Non-GUM dataset, 
representing 14% to 17% of tests among 15 to 24 year-olds each year from 
2008 to 2011).  
Taken together, these datasets provide a complete picture of NHS-
commissioned chlamydia tests among 15 to 24 year-olds in England up to 
2011. Since the start of the programme, these data have been used to monitor 
the performance of local areas and drive service improvement in terms of 
chlamydia testing coverage and, in more recent years, diagnosis rates.114,218 
While this is a key function of surveillance data, the extent to which this 
routinely-collected information from individuals accessing chlamydia testing can 
be used to monitor burden of infection within the population is unclear given 
both the bias associated with healthcare-attending populations and the 
considerable changes in the way that screening has been implemented in 
England over the past decade (section 2.5). As set out in the previous chapter it 
is feasible that trends in the number of case reports and percentage testing 
positive for chlamydia may be confounded by a change in the population tested, 
which in turn may limit the utility of routine data for monitoring the burden of 
infection.  
4.2 Aims & objectives  
The aim of this analysis was to determine whether trends in the percentage 
testing positive for chlamydia provide any evidence to suggest a decrease in 
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chlamydia prevalence since the national implementation of chlamydia screening 
in 2008. This aim was addressed through the following objectives: 
 To describe trends in percentage testing positive for chlamydia among 15 to 
24 year-olds tested for chlamydia as part of the National Chlamydia 
Screening Programme (between 2008 and 2011), or tested in GUM clinics 
(between 2009 and 2011). 
 To investigate the extent to which time trends in percentage testing positive 
for chlamydia are subject to confounding due to changes over time in the 
characteristics of the population tested by adjusting trends for a range of 
sociodemographic and behavioural variables. 
4.3 Methods 
4.3.1 Data sources 
Data on chlamydia tests among 15 to 24 year-old women and men in England 
reported through the NCSP dataset or GUMCAD were includedk. The analysis 
period varied slightly between datasets: 2008 was included as the earliest year 
for analysis of the NCSP dataset as this was the first full year of the NCSP; the 
earliest year for analysis of GUMCAD was 2009 as this was the first year the 
system was nationally-implemented. From 2012 onwards, the NCSP dataset 
and the Non-NCSP Non-GUM dataset were replaced by a laboratory-based 
reporting system (the Chlamydia Testing Activity Dataset, CTAD). This dataset 
does not incorporate the same demographic and sexual behaviour variables as 
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 Data are subject to minor revision due to retrospective submission of data, thus exact numbers 
may vary from published figures. These analyses are based on extracts dated February 2012 
(NCSP dataset) and 17 August 2012 (GUMCAD). 
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the NCSP dataset, thus analyses were limited to tests performed up to the end 
of 2011.  
Within the NCSP dataset, test records with a matching postcode of residence, 
date of birth and gender were considered to refer to the same person and were 
used for de-duplication.l In GUMCAD, individuals with more than one clinic visit 
were linked using their clinic number (this is unique within a clinic)m. All 
analyses were conducted on the basis of ‘testing episodes’ Test (and diagnosis) 
records within 6 weeks of a previous test were considered to be the same 
testing episode and were excluded. Individuals were allowed to contribute more 
than one testing episode during the analysis period. Analyses were carried out 
separately in the NCSP and GUMCAD datasets, as although individuals can 
attend more than one service they cannot be linked between the datasets.   
Demographic, test and behavioural information are collected in the NCSP 
dataset and GUMCAD, although different items are collected in each (Table 
4-1). An area-level indicator of socioeconomic deprivation (the Index of Multiple 
Deprivation, IMD220) was assigned to all test records by mapping postcodes of 
residence to lower super output areas (LSOA, an area of average population of 
1,500 individuals221) of residence. Ranks of IMD scores were grouped into 
quintiles. Having a previous chlamydia diagnosis is a known risk factor for 
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 Where a test record in the NCSP dataset had a postcode of residence equal to the postcode of 
testing venue, the postcode of residence was set to ‘missing’, as this was considered a likely 
data entry error.  
m
 Chlamydia tests and diagnoses are recorded separately in GUMCAD, and may be recorded 
on different dates. All recorded sexual health screens were considered to include a chlamydia 
test (as specified in coding guidelines
219
). A test was considered positive if there was a 
chlamydia diagnosis recorded on the same day or within the following 6 weeks. A chlamydia 
diagnosis reported without an accompanying sexual health screen was included as a positive 
test. 
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subsequent infection.48,51,56 Testing episodes were therefore categorised as 
having a recorded chlamydia diagnosis in the past 12 months by linking tests 
records for individuals within each dataset. The sexual behaviour variables were 
combined into a single ‘risk group’ variable, in order to avoid collinearity in 
multivariable models (high risk: answered ‘yes’ to both sexual behaviour 
variables; medium risk: answered ‘yes’ to one sexual behaviour variable; low 
risk: answered ‘no’ to both sexual behaviour variables).  
Table 4-1: Comparison of data items included in the NCSP dataset and the 
genitourinary medicine clinic activity dataset (GUMCAD) used in the analysis  
 NCSP Dataset GUMCAD 
Date of test   
Year of age   
Ethnic group   
Region (Strategic Health Authority)   
LSOA of residence*   
Testing venue type  Not applicable 
Specimen type (urine/vulvovaginal swab/cervical 
swab)  
  
Reports having a new sexual partner in the previous 
three months (yes/no)
^
 
  
Reports and more than one sexual partners in the 
previous 12 months (yes/no)
^
 
  
Sexual orientation
$ 
 
  
*LSOA: Lower super output area 
^
These sexual behaviour variables were included in the ‘core dataset’, which all local areas 
were required to submit as part of the NCSP dataset return. Other optional items were available 
as part of the NCSP dataset (including condom use), but were not included in this analysis as 
not all areas returned these items.
 
$
Sexual orientation is collected in GUMCAD at each clinic visit. Men who reported having sex 
with a man at any clinic visits were categorised as men who have sex with men (MSM). 
4.3.2 Statistical analyses 
Test, demographic and sexual behavioural characteristics were compiled for 
NCSP and GUMCAD testing episodes. The total number of testing episodes, 
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percentage testing positive and reported test, demographic and behavioural 
characteristics, are presented by year, calendar quarter and dataset. 
The relative annual change in the percentage testing positive was estimated 
using univariable logistic regression, with test result included as the outcome 
variable, and year as a continuous predictor variable. Odds ratios were 
interpreted as a reasonable proxy for relative risk, due to the generally low 
prevalence of chlamydia in these analyses.222 Annual trends were calculated by 
gender and other factors including age, venue of test, sexual risk group (NCSP 
dataset) and sexual orientation (GUMCAD).  
It is reasonable to assume that the likelihood of attending a GUM clinic with a 
symptomatic STI may be less subject to changes in sexual health policies and 
service provision than the likelihood of an asymptomatic attendance, meaning 
individuals attending with symptoms may provide a more stable population in 
which to monitor chlamydia infection. The proportion of attendances in 2009 to 
2011 where a chlamydia testing episode was recorded was higher for those 
where a diagnosis of genital warts, candidosis, genital herpes or - for women -
bacterial vaginosis was made (Table 4-2). Trends in percentage testing positive 
for chlamydia were therefore also explored in a subgroup analysis limited to 
GUM clinic attendances where a diagnosis of these selected symptomatic 
conditions was made.  
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Table 4-2: Proportion of GUM attendances with a chlamydia testing episode 
recorded, by gender (15 to 24 year-old women and men, GUMCAD, 2009-2011) 
  
Women Men 
  N % tested N 
% tested 
All GUM attendances 1,628,320 59% 996,862 
63% 
Attendances with diagnosis of 
selected symptomatic condition: 
    
Genital warts 68,148 83% 57,025 
85% 
Candidosis 121,518 88% 12,968 
87% 
Genital herpes 26,307 66% 10,782 
85% 
Bacterial vaginosis 137,552 92%   
 
4.3.3 Factors associated with testing positive 
The association between demographic and sexual behaviour variables and 
testing positive for chlamydia were explored using univariable and multivariable 
logistic regression. All variables significant in univariable analyses (p<0.05) 
were entered into a multivariable model.  
4.3.4 Assessment of confounding of time trends in percentage testing 
positive introduced by changes in risk factors over time 
In order to investigate potential confounding of trends in percentage testing 
positive for chlamydia arising from changes in the population tested, a series of 
‘bivariable’ logistic regression models were constructed, which included test 
result as the outcome variable, and year (entered as a continuous variable) and 
one other variable as predictors (e.g. year and age, year and ethnicity, year and 
region). The estimated annual change in percentage testing positive was 
compared between the models when each variable was included or excluded to 
explore whether allowing for changes in each variable would change the 
estimated trend in percentage testing positive. Variables that were significantly 
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associated (p<0.05) with testing positive in each of the bivariable models were 
included in a multivariable model, along with year. 
NCSP testing episodes had considerable levels of item non-response for 
variables of interest (Table 4-3). The percentage of testing episodes with 
missing data increased between 2008 and 2011, from 42% to 58% among 
women and 58% to 69% among men, and varied by venue of testing service. 
The lowest levels of missing data were seen for testing episodes returned 
through remote testing (29% missing data among women, 32% among men). 
The percentage testing positive was higher among testing episodes with 
complete data compared to those with missing data for both women (6.9% 
versus 6.0%) and men (6.4% versus 4.5%). As the purpose of the analysis was 
to compare the impact on the annual change in percentage testing positive 
when adjusting for different variables, this analysis was limited to testing 
episodes with complete data on all of the variables of interest. A sensitivity 
analysis was carried out to determine whether the same patterns were 
observed when using data that were complete on each individual item of 
interest. Sensitivity analyses were not carried out in the GUMCAD analysis as 
the percentage of GUMCAD tests with missing data was lower (13.9%). 
All tabulations and models were constructed separately by gender and by 
dataset. All statistical analyses were performed using Stata version 12.0 
(StataCorp, College Station, Texas, USA). Statistical significance is considered 
as p<0.05 for all analyses. 
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Table 4-3: Percentage of tests with missing data on one or more variable (NCSP 
dataset, 15-24 year-old women and men, 2008-2011) 
 Women Men 
 
N 
(Total=2,564,925) 
% 
missing 
N 
(Total=1,537,178) 
% 
missing 
By variable of interest     
>1 sexual partner in previous 
year 
 
43% 
 
56% 
At least 1 new sexual partner 
in previous 3 months 
 
40% 
 
53% 
Ethnicity  25%  34% 
IMD of LSOA of residence  10%  17% 
Known chlamydia diagnosis in 
previous year 
 
10% 
 
17% 
Specimen type  2%  n/a 
One or more of the above  52%  66% 
By venue type of testing     
Hospital 90,751 51% 15,281 54% 
Outreach 305,175 74% 441,452 78% 
Occupational Health 717 54% 1,298 73% 
Pharmacy 71,300 41% 27,192 47% 
Sexual and Reproductive 
Health Services 767,747 48% 207,617 54% 
General Practice 475,269 47% 157,400 48% 
Remote testing 257,782 29% 151,556 32% 
Military
$ 
5,590 87% 55,242 93% 
Prisons & Youth Offender 
Institutions
$ 
4,758 89% 55,396 96% 
Chlamydia Screening Offices 114,054 50% 87,836 60% 
Abortion services 89,639 57% 884 56% 
Education 297,569 69% 278,137 75% 
Youth 84,574 53% 57,887 61% 
By year of test     
2008 385,483 42% 181,539 58% 
2009 645,276 48% 357,241 61% 
2010 830,172 56% 569,272 68% 
2011 703,994 58% 429,126 69% 
IMD: Index of multiple deprivation, quintile based on lower super output area (LSOA) of 
residence;  *All tests had age, gender and venue of test; 
$
Missing data in these venues is 
largely accounted for by missing postcode of residence, as the validation algorithm for 
postcodes did not allow  postcode of residence was not allowed to equal the postcode of testing 
venue. 
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4.4 Results 
4.4.1 Number of tests and percentage testing positive in the NCSP 
dataset and GUMCAD 
Between 2008 and 2011, 4,102,103 chlamydia testing episodes among 15 to 24 
year-olds (62.5%, [2,564,925] in women) were reported in the NCSP dataset, of 
which 6.5% among women and 5.2% among men resulted in a positive 
diagnosis. Between 2009 and 2011 there were 1,585,395 testing episodes 
(60.5% [958,864] in women) reported in GUMCAD; 11.2% in women and 12.6% 
among men were positive.  
Between 2008 and 2011, the number of NCSP chlamydia testing episodes 
almost doubled, from 567,022 to 1,133,120 (Figure 4-1a, Table 4-4). The 
percentage testing positive during this period decreased among both women 
(from 8.7% to 5.8%, OR per additional year 0.86, 95% confidence interval[CI] 
0.86 to 0.87) and men (from 7.7% to 4.8%, OR 0.84, 95%CI 0.83-0.84).  
The number of GUMCAD chlamydia testing episodes remained relatively stable 
during the analysis period (Figure 4-1b, Table 4-5). The percentage testing 
positive declined from 11.8% in 2009 to 10.8% 2011 among women (OR 0.95, 
95%CI 0.94 to 0.95) and 12.9% to 12.4% among men (OR 0.98, 95%CI 0.97 to 
0.99).  
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Figure 4-1: Numbers of testing episodes and percentage testing positive by 
gender, NCSP dataset and GUMCAD  
a) NCSP Dataset b) GUMCAD 
  
 
4.4.2 Factors associated with testing positive  
All variables were statistically significantly associated with testing positive in 
univariable and multivariable analyses for NCSP (Table 4-4) and GUMCAD 
testing episodes (Table 4-5). Among NCSP testing episodes, there was 
substantial variation in the percentage testing positive by the type of testing 
venue, which remained after adjusting for the other variables in the multivariable 
analysis (Figure 4-2; Table 4-4). Testing episodes in educational venues and 
outreach settings were less likely to result in a positive diagnosis than those in 
general practice, whereas tests in sexual and reproductive health services, 
abortion services, prisons and hospital settings were more likely to be positive.  
In NCSP testing episodes, reporting both a new sexual partner in the past three 
months and more than one sexual partner in the previous year was associated 
with at least a two-fold increase in the odds of testing positive compared with 
those reporting no more than one sexual partner in the last year and no new 
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sexual partner in the last three months (women: AOR 2.24, 95%CI 2.20-2.28; 
men: AOR 2.09, 95%CI 2.03-2.16). In both the NCSP dataset and GUMCAD, 
the odds of testing positive were higher in those with a known chlamydia 
diagnosis than those without in both women (AOR NCSP: 1.13, 95%CI 1.09-
1.18; AOR GUMCAD: 1.04, 95%CI 1.01-1.07) and men (NCSP AOR: 1.27, 
1.17-1.37; GUMCAD AOR: 1.15, 1.10-1.20). 
Being of black or mixed ethnicity and living in more deprived LSOA was 
significantly associated with having higher odds of testing positive after 
controlling for other variables, with the exception of in GUMCAD testing 
episodes among women, where those of black ethnicity had a lower odds pf 
testing positive than those of white ethnicity. MSM had a lower risk of testing 
positive compared to non-MSM in both univariable and multivariable analyses 
(AOR, 0.64 95%CI 0.62-0.67) of GUMCAD testing episodes. 
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Figure 4-2: Adjusted* odds ratio (and 95% confidence intervals) of testing 
positive by venue of test and gender, compared to General Practice (NCSP 
testing episodes, 15-24 year-old women and men) 
 
*Adjusted for age, ethnicity, risk group, IMD quintile of LSOA of residence, known chlamydia 
diagnosis in the previous 12 months and year of test. 
SRH: Sexual and reproductive health services; CSO: chlamydia screening office; YOI: Youth 
offending institution. Outreach: tests performed in non-clinical settings including entertainment 
and leisure venues; Remote testing: tests performed without face to face contact with a health 
professional at the time of test, includes tests performed through the internet. 
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Table 4-4 (a): Number of tests, percentage testing positive, unadjusted and 
adjusted odds ratios for testing positive by sociodemographic, sexual 
behavioural, and test characteristics (NCSP dataset, 15-24 year-old women, 2008-
2011) 
 
Number of 
tests 
% 
positive 
Univariable analysis Multivariable analysis 
OR 95%CI p AOR 95%CI p 
Overall 2,564,925 6.5%         
           
Sociodemographic 
characteristics           
Age (years)               
15 146,897 5.2% Ref    <0.001 Ref   0.000 
16 298,915 5.8% 1.11 1.08 -1.14  1.22 1.17 -1.27  
17 343,314 6.8% 1.32 1.29 -1.36  1.44 1.39 -1.50  
18 341,651 7.5% 1.47 1.43 -1.51  1.58 1.52 -1.64  
19 311,826 7.6% 1.50 1.46 1.54  1.60 1.54 -1.66  
20 278,653 7.2% 1.41 1.38 -1.45  1.51 1.45 -1.57  
21 243,679 6.7% 1.30 1.26 -1.34  1.38 1.33 -1.44  
22 216,592 5.9% 1.13 1.10 -1.16  1.21 1.16 -1.26  
23 199,985 5.0% 0.96 0.93 -0.99  1.03 0.98 -1.07  
24 183,413 4.6% 0.87 0.84 -0.89  0.95 0.91 -1.00  
Ethnic group           
White 1,638,982 6.8% Ref    <0.001 Ref   0.000 
Black 107,978 8.1% 1.22 1.19 -1.25  1.32 1.28 -1.36  
Asian 77,163 3.3% 0.47 0.45 -0.49  0.57 0.54 -0.60  
Chinese 9,401 4.7% 0.68 0.62 -0.75  0.92 0.82 -1.03  
Other 12,486 5.5% 0.80 0.74 -0.86  0.95 0.86 -1.06  
Mixed 70,359 8.6% 1.29 1.26 -1.33  1.28 1.24 -1.32  
Unknown 648,556 5.5%             
Region           
London 385,755 5.7% Ref   0.000 Ref   0.000 
North East 113,668 6.5% 1.15 1.12 - 1.18  1.47 1.41 -1.53  
North West 379,340 7.9% 1.40 1.38 - 1.43  1.35 1.32 -1.39  
Yorkshire & Humber 232,092 7.3% 1.29 1.27 - 1.32  1.36 1.32 -1.40  
East Midlands 203,013 6.2% 1.08 1.06 - 1.11  1.25 1.21 -1.29  
West Midlands 246,320 6.5% 1.14 1.12 - 1.17  1.28 1.24 -1.32  
East of England 229,985 5.6% 0.96 0.94 - 0.99  1.09 1.06 -1.12  
South East Coast 152,567 5.6% 0.97 0.95 - 1.00  1.02 0.98 -1.06  
South Central 169,175 5.7% 1.00 0.97 - 1.02  1.08 1.04 -1.12  
South West 202,890 6.9% 1.21 1.18 - 1.23  1.20 1.16 -1.24  
Other / Unknown 250,120 6.2%         
IMD quintile of 
LSOA of residence
y
           
Least deprived 317,630 5.1% Ref    <0.001 Ref    <0.001 
2 356,775 5.7% 1.13 1.11 -1.15  1.09 1.06 -1.12  
3 428,577 6.0% 1.19 1.17 -1.22  1.17 1.14 -1.20  
4 541,366 6.7% 1.33 1.30 -1.35  1.28 1.25 -1.31  
Most deprived 670,007 7.7% 1.54 1.51 -1.57  1.42 1.39 -1.46  
Unknown 250,570 6.2%             
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Table 4-4(a) continued. 
 
Number of 
tests 
% 
positive 
Univariable analysis Multivariable analysis 
OR 95%CI p AOR 95%CI p 
Sexual behaviour 
characteristics           
>1 sexual partner in 
last year           
No 797,995 5.0% Ref    <0.001       
Yes 670,897 9.4% 1.97 1.95 -2.00        
Unknown 1,096,033 5.7%             
>1 new sexual 
partner in last 3 
months               
No 828,197 5.3% Ref    <0.001       
Yes 721,027 8.9% 1.73 1.71 -1.75        
Unknown 1,015,701 5.6%             
Sexual risk group
x
           
Low 607,446 4.6% Ref   <0.001 Ref   <0.001 
Medium 405,590 7.4% 1.66 1.63 -1.69  1.65 1.62 -1.68  
High  493,167 9.8% 2.28 2.24 -2.31  2.24 2.20 -2.28  
Unknown 1,058,722 5.6%             
Test and clinical 
characteristics           
Venue of test
z
           
GP 475,269 6.1% Ref    <0.001 Ref    <0.001 
Hospital 90,751 6.6% 1.10 1.07 -1.14  1.10 1.06 -1.14  
Outreach 305,175 4.2% 0.69 0.67 -0.70  0.68 0.66 -0.71  
Occupational Health 717 7.8% 1.31 1.00 -1.73  1.26 0.86 -1.83  
Pharmacy 71,300 7.0% 1.18 1.14 -1.21  1.03 0.99 -1.07  
Sexual and 
Reproductive Health 
Services 767,747 8.4% 1.43 1.41 -1.45 
 
1.14 1.11 -1.16 
 
Remote testing 257,782 6.4% 1.06 1.04 -1.08  0.94 0.91 -0.96  
Military 5,590 6.5% 1.08 0.97 -1.20  1.19 0.92 -1.54  
Prisons & Youth 
Offending Institutions 4,758 9.4% 1.60 1.45 -1.77 
 
1.47 1.14 -1.90  
Chlamydia Screening 
Offices 114,054 6.8% 1.13 1.10 -1.16 
 
1.01 0.98 -1.05  
Abortion services 89,639 7.1% 1.18 1.15 -1.22  1.13 1.09 -1.18  
Education 297,569 3.3% 0.53 0.52 -0.55  0.51 0.49 -0.53  
Youth services 84,574 7.9% 1.32 1.29 -1.36  1.03 0.99 -1.07  
Specimen type           
Urine 1,376,209 6.2% Ref   <0.001    <0.001 
Cervical swab 98,527 7.0% 1.13 1.10 -1.16  1.04 1.00 -1.08  
Vulvovaginal swab 1,020,224 6.7% 1.08 1.07 -1.10  1.07 1.05 -1.09  
Other 30,878 7.3% 1.19 1.14 -1.24  1.27 1.19 -1.35  
Unknown 39,087 5.0%         
Known chlamydia 
diagnosis in last 
year      
 
    
No 2,261,502 6.4% Ref    <0.001 Ref    <0.001 
Yes 53,921 9.1% 1.47 1.43 - 1.51  1.13 1.09 -1.18  
Unknown 249,502 6.2%             
Year of test           
2008 385,483 8.7% Ref    <0.001 Ref    <0.001 
2009 645,276 6.8% 0.77 0.76 - 0.78  0.81 0.80 -0.83  
2010 830,172 5.7% 0.64 0.63 - 0.65  0.72 0.71 -0.74  
2011 703,994 5.8% 0.65 0.64 - 0.66  0.72 0.71 -0.74  
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Table 4-4 (b): Number of chlamydia tests, percentage testing positive, 
unadjusted and adjusted odds ratios for testing positive by sociodemographic, 
sexual behavioural, and test characteristics (NCSP dataset, 15-24 year-old men, 
2008-2011) 
 
Number 
of tests 
% 
positive 
Univariable analysis Multivariable analysis 
OR 95%CI p OR 95%CI p 
Overall 1,537,178 5.2%         
           
Sociodemographic 
characteristics               
Age (years)           
15 64,416 1.6% Ref    <0.001  Ref    <0.001 
16 180,426 1.9% 1.23 1.14 -1.32  1.36 1.22 -1.52  
17 211,271 3.4% 2.19 2.05 -2.34  2.30 2.08 -2.55  
18 225,775 4.8% 3.18 2.98 -3.40  3.34 3.02 -3.70  
19 206,138 6.2% 4.10 3.84 -4.37  4.19 3.78 -4.63  
20 179,374 6.7% 4.52 4.24 -4.82  4.53 4.09 -5.01  
21 145,461 7.1% 4.77 4.47 -5.09  4.62 4.17 -5.11  
22 121,871 7.2% 4.85 4.54 -5.18  4.62 4.17 -5.11  
23 107,345 6.7% 4.45 4.16 -4.76  4.16 3.75 -4.61  
24 95,101 6.6% 4.40 4.12 -4.71  4.13 3.72 -4.58  
Ethnic group         
White 834,785 5.7% Ref   <0.001  Ref   <0.001 
Black 66,682 8.8% 1.58 1.54 -1.63  1.69 1.61 -1.76  
Asian 71,650 2.0% 0.33 0.31 -0.35  0.46 0.42 -0.49  
Chinese 3,882 3.0% 0.51 0.42 -0.61  0.65 0.52 -0.81  
Other 8,533 4.1% 0.70 0.63 -0.78  0.74 0.62 -0.88  
Mixed 34,200 7.6% 1.36 1.30 -1.42  1.33 1.26 -1.41  
Unknown 517,446 4.2%           
Region         
London 246,329 4.1% Ref  <0.001   <0.001 
North East 97,200 4.7% 1.13 1.09 -1.18  1.93 1.83 -2.05  
North West 160,533 7.2% 1.81 1.76 -1.86  1.68 1.61 -1.75  
Yorkshire & Humber 131,424 6.8% 1.70 1.65 -1.75  1.88 1.79 -1.97  
East Midlands 125,824 4.5% 1.09 1.05 -1.12  1.48 1.40 -1.56  
West Midlands 161,981 4.5% 1.11 1.07 -1.14  1.49 1.42 -1.56  
East of England 120,757 4.6% 1.13 1.09 -1.17  1.32 1.26 -1.39  
South East Coast 63,808 4.7% 1.14 1.09 -1.19  1.33 1.25 -1.41  
South Central 77,906 4.9% 1.18 1.14 -1.23  1.32 1.25 -1.40  
South West 85,516 6.7% 1.66 1.60 -1.72  1.58 1.51 -1.66  
Other / Unknown 265,900 5.1%       
IMD quintile of 
LSOA of residence
y
         
Least deprived 182,535 4.1% Ref   <0.001 Ref   <0.001 
2 195,929 4.7% 1.13 1.10 -1.17  1.10 1.05 -1.14  
3 234,047 4.8% 1.17 1.14 -1.21  1.14 1.09 -1.18  
4 293,142 5.3% 1.30 1.27 -1.34  1.21 1.16 -1.26  
Most deprived 365,386 6.2% 1.52 1.48 -1.56  1.31 1.26 -1.36  
Unknown 266,139 5.1%           
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Table 4-4(b) continued. 
 
Number 
of tests 
% 
positive 
Univariable analysis Multivariable analysis 
OR 95%CI p OR 95%CI p 
Sexual behaviour 
characteristics         
>1 sexual partner in 
last year         
No 283,042 3.9% Ref   <0.001     
Yes 397,964 8.3% 2.24 2.19 -2.29      
Unknown 856,172 4.2%          
>1 new sexual 
partner in last 3 
months            
No 307,386 4.7% Ref   <0.001     
Yes 411,533 7.7% 1.71 1.68 -1.75      
Unknown 818,259 4.1%          
Sexual risk group
x
         
Low 205,729 3.6% Ref  <0.001 Ref  <0.001 
Medium 186,169 6.3% 1.79 1.74 -1.84  1.71 1.65 -1.77  
High  311,664 8.5% 2.48 2.41 -2.54  2.09 2.03 -2.16  
Unknown 833,616 4.1%           
Test and clinical 
characteristics         
Venue of test
z
         
GP 157,400 6.2% Ref   <0.001  Ref   <0.001 
Hospital 15,281 9.1% 1.51 1.42 -1.60  1.44 1.33 -1.55  
Outreach 441,452 2.7% 0.42 0.41 -0.43  0.46 0.44 -0.48  
Occupational Health 1,298 4.2% 0.65 0.50 -0.86  0.47 0.27 -0.80  
Pharmacy 27,192 8.1% 1.33 1.27 -1.40  1.33 1.25 -1.42  
Sexual and 
Reproductive Health 
Services 207,617 11.1% 1.88 1.83 -1.92 
 
1.57 1.52 -1.63 
 
Remote testing 151,556 6.5% 1.05 1.02 -1.08  0.86 0.83 -0.89  
Military 55,242 5.3% 0.84 0.81 -0.88  0.92 0.82 -1.03  
Prisons & Youth 
Offending Institutions 55,396 7.8% 1.27 1.22 -1.32 
 
1.33 1.15 -1.53 
 
Chlamydia Screening 
Offices 87,836 7.2% 1.17 1.13 -1.21 
 
1.16 1.11 -1.22 
 
Abortion services 884 10.3% 1.73 1.39 -2.15  2.01 1.48 -2.71  
Education 278,137 1.7% 0.26 0.25 -0.27  0.34 0.32 -0.36  
Youth services 57,887 5.8% 0.92 0.89 -0.96  1.04 0.98 -1.11  
Known chlamydia 
diagnosis in last 
year         
No 1,259,011 5.2% Ref   <0.001  Ref   <0.001 
Yes 12,601 11.2% 2.33 2.20 2.46  1.27 1.17 -1.37  
Unknown 265,566 5.1%           
Year of test         
2008 181,539 7.7% Ref   <0.001  Ref   <0.001 
2009 357,241 5.8% 0.73 0.71 -0.75  0.76 0.74 -0.79  
2010 569,272 4.3% 0.54 0.53 -0.55  0.68 0.65 -0.70  
2011 429,126 4.8% 0.60 0.59 -0.62  0.72 0.69 -0.74  
OR: Odds ratio; AOR: Adjusted odds ratio; 
x
Sexual risk group: High: more than 1 sexual partner 
in the last year and at least one new sexual partner in the last 3 months; Medium: either more 
than 1 sexual partner in the last year or at least one new sexual partner in the last 3 months; 
Low: neither more than 1 sexual partner in the last year nor at least one new sexual partner in 
the last 3 months; 
y
 IMD: Index of multiple deprivation, quintile based on lower super output area 
(LSOA) of residence;  Outreach: tests performed in non-clinical settings including entertainment 
and leisure venues. Remote testing: tests performed without face to face contact with a health 
professional at the time of test, includes tests performed through the internet. 
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Table 4-5 (a): Number of tests, percentage testing positive, univariable and 
multivariable logistic regression results by reported characteristics (GUMCAD, 
women aged 15-24, 2008 to 2011) 
 Total (n) 
% 
positive 
Univariable analysis Multivariable analysis 
OR 95%CI p OR 95%CI p 
Overall 958,864 11.2%         
           
Age (years)           
15 17,866 13.4% Ref    <0.001  Ref    <0.001 
16 40,984 15.2% 1.15 1.10 -1.21  1.17 1.11 -1.24  
17 70,783 14.6% 1.10 1.05 -1.15  1.13 1.07 -1.19  
18 100,665 14.5% 1.09 1.04 -1.15  1.14 1.08 -1.19  
19 124,957 13.2% 0.98 0.93 -1.02  1.02 0.97 -1.07  
20 133,549 11.5% 0.84 0.80 -0.88  0.87 0.83 -0.91  
21 131,255 10.4% 0.75 0.72 -0.79  0.78 0.74 -0.82  
22 122,945 9.2% 0.65 0.62 -0.68  0.69 0.66 -0.73  
23 113,470 8.2% 0.58 0.55 -0.61  0.62 0.58 -0.65  
24 102,390 7.4% 0.52 0.49 -0.54  0.55 0.52 -0.58  
Ethnicity           
White 725,062 11.6% Ref     <0.001 Ref     <0.001 
Mixed 41,600 11.8% 1.02 0.99 -1.06  1.03 1.00 -1.06  
Asian 21,256 7.5% 0.62 0.59 -0.66  0.70 0.66 -0.73  
Black 85,950 10.1% 0.86 0.84 -0.88  0.92 0.90 -0.95  
Other 16,636 9.4% 0.80 0.76 -0.84  0.91 0.86 -0.96  
Unknown 68,360 9.8%             
Region      <0.001    <0.001 
London 217,730 9.2% 1.58 1.54 -1.63  1.47 1.42 -1.52  
North East 51,094 13.7% 1.57 1.53 -1.60  1.50 1.46 -1.54  
North West 109,266 13.6% 1.53 1.49 -1.57  1.43 1.39 -1.47  
Yorkshire & Humber 85,812 13.3% 1.59 1.55 -1.63  1.56 1.51 -1.61  
East Midlands 61,558 13.8% 1.34 1.31 -1.37  1.31 1.28 -1.35  
West Midlands 91,282 11.9% 1.20 1.17 -1.23  1.28 1.24 -1.32  
East of England 81,575 10.8% 1.05 1.02 -1.08  1.10 1.07 -1.13  
South East Coast 74,954 9.6% 1.00 0.97 -1.03  1.05 1.02 -1.08  
South Central 79,494 9.1% 1.16 1.13 -1.19  1.20 1.16 -1.24  
South West 81,707 10.4% 1.58 1.54 -1.63  1.47 1.42 -1.52  
Unknown 24,392 11.7%         
IMD quintile of 
LSOA of residence
x
           
Least deprived 130,793 9.6% Ref     <0.001 Ref      <0.001 
2 142,850 10.2% 1.07 1.04 -1.10  1.05 1.03 -1.08  
3 172,915 10.6% 1.12 1.09 -1.15  1.15 1.12 -1.18  
4 211,293 11.4% 1.22 1.19 -1.25  1.26 1.23 -1.30  
Most deprived 235,443 12.8% 1.39 1.36 -1.42  1.42 1.38 -1.45  
Unknown 65,570 11.6%               
Known chlamydia 
diagnosis in last 
year           
No 921,201 11.2% Ref    <0.001 Ref    <0.001 
Yes 37,663 12.2% 1.11 1.07 -1.14  1.04 1.01 -1.07  
Year           
2009  317,081 11.8% Ref      <0.001 Ref      <0.001 
2010 309,295 11.0% 0.92 0.91 -0.94  0.93 0.91 -0.95  
2011 332,488 10.8% 0.90 0.88 -0.91  0.91 0.89 -0.92  
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Table 4-5(b): Number of tests, percentage testing positive, univariable and 
multivariable logistic regression results by reported test characteristics 
(GUMCAD, men aged 15-24, 2008 to 2011)  
 Total (n) 
% 
positive 
Univariable analysis Multivariable analysis 
OR 95%CI p OR 95%CI p 
Overall 626,531 11.2%         
           
Age (years)           
15 3,777 8.0% Ref   <0.001 Ref   <0.001       
16 11,819 10.9% 1.40 1.22 -1.59  1.48 1.28 -1.70  
17 26,134 12.7% 1.67 1.47 -1.89  1.73 1.52 -1.98  
18 48,424 13.9% 1.85 1.64 -2.09  1.91 1.68 -2.18  
19 72,174 13.8% 1.83 1.63 -2.07  1.93 1.69 -2.20  
20 88,315 13.6% 1.80 1.60 -2.03  1.89 1.66 -2.15  
21 95,575 13.3% 1.75 1.56 -1.98  1.83 1.61 -2.08  
22 96,274 12.4% 1.63 1.45 -1.84  1.74 1.53 -1.98  
23 93,941 11.4% 1.48 1.31 -1.66  1.58 1.39 -1.80  
24 90,098 10.7% 1.38 1.22 -1.55  1.48 1.30 -1.69  
Ethnicity           
White 466,201 12.4% Ref   <0.001 Ref   <0.001 
Mixed 24,701 14.5% 1.20 1.16 -1.25  1.24 1.19 -1.29  
Asian 20,587 6.9% 0.53 0.50 -0.56  0.55 0.52 -0.58  
Black 57,530 16.3% 1.38 1.34 -1.41  1.46 1.42 -1.50  
Other 10,080 10.2% 0.81 0.76 -0.86  0.88 0.82 -0.95  
Unknown 47,432  11.8%         
Region           
London 128,002 10.9% Ref    Ref   <0.001 
North East 35,713 15.1% 1.46 1.41 -1.51  1.59 1.54 -1.66  
North West 78,871 13.9% 1.33 1.29 -1.36  1.45 1.41 -1.50  
Yorkshire & Humber 60,094 14.0% 1.34 1.30 -1.38  1.47 1.42 -1.52  
East Midlands 43,295 14.5% 1.40 1.35 -1.44  1.57 1.51 -1.62  
West Midlands 59,142 13.2% 1.25 1.21 -1.28  1.38 1.33 -1.43  
East of England 53,295 12.0% 1.12 1.09 -1.16  1.33 1.28 -1.38  
South East Coast 46,545 11.2% 1.03 1.00 -1.07  1.29 1.24 -1.34  
South Central 49,477 10.7% 0.99 0.95 -1.02  1.17 1.13 -1.21  
South West 51,526 12.2% 1.15 1.11 -1.18  1.33 1.28 -1.38  
Unknown 20,571 12.9%         
IMD quintile of LSOA 
of residence
x
           
5 (Least deprived) 87,870 10.6% Ref   <0.001 Ref   <0.001 
4 94,222 11.6% 1.10 1.07 -1.14  1.10 1.06 -1.13  
3 110,858 12.1% 1.16 1.13 -1.20  1.17 1.14 -1.21  
2 131,768 13.1% 1.27 1.24 -1.30  1.30 1.26 -1.33  
1 (Most deprived) 154,169 14.2% 1.40 1.36 -1.43  1.38 1.34 -1.42  
Unknown 47,644 12.4%         
Ever MSM
y
           
No 577,650 12.9% Ref   <0.001 Ref   <0.001 
Yes 48,881 8.4% 0.62 0.60 -0.64  0.64 0.62 -0.67  
Known chlamydia 
diagnosis in last year          
No 606,099 12.5% Ref   <0.001 Ref   <0.001 
Yes 20,432 15.1% 1.25 1.20 -1.30  1.15 1.10 -1.20  
Year            
2009 213,012 12.9% Ref   <0.001 Ref   <0.001 
2010 203,076 12.3% 0.95 0.93 -0.97  0.96 0.94 -0.98  
2011 210,443 12.4% 0.96 0.94 -0.98  0.97 0.95 -0.99  
x
IMD: Index of multiple deprivation, quintile based on lower super output area (LSOA) of 
residence; 
y
Ever MSM: Any record in GUMCAD where reports having sex with a man.  
OR: Odds ratio; AOR: Adjusted odds ratio. 
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4.4.3 Trends in test, demographic and sexual behaviour characteristics 
Among NCSP testing episodes, demographic and sexual behaviour variables 
remained relatively stable during the analysis period, although between 2010 
and 2011 there was a small increase seen in the proportion where the individual 
tested reported having at least one new sexual partner in the last year and in 
the proportion of tests among those of non-white ethnicity (Figure 4-3). In both 
women and men there was a small increase between 2010 and 2011 in the 
percentage with a known previous diagnosis in the last year, increasing from 
2.4% to 2.7% in women and from 0.9% to 1.2% in men.  
The distribution of testing venue types within the NCSP dataset changed 
considerably over the analysis period (Figure 4-4). Among women, the 
percentage of tests which were from sexual and reproductive health services 
declined from 41% in 2008 to 29% in 2011, while the percentage from GP 
settings increased from 16% in 2008 to 20% in 2011. Among men, the 
percentage of tests reported through outreach settings (including testing in non-
clinical venues such as bars and pubs, music festivals and other one off 
events), increased substantially between 2008 and 2010, from 18% to 35%, and 
then fell to 29% in 2011. The percentage of tests that were from sexual and 
reproductive health services decreased from 20% in 2008 to 14% in 2011.  
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Figure 4-3: Trends in reported characteristics (NCSP dataset, 15-24 year-old 
women and men, 2008-2011) 
a) Women b) Men 
  
 
*Proportions reported among tests with complete data on each variable; High risk group: 
reported more than 1 sexual partner in the previous year and at least one new sexual partner in 
the previous 3 months; SP: sexual partner; Resident in most deprived area: resident in one of 
the 20% most deprived LSOAs in England, as defined by the Index of Multiple Deprivation 
(IMD); Ct: Chlamydia.  
 
Figure 4-4: Percentage of NCSP tests carried out in different testing venue types 
(15 to 24 year-old women and men, 2008 to 2011) 
a) Women b) Men 
 
 
 
*Other: Hospital, occupational health, pharmacy, military, prisons & youth offenders institutions 
and abortion services (abortion services included in ‘other’ category in men only); CSO: 
Chlamydia Screening Office; SRH: Sexual and Reproductive Health services 
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There was no change during the analysis period in the proportion of GUMCAD 
testing episodes that were in people of non-white ethnicity, nor in that among 
those living in the most deprived areas (Figure 4-5). A slight decline in the 
percentage of testing episodes from 15 to 19 year-olds was observed among 
both women and men (39% to 36% among women; 27% to 25% among men). 
The percentage of testing episodes among men that were in MSM increased 
from 7% to 9%. In both women and men there was a small decrease between 
2010 and 2011 in the percentage with a known previous diagnosis in the last 
year, decreasing from 4.8% to 4.6% in women and from 4.0% to 3.8% in men.  
Figure 4-5: Trends in reported characteristics, GUMCAD (15 to 24 year-old 
women and men, 2009 to 2011) 
Women Men 
  
 
*Proportions reported among tests with complete data on each variable; Resident in most 
deprived area: resident in one of the 20% most deprived LSOAs in England, as defined by the 
Index of Multiple Deprivation (IMD); Ct: Chlamydia; MSM: Men who have sex with men. 
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4.4.4 Trends in percentage testing positive by subgroup 
Among NCSP testing episodes, the percentage testing positive declined during 
the analysis period across all subgroups defined by age group, sexual risk 
group and venue of testing (Figure 4-6).  In several subgroups among men, 
increases in the percentage testing positive were observed between 2010 and 
2011.  
Among GUMCAD testing episodes, between 2009 and 2011 the percentage 
testing positive declined among both 15 to 19 year-old and 20 to 24 year-old 
women (Figure 4-7).  Among men, the percentage testing positive declined 
among 20 to 24 year-olds, but there was no change among 15 to 19 year-olds. 
In contrast to other subgroups, the percentage testing positive among MSM in 
GUMCAD increased from 7.9% in 2009 to 9.0% in 2011 (OR 1.08 95%CI 1.03 
to 1.12). A declining trend in percentage testing positive was observed in all the 
symptomatic condition subgroups (i.e. in attendances where a diagnosis of 
genital warts, bacterial vaginosis, candidosis or genital herpes was made). 
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Figure 4-6: Percentage testing positive by year and gender, stratified by age 
group (a), sexual risk group (b), and venue of test (c) (NCSP dataset, 15 to 24 
yea-old women and men, 2008 to 2011) 
Women Men 
a) By age group  
  
 
b) By sexual risk groupx  
  
 
c) By venue type of testingy  
  
 
x
Sexual risk group: High: more than 1 sexual partner in the last year and at least one new 
sexual partner in the last 3 months; Medium: either more than 1 sexual partner in the last year 
or at least one new sexual partner in the last 3 months; Low: neither more than 1 sexual partner 
in the last year nor at least one new sexual partner in the last 3 month; 
y
SRH: Sexual and 
reproductive health services;  Outreach: tests performed in non-clinical settings including 
entertainment and leisure venues; Remote testing: tests performed without face to face contact 
with a health professional at the time of test, includes tests performed through the internet. 
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Figure 4-7: Percentage testing positive by year and gender, stratified by age 
group. (GUMCAD, 15 to 24 year-olds) 
Women Men 
a) By age group  
  
 
 b) By sexual orientation 
 
 
 
 
 
c) By symptomatic conditionx  
  
 
x
Among attendances where a chlamydia test and one of the specified symptomatic conditions 
were recorded on the same date. For genital warts and genital herpes, data are presented for 
first episodes (as recurrences are possible). 
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4.4.5 Trends by calendar quarter 
Quarterly trends in the percentage testing positive varied by dataset and venue 
type (Figure 4-8). In 2009 to 2011, there was a peak in numbers of testing 
episodes reported through the NCSP dataset between January and March of 
each year, which corresponded to a simultaneous drop in the percentage 
testing positive. This was also accompanied by a nadir in the proportion of tests 
coming from women in the ‘high risk’ sexual behaviour category (Figure 4-9). 
Among women, this seasonality in patterns of testing and of percentage testing 
positive was evident for tests in education settings, but was not seen in testing 
performed in sexual and reproductive health services or GP settings or in tests 
reported through GUMCAD. 
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Figure 4-8: Numbers of tests and percentage testing positive by calendar 
quarter, dataset and location of testing (15-24 year-old women and men) 
 WOMEN MEN  
 a) All NCSP tests   
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b) NCSP tests: Sexual and Reproductive Health services  
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 c) NCSP tests: General Practice 
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d) NCSP tests: Education venues 
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e) All GUMCAD tests 
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Figure 4-9: Trends in reported characteristics by calendar quarter, NCSP dataset 
(15 to 24 year-old women and men, 2008 to 2011) 
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4.4.6 Assessing the selection effects introduced by changes in risk 
factor variables over time 
Figure 4-10 and Figure 4-11 show the estimated annual change in the 
percentage testing positive among NCSP and GUMCAD testing episodes 
before adjusting for other variables (unadjusted), after adjusting for one 
additional variable at a time (age, ethnicity, region, deprivation, sexual risk 
group, known chlamydia diagnosis in the last year, testing venue type and, for 
women, specimen type; the bivariable models) and after adjusting for all 
variables (multivariable analyses).  
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Figure 4-10: Unadjusted and adjusted odds ratios (and 95%CI) of testing positive 
per additional year, estimated from univariable, bivariable and multivariable 
models (NCSP tests, 15 to 24 year-olds 2008 to 2011)* 
Open diamonds show the unadjusted odds ratio (OR) of testing positive per year, without adjusting for any 
other variables; closed diamonds show the adjusted OR  of testing positive per year after including the 
stated risk factor variable of interest in the logistic regression model, either one additional variable at a 
time (bivariable analysis) or with all variables included (multivariable analysis). The dashed line shows the 
unadjusted OR.  
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Analyses are limited to tests with complete data on all variables included in the multivariable analysis. IMD: Index of 
Multiple Deprivation; Risk group: High: more than 1 sexual partner (SP) in the previous year and at least one new SP in 
the previous 3 months; Medium: either more than 1 SP in the previous year or at least one new SP in the previous 3 
months; Low: neither more than 1 SP in the previous year nor at least one new SP in the previous 3 months. 
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Among NCSP testing episodes, unadjusted and adjusted ORs of testing 
positive were less than 1. Thus between 2008 and 2011, there was a reduction 
in the percentage testing positive, even after adjusting for all available 
demographic and behaviour variables (Figure 4-10). 
In the bivariable models, adjusting for venue type had the largest and only 
notable effect on the estimated trend in percentage testing positive. Among 
women, a 14% annual decline was observed before adjustment (OR 0.86, 
95%CI 0.86-0.87), compared to an 11% annual decline after adjusting for venue 
type of test (AOR 0.89, 95%CI 0.88-0.89). Among men, a 16% annual decline 
was observed in the unadjusted analysis, compared to a 12% decline after 
adjustment for venue testing type (unadjusted OR 0.84, 95%CI 0.83-0.84; AOR 
0.88, 95%CI 0.83-0.84).  
In the multivariable models, (adjusting for age, ethnicity, sexual risk group, IMD 
quintile of LSOA, having a known chlamydia diagnosis in the past year, testing 
venue type and specimen type [women only]), among women, there was a 12% 
annual decline before adjustment, and an 11% annual decline after adjustment 
(unadjusted OR 0.88, 95%CI 0.88-0.89; AOR 0.89, 95%CI 0.88-0.90).  Among 
men there was a 12% annual decline before controlling for the other variables, 
and a 10% annual decline after adjustment (unadjusted OR 0.88, 95%CI 0.87-
0.89; AOR 0.90, 95%CI 0.89-0.91). 
Sensitivity analyses using those NCSP testing episodes with complete data on 
each variable showed similar patterns, whereby adjusting for venue type of test 
was the most important variable, and changes in other variables led to little 
difference between unadjusted and adjusted ORs (data not shown).   
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Among tests reported to GUMCAD, all unadjusted and adjusted ORs were less 
than 1 among women and men, indicating a decline in the percentage testing 
positive during the analysis period (2009 to 2011). All ORs of testing positive 
among MSM were >1, indicating an increase in the percentage testing positive 
per year (Figure 4-11 (a-b)). Adjustment made a negligible difference to the 
measured trend in positivity among GUMCAD testing episodes in any of the 
bivariable or multivariable analyses (Figure 4-11 (c)). 
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Figure 4-11: Unadjusted and adjusted odds ratios (and 95%CI) of testing positive 
per additional year, estimated from univariable, bivariable and multivariable 
models (GUMCAD tests, 15 to 24 year-olds 2009 to 2011) 
Open diamonds show the unadjusted odds ratio (OR) of testing positive per year, without adjusting for any 
other variables; closed diamonds show the adjusted OR  of testing positive per year after including the 
stated risk factor variable of interest in the logistic regression model, either one additional variable at a 
time (bivariable analysis) or with all variables included (multivariable analysis). The dashed line shows the 
unadjusted OR. 
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Figure 4-11continued 
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*Analyses are limited to tests with complete data on all variables included in the multivariable 
analysis.  
 
4.5 Discussion 
4.5.1 Key findings 
The number of 15 to 24 year-olds who tested for chlamydia increased between 
2008 and 2011, while the percentage testing positive decreased. There was 
considerable variation over time in the relative contributions made by different 
testing venue types. Among those tested, people reporting more sexual 
partners and those reporting a previous chlamydia diagnosis were more likely to 
test positive, as were those living in more deprived areas.  
Testing venue type was an important confounder in the relationship between 
test result and year among the tests reported to the NCSP. In men tested 
through the NCSP, there was evidence of confounding of the relationship 
between year and test result arising from differences in the distribution of age 
1.00 1.10 1.15 1.05 
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and ethnicity in each year. In women and in men tested in GUM clinics, there 
was no evidence of confounding arising from changes in other demographic or 
sexual behaviour variables for which data are available among those who 
tested as part of the NCSP or in GUM clinics, suggesting that these variables 
did not change sufficiently over time to introduce substantial error.  
4.5.2 Strengths and limitations 
The main strength of this analysis is that it used two large datasets with national 
coverage and individual-level data that allowed investigation of the relationship 
between testing positive for chlamydia and trends in percentage testing positive 
and the characteristics of those tested. However it should be noted that the size 
of the datasets means that even small differences would likely be statistically 
significant, thus the size and direction of the associations should be considered 
when determining public health significance.  
The analysis was limited by the completeness of data reporting. A large 
proportion of NCSP tests had missing data on one or more variable of interest 
and the primary analysis looking at the impact of changes in the population 
tested on trends in percentage testing positive had to be limited to tests with 
complete data. However, sensitivity analysis showed that the same patterns 
were seen among tests with complete data on each variable as when the limited 
dataset was used. The analysis was also limited as individuals could not be 
linked between datasets, meaning that the number with a previous known 
diagnosis is likely to be underestimated. It was interesting to note that the 
percentage of women and men with a known diagnosis in the last year 
increased in the NCSP dataset but decreased in GUMCAD between 2010 and 
2011. While re-infections have a potentially important part to play in the 
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transmission, these divergent trends likely reflect changing patterns of service 
use with under 25 year-olds increasingly accessing testing outside of GUM 
services.  
As described in Chapter 3, previous studies in the US, Scotland and the 
Netherlands have shown that trends in percentage testing positive for 
chlamydia among sentinel and clinic populations can be particularly affected by 
changes in test technology.203-205,223 This is unlikely to have been influential in 
this analysis, as NAATs were universally in use during the analysis period128. It 
is feasible however that differences in the exact test used may have had a 
minor effect on the data which has not been accounted for in this analysis.  
4.5.3 Implications for evaluation of chlamydia control 
Changes in the distribution of venue testing types can explain some, but not all, 
of the observed decline in percentage testing positive for chlamydia among 15 
to 24 year-olds tested within the NCSP between 2008 and 2011. Thus this  
analysis of surveillance data up to 2011 provide some support for there having 
been a decrease in chlamydia infection over this period. However, this analysis 
also demonstrates that trends in the percentage testing positive in England are 
subject to measured and, potentially, unmeasured confounding. Specifically, 
venue type remained significantly associated with testing positive even after 
adjusting for all other available demographic and sexual behaviour variables. 
This demonstrates that the available data were not able to fully capture risk of 
testing positive for chlamydia. Thus, even after adjusting for sexual behaviour, 
trends in percentage testing positive will still be subject to unmeasured 
confounding and cannot be reliably attributed to there having been a change in 
the incidence or prevalence of infection. Stratifying analyses by venue of test 
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will reduce some of this potential error, but it is not possible with the available 
data to know whether this will fully eliminate the potential for confounding of 
trend estimates.  
This raises the question as to what other data would be needed to improve the 
utility of surveillance data for monitoring the impact of chlamydia control 
programmes.  
Firstly, more detailed sociodemographic and sexual behaviour variables may be 
useful. Only limited data were included in each dataset meaning it is possible 
that there were changes in the risk profile of those tested that were not 
captured. In the NCSP dataset, number of partners was recorded as a binary 
variable (<1 / >2). Thus people with 2 partners in the last year could not be 
distinguished from those with many more sexual partners in the last year, even 
though their risk of infection would be very different.133 A greater level of detail 
about sexual risk would be useful to allow adjustment for differences in 
characteristics of the population tested, which arise from changes in service use 
patterns or from underlying changes in sexual behaviour.  
Secondly, data were not available on whether tests had been carried out as a 
result of partner notification. More recently-available data suggest that around 
35% of people who attend GUM clinics as a result of partner notification (i.e. 
informed of having an infected partner) test positive for chlamydia.224 Thus 
changes in partner notification rates over this period could also have had an 
effect on trends in percentage testing positive. Since 2012, GUMCAD has 
included a variable on whether tests were carried out as a result of partner 
notification. This variable should be incorporated into any future analyses of 
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trends in percentage testing positive using GUMCAD data. Data on numbers of 
partners tested were collected for tests performed through the NCSP up to 
2012. However, these data were collected in a separate, aggregate dataset and 
as such could not be linked to data on tests and diagnoses. The data were also 
subject to considerable data quality issues and under-reporting (personal 
communication Alireza Talebi) and as such have not been reported in this 
chapter and were not incorporated into this analysis. 
It was not possible to measure uptake of testing (i.e. number tested / number 
attending) among those attending all venues. This would have been possible 
with data from GUM clinics as a clinic-attending denominator is available. 
However as the offer and uptake of a chlamydia test is less likely to vary in 
GUM settings this was not investigated in this analysis. Developments in the 
GUMCADv2 surveillance system, whereby comparable information to that 
collected in GUM clinics is now being collected for other commissioned non-
GUM sexual health services, mean that a measure of uptake of testing within 
sexual and reproductive health services and some GP clinics will be available in 
coming years. The extent to which percentage testing positive varies with test 
uptake within a setting would be useful to explore in future analyses. 
4.5.4 Summary 
In summary, given the potential for residual unmeasured confounding, the 
observed decreases in percentage testing positive in the NCSP dataset or 
GUMCAD do not provide strong evidence of there having been a decrease in 
chlamydia incidence or prevalence between 2008 and 2011, in years with 
relatively high levels of screening among under 25 year-olds. While useful to 
identify volumes of testing and diagnoses and factors associated with being 
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infected at the time of testing, these surveillance data alone do not provide 
sufficiently reliable measures of chlamydia infection over time for the purposes 
of evaluating chlamydia screening. More robust outcome measures are needed 
to evaluate the impact of chlamydia screening. In the next three chapters, I turn 
to measures of chlamydia prevalence among general population samples. 
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5 Pilot of a postal survey designed to measure the 
population prevalence of chlamydia among young 
women  
In the previous chapter I investigated the use of surveillance data for monitoring 
trends in percentage testing positive for chlamydia. I showed that such data alone 
are unsuitable for evaluating the impact of chlamydia screening, in part due to the 
potential for unmeasured confounding arising from changing patterns of service use 
over time that could not be adjusted for using the available data. One option to 
address this issue is to establish repeated cross-sectional surveys among young 
adults, as the population targeted by the NCSP. In this chapter I present a pilot study 
which I carried out to investigate the feasibility of a repeated postal survey of 
chlamydia prevalence with anonymous testing for chlamydia in England. The pilot 
was conducted between June and August 2011 in two primary care trusts (PCTs) in 
England and was carried out in conjunction with the Health Protection Agency 
(HPA)14.  
5.1 Aims & objectives 
The aim of the study presented in this chapter was to determine whether repeat 
cross-sectional surveys using postal invitations and anonymous testing (i.e. 
without return of test result) could be a feasible method of population-based 
chlamydia prevalence monitoring in England. This aim was addressed through 
the following objectives: 
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 Part of Public Health England since 2013. 
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 To design and pilot a cross-sectional survey of chlamydia prevalence using 
postal invitations and anonymous testing in two primary care trusts (PCTs) 
in England. 
 To compare participation rates using different invitation approaches (+/- 
provision of a test kit; +/- offer of small financial incentive). 
 To investigate selection bias and costs associated with the different 
approaches. 
5.2 Methods 
5.2.1 Participants 
Women aged 17 or 18 and resident in two PCTs (NHS Northamptonshire and 
NHS Sutton & Merton) were eligible for inclusion in the study.  
This age group was selected for a number of reasons. Firstly, a high proportion 
of this age group would be expected to be sexually active133 and thus be an 
appropriate target group for monitoring changes in prevalence. Secondly, the 
proportion of young adults living with their parents declines steeply with age 
over 16 years225 meaning the reliability of address data reduces with age. 
Thirdly, chlamydia prevalence was expected to be relatively high among this 
age group,123 thus providing a good opportunity to detect small changes in 
prevalence over time that might be expected from mathematical models81. 
However, only 18 year-old women were included in NHS Northamptonshire in 
order to comply with local guidance about research involving children (see 
section 5.2.4).  
The sample was limited to women as levels of chlamydia screening are higher 
in women than men.226,227 Any direct impact of screening on prevalence is 
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therefore likely to be greater in women. Furthermore, the most serious 
complications of chlamydia such as PID, ectopic pregnancy and infertility, occur 
in women, making monitoring of prevalence in women arguable more important. 
Trends in chlamydia prevalence in women should be indicative of changes in 
prevalence among heterosexual men.  
The two pilot sites were chosen for pragmatic purposes, to include one site in 
London and one outside of London and to include areas with different levels of 
screening activity. Table 5-1 shows the estimated proportion of 15-24 year-olds 
tested, the diagnosis rate (diagnoses per 100,000 population) and percentage 
testing positive in the two participating PCTs compared to England. 
 
Table 5-1: Opportunistic screening uptake, diagnosis rates and PCT 
characteristics in the participating PCTs, 2011/12228 
 Northamptonshire 
Sutton & 
Merton 
England 
Estimated coverage (number of tests per 100 
population of 15-24 year-olds) 
34% 24% 29% 
Rank (1=PCT with highest coverage) 35/151 108/151 N/A 
Diagnosis rate (diagnoses per 100,000 
population of 15-24 year-olds) 
2,457 2,008 2,090 
Rank (1=PCT with highest diagnosis rate) 38/151 85/151 N/A 
Percentage testing positive 7.2% 8.3% 7.3% 
Classification Rural Urban N/A 
*Urban: PCTs with 50 percent of their population in one of the 17 urban areas with a population 
of at least 250,000; *Rural:  PCTs with more than 26 percent of their population in rural 
settlements and larger market towns.  
 
Eligible individuals were identified using lists of people registered with a GP in 
the two participating PCTs. A total of 3,857 women in NHS Sutton & Merton and 
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3,687 women in Northamptonshire were eligible.15 The study aimed to establish 
a sampling frame that could be used to send postal invitation to a random 
sample representative of the general population of young women in England. 
The sampling frame therefore needed to have current address information for 
named individuals, of known age. As discussed in section 3.2.2.2, GP lists are 
known to be limited by potential inaccuracies. However GP lists were chosen as 
the most comprehensive source of this information in England that was 
available for use, and as sampling via household lists was considered too 
resource intensive.  
5.2.2 Study procedures 
As described in the Chapter 3, response rate would likely be a key issue in 
determining feasibility and bias of any survey estimates. Participants in the pilot 
were therefore allocated into three different groups to allow comparison of 
response rates using different recruitment approaches (Table 5-2). All of the 
selected women were sent an invitation letter by post. Group A were sent a test 
kit with their invitation. The test kit included: an invitation letter; a cover letter 
from the participating PCT; a study information leaflet; a short questionnaire 
including questions on sexual behaviour; a vulvovaginal swab (VVS); an 
instruction leaflet on how to use the swab and return the sample and a pre-paid 
return envelope. Group B were sent a test kit and also offered a £5 voucher for 
high-street shops on return of sample. Group C were not sent a test kit but 
instead were invited to contact the study team by text message, email or return 
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 In order to comply with regulatory approvals (section 5.2.4), invitations were sent out by staff 
at the participating PCTS; none of the study personnel at the HPA had access to name or 
address information of those invited. 
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of postcard to request a kit. A reminder letter was sent to non-responders three 
weeks after the initial invitation. Individuals who did not wish to participate in the 
survey were asked to complete and return a pre-paid postcard to the research 
team, indicating the reason they did not want to participate.  
Table 5-2: Invitations sent by randomisation group 
 Minimum number of 
invitations required* 
Number of 
invitations sent 
per PCT 
Number of 
invitations sent in 
total 
Group A: Kit 968 500 1,000 
Group B: Kit + voucher 484 250 500 
Group C:  No kit 484 250 500 
*Sufficient to estimate the difference in response rate of 5 percentage points with 95% 
confidence. Randomised in a ratio of 1:2 (B:A and C:A).  
 
The study questionnaire was designed to include questions that matched those 
in the Natsal-2 as closely as possible, to allow comparisons between the 
surveys (see Appendix 1). In order to maximise the acceptability of the study 
invitations, feedback was obtained on draft versions of the study paperwork 
(invitation letter and patient information leaflet) using two focus groups among a 
total of 17 women aged 16 to 18 years old. Focus group participants were 
recruited from a local higher education college and groups were facilitated by 
two female facilitators (Woodhall and Collander-Brown). Participants were 
provided with a £20 voucher as a token of appreciation. Feedback from the 
focus groups led to the information leaflet being redesigned to make it brighter, 
and more eye-catching, to reduce the amount of text in the leaflet, and to revise 
the invitation letter and information leaflet to emphasise that the invitation was 
being sent only on the basis of the age of the participant, and was not linked to 
any knowledge about the invitee’s sexual activity.  
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A total of 1,000 individuals from each PCT were selected at random for 
invitation, and were subsequently allocated to three study arms using simple 
randomisation.16 The sample size was sufficient to identify a minimum 5% 
difference in response rate between three different types of postal invitation 
(Table 5-2). Group B was expected to have higher costs per invitation due to 
the offer of the £5 voucher. The main comparison was planned between group 
A and B and group A and C. The groups were therefore randomised in a ratio of 
1:2 (B:A and C:A) for the purposes study costs and logistics.  
5.2.2.1 Return of biological sample for anonymous testing 
Consenting participants returned the questionnaire and self-taken vulvovaginal 
swab to the HPA. The vulvovaginal swabs were sent to the Sexually 
Transmitted Bacteria Reference Unit (STBRU) for unlinked anonymous testing. 
Samples were tested using the APTIMA COMBO 2 assay for both chlamydia 
and gonorrhoea (Gen-probe Inc., San Diego, CA). Reactive samples were 
confirmed according to the manufacturers’ instructions.  
Test results could not be linked to any personal identifiable information, and 
participants were not sent any test results. Testing was carried out 
anonymously for a number of reasons. Firstly, as discussed in the Chapter 3, it 
is reasonable to expect that propensity to participate in a survey of chlamydia 
prevalence may be related to risk of having chlamydia. If test results had been 
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 Random selection and allocation was performed by the local lead at the PCT using an Excel 
spreadsheet and written procedure to standardise the process across participating sites. Study 
sites entered the eligible participants into the spreadsheeet which assigned a random number to 
each eligible participant. Participants were then re-ordered  by random number and the first 
1,000 were selected. The first 500 were allocated to group A, the second 250 to group B and 
the third 250 to group C. 
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provided then it was expected that those who had taken a test recently or who 
did not consider themselves to be at risk from having chlamydia would be less 
likely to participate. There were also logistical considerations. In returning 
results to participants, it would have been necessary to adhere to governance 
standards for clinical testing, including timely return of results, and arranging 
partner notification and treatment.229 It was not considered practical to try to 
achieve these standards within the resources of the pilot or future surveys. This 
aspect of the methodology formed an important part of the ethical review of the 
study (see section 5.2.4). The study was conducted in the context of 
widespread availability of chlamydia screening and testing. The study 
information leaflet provided detailed information on where a named test could 
be obtained locally. The Natsal-3 survey provided an important precedent for 
this decision, where anonymous testing for STIs without return of results was 
found to be an acceptable approach.230 
5.2.3 Analysis 
Participation rates were defined as the number of samples returned with 
consent for testing divided by the number of invitations sent and were measured 
in each PCT and in each randomisation group. Reasons for non-response 
derived from the pre-paid postcard were compiled. 
Reported sexual behaviours were compared between randomisation groups 
using a chi-squared test. In order to assess whether the recruited sample was 
comparable to the general population, I also compared reported sexual 
behaviours among study participants in each randomisation group to responses 
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from 17 and 18 year-old female participants in Natsal-2 (n=359) and the Health 
Survey for England conducted in 2010 (HSE2010, n=108).17 Sampling weights 
were applied according to the data analysis guides for each survey. The 
complex survey function in Stata was used to calculate standard errors, in order 
to allow for clustering and stratification. 
In order to identify whether the population tested through this population-based 
postal survey with anonymous testing was different to the population being 
tested through the NCSP, the reported sexual behaviour in the pilot survey was 
compared to information from same-aged women (17 to 18 in Sutton & Merton, 
18 in Northamptonshire), tested through the NCSP in the two participating PCTs 
in 2011 (n=3,485). Table 5-3 shows the variables that were available in each of 
the comparator datasets, and were used for analysis. All statistical analyses 
were performed using Stata version 12.0 (StataCorp, College Station, Texas, 
USA). 
  
                                                             
 
17
 Although data from Natsal-3 would provide more timely results for comparison, the data were 
not available at the time of this analysis. 
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Table 5-3: Sexual behaviour variables available in the pilot survey and 
comparator samples 
Variable Pilot 
survey 
Natsal-2 HSE 
2010 
NCSP 
2011 
Ever had chlamydia test  x  x 
Ever had sex    x 
More than one sexual partner in the past year*     
At least one new sexual partner in the past year*   x x 
More than one sexual partner in the past three months*   x x 
At least one new sexual partner in the past three 
months*  
x x  
Condom used at last intercourse   x x 
*Variables were collected as continuous variables in the pilot questionnaire (number of sexual 
partners in past year, number of new sexual partner per year etc). Due to the small numbers 
available, responses were categorised into binary variables for the purposes of comparison.   
 
An area-level indicator of socioeconomic deprivation (IMD220) was assigned to 
all invited individuals by mapping postcodes of residence to LSOA of residence. 
Ranks of IMD scores were grouped into quintiles. The distribution of IMD 
quintiles was then compared between participants and the invited population. 
The marginal costs per invitation and per sample received for each 
randomisation group were estimated (defined as the total of the unit costs of all 
consumables, postage and testing, divided by the number of invitations sent or 
the number of samples returned with consent for testing (Table 5-4). Staff and 
overhead costs were not included, as these were assumed to be equivalent for 
all recruitment methods. 
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Table 5-4: Unit costs of consumables 
Item Cost per 
unit 
PRINTING: Letters & information sheets  
Printing of invitation letter £0.05 
Printing of PCO cover letter £0.05 
Printing of participant information £0.10 
Printing of participant instruction leaflet £0.10 
Printing of sample collection kit request card/voucher request card £0.02 
Printing of questionnaire £0.11 
Letter to accompany requested sample collection kits £0.05 
Reminder letters £0.05 
Letter to accompany music voucher £0.05 
ENVELOPES: Addressed envelopes for:   
Invitations (group C) (size: A5) £0.01 
Reminder letters (size: A5) £0.01 
Gift voucher/Kit request card (size: DL) £0.01 
Address label £0.02 
POSTAGE  
Invitation - without kit (2nd class letter) £0.25 
Invitation - with kit @ £0.44 (2nd class Large letter)  £0.44 
Sample collection kits  @ £0.44 (2nd class Large letter) £0.44 
Reminder letters (2nd class letter) £0.28 
Gift voucher (2nd class letter) £0.28 
Freepost for test request slip return (2nd class Freepost, standard response) £0.32 
Freepost for sample return (1st class Freepost, standard response) £0.42 
INCENTIVES  
Gift voucher (£5 each) £5.00 
SAMPLE COLLECTION KITS  
Rigid container+absorbent pad £0.25 
Outer envelope £0.07 
Return envelope £0.15 
Tube label  £0.06 
Collection kits @ 1.39 plus VAT  £1.63 
LABORATORY TESTING  
Testing (includes sample collection kit) @ £5 plus VAT £5.88 
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5.2.4 Regulatory approval 
Participants indicated their consent for testing and storage of samples using a 
tick box on the questionnaire. Signed consent was not requested in order to 
maintain anonymity of participants.  
The study was approved by North London Research Ethics Committee.18 
Research governance approval was obtained from both participating PCTs. 
Research governance approval was sought to invite both 17 and 18 year-olds. 
This age group was approved by the Research Ethics Committee. However 
research governance approval for NHS Northamptonshire was only granted for 
18 year-olds due to local guidance on the use of personal information for under-
18 year-olds.  
National Information Governance Board (NIGB) approval was originally sought 
to obtain lists of names and addresses of eligible participants from the PCTs, to 
enable the study team to send invitations directly from the HPA. Approval was 
not granted, meaning that the initial invitation letter was sent by the PCT, and 
the HPA study team did not have access to any personal identifiable information 
from the women invited to the study.19 
  
                                                             
 
18
  REC reference number: 10/H0717/57 
19 Except personal identifiable information provided by participants, in order to request kits or 
vouchers. This information was not linked to any test result or study information 
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5.3 Results 
5.3.1 Participation rates 
A total of 155/2,000 (7.8%) samples were returned with consent, 33 of which 
were returned after receipt of a reminder letter (Table 5-5). Consent was 
declined by a further 48 women, and 30 invitations were returned as 
undelivered. Participation rates were higher in Northamptonshire (90/1,000; 
9.0%) than Sutton & Merton (65/1,000; 6.5%) (p=0.04). Participation rates 
varied by randomisation group; 78/1,000 (7.8%) of those in Group A, 72/500 
(14.4%) in Group B and 5/500 (1%) in Group C returned a sample and provided 
consent (A v B: p<0.001). All received samples had sufficient material for 
testing; 3/155 (2%) tested positive for chlamydia (1 in Group A, 2 in Group B). 
Table 5-5: Participation rates by randomisation group 
Participation rates 
Randomisation Group Overall 
(n=2,000) 
A: Kit 
(n=1,000) 
B: Kit + voucher 
(n=500) 
C: No kit 
(n=500) 
n % n % n % n % 
NHS Northamptonshire  47/500 9.4% 41/250 16% 2/250 0.8% 90/1,000 9.0% 
NHS Sutton & Merton 31/500 6.2% 31/250 12% 3/250 1.2% 65/1,000 6.5% 
Overall 78/1,000 7.8% 72/500 14% 5/500 1.0% 155/2,000 7.8% 
 
5.3.2 Assessment of selection bias 
Figure 5-1 shows the reported characteristics among Groups A and B 
compared to 17 and 18 year-old participants in Natsal-2 and HSE2010, as well 
as data for 17 and 18 year-old females tested through the NCSP in the two 
participating PCTs in 2011. 
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Figure 5-1: Reported sexual behaviours among pilot survey participants, same 
aged Natsal-2 participants, HSE 2010 participants and NCSP test carried out in 
participating PCTs in 2011 
 
*Comparable questions are not available from all sources. Bars show proportions, with 95% 
confidence intervals shown as error bars. Everyone tested through the NCSP was assumed to 
be sexually experienced. 
A total of 78% participants were sexually-experienced (reported at least one 
lifetime sexual partner, Figure 5-1). Due to the small sample size in Group C 
(n=5), no comparisons of reported behaviour or demographic characteristics are 
reported for this group. A higher proportion of participants in Group B than 
Group A were sexually-experienced (81% in Group B versus 75% in Group A, 
p=0.47), reported ever having had a chlamydia test (58% versus 54%, p=0.58) 
and reported more than one sexual partner in the past 12 months (45% versus 
33% among sexually active participants, p=0.18). None of the observed 
differences were statistically significant (at the 0.05 level).  
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Responses from participants in the pilot survey were broadly similar to Natsal-2 
responses, although there was some heterogeneity. A higher proportion of 
same-aged sexually experienced Natsal-2 participants reported condom use at 
last intercourse compared to pilot study participants (46% versus 31% in Group 
A, p=0.048; and versus 32% in Group B, p=0.045). The percentages of 
participants who reported ever having had a chlamydia test and who reported 
being sexually-experienced were higher than those reported among HSE2010 
participants (Figure 5-1). 
The percentage of participants who reported having had at least one new 
sexual partner in the last three months was lower than that reported among 
same-aged women tested through the NCSP in 2011 (40% in both Groups A 
and B versus 56% in NCSP tests. p=0.02).  
The low response rates prevented a subgroup analysis of response rates by 
IMD quintile. However in both groups A and B, participation rates were higher 
among those living in less deprived areas (Figure 5-2). Participation rates varied 
less by IMD quintile in Group B.  
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Figure 5-2: Participation rates by IMD quintile and randomisation group 
 
IMD: Index of multiple deprivation, quintile based on lower super output area of residence. 
 
5.3.3 Cost per invitations and cost per sample received 
The marginal cost per initial invitation was £3.00 for group A, £3.10 for Group B 
and £0.50 for Group C. The marginal cost per sample received was £51 for 
Group A, £36 for Group B and £93 for Group C (Table 5-6). 
 
Table 5-6: Costs per invitation sent and sample received by randomisation group 
 Group A 
(Kit) 
Group B 
(Kit + 
voucher) 
Group C 
(No kit) 
Per invitation £3.00 £3.10 £0.50 
Per sample £51 £36 £93 
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A total of 48 women declined consent by returning the pre-paid postcard (3% of 
all women who did not return a sample). The most commonly cited reasons for 
non-participation were that women did not want to use the swab (19/48, 40%), 
did not have the time (12/48, 25%), were not sexually active (9/48, 19%) or 
were not interested in chlamydia (7/48, 15%). Two respondents (4%) indicated 
that they wanted to receive their results (Figure 5-3). 
 
Figure 5-3: Reported reasons for non-participation (n=48)  
 
Respondents could choose more than one option. Responses marked * were derived from free-
text responses. 
 
5.4 Discussion 
5.4.1 Key findings 
This pilot of a postal survey of young women with anonymous testing for 
chlamydia achieved a maximum response rate of 14%.  Given this low 
response rate, the piloted methodology is not a feasible approach for obtaining 
regular measures of chlamydia prevalence among young women. 
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5.4.2 Strengths and limitations 
The main strength of this pilot study was that invitations were randomly 
allocated into different groups to allow investigation of the response rates that 
could be expected given different approaches. This showed that offering a small 
financial incentive slightly increased participation, and reduced the cost per 
sample received, although none of the piloted approaches achieved an 
acceptable response rate.  
The study was subject to limitations. Firstly, it was not possible to determine 
whether participation rates would have been higher if participants had been 
offered their results. People who take part in named chlamydia testing are, on 
average, at higher risk of infection than the general population182. Therefore 
participants were not provided with their test results to reduce potential non-
response bias (section 3.2.2.1). Among the 48 individuals who provided a 
reason for non-participation using the pre-paid postcard, only 2 respondents 
stated that they did not take part because they wanted to receive their test 
results. Although this is a small sample and only indicative of potential reasons 
for non-participation in the overall population, this suggests that providing test 
results would not have led to substantially higher response rates. This is 
consistent with the low participation rates in other recent postal chlamydia 
screening studies, where named testing was used88,158. However it is possible 
that offering test results may have led to a larger sample size. 
A further limitation is that the age of those eligible and of participants was not 
known, meaning that not possible to determine whether the difference in 
participation rates between Northamptonshire and Sutton & Merton was 
associated with age or whether this was more likely to be due to local variation 
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in the willingness to participate or completeness of the GP registers. It was 
originally envisaged that year and month of birth would be provided from the 
participating PCTs, but this was unavailable. A lower response rate in the 
London PCT (Sutton & Merton) would be consistent with other studies that have 
shown lower participation rates within London compared to the rest of the 
country171.  
The GP registers may not have been accurate in terms of registered patients’ 
addresses. A total of 30/1,845 (1.6%) invitations among non-participants were 
returned to sender, indicating that they never reached the intended participant. 
This is unlikely to be the total number of undelivered invitations. These 
undelivered invitations were included in the denominator for participation rates. 
If the proportion of ‘ghost’ patients seen in the ClaSS study (26%, see section 
3.2.2.2)10 is applied to the results of this pilot, then the participation rate among 
those likely to have received the sample would be higher, but still low (11% in 
Group A, 19% in Group B, 1% in Group C).  
The most commonly stated reason for non-participation was not wanting to use 
the self-taken VVS.  While VVS have been found to be an acceptable method of 
sampling for diagnostic tests or chlamydia screening, as no clinical result was 
being returned, this may have reduced the willingness to use the swab. Urine 
samples are possible alternatives, but the sensitivity of NAAT tests among 
women is lower using urine compared to VVS samples231.  
5.4.3 Implications for evaluation of chlamydia control 
Low response rates do not necessarily lead to biased estimates of outcome 
measures; bias will only occur if participants and non-participants differ in 
139 
respect to the outcome of interest. In order to gain some insight into the non-
response bias in this survey, participation rates were compared by residence 
based deprivation, and responses from the pilot were compared to three other 
samples (Natsal-2, HSE2010 and women tested through the NCSP). 
Participation rates were higher among those in less deprived areas. As 
residence-based deprivation measures have been found to be a risk factor for 
chlamydia infection,133 this suggests there may have been some important 
differences between participants and non-participants that may have introduced 
bias. Although limited by sample size, there was some evidence to suggest that 
these differences (and the potential resulting bias) were reduced with the offer 
of a voucher. There were minimal differences between our participants and the 
same aged Natsal-2 or HSE respondents. While this suggests that the findings 
from these three sources may be consistent, the utility of these comparisons is 
limited by the sample size in Natsal-2 and HSE for 17 and 18 year-old women 
and as Natsal-2 and HSE2010 provide national estimates that would mask local 
variation. Furthermore, Natsal-2 was carried out over 10 years ago, which may 
limit comparability of findings. Results from the more-recently conducted Natsal 
(Natsal-3, conducted 2010-12) were not available at the time of the pilot study. 
One alternative approach to explore the non-response bias would be to 
compare those who responded before or after a reminder was sent. If 
differences between groups are seen, then it is also reasonable to assume 
there to be important differences between participants and non-participants232. 
However numbers were too small for meaningful comparisons within this pilot 
survey. 
Although it was not possible in this pilot to establish with certainty whether 
participants and non-participants had the same risk of having chlamydia, given 
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the low participation rates, a survey using the piloted methodology would be 
open to substantial, and potentially variable, selection bias. Even if the 
prevalence of infection among participants and non-participants did not differ, 
the costs of implementing repeated cross-sectional surveys would be 
prohibitively large, due to the number of invitations needed to achieve the 
sample size needed to measure relatively small changes in prevalence between 
surveys. 
5.4.4 Summary 
In summary, this pilot study showed that repeated cross-sectional studies of 
chlamydia prevalence using postal invitations with anonymous testing for 
chlamydia is not a suitable method for measuring chlamydia prevalence in the 
general population. Other methods for measuring chlamydia prevalence are 
therefore required, and in the next chapter I explore the use of data from large 
nationally-representative sexual behaviour surveys as an alternative to 
chlamydia-specific surveys. 
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6 Chlamydia prevalence measured in the second and third 
National Surveys of Sexual Attitudes and Lifestyles 
(Natsal-2 and Natsal-3) 
The results of the previous chapter show that a postal survey of chlamydia 
prevalence is unfeasible, would incur unjustifiably high costs and would be open to 
considerable selection bias. Repeated cross-sectional postal surveys are not suitable 
for population-based monitoring of chlamydia prevalence among young women in 
England. Other methods for monitoring chlamydia prevalence over time are 
therefore required. In the following two chapters I investigate the use of the National 
Surveys of Sexual Attitudes and Lifestyles (Natsal) as a means of comparing age-
specific chlamydia prevalence among a sample of the general population at different 
time points (presented in this chapter) and to explore how chlamydia screening had 
been delivered up to 2012, and what the epidemiology of infection in relation to 
testing can tell us about the actual or expected impact of chlamydia screening 
(Chapter 7). 
6.1 Background 
The analyses in this and the subsequent chapter use data from the second and 
third National Surveys of Sexual Attitudes and Lifestyles (Natsal-2 and Natsal-3 
respectively). Natsal are three, stratified probability sample surveys of the 
British general population. The first survey (Natsal-1) was conducted in 1990-
1991,170 Natsal-2 in 1999-2001171 and  Natsal-3 in 2010-12.172 In both Natsal-2 
and Natsal-3, chlamydia prevalence was estimated from urine samples among 
a subset of participants.23 The surveys also provide a wealth of information on 
sexual behaviour, attitudes and lifestyles, experience of STI diagnoses 
(including chlamydia) and, in Natsal-3, chlamydia testing.  
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As both Natsal-2 and Natsal-3 measured the prevalence of C. trachomatis 
detected in urine (hereafter termed ‘prevalent infection’), the surveys provide a 
unique opportunity to compare estimates of chlamydia prevalence among the 
general population of young adults before and after the widespread 
implementation of chlamydia screening. However, as described in detail below, 
there were differences in the detection strategy used in each survey, meaning 
that such comparisons should be made with caution. The analyses presented in 
this chapter were conducted to explore how this and other differences between 
the surveys might affect the conclusions that can be made about changes in 
chlamydia prevalence among young adults using a series of adjustments and 
counterfactual scenarios.  
6.2 Aims & objectives 
To investigate whether the Natsal surveys can be used to compare chlamydia 
prevalence before and after the implementation of the NCSP and determine 
how differences between the surveys and underlying changes in sexual 
behaviour affect the conclusions that can be made about change in chlamydia 
prevalence between 1999-2001 and 2010-12. This aim was addressed through 
the following objectives: 
 To compare chlamydia prevalence among 18 to 24 year-old participants in 
the Natsal-2 and Natsal-3 surveys. 
 To adjust Natsal-2 and Natsal-3 prevalence estimates and comparisons for 
known and possible differences between the surveys.  
 To describe differences in reported sexual behaviour and markers of sexual 
behaviour between the surveys and their potential impact on chlamydia 
prevalence. 
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6.3 Methods 
6.3.1 Summary of survey methodology and testing of biological 
specimens in Natsal-2 and Natsal-3 
Full details of the survey methods and questionnaire have been described 
elsewhere.172 In summary, both surveys used an independently designed, multi-
stage, clustered, stratified probability sample, using the ‘small-user’ Postcode 
Address File, a list of all addresses (delivery points) in the Britain, as the 
sampling frame. Postcode sectors were selected as the primary sampling units, 
addresses within them were selected at the second stage, and finally one 
eligible adult per address was randomly selected at the final stage. In both 
surveys, participants were interviewed in their own homes using computer-
assisted face-to-face and computer-assisted self-interview for the most 
sensitive questions.4,5 Most questions in Natsal-3 were identical in wording to 
those used in Natsal-2. However, there were some questions used in Natsal-3 
that were not used in Natsal-2, including whether someone had been tested for 
chlamydia in the last year and reason for testing. Some questions had slightly 
altered in wording, the only relevant one for the analyses presented in this 
thesis being the wording for self-reported diagnosis in the last year (see Box 
6-1). A summary of the key features and differences between Natsal-2 and 
Natsal-3 is provided in Table 6-1.  
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Table 6-1: Key features of the second and third National Surveys of Sexual 
Attitudes and Lifestyles5,172 
 Natsal-2 Natsal-3 
Age range 16 to 44 years 16 to 74 years* 
Number of participants 11,161
$
 15,162 
Survey method Computer-assisted personal interviewing (CAPI) including 
computer-assisted self-interview (CASI) 
Response rate
^
 65% 58% 
Self-reported chlamydia test 
in the last year collected? 
No Yes 
Self-reported chlamydia 
diagnosis in the last year 
collected? 
Yes – calendar year of last 
diagnosis. 
Yes 
Eligibility to provide a urine 
sample 
A subset of sexually-
experienced participants
133
 
 
All 16 to 17 year-olds 
(regardless of reported 
sexual activity); 
all sexually-experienced 18 
to 24 year-olds; 
a random subsample of 25 to 
44 year-olds
23
. 
Urine collection device Urine cup ‘FirstBurst’ urine collection 
device 
Diagnostic assay Ligase Chain Reaction (LCx) 
(Abbott Diagnostics) 
133
 
Aptima Combo 2 (AC2) 
(Hologic Gen-Probe) 
23
 
Did participants receive their 
chlamydia test results?  
Yes No 
* Younger adults aged 16 to 34 years were oversampled to increase statistical analysis power 
for this group. 
^
As eligibility within households was not known for those households not contacted, these 
calculated response rates use an estimated denominator of eligible using data from households 
that could be contacted.
4,5
 
$
 Natsal-2 also included a boost sample of adults of Black and Asian ethnicity, but these data 
were not included in the analyses presented in this thesis.  
 
In both surveys, a subset of participants was invited to provide a urine sample 
for testing for C. trachomatis testing. In Natsal-2, consenting participants were 
asked to collect a first-catch urine specimen in a plastic urine cup and transfer 
this to a 20ml universal container (containing 1 mg boric acid as a stabilising 
agent) for posting to the laboratory where they were tested for chlamydia using 
the ligase chain reaction test by Abbott Diagnostics (hereafter termed LCx)133. 
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Positive samples were confirmed through a repeat test using the LCx on the 
same sample (personal correspondence, C Carder. 2013). In Natsal-3, 
participants were asked to collect a urine specimen using a ‘FirstBurst’ urine 
collection device, which diverts the first 4-5mls of urine flow into specimen 
collection tube, without dilution from subsequent urine flow. This device 
increases the bacterial load in the specimen held in the specimen collection 
tube  compared to a first catch specimen using a urine cup.233 Urine samples 
were posted to Public Health England (PHE) where they were tested for 
Chlamydia trachomatis using the Aptima Combo 2 assay (Hologic Gen-Probe); 
all positive and equivocal results were confirmed with the Aptima chlamydia 
monospecific assay.23  
In Natsal-2, participants received their chlamydia test results if they were 
positive whereas testing in Natsal-3 was carried out anonymously (i.e. without 
return of results) and participants did not receive their results for any of the 
other STI tests. The rationale for STI test results not being provided in Natsal-3 
has been provided elsewhere.230 Briefly, this was deemed appropriate and 
ethical for Natsal-3 given the availability of free STI testing and advice at the 
time of the survey. Furthermore, urine samples were tested for other STI (HPV, 
gonorrhoea, Mycoplasma genitalium and HIV), and for some of these (HPV and 
Mycoplasma genitalium) the result would be of uncertain clinical value. 
Timeliness of testing and in some cases test accuracy were also limited given 
the constraints of the survey conditions and specimen type meaning that STI 
testing would not be fully compliant with clinical standards. Participants were 
given information about where to obtain free diagnostic STI and HIV testing and 
sexual health advice.  
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In both surveys, urine specimens were also tested for HPV using an in-house 
Luminex-based genotyping assay for detection of HPV types 6, 11, 16, 18, 26, 
31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73 and 82. In Natsal-2, this 
testing was carried out following storage at -80C as part of a separate, ethically-
approved study234. In Natsal-3, participants consented to their specimen being 
anonymously tested for HPV, and testing was carried out shortly after 
collection.23,234 
6.3.2 Participants 
All analyses in this chapter are based on data from sexually-experienced 
participants in Natsal-2 or Natsal-3. Apart from summary estimates of the key 
outcome measures (see below), which were produced for 16 to 44 year-olds, all 
analyses were conducted among women and men aged 18 to 24 year-old as 
the age group targeted for chlamydia screening by the NCSP and as urine 
samples were not collected from 16 to 17 year-old participants in Natsal-2. 
The key outcomes of interest were prevalent infection, self-reported chlamydia 
diagnosis in the last year (‘recent diagnosis’), self-reported chlamydia diagnosis 
at any time prior to the interview date (‘ever diagnosed’) and, for analyses 
among Natsal-3 participants, self-report of a chlamydia test in the last year 
(‘recent testing’).  
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Figure 6-1: Flow chart showing participants included (16 to 44 year-old Natsal-2 
& Natsal-3) 
 
 
 
 
 
 
 
 
 
 
 
6.3.3 Statistical analysis 
6.3.3.1 Complex survey sampling and weighting 
All analyses were carried out using Stata 12.1, accounting for the weighting, 
clustering and stratification of the Natsal data.23,172,235 In both surveys, weights 
constructed and provided by the survey team were applied to adjust for unequal 
probability of selection and non-response to ensure the sample data were 
broadly representative of the British general population, according to the most 
recent census, in terms of gender, age group and Government Office 
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(Natsal-2=3,386; Natsal-3=4,452) 
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(Natsal-2=6,868; Natsal-
3=4,108) 
 
16 to 44 year-old participants 
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3=9,902) 
 
Sexually-experienced 
(Natsal-2=10,403; Natsal-
3=8,947 
 
Did not report any sexual 
partner over the lifetime 
(Natsal-2=758; Natsal-3=955) 
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Region236,237 and the differential provision of urine samples by demographic and 
selected sexual behaviours.5,172  
Questions about self-reported diagnosis of chlamydia differed slightly between 
surveys. For estimates of diagnoses in the last year among Natsal-2 
participants, I therefore constructed an additional weight to correct for the 
overestimate of recent diagnosis in the last year and to allow comparisons 
between the surveys (Box 6-1). 
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Box 6-1: Construction of additional weight for diagnosis in the last year 
In Natsal-2, participants were asked the calendar year of their most recent chlamydia 
diagnosis, whereas in Natsal-3, participants were asked whether they had been 
diagnosed in the 12 months before the interview. A further weighting was therefore 
applied when estimating self-reported diagnosis in the last year in Natsal-2 to allow 
comparisons between the surveys. These additional ‘diagnosis weights’ were 
constructed as the number of days in the year specified that would have been in the 12 
months before the interview. Weights were constructed for each month, assuming the 
date of interview was at the midpoint of the month (15th of the month, apart from 
February, where 14th was used).  
For example, for a participant interviewed on the 15th of January 2000 who reported 
their last diagnosis was in 1999, 351 of the 365 days in 1999 would have been within 
the 12 months preceding the interview, thus the ‘diagnosis weight’ was 351/365=0.96. 
For a participant interviewed on the 15th of December 2000, only 16/365 days in 1999 
would have been within the 12 months before the interview, resulting in a weight of 
0.04. Table 6-2 below shows diagnosis weights calculated for each month. Diagnosis 
weights were then multiplied by the urine weights (which incorporate unequal 
probability of selection, nonresponse to main survey and urine sub-study), and used as 
final weights for estimate of diagnosis in the last year in Natsal-2.  Figure 6-2 shows the 
difference in the estimated proportion with a chlamydia diagnosis in the last year by 
gender and age group. 
 
Table 6-2: Diagnosis weights by month of interview 
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Days within preceding year 351 321 291 260 230 199 169 138 107 77 46 16 
‘Diagnosis weight’* 0.96 0.88 0.8 0.71 0.63 0.55 0.46 0.38 0.29 0.21 0.13 0.04 
*Number of days within preceding year / 365. Presented to 2 decimal places. 
 
Figure 6-2: Impact of ‘diagnosis weights’ on estimated proportion diagnosed in the last 
year by age group (Natsal-2) 
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6.3.3.2 Comparison of chlamydia prevalence and diagnoses in Natsal-3 
versus Natsal-2 among under-25 year-olds 
The prevalence of infection and of self-reported diagnoses (ever or in the last 
year) in Natsal-3 was compared to Natsal-2 using univariable logistic regression 
with survey (i.e. Natsal-2 or Natsal-3) entered as the independent variable.  
These comparisons were further explored by setting up a series of 
counterfactual scenarios to investigate the impact of differences between 
surveys on comparisons of chlamydia prevalence between them.  
6.3.3.3 Correction for measurement error arising from imperfect 
diagnostic tests 
As set out in section 6.3.1 above, different specimen collection devices and 
diagnostic tests were used in Natsal-2 and Natsal-3, reflecting changes in 
technologies between them. Differences in the detection strategy (i.e. the 
combination of tests, confirmation procedures and specimen collection devices) 
used in each survey may affect prevalence estimates and their 
comparability.140,238,239 Imperfect tests lead to misclassification bias, whereby 
tests with <100% sensitivity result in individuals with an infection being 
incorrectly classified as negative (‘false negatives’) and tests with <100% 
specificity in individuals without an infection being categorised as having an 
infection (‘false positives’). Thus imperfect tests can over or underestimate ‘true’ 
prevalence.240-243 The extent and direction of this error will depend on both the 
sensitivity and specificity of the test used and the true prevalence of infection 
within the population (Figure 6-3).  
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Figure 6-3: Difference between observed and true prevalence with different test 
characteristics 
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Where the sensitivity and specificity of a diagnostic test is known, the ‘true’ 
prevalence of infection (i.e. that would have been measured, had a perfect test 
been used), can be calculated using the following formula set out by Rogan and 
Gladen:243 
Prevalenceadjusted = Prevalenceobserved + specificity – 1  [1]  
   sensitivity + specificity - 1  
 
By applying this equation to observed prevalence estimates, the ‘true’ 
prevalence can be calculated. However this relies on knowing the true 
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sensitivity and specificity of the test, which in turn relies on having a perfect 
‘gold standard’ test, i.e. a test (or combination of tests, also termed a ‘reference 
standard’) that is capable of classifying individuals into those who do and do not 
have an infection. Estimates of the sensitivity and specificity of chlamydia 
NAATs have been shown to vary according to the gold standard used.238,240,244 
Estimated performance characteristics of earlier NAATs (such as LCx) are 
particularly subject to error, where less sensitive assays (i.e. culture or enzyme 
immunoassays) have been used as the gold standard, or when discrepant 
analysis20 has been applied.238,240,245-247 Adjusting prevalence estimates to 
achieve a true prevalence is therefore problematic. To address this, the 
prevalence estimated in Natsal-2 was adjusted to estimate the prevalence of 
chlamydia that would have been measured, had the same detection strategy 
been used in Natsal-2 as was used in Natsal-3, thereby increasing the 
comparability of the prevalence estimates while acknowledging that they both 
may remain imperfect estimates of true prevalence.   
To do this, firstly the ‘test-adjusted’ prevalence was calculated by applying the 
Rogan & Gladen formula [1] to the prevalence estimates and 95% confidence 
intervals248 in Natsal-2, using the sensitivity (91.1%) and specificity (99.1%) of 
the LCx compared to the AC2 NAAT from a head to head study of the two 
assays reported by Gaydos et al249 (Box 6-2). A ‘detection strategy-adjusted’ 
prevalence was then calculated by applying this formula [1] to the ‘test-adjusted’ 
prevalence. The sensitivity (97.1%) and specificity (100%) estimates for the 
                                                             
 
20
 A method introduced to overcome problems of the gold standard being less sensitive than the 
test under evaluation. Specimens that were positive for chlamydia on the assay under 
evaluation but negative by the gold standard (usually culture) were tested using an additional 
assay. This ‘discrepant analysis’ approach was subsequently discredited as it leads to 
systematic overestimation of the sensitivity and specificity of the test under evaluation.
240
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FirstBurst were taken from a study of urine specimens collected from 534 men 
using both a urine cup and the FirstBurst device and tested using the Amplicor 
CT/NG PCR assay (Roche Molecular Systems, Branchburg, NJ).233 
As Natsal-2 and Natsal-3 are complex surveys, the standard errors are 
estimated using the complex survey function in Stata to account for the 
stratification and clustering of the surveys. However, as the ‘detection strategy-
adjusted’ estimates were calculated based on the previously estimated point 
estimates (and 95%CIs) of chlamydia prevalence, the complex survey analysis 
function in Stata could not be applied. An approximate method was therefore 
used to compare the adjusted Natsal-2 prevalence estimates to Natsal-3 
prevalence, while also taking into account the original clustering of the sample. 
Firstly, the effective sample size (the sample size which equates to the given 
confidence intervals, if the survey had been conducted as a simple random 
sample), was derived using the adjusted prevalence estimates, and the design 
effects for each age group.250 A simulated dataset was then created where the 
number of observations was equal to the effective sample size and the number 
with a positive chlamydia test result corresponded to the ‘detection strategy-
adjusted’ point estimates. The simulated dataset was then used to calculate the 
odds ratio for prevalence in Natsal-3 versus ‘detection strategy adjusted’ 
prevalence in Natsal-2 using logistic regression.  
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Box 6-2: Literature review of sensitivity and specificity of ligase chain reaction 
(LCx) and Aptima Combo 2 (AC2) assays for Chlamydia trachomatis detection 
In order to adjust the Natsal-2 prevalence to determine the prevalence that would have 
been observed had the same detection strategy been used as was used in Natsal-3, 
the relative sensitivity and specificity of the LCx compared to the AC2 was needed. A 
literature review was therefore carried out to identify i) systematic reviews of the 
sensitivity and specificity of the LCx and AC2 and ii) studies where the LCx had been 
compared directly to the AC2. Along with a search of an electronic database 
(MEDLINE), unpublished data were obtained via contact with experts in the field 
(personal communication, Prof Catherine Ison). 
Two reviews were identified that provide summary estimates of the sensitivity and 
specificity of the LCx and AC2. In a systematic review by Nelson et al251 estimated 
sensitivity of LCx among non-pregnant women ranged from 70% to 96% and specificity 
between 99% and 100%. In a review of non-invasive testing for chlamydia and 
gonorrhoea, Cook et al252 included studies which compared urine to other sample types 
and reported pooled estimates for TMA (ACT or AC2) in urine of 92.5% (95%CI 88.0%-
97.0%) sensitivity and 98.6% (95%CI 97.7%-99.6%) specificity in women and 87.7% 
(95%CI 80.1%-95.2%) sensitivity and 99.4% (95%CI 98.7% - 100%) specificity in men. 
However the gold standards used for the studies included in these reviews vary 
considerably, with earlier studies of the LCx often comparing to culture.  
Five studies were identified which included a head to head comparison of LCx and 
AC2.249,253-256 However only in the study by Gaydos et al, where 506 first catch urine 
samples were tested with both the LCx and AC2,  can the performance characteristics 
of LCx in relation to AC2 (i.e. using AC2 as a gold standard) be calculated from the 
results reported.249 In this study, 506 first catch urine samples from women and men 
aged 12 to 20 years old attending school-based clinics for routine screening were 
tested with both the LCx and AC2.249 This resulted in a sensitivity and specificity of the 
LCx compared to the AC2 of 91.1% and 99.1% respectively. 
Table 6-3: Comparison of results from LCx and AC2 from 506 urine specimens 
(Based on Table 1, Gaydos et al 2004
249
) 
  AC2 (‘gold standard)  Samples that were positive only on 
the AC2 were retested using the 
APTIMA chlamydia monospecific 
assay (ACT) 
249
. Results shown for 
the AC2 are based on AC2 plus 
confirmation with ACT where both 
tests were available as this is closest 
to the detection strategy used in 
Natsal-3.
23 
    Positive Negative Total  
LCx 
Positive 72 4 76  
Negative 7 423 430  
Total 79 427 506  
  Sensitivity of LCx relative to AC2: 91.1% 
  Specificity  of LCx relative to AC2: 99.1% 
 
AC2: Aptima Combo 2; LCx: Ligase chain reaction; ACT: Aptima chlamydia monospecific assay 
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6.3.3.4 Combining urine infections with recent screen-detected diagnoses 
The average duration of an untreated, asymptomatic chlamydia infection is 
estimated to be in the region of 16 months.18 Therefore in both surveys, a 
proportion of the individuals who had been diagnosed with chlamydia in the last 
year might have had an infection at the time of the survey had they not been 
tested and appropriately treated (i.e., had their duration of infection not been 
shortened by treatment). A hypothetical scenario was constructed to estimate 
what the prevalence of infection would have been in Natsal-3, had there been 
no asymptomatic screening among young adults in the year before the survey.  
In order to do this, diagnoses were categorised as being either ‘screen-
detected’ or not, based on the reason reported for most recent test. The Natsal-
3 questionnaire did not ask where an individual was last diagnosed or why they 
had been tested. Reason of most recent test among those diagnosed in the last 
year was therefore assumed to refer to the test associated with the diagnosis. 
Reported tests in the last year were considered to be ‘clinically-indicated’ where 
the reason for last test was reported as either having had symptoms, having a 
partner diagnosed with chlamydia or who had symptoms, or a repeat test after a 
previous positive result. Individuals who reported having been diagnosed with 
chlamydia in the last year were considered to have a ‘screen-detected’ 
diagnosis if they reported a non-clinically indicated reason for their last test 
(“wanted a check-up”; “offered a test” or “worried about risk”). Reason for test 
was not collected in Natsal-2. For the purposes of this analysis, all reported 
diagnoses in Natsal-2 were considered to be a result of clinically-indicated 
testing, as the survey was carried out before the implementation of widespread 
chlamydia screening.  
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The proportion of Natsal-3 participants who had a ‘screen-detected’ diagnosis in 
the last year was estimated. As the simplest scenario, it is assumed that all of 
these ‘screen-detected’ infections would have persisted to the time of the 
Natsal-3 interview in the absence of screening. The estimated prevalence in 
Natsal-2 was then compared to the combined prevalence of infection and/or 
‘screen-detected’ diagnoses in Natsal-3 using logistic regression.21  
6.3.3.5 Adjustment for hypothetical and unmeasured differences between 
participants and non-participants 
Survey estimates may be biased where participants and non-participants differ 
with regard to the outcome of interest. As described in section 6.3.3, the 
weights applied to the Natsal-2 and Natsal-3 data were designed to minimise 
such participation bias arising firstly for non-response in the Natsal survey, and 
secondly for differential participation in the biological sampling part of the 
survey. In the weights to address the former, adjustments could be made to 
ensure the  achieved sample was representative of the British population with 
regard to gender, age group and Government Office Region.236,237 Weights 
could not adjust for differences in sexual behaviour, as no information was 
available from non-participants. As detailed demographic and behavioural data 
were available from survey participants who did and did not consent to provide 
a urine sample for chlamydia testing, survey weights could provide a more 
detailed adjustment for non-participation bias.5,172 However it is feasible that 
participation bias remains in each survey due to unmeasured differences 
between participants and non-participants.  
                                                             
 
21
  With additional weights applied for estimation of recent diagnoses in Natsal-2 as described in 
Box 6-1. 
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The potential impact of unmeasured/uncorrected-for participation bias was 
explored by calculating a range of ‘participation-adjusted’ prevalence estimates 
for Natsal-2 and Natsal-3, by varying the (hypothetical) participation bias in 
each survey from the estimated chlamydia prevalence being 50% lower to being 
50% higher than among non-participants. The resulting odds ratios for each 
combination were then calculated and plotted against the participation bias in 
Natsal-2 and Natsal-3.  In all scenarios response rates were assumed to be 
equivalent to those seen in each survey.22 The resulting scenarios represent 
hypothetical differences between participants and non-participants which have 
not been captured by either the post-stratification weighting to account for non-
participation in the main survey, or by the weights applied for differential 
provision of urine samples by demographic and behavioural characteristics. 
6.3.3.6 Indicators of change in sexual behavioural risk of transmission 
Identification and treatment of chlamydia infections is only one of the factors 
that affect chlamydia transmission and prevalence. If sexual behaviours 
changed in the ten year period between the Natsal surveys, then in the absence 
of widespread screening, chlamydia prevalence may have either increased or 
decreased.  In order to explore whether there is any evidence for a change in 
the behavioural risk of STI transmission, the estimated prevalence of reported 
sexual behaviours (condom use at last sex; numbers of new or condomless 
sexual partners in the last year; number of lifetime sexual partners) was 
compared between 18-24 year-old participants in Natsal-2 and Natsal-3. The 
proportion of Natsal-3 participants who reported having had their first 
                                                             
 
22
 Overall participation rate in Natsal-2 (65.4%)
171
; 16-29 year-old boost sample in Natsal-3 
(67.3%)
5
. 
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heterosexual sexual intercourse before the age of 16 was estimated and plotted 
by year the participant turned 16.  
The prevalence of non-vaccine-HPV types detected in urine was also compared 
between the surveys, as a biological marker of sexual behaviour change. Non-
vaccine types comprised high-risk HPV types other than those included in the 
bivalent HPV vaccine (HPV 16, 18) and those with evidence of cross-protection 
(HPV 31, 33, 45).257 HPV 6 and 11, which were also tested for, were considered 
non-vaccine types for the purposes of this analysis as although a quadrivalent 
vaccine is available that protects against HPV 6 and 11, the bivalent vaccine 
was used within the national vaccination campaign up to 2012.258 Thus Natsal-3 
participants would not have been eligible for quadrivalent vaccination. 
Participants who were HPV positive but where no type-specific data were 
available were excluded (Figure 6-4).  
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Figure 6-4: Flowchart showing samples included in analysis of non-vaccine HPV 
prevalence (18-24 year-old sexually-experienced women and men) 
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6.3.4 Regulatory approval 
Natsal-2 obtained ethical approval from University College Hospital, North 
Thames Multicentre, and all local research ethics committees in Britain.133 
Natsal-3 was approved by Oxfordshire Research Ethics Committee A 
(reference 09/ H0604/27). Approval for use of these data for this analysis was 
granted by the Natsal-3 Project Management Team. 
6.4 Results  
6.4.1 Summary of prevalence, diagnosis and testing by age group and 
gender (Natsal-3) 
Table 6-4 shows the prevalence of chlamydia infection and of self-reported 
chlamydia testing and diagnosis in the last year among sexually-experienced 16 
to 44 year-olds. Chlamydia prevalence and recent diagnoses peaked among 20 
to 24 year-olds in men, and among 16 to 19 year-olds in women. No prevalent 
infections were detected among 16 to 18 year-old men.23 Testing was highest in 
16 to 19 year-olds among both men and women. The proportion who had ever 
been diagnosed with chlamydia peaked in an older age group than the peak for 
recent diagnoses (i.e in 25 to 29 year-olds in men and 20 to 24 year-olds in 
women). Reported diagnoses and testing were higher among women than men 
across all age groups.  
Among 16 to 24 year-olds, 3.1% of women and 2.3% of men had a prevalent 
chlamydia infection, 62.5% of women and 43.2% of men had either been tested, 
or offered a chlamydia test in the last year and 12.3% of women and 5.3% men 
had ever been diagnosed with chlamydia.  
 Table 6-4: Prevalence of chlamydia (detected in urine), and self-reported testing and diagnosis by age group and sex (sexually-experienced 
16-44 year-olds, Natsal-2 and Natsal-3) 
 
Prevalent infection** Ever diagnosed with chlamydia 
Diagnosed with chlamydia in the 
last year 
Tested in the last 
year 
Offered, not 
tested in last year 
Bases, Wt, Unwt 
Prevalent 
infection 
Tested/offered/
ever diagnosed 
Diagnosed in 
the last year 
Age 
group 
(years) 
Natsal-2 Natsal-3 Natsal-2 Natsal-3 Natsal-2* Natsal-3* Natsal-3 Natsal-3 
N2 N3 N2 N3 N2 N3 
Women                 
      
16-19  3.9% (1.4-10.3) 3.8% (2.2-6.3) 1.3% (0.6-3.2) 7.4% (5.5-9.9) 1.1% (0.5-2.8) 3.4% (2.2-5.2) 56.6% (52.5-60.6) 10.4% (8.2-13.1) 
86, 
73 
234, 
343 
451, 
387 
374, 
582 
451, 
387 
374, 
582 
20-24  2.8% (1.5-5.2) 2.7% (1.7-4.3) 5.3% (3.9-7.2) 14.9% (12.7-17.5) 1.7% (1.0-2.9) 2.7% (1.8-4.1) 52.8% (49.2-56.4) 7.1% (5.5-9.2) 
271, 
209 
391, 
497 
773, 
598 
629, 
793 
771, 
598 
629, 
793 
25-29  2.1% (1.1-4.0) 2.2% (1.2-4.0) 3.5% (2.6-4.8) 12.3% (10.5-14.3) 0.3% (0.1-0.6) 0.9% (0.5-1.6) 30.0% (27.2-32.9) 3.9% (2.9-5.3) 
328, 
256 
422, 
419 
869, 
777 
651, 
826 
867, 
777 
651, 
826 
30-34  1.4% (0.6-3.0) 0.8% (0.4-1.9) 3.8% (2.8-5.0) 9.3% (7.6-11.3) 0.2% (0.1-0.5) 0.1% (0.0-0.5) 16.5% (14.2-19.2) 0.6% (0.3-1.3) 
375, 
318 
385, 
274 
1008, 
950 
654, 
630 
1008, 
950 
654, 
630 
35-39  1.0% (0.4-2.5) 0.6% (0.1-2.6) 3.2% (2.4-4.3) 5.0% (3.5-7.1) 0.0% (0.0-0.1) 0.0% - 10.1% (7.8-12.9) 0.9% (0.4-2.2) 
384, 
311 
393, 
167 
1059, 
881 
671, 
382 
1059, 
881 
671, 
382 
40-44  0.2% (0.0-1.4) 0.0% - 1.5% (0.9-2.5) 4.6% (3.2-6.7) 0.1% (0.0-0.3) 0.0% - 8.3% (6.3-10.8) 0.2% (0.0-1.1) 
305, 
269 
441, 
185 
946, 
798 
724, 
408 
946, 
798 
724, 
408 
Men                       
16-19  2.8% (0.7-11.1) 0.3% (0.1-1.4) 0.2% (0.0-1.4) 3.5% (2.2-5.7) 0.2% (0.0-1.4) 1.9% (1.0-3.7) 40.4% (35.9-45.1) 8.0% (5.9-10.8) 
94, 
94 
214, 
395 
455, 
410 
344, 
675 
454, 
410 
344, 
675 
20-24  2.9% (1.1-7.4) 3.4% (2.2-5.2) 1.9% (0.9-3.8) 6.3% (4.8-8.4) 0.7% (0.2-2.0) 2.1% (1.2-3.5) 31.1% (27.8-34.7) 8.9% (6.8-11.4) 
254, 
272 
383, 
597 
791, 
778 
624, 
1065 
785, 
778 
624, 
1065 
25-29  4.6% (2.3-9.0) 0.8% (0.3-1.9) 2.1% (1.2-3.4) 10.2% (8.2-12.7) 0.6% (0.2-1.5) 0.8% (0.3-2.0) 19.4% (16.6-22.5) 3.0% (1.9-4.6) 
313, 
398 
412, 
650 
920, 
1143 
670, 
1364 
918, 
1143 
670, 
1364 
30-34  1.4% (0.5-3.5) 1.2% (0.5-3.0) 1.8% (1.1-2.9) 9.2% (7.0-12.1) 0.1% (0.0-0.4) 0.4% (0.1-1.4) 9.5% (7.2-12.3) 0.7% (0.3-1.7) 
368, 
466 
397, 
496 
1065, 
1325 
653, 
1033 
1063, 
1325 
653, 
1033 
35-39  1.4% (0.5-4.0) 0.6% (0.1-4.4) 1.4% (0.8-2.4) 4.4% (2.7-7.1) 0.1% (0.0-0.4) 0.1% (0.0-0.9) 4.7% (3.1-7.2) 0.0% - 
344, 
415 
421, 
268 
1085, 
1252 
673, 
591 
1084, 
1252 
673, 
591 
40-44  0.5% (0.1-3.3) 0.0% - 0.6% (0.2-1.6) 2.8% (1.5-5.1) 0.0% - 0.6% (0.2-1.6) 3.5% (2.1-5.9) 0.5% (0.1-3.2) 
309, 
376 
457, 
259 
966, 
1104 
751, 
598 
965, 
1104 
751, 
598 
*Estimates of proportion diagnosed in last year in Natsal-2 have been calculated using additional weights to adjust for over-estimation and to make comparable 
between surveys. See Box 6-1 for details. **Natsal-2 prevalence estimates in the youngest age group are among 18-24 year-olds, as 16-17 year-olds were not 
tested for chlamydia. 
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6.4.2 Comparison of chlamydia prevalence and diagnoses in Natsal-3 
versus Natsal-2 among under-25 year-olds 
Table 6-5 compares the prevalence of self-reported chlamydia diagnoses (ever 
and in the last year) for 16 to 24 year-olds in Natsal-2 and Natsal-3 and the 
corresponding estimates of chlamydia prevalence for 18 to 24 year-olds. In 
univariable analyses, there was no significant difference between the 
prevalence of chlamydia among 18 to 24 year-olds in Natsal-3 compared to 
Natsal-2 (OR 1.04, 0.53-2.01 in women; OR 0.91, 0.36-2.27 in men). Among 16 
to 24 year-olds, there was at least a three-fold increase in the odds of ever 
having been diagnosed with chlamydia (OR in women: 3.52, 2.47-5.01; OR in 
men: 4.40, 2.11-9.16), and at least a two-fold increase in the odds of having 
been recently diagnosed (OR in women 1.99, 1.12-3.54; OR in men 4.08, 1.40-
11.8). There was no notable difference in these comparisons when limiting to 
participants resident in England (data not shown).  
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Table 6-5: Percentage with a prevalent chlamydia infection, ever diagnosed with 
chlamydia and recently diagnosed with chlamydia by survey and odds ratio (OR) 
for difference between surveys (sexually-experienced 16-24 year-olds) 
 Natsal-2 Natsal-3 Natsal-3 v Natsal-2 Bases (W,UW) 
  % 95%C.I % 95%C.I OR 95%CI p Natsal-2 Natsal-3 
Women            
Ever diagnosed with 
chlamydia 
3.8% (2.8-5.2) 12.3% (10.6-14.1) 3.52 (2.47 - 5.01) <0.001 1246, 1188 968, 1740 
Diagnosed with 
chlamydia in the last 
year 
1.5% (0.9-2.4) 3.0% (2.2-4.0) 1.99 (1.12 - 3.54) 0.019 1239, 1188 968, 1740 
Prevalent chlamydia 
infection
a
 
3.1% (1.8-5.2) 3.2% (2.2-4.6) 1.04 (0.53 - 2.01) 0.92 348, 366 513, 821 
Men            
Ever diagnosed with 
chlamydia 
1.3% (0.6-2.5) 5.3% (4.1-6.7) 4.40 (2.11 - 9.16) <0.001 1224, 985 1003, 1375 
Diagnosed with 
chlamydia in the last 
year 
0.5% (0.2-1.3) 2.0% (1.3-3.0) 4.08 (1.40 - 11.84) 0.010 1222, 985 1003, 1375 
Prevalent chlamydia 
infection
a
 
2.9% (1.3-6.3) 2.6% (1.7-4.0) 0.91 (0.36 - 2.27) 0.83 357, 282 533, 690 
a
18 to 24 year-olds 
 
6.4.2.1 Correction for measurement error arising from imperfect 
diagnostic tests 
The difference between the ‘test-adjusted’ (i.e. adjusted for assay used) and the 
‘detection strategy-adjusted’ (i.e. adjusted for assay and specimen collection 
device) prevalence estimates was negligible (<0.1% difference among men; 
0.1% difference among women). This is to be expected, as nucleic acid 
amplification tests (NAATs) can detect chlamydia at very low organism 
loads,259,260 thus the additional urine concentration provided by the FirstBurst 
device makes little difference to the results achieved using NAATs.233 Given this 
negligible difference, the ‘detection strategy-adjusted’ estimates are presented 
for completeness.  
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The point estimate of the ‘detection strategy-adjusted’ prevalence was slightly 
lower than the unadjusted prevalence estimate in Natsal-2 among both women 
and men aged 18 to 24 (Figure 6-5). This might seem initially counterintuitive, 
as there is often a tendency to focus on imperfect sensitivity of tests and 
resultant false-negatives, thus creating an expectation that the lower sensitivity 
of LCx compared to AC2 would have underestimated chlamydia prevalence in 
Natsal-2. However, at such low levels of prevalence, small differences in the 
specificity dominate the direction of the measurement error.  
After adjustment for differences in the detection strategy, the prevalence in 
Natsal-3 was non-significantly higher than the adjusted prevalence in Natsal-2 
among both men (2.6% vs 2.2%, OR 1.12, 0.38-3.28) and women (3.2% vs 
2.5%, OR 1.35, 0.69-2.68). Thus, all else being equal, if Natsal-2 tests had 
been carried out using the same detection strategy as in Natsal-3 the estimated 
prevalence in Natsal-3 would likely have been higher than that of Natsal-2, but 
this would not have amounted to a statistically significant difference. 
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Figure 6-5: Odds ratio of chlamydia prevalence in Natsal-3, compared to 
unadjusted and ‘detection strategy adjusted’ prevalence in Natsal-2 (sexually-
experienced 18-24 year-old women and men) 
The solid markers and red dashed lines, show the unadjusted OR for prevalence in Natsal-3 
compared to Natsal-2. Each open marker shows the OR of the unadjusted Natsal-3 prevalence 
compared to the ‘detection strategy adjusted’ prevalence in Natsal-2.  
Women aged 18-24    
Natsal-2 comparison 
prevalence 
Natsal-2 
‘prevalence’ 
Natsal-3 
prevalence 
 Odds ratio  
(Natsal-3 v Natsal-2) 
Unadjusted 3.1% (1.8-5.2) 3.2% (2.2-4.6) 
 
1.04 (0.53-2.01) 
Natsal-2 adjusted for test and 
specimen-collection 
2.5%(1.0-4.9) 3.2% (2.2-4.6) 1.35 (0.69-2.68) 
    
   Odds ratio    
  Prevalence lower in Natsal-3           Prevalence higher in Natsal-3 
Men aged 18-24     
Natsal-2 comparison 
prevalence 
Natsal-2 
‘prevalence’ 
Natsal-3 
prevalence 
 Odds ratio  
(Natsal-3 v Natsal-2) 
Unadjusted  2.9% (1.3-6.3) 2.6% (1.7-4.0) 
 
0.91 (0.36-2.27) 
Natsal-2 adjusted for test and 
specimen-collection 
2.2% (0.4-6.2) 2.6% (1.7-4.0) 1.12 (0.38-3.28)   
    
   Odds ratio    
  Prevalence lower in Natsal-3            Prevalence higher in Natsal-3 
 
 
 
6.4.2.2 Combining urine infections with recent screen-detected diagnoses 
In Natsal-3, 0.9% of men and 1.6% of women aged 18 to 24 with a valid 
chlamydia test result had a ‘screen-detected’ diagnosis (i.e. reported a non-
clinically indicated reason for their last test) in the last year. Thus in Natsal-3, 
4.4% of women and 3.5% of men aged 18 to 24 years had a prevalent 
chlamydia infection and/or a screen-detected diagnosis in the last year. The 
proportion of Natsal-3 participants who had either a screen-detected diagnosis 
or a prevalent infection was non-statistically significantly higher than the 
proportion with a prevalent infection in Natsal-2 among both women (4.4% 
versus 3.1%, OR 1.45 95%CI 0.75-2.80) and men (3.5% versus 2.9%, OR 1.21 
 0.1  1.0  10.0
 0.1  1.0  10.0
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95%CI 0.49-2.97 ) (Figure 6-6). Thus, all else being equal, and assuming a) that 
in the absence of screening all these  ‘screen-detected’ infections would have 
persisted to the point of the Natsal-3 interview and b) that there were no screen-
detected infections in Natsal-2, there would have been a greater increase in 
prevalence between surveys than was observed. This would not have been 
detectable as a significant difference.   
Figure 6-6: Hypothetical scenario, showing odds ratio of chlamydia prevalence 
plus ‘screen-detected’ diagnosis in Natsal-3, compared to unadjusted prevalence 
in Natsal-2 (sexually experienced 18-24 year-old women and men).  
The solid markers and red dashed lines, show the unadjusted OR for prevalence in Natsal-3 
compared to Natsal-2. Each open marker shows the OR of the ‘screen-detected diagnoses’-
adjusted prevalence in Natsal-3 compared to the unadjusted Natsal-2 prevalence.  
Women aged 18-24    
Natsal-3 comparison prevalence 
Natsal-2 
prevalence 
Natsal-3 
‘prevalence’ 
 Odds ratio 
(Natsal-3 v Natsal-2) 
Unadjusted 3.1% (1.8-5.2) 3.2% (2.2-4.6) 
 
1.04 (0.53-2.01) 
Natsal-3 adjusted for recent, 
‘screen-detected’ diagnoses 
3.1% (1.8-5.2) 4.4% (3.1-6.3) 1.45 (0.75-2.80) 
    
   Odds ratio    
  Prevalence lower in Natsal-3    Prevalence higher in Natsal-3 
Men aged 18-24     
Natsal-3 comparison prevalence 
Natsal-2 
prevalence 
Natsal-3 
‘prevalence’ 
 Odds ratio  
(Natsal-3 v Natsal-2) 
Unadjusted 2.9% (1.3-6.3) 2.6% (1.7-4.0) 
 
0.91 (0.36-2.27) 
Natsal-3 adjusted for recent, 
‘screen-detected’ diagnoses 
2.9% (1.3-6.3) 3.5% (2.4-5.0) 1.21 (0.49-2.97) 
    
   Odds ratio    
  Prevalence lower in Natsal-3    Prevalence higher in Natsal-3 
    
 
 
6.4.2.3 Adjustment for hypothetical unmeasured differences between 
participants and non-participants  
Figure 6-7 shows the ‘participation-adjusted’ OR across the range of 
hypothetical combinations of participation bias in Natsal-2 and Natsal-3 
specified in section 6.3.3.5 for 18 to 24 year-old women and men. ORs 
 0.1  1.0  10.0
 0.1  1.0  10.0
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presented in red boxes are those where the comparison of ‘participation-
adjusted’ prevalence estimates (Table 6-6) resulted in an OR smaller than that 
using the unadjusted prevalence estimates; those in blue are where the 
participation-adjusted OR are greater than the unadjusted OR and those which 
are unshaded indicate where the participation-adjusted and unadjusted OR 
where equivalent (to 2 decimal places). Under the applied assumptions, the 
‘participation-adjusted’ OR of prevalent infection in Natsal-3 compared to 
Natsal-2 ranged from 0.68 to 1.58 for women and 0.59 to 1.37 for men. 
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Figure 6-7 Hypothetical odds ratio of prevalent infection in Natsal-3 versus 
Natsal-2 under different assumptions of unmeasured participation bias (sexually-
experienced 18-24 year-olds) 
Figures show hypothetical, ‘participation-adjusted’ odds ratios of prevalent infection in Natsal-3 
versus Natsal-2 using a weighted prevalence under different assumptions of the relative risk of 
having a prevalent infection in participants versus non-participants in each survey (see Table 
6-6). The colours of the boxes show whether the participation-adjusted’ OR is smaller (red 
boxes), larger (blue boxes) or the same (unshaded boxes) as the OR estimated using the 
unadjusted prevalence estimates.   
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Key:   
1.00 
OR of ‘participation-adjusted prevalence is smaller than that using unadjusted prevalence (i.e. 
OR of difference between surveys would have been underestimated) 
  
1.00 
OR of ‘participation-adjusted prevalence is equivalent to that using unadjusted prevalence (i.e. 
OR of difference between surveys would not have been affected.) 
  
1.00 
OR of ‘participation-adjusted prevalence is larger than unadjusted prevalence (i.e. OR of 
difference between surveys would have been overestimated) 
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Table 6-6: Hypothetical effect of unmeasured participation biases on estimates of 
difference in prevalence in Natsal-2 and Natsal-3 (sexually-experienced 18-24 
year-olds) 
Natsal-2 Natsal-3 
(a) Relative risk 
of prevalent 
infection, 
participants v 
non-
participants 
(b) Hypothetical 
prevalence in 
non-participants 
(c)Hypothetical 
‘participation-
adjusted’ 
prevalence 
 
(d Relative risk 
of prevalent 
infection, 
participants v 
non-
participants 
(e) Hypothetical 
prevalence in 
non-
participants 
 
(f) Hypothetical 
‘participation-
adjusted’ 
prevalence 
 
0.5 6.2% 4.2% 0.5 6.4% 4.3% 
0.5 6.2% 4.2% 0.75 4.3% 3.6% 
0.5 6.2% 4.2% 1 3.2% 3.2% 
0.5 6.2% 4.2% 1.25 2.6% 3.0% 
0.5 6.2% 4.2% 1.5 2.1% 2.9% 
0.75 4.1% 3.5% 0.5 6.4% 4.3% 
0.75 4.1% 3.5% 0.75 4.3% 3.6% 
0.75 4.1% 3.5% 1 3.2% 3.2% 
0.75 4.1% 3.5% 1.25 2.6% 3.0% 
0.75 4.1% 3.5% 1.5 2.1% 2.9% 
1 3.1% 3.1% 0.5 6.4% 4.3% 
1 3.1% 3.1% 0.75 4.3% 3.6% 
1 3.1% 3.1% 1 3.2% 3.2% 
1 3.1% 3.1% 1.25 2.6% 3.0% 
1 3.1% 3.1% 1.5 2.1% 2.9% 
1.25 2.5% 2.9% 0.5 6.4% 4.3% 
1.25 2.5% 2.9% 0.75 4.3% 3.6% 
1.25 2.5% 2.9% 1 3.2% 3.2% 
1.25 2.5% 2.9% 1.25 2.6% 3.0% 
1.25 2.5% 2.9% 1.5 2.1% 2.9% 
1.5 2.1% 2.7% 0.5 6.4% 4.3% 
1.5 2.1% 2.7% 0.75 4.3% 3.6% 
1.5 2.1% 2.7% 1 3.2% 3.2% 
1.5 2.1% 2.7% 1.25 2.6% 3.0% 
1.5 2.1% 2.7% 1.5 2.1% 2.9% 
Notes on calculations 
(b) Measured prevalence in participants (3.1%) x (a) 
(c) Weighted prevalence of (b) and 3.1% using response rate (65.4%)
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(e) Measured prevalence in participants (3.2%) x (d) 
(f) Weighted prevalence of (b) and 3.2% using response rate (67.3%)
5
 
 
Figure 6-7 shows that where the extent and direction of the hypothetical 
participation bias was similar in each year, even though each estimate of 
prevalence may itself be biased, the impact on comparisons between the years 
was minimal. For example, if in both Natsal-2 and Natsal-3, the relative risk of 
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having a prevalent infection in participants v non-participants in 18 to 24 year-
old women was 1.25 in each year, the ‘participation-adjusted’ prevalence would 
have been 2.9% in Natsal-2, compared to the 3.1% that was actually estimated 
in the survey; in Natsal-3, the ‘participation-adjusted’ prevalence would have 
been 3.0%, compared to the 3.2% actually measured. Although in this scenario 
the actual estimates in both Natsal-2 and Natsal-3 would have been biased 
towards a higher prevalence, the resulting ORs of testing positive in Natsal-3 
versus Natsal-2 are equivalent (to 2 decimal places), being 1.04 for both the 
‘participation-adjusted’ OR and the unadjusted OR.  
Figure 6-7 also shows that the potential for comparisons between surveys to be 
affected was greater where the direction of the hypothetical bias was the same, 
but the extent was different. Again taking the example of 18 to 24 year-old 
women, if the relative risk of having a prevalent infection in participants v non-
participants was 1.25 in Natsal-2 but 1.5 in Natsal-3, the ‘participation-adjusted’ 
OR would be 0.99, compared to the unadjusted OR of 1.04.  The most extreme 
impact on comparisons between surveys arose from where the direction of bias 
was assumed to be different in each survey, and the difference between 
participants and non-participants in each year was large.  
6.4.2.4 Indicators of change in sexual behavioural risk of transmission 
Reported numbers of sexual partners, non-condom use and prevalence of non-
vaccine HPV types (see section 6.3.3.6), tended to be similar or slightly higher 
for women and lower for men in Natsal-3 compared to Natsal-2 (Figure 6-8), 
although none of the observed differences were statistically significant. In both 
women and men, the proportion reporting non-use of condoms at last sex was 
very similar between the surveys. However, after stratifying by partnership type, 
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the percentage who reported not having used a condom at last sex increased 
between surveys from 43% to 56% in women and 34% to 38% in men whose 
last sex was with a non-steady partner. This was not a statistically significant 
difference.  
There was no change in the median age at first intercourse among sexually-
experienced 18 to 24 year-olds between Natsal-3 and Natsal-2 (16 years 
among women and men). However, among Natsal-3 participants, the proportion 
who reported having had sex by the age of 16 increased with decreasing age. 
The proportion of women who reported having sex by age 16 increased by an 
average of 3% per year (relative to that measured in the previous year) from 
2000 to 2012 in both women (prevalence ratio 1.03, 1.02-1.05, p<0.001) and 
men (prevalence ratio 1.03, 1.01-1.06, p=0.003) (Figure 6-9). 
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Figure 6-8: Prevalence of non-vaccine HPV and selected sexual behaviours 
among sexually experienced 18-24 year-olds in Natsal-2 and Natsal-3  
Error bars show 95% confidence intervals on the prevalence of non-vaccine HPV or reported 
sexual behaviour. OR: Unadjusted odds ratio (95%CI shown in parentheses) for Natsal-3 
versus Natsal-2, derived using logistic regression. Reference groups are those without the 
reported characteristic. 
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Figure 6-9: Proportion reporting having had heterosexual sex before the age of 
16 by year turned 16 (Natsal-3) 
The shaded area shows 95% confidence intervals. Participants who report having had sex 
before the age of 13 are excluded from the denominator. 
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6.5 Discussion 
6.5.1 Key findings 
There was no significant difference in chlamydia prevalence, as measured in 
the second and third Natsal surveys, in 2010-12 compared to that in 1999-2001. 
Adjusting for the different tests used in each survey did not alter the conclusions 
that can be made about the difference in chlamydia prevalence.  
6.5.2 Strengths and limitations 
The main strength of this analyses was that it used data from two probability 
surveys with high response rates, with the two surveys having been carried out 
before (Natsal-2) and after (Natsal-3) the implementation of the NCSP.  
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The sample size available was the main limitation for the comparisons of 
prevalence for each year. As a result, the Natsal surveys were consistent with a 
wide range of scenarios, from at least a halving of the odds of infection to more 
than doubling of the odds of infection between surveys (unadjusted 95%CIs 
ranged from at least 0.5 to 2  in both women and men). None of the adjusted 
estimates (i.e. adjusted for detection strategy, for screen-detected diagnoses or 
for hypothetical unmeasured participation bias) approached statistical 
significance, although the direction of the adjustments was informative. This 
analysis showed that in some scenarios, unmeasured participation bias may 
affect comparisons between surveys. However even after adjustment for a wide 
range of scenarios, the point estimates for prevalence differences lay within the 
95% confidence intervals for odds ratios based on the unadjusted Natsal 
estimates, again emphasising the limitations arising from the available sample 
size. One alternative to investigating change in chlamydia prevalence relative to 
HPV prevalence and sexual behaviours would have been to include these 
variables as confounders in a regression model. The small absolute numbers of 
prevalent infections meant results from such an analysis would be subject to 
considerable error, so this was not pursued. 
Adjustment for the differences in the detection strategy used in each survey was 
limited by the data available on the sensitivity and specificity of the LCx and the 
AC2 and the urine cup compared to the FirstBurst urine collection device. As 
the adjusted prevalence used the AC2 as the gold standard, this may be a 
biased estimator of the ‘true’ prevalence of infection in the population if the AC2 
is not a perfect test. An alternative approach would have been to also adjust the 
Natsal-3 prevalence for AC2 performance characteristics. However this 
approach would introduce substantial uncertainty, as measuring the sensitivity 
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and specificity of diagnostic tests is highly dependent on the gold standard 
used, and there is no agreed reference standard for chlamydia NAATs.244 The 
use of the point estimate of the sensitivity and specificity LCx versus AC2 is 
also an oversimplification, which did not incorporate the error within the 
sensitivity and specificity measurement. However as there was no significant 
difference when using these adjusted estimates, even wider confidence 
intervals would not alter the interpretation. There is only one published study 
which compares the FirstBurst to the urine cup. This was limited to samples 
from men and used a different NAAT (Amplicor CTY/NG PCR)233. However 
additional studies are unlikely to have affected these findings as low 
prevalences are more subject to error arising from imperfect specificity rather 
than sensitivity, and only marginal additional benefit would be expected from 
increased organism load when measuring chlamydia prevalence among the 
general population. 
In comparing the prevalence plus ‘screen-detected’ diagnoses, it was assumed 
that all diagnoses in Natsal-2 had come about as a result of clinically-indicated 
testing. As no data were collected on reason for test, this is a simplification and 
it is feasible that a proportion of diagnoses may have come about as a result of 
asymptomatic screening activity.  
The analysis did not account for all of the differences between the surveys. 
Degradation of specimens during transit (and storage, for HPV) may also have 
led to prevalence having been underestimated in Natsal-2 and Natsal-3. This 
was not investigated in detail, as quantitative estimates of the loss of precision 
were not available. This was acknowledged at the time of the Natsal-2 survey 
as a potential cause of underestimating prevalence.133,234 Degradation is also 
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feasible in Natsal-3, although all specimens were transported in accordance 
with the manufacturer’s instructions, and AC2 specimens are considered to be 
stable at room temperature for several months. Given the large confidence 
intervals on the unadjusted and adjusted estimates of prevalence difference, 
this potential difference is again unlikely to materially affect conclusions which 
can be made based on the Natsal surveys. 
Prevalent chlamydia infection was measured in urine samples. This may have 
missed some infections in women among whom vulvovaginal swabs 
demonstrate marginally higher sensitivity.261 Urine sampling will also have 
missed rectal infections, leading to underestimation of the total currently 
infected with chlamydia. However, the impact on our findings is likely minimal as 
men who have sex with men made up a small proportion of this sample of 
Natsal participants.235 
6.5.3 Implications for evaluation of chlamydia control 
Although comparisons between the surveys had limited power due to the 
sample size available, there was no evidence to support there having been a 
decrease in prevalence between the surveys. However, there was some 
indication that risk behaviours relating to transmission risk may have increased 
among young women, but not in men. Additionally, the analysis that combined 
‘screen-detected’ diagnoses with prevalent infections in Natsal-3 suggested that 
if all screen-detected infections in Natsal-3 had persisted to the time of the 
interview, then the prevalence in Natsal-3 would have been higher. Thus, in the 
absence of widespread chlamydia screening, chlamydia incidence and 
prevalence might have been expected to increase.  However this remains an 
unproven hypothesis, as there is no evidence to determine how many, if any of 
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the ‘screen-detected’ infections would have persisted to the point of the 
interview and an increase in risk behaviours was not seen in all groups, or 
consistently across several behaviours, and there was no increase seen in non-
vaccine high risk HPV types among women.  
6.5.4 Summary 
In summary, there is no definitive evidence from the Natsal surveys to suggest 
that chlamydia prevalence has changed in either absolute terms or relative to 
indicators of sexual behavioural risk during a period of increased chlamydia 
testing and screening. Returning to the notion of process monitoring described 
in Chapter 2, it is important to understand how chlamydia screening has been 
delivered to consider whether we would have expected prevalence to have 
decreased over this period. In the next chapter, I use data from Natsal-3 to 
investigate the implementation of chlamydia screening in relation to risk of 
infection in more detail.  
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7 Chlamydia prevalence, diagnosis and testing among 16 
to 24 year-old participants in the third National Survey of 
Sexual Attitudes and Lifestyles (Natsal-3)  
In the previous chapter I compared the prevalence of chlamydia estimated in the 
second and third Natsal surveys, which were conducted before and after the 
implementation of the NCSP, and found no definitive evidence to suggest that 
chlamydia prevalence had decreased in the ten years between the surveys. In this 
chapter I use Natsal-3 data to further our understanding of how chlamydia screening 
had been delivered in practice up to 2012.  
7.1 Background 
As Natsal-3 measured prevalent infection and also collected data on self-
reported chlamydia testing and diagnoses, the survey presents a unique 
opportunity to explore factors associated with testing and infection within the 
same population, three to five years after the NCSP had been nationally-
implemented. Sonnenberg et al have previously reported an overview of STI 
prevalence and service use using data from Natsal-3, including chlamydia 
prevalence and self-reported testing in the last year among 16 to 24 year-olds.23 
Although Sonnenberg et al reported prevalence by age group, factors 
associated with prevalent infection were assessed among all 16 to 44 year-olds 
and only a limited number of factors associated with chlamydia prevalence and 
testing were explored (age group, area-level deprivation, number of sexual 
partners in the last year, sexual partners in the last year without a condom 
[investigated for prevalence only], age at first sex and any same-sex 
experience). In this chapter, a detailed analysis of 16 to 24 year-olds in Britain 
(as the age group targeted by the NCSP) is presented. Factors associated with 
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prevalent chlamydia infection, previous chlamydia diagnosis and chlamydia 
testing are described and compared to assess the extent to which, up to 2012, 
opportunistic chlamydia screening was reaching 16 to 24 year-olds at risk of 
chlamydia. 
7.2 Aims & objectives 
To investigate whether chlamydia screening patterns indicate that chlamydia 
screening has been delivered in such a way that we would expect it to effect a 
reduction in the incidence or prevalence of infection. This aim was addressed 
through the following objectives: 
 Using data from Natsal-3, to describe self-reported chlamydia testing, self-
reported diagnosis and prevalent infection (detected in urine) among 16 to 
24 year-olds living in Britain in 2010-12 by sociodemographic, clinical and 
behavioural variables. 
 To compare factors associated with self-reported chlamydia testing, self-
reported diagnosis and prevalent infection (detected in urine) among 16 to 
24 year-olds in Natsal-3. 
 
7.3 Methods 
7.3.1 Participants 
A flow chart of participants included in this analysis is presented in Figure 7-1. 
Analyses of recent testing (self-reported testing in the last year) and recent 
diagnosis (self-reported diagnosis in the last year) were based on sexually-
experienced 16 to 24 year-olds (n=3,115). Analyses of prevalent infection (C. 
trachomatis detected in urine) were among those who provided a urine sample 
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for STI testing and for whom a valid chlamydia test result is available (n=1,832, 
62 of whom had a prevalent chlamydia infection detected in urine).  
Figure 7-1: Flow chart showing participants included in analyses of self-reported 
chlamydia testing, self-reported diagnosis and prevalent infection detected in 
urine (16 to 24 year-old Natsal-3 participants) 
 
 
 
 
 
 
 
 
Key 
Stat 
 
 
 
  
Participants included in 
analyses of self-reported 
testing and diagnoses 
Participants included in 
analyses of prevalent 
infection 
Urine sample provided 
(n=1,952) 
Valid chlamydia test result 
(n=1,832: 992 women, 840 
men) 
Insufficient samples, 
mislabelled or missing 
consent (n=120) 
Chlamydia detected in urine 
(n=62 [37 women; 25 men]) 
Chlamydia not detected in urine 
(n=1,770) 
Did not agree to provide 
a urine sample (n=1,163) 
16 to 24 year-old 
participants 
(n=3,869) 
Sexually-experienced 
(n=3,115: 1,740 women; 
1,375 men) 
Did not report any sexual 
partner over the lifetime 
(n=754) 
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7.3.2 Statistical analysis 
Analyses were carried out using Stata 12.1, accounting for the weighting, 
clustering and stratification of the Natsal data23,172,235 as set out in the previous 
chapter (section 6.3.3). 
Factors associated with prevalent infection, recent diagnosis and recent testing 
were investigated using univariable and multivariable logistic regression, for 
women and men separately. While the overall percentage of 16 to 24 year-olds 
who reported having been diagnosed with chlamydia (ever or in the last year) is 
reported among the sexually-experienced population, risk factors for recent 
diagnosis were investigated among those with a recent test so that results 
represent associations with infection at the time of test and not with testing per 
se. Sociodemographic and behavioural factors reported to be associated with 
STI risk were included as predictor variables.133,262,263 Associations with 
deprivation were explored using both residence-based (quintile of IMD for the 
LSOA of residence) and individual-based (age left school) measures. Sexual 
behaviours investigated included numbers of sexual partners in the last year 
(total, new, without a condom), number of lifetime sexual partners and condom 
use at last sex.  Frequency of binge drinking (>6/8 units on one occasion in 
women/men) was included as a proxy for sexual risk behaviour that may not be 
captured in reported numbers of sexual partners. 
Two approaches to multivariable modelling were explored; maximal and 
parsimonious models were constructed for all outcomes of interest. To fit 
parsimonious models, variables found significant at p<0.1 in univariable 
analyses were entered into a multivariable model selection process based on 
backwards selection whereby variables were removed from the model if the 
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statistical significance of their association with the outcome had an associated p 
value of >0.05. Only those variables significantly associated with the outcome 
were retained in the final parsimonious models. For maximal models, all 
variables included in univariable models were included with two exceptions: 
number of sexual partners in the last year was not included due to collinearity 
with other sexual partnership variables; age left school was not included as data 
were unavailable for 16 year-olds. The results from the two models were largely 
comparable (see Appendix 2 for a detailed comparison). Results from the 
maximal models are therefore presented in the results section below to provide 
odds ratios (OR) adjusted for potential confounders.  
In order to explore how chlamydia infections were distributed across different 
risk groups, the proportion reporting different demographic and behavioural 
factors was calculated among a) individuals with a prevalent infection, b) 
individuals with a recent diagnosis and c) the sexually-experienced population. 
Sub-group analyses by country (England, Scotland and Wales) were performed 
when the difference in screening practice between countries was of potential 
relevance.  
7.4 Results 
7.4.1.1 Reason and location for last test (Natsal-3) 
Among 16 to 24 year-olds who reported recently testing, fewer than 10% 
reported a clinical indication (symptoms; a partner with chlamydia/symptoms; 
check-up after a previous diagnosis) for their last test (Table 7-1). Around three-
quarters of women and half of men had last been tested in either a sexual 
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health clinic, GP surgery, or a family planning clinic. When limiting to women 
and men recently diagnosed, 29.0% had last been tested due to having 
symptoms and 20.9% due to having a partner diagnosed with chlamydia or with 
symptoms (Table 7-1). Almost all of (95.4%) of those recently diagnosed had 
been most recently tested in a sexual health clinic, family planning clinic, or GP 
surgery. Whereas 17% of all recent tests had been carried out in educational 
settings, only 1.7% of those recently diagnosed reported their last test in this 
setting.  
Table 7-1: Reason and location of most recent chlamydia test, among those 
tested for chlamydia in the last year, by whether diagnosed in last year (16-24 
year-old sexually-experienced women and men)  
 By sex By whether diagnosed in the last 
year
a
 
 
Women Men 
Diagnosed in the last 
year 
Not diagnosed in 
the last year 
 
Percent 95%CI Percent 95%CI Percent 95%CI Percent 95%CI 
Denominator (W,UW) 523, 943 347, 475 48, 81 816, 1330 
Reason for most recent test 
Had symptoms 4.2% (3.0-5.8) 4.2% (2.7-6.5) 29.0% (19.0-41.5) 2.7%  (1.9-3.8) 
Partner diagnosed with 
chlamydia or had symptoms 
2.8% (1.7-4.5) 3.8% (2.4-6.1) 20.9% (12.8-32.2) 2.2%  (1.4-3.4) 
Check up after a previous 
positive 
1.3% (0.63-2.6) 0.95% (0.33-2.7) 8.6% (3.2-21.1) 0.7%  (0.4-1.4 
Wanted a check-up / offered 
a test / worried about risk 
84.9% (82.1-87.4) 87.3% (83.8-90.1) 37.2% (26.2-49.86) 88.7%  (86.8-90.4) 
Other 6.8% (5.3-8.7) 3.7% (2.3-6.0) 4.3% (1.5-12.0) 5.7%  (4.5-7.1) 
Location of most recent chlamydia test 
Sexual health clinic 28.9% (25.5-32.6) 30.5% (25.9-35.5) 62.9% (50.4-73.9) 27.6%  (25.0-30.4) 
GP surgery 35.1% (31.7-38.6) 17.0% (13.6-20.9) 27.1% (17.7-39.1) 28.0%  (25.3-30.8) 
NHS FP clinic 9.2% (7.4-11.4) 4.3% (2.7-6.8) 5.4% (1.6-16.3) 7.3%  (6.0-8.9) 
School, college or university 11.6% (9.4-14.2) 24.5% (20.4-29.1) 1.7% (0.4-7.2) 17.5%  (15.2-20.1) 
Elsewhere 15.2% (12.9-17.8) 23.8% (19.3-28.9) 2.9% (1.0-8.1) 19.6%  (17.2-22.2) 
GP: General practice; FP: Family planning. 
a
Women and men were combined due to small 
denominator for diagnosed in the last year. 
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7.4.1.2 Factors associated with infection, diagnosis and testing 
Table 7-2 explores associations between sociodemographic and behavioural 
variables and prevalent infection, recent testing and recent diagnosis. In 
univariable analyses, higher numbers of sexual partners (total/new/without a 
condom) in the last year were significantly (p<0.05) associated with prevalent 
infection among women and men. In women, area-level deprivation and 
frequency of binge drinking were also associated with prevalent infection. 
Among men, number of lifetime sexual partners, age group, age left school, age 
at first sex, and condom non-use at last sex were significantly associated with 
prevalent infection. Similar factors were associated with recent diagnosis 
among those tested. In multivariable analyses, living in more deprived areas 
and more frequent binge drinking remained significantly associated with having 
a prevalent infection in women (AOR 4.23, 95%CI 1.53-11.6, p=0.01; AOR 
2.51, 95%CI 1.08-5.76, p=0.01 respectively). Being aged 20 to 24 years (AOR 
7.54, 95%CI 1.37-41.3, p=0.02), living in more deprived areas (AOR 3.75, 
95%CI 1.11-12.5, p=0.04) and higher numbers of lifetime sexual partners (>10 
versus 1-4, AOR 8.69, 1.21-62.0, p=0.03) remained significantly associated with 
prevalent infection in men.  
 Table 7-2a: Percentage, unadjusted and adjusted odds (OR/AOR) ratios for prevalent chlamydia infection, self-reported diagnosis in the 
last year and self-reported testing by sociodemographic and behavioural factors (16-24 year-old sexually-experienced women, Natsal-3) 
 
Prevalent chlamydia infection detected in urine 
(n=992) 
Diagnosed with chlamydia in the last year 
(among those tested in the last year) (n=940) 
Tested for chlamydia in the last year 
(n=1,736) 
Denominator  
(weighted, unweighted)
 a
 
 
% (95%CI) OR (95%CI) p AOR
b
 (95%CI) p % (95%CI) OR (95%CI) p AOR
b
 (95%CI) p % (95%CI) OR (95%CI) p AOR
b
 (95%CI) p Infection Diagnosis Tested 
Age group                           
16-19 3.8% (2.2-6.3) 1.00 - 0.36 1.00 - 0.50 6.0% (3.8-9.2) 1.00 - 0.62 1.00 - 0.58 56.6% (52.5-60.6) 1.00 - 0.16 1.00 - 0.15 214, 395 193, 375 343, 672 
20-24 2.7% (1.7-4.3) 0.71 (0.35-1.46)  0.71 (0.27-1.87)  5.1% (3.4-7.6) 0.86 (0.46-1.60)  0.80 (0.35-1.78)  52.8% (49.2-56.4) 0.86 (0.69-1.06)  0.82 (0.62-1.07)  383, 597 329, 565 623, 1064 
Country
c
                            
England 2.9% (2.0-4.3) 1.00 - 0.53 1.00 - 0.48        57.1% (54.1-60.1) 1.00 - <0.01 1.00 - <0.01 504, 817 469, 832 823, 1452 
Scotland 3.1% (1.1-8.6) 1.08 (0.35-3.33)  1.34 (0.43-4.14)         32.4% (24.4-41.5) 0.36 (0.24-0.54)  0.29 (0.18-0.45)  56, 103 30, 58 91, 178 
Wales 5.3% (1.9-13.8) 1.87 (0.63-5.60)  1.88 (0.63-5.54)         45.6% (36.2-55.4) 0.63 (0.42-0.94)  0.53 (0.32-0.85)  37, 72 24, 50 52, 106 
IMD quintile of LSOA of residence
d
                    
2 least deprived  1.3% (0.5-3.4) 1.00 - 0.01 1.00 - 0.01 4.8% (2.8-8.1) 1.00 - 0.23 1.00 - 0.36 54.2% (49.5-58.8) 1.00 - 0.99 1.00 - 0.94 213, 355 183, 319 338, 595 
Middle quintile 1.8% (0.8-4.2) 1.37 (0.38-4.90)  1.40 (0.39-4.98)  3.5% (1.6-7.3) 0.71 (0.27-1.86)  1.06 (0.37-3.04)  54.4% (48.0-60.7) 1.01 (0.74-1.38)  1.03 (0.71-1.48)  111, 174 102, 176 189, 324 
2 most deprived 4.9% (3.3-7.3) 3.82 (1.35-10.8)  4.23 (1.53-11.6)  6.8% (4.6-10.0) 1.46 (0.73-2.93)  1.70 (0.73-3.91)  54.0% (49.8-58.2) 0.99 (0.77-1.27)  0.97 (0.73-1.29)  273, 463 236, 445 439, 817 
Age left school
e
                            
17+ 3.2% (2.1-4.8) 1.00 - 0.88    5.2% (3.6-7.5) 1.00 - 0.58    54.3% (51.0-57.6) 1.00 - 0.70    445, 700 387, 658 715, 1217 
16 3.4% (1.9-6.0) 1.06 (0.50-2.22)     6.2% (3.7-10.5) 1.21 (0.62-2.37)     55.5% (50.1-60.8) 1.05 (0.82-1.35)     120, 229 109, 228 196, 405 
Frequency of binge drinking                    
Never / <monthly 2.5% (1.5-4.1) 1.00 - <0.01 1.00 - 0.01 3.7% (2.4-5.7) 1.00 - 0.03 1.00 - 0.28 52.1% (48.7-55.5) 1.00 - 0.01 1.00 - 0.08 373, 598 312, 561 601, 1085 
Monthly 1.2% (0.5-3.3) 0.49 (0.16-1.52)  0.46 (0.13-1.51)  6.6% (3.6-11.8) 1.85 (0.85-4.01)  1.91 (0.74-4.89)  52.4% (46.6-58.2) 1.01 (0.78-1.32)  0.75 (0.54-1.02)  130, 226 112, 200 214, 375 
>weekly  7.9% (4.7-13.1) 3.35 (1.55-7.25)  2.51 (1.08-5.76)  9.4% (5.2-16.3) 2.69 (1.25-5.80)  2.06 (0.75-5.61)  64.4% (57.6-70.7) 1.66 (1.22-2.27)  1.16 (0.81-1.64)  95, 168 97, 177 151, 274 
Age at first heterosexual sex                      
17+ 1.6% (0.7-3.7) 1.00 - 0.15 1.00 - 0.42 4.1% (1.8-8.9) 1.00 - 0.37 1.00 - 0.93 43.9% (38.7-49.1) 1.00 - <0.01 1.00 - 0.05 188, 246 137, 215 313, 489 
16 3.9% (2.1-6.9) 2.52 (0.86-7.36)  2.20 (0.67-7.17)  5.0% (2.8-8.9) 1.24 (0.44-3.55)  0.80 (0.26-2.42)  56.4% (51.6-61.1) 1.66 (1.25-2.20)  1.39 (0.99-1.92)  178, 304 154, 272 273, 503 
<16 4.0% (2.4-6.6) 2.65 (0.95-7.36)  1.82 (0.60-5.42)  6.9% (4.8-9.9) 1.76 (0.70-4.41)  0.89 (0.35-2.25)  63.9% (59.8-67.9) 2.27 (1.75-2.94)  1.44 (1.05-1.97)  213, 415 220, 429 344, 680 
Condom used for most recent sex with most recent partner                    
Yes 2.8% (1.5-5.3) 1.00 - 0.53 1.00 - 0.29 3.4% (1.6-7.0) 1.00 - 0.14 1.00 - 0.14 51.6% (46.9-56.3) 1.00 - 0.03 1.00 - 0.97 202, 314 170, 303 330, 586 
No 3.6% (2.4-5.4) 1.28 (0.59-2.80)  1.59 (0.67-3.74)  6.3% (4.4-8.9) 1.90 (0.81-4.49)  1.88 (0.81-4.32)  58.0% (54.6-61.3) 1.30 (1.03-1.63)  1.01 (0.74-1.35)  352, 613 328, 592 567, 1027 
Number of sexual partners in the last year                    
0 or 1 2.5% (1.5-4.0) 1.00 - 0.03    3.0% (1.7-5.4) 1.00 - 0.01    46.6% (43.3-50.0) 1.00 - <0.01    387, 600 291, 507 624, 1096 
2 3.9% (1.8-8.5) 1.62 (0.63-4.15)     6.6% (3.7-11.6) 2.25 (0.98-5.18)     65.2% (58.8-71.1) 2.15 (1.59-2.89)     90, 161 93, 178 143, 275 
3 to 4 1.9% (0.7-5.1) 0.75 (0.24-2.33)     8.8% (5.2-14.6) 3.08 (1.34-7.05)     69.7% (62.0-76.4) 2.63 (1.82-3.80)     63, 127 76, 146 111, 210 
5+ 8.3% (3.9-16.8) 3.57 (1.39-9.17)     11.6% (6.2-20.8) 4.19 (1.69-10.4)     74.8% (64.4-83.0) 3.40 (2.05-5.65)     49, 93 58, 101 77, 135 
 
  
 Table 7-2a continued.  
 
Number of new sexual partners in the last year                   
0 2.2% (1.3-3.7) 1.00 - 0.03 1.00 - 0.70 2.8% (1.5-5.0) 1.00 - <0.01 1.00 - 0.11 45.6% (41.9-49.3) 1.00 - <0.01 1.00 - <0.01 313, 495 226, 397 495, 873 
1 2.8% (1.2-6.3) 1.26 (0.47-3.41)  1.17 (0.38-3.52)  4.8% (2.5-9.1) 1.76 (0.71-4.38)  1.89 (0.69-5.16)  59.2% (54.0-64.2) 1.73 (1.34-2.23)  1.69 (1.25-2.27)  160, 263 156, 287 264, 485 
2+ 5.9% (3.5-9.8) 2.73 (1.26-5.93)  1.65 (0.50-5.39)  10.7% (7.3-15.6) 4.23 (2.04-8.79)  3.09 (1.07-8.86)  70.0% (63.8-75.6) 2.79 (2.03-3.84)  1.46 (0.95-2.21)  118, 225 137, 249 197, 359 
Number of sexual partners in the last year without a condom                  
0 2.9% (1.2-7.1) 1.00 - 0.03 1.00 - 0.18 4.2% (1.5-11.6) 1.00 - <0.01 1.00 - 0.84 36.4% (30.8-42.3) 1.00 - <0.01   0.05 120, 173 76, 130 210, 361 
1 2.2% (1.4-3.6) 0.76 (0.26-2.17)  0.34 (0.10-1.10)  3.8% (2.4-6.1) 0.90 (0.27-2.94)  0.72 (0.15-3.21)  54.7% (51.4-58.0) 2.11 (1.61-2.78)  1.52 (1.03-2.24)  368, 606 319, 567 585, 1049 
2+ 6.3% (3.5-11.2) 2.25 (0.73-6.93)  0.49 (0.12-1.83)  10.3% (7.0-15.0) 2.60 (0.80-8.46)  0.90 (0.18-4.49)  74.2% (68.3-79.4) 5.04 (3.47-7.32)  1.86 (1.09-3.15)  108, 212 126, 241 169, 322 
Concurrent partnerships in last year
f
                     
No 2.7% (1.8-4.2) 1.00 - 0.19 1.00 - 0.85 4.3% (2.9-6.4) 1.00 - 0.13 1.00 - 0.46 51.0% (47.8-54.2) 1.00 - <0.01 1.00 - 0.05 439, 706 361, 639 710, 1256 
Yes 6.3% (2.9-13.4) 2.40 (0.94-6.15)  1.34 (0.48-3.70)  8.1% (4.1-15.3) 1.95 (0.84-4.54)  0.75 (0.27-2.00)  74.6% (67.1-80.8) 2.81 (1.93-4.09)  1.46 (0.93-2.28)  66, 134 78, 146 105, 196 
Unknown 3.1% (1.3-7.2) 1.14 (0.43-3.04)  1.13 (0.38-3.31)  7.8% (4.3-13.9) 1.88 (0.90-3.94)  1.46 (0.62-3.38)  64.6% (57.5-71.2) 1.76 (1.27-2.42)  1.53 (1.02-2.28)  73, 127 76, 144 117, 226 
Number of lifetime sexual partners                    
1 to 4 2.4% (1.4-4.2) 1.00 - 0.14 1.00 - 0.67 2.1% (1.1-4.0) 1.00 - <0.01 1.00 - 0.08 43.5% (40.0-47.1) 1.00 - <0.01 1.00 - <0.01 321, 482 218, 391 503, 894 
5 to 9 2.8% (1.4-5.2) 1.15 (0.48-2.75)  0.87 (0.32-2.32)  6.2% (3.7-10.3) 3.07 (1.33-7.07)  2.40 (0.90-6.37)  63.8% (58.5-68.7) 2.29 (1.76-2.96)  1.96 (1.43-2.69)  150, 267 161, 289 252, 453 
10+ 5.4% (2.9-9.7) 2.29 (0.97-5.39)  1.39 (0.45-4.18)  9.9% (6.5-14.7) 5.12 (2.31-11.3)  3.76 (1.19-11.8)  69.6% (63.9-74.7) 2.97 (2.22-3.98)  2.11 (1.41-3.13)  121, 234 141, 254 202, 373 
Ever had any same sex experience/contact                    
No 3.1% (2.1-4.4) 1.00 - 0.92 1.00 - 0.49 5.3% (3.7-7.5) 1.00 - 0.72 1.00 - 0.44 51.9% (48.8-55.0) 1.00 - <0.01 1.00 - 0.24 473, 750 388, 704 749, 1352 
Yes 3.2% (1.4-7.1) 1.05 (0.42-2.63)  0.74 (0.30-1.76)  5.9% (3.5-10.0) 1.13 (0.57-2.24)  0.71 (0.30-1.68)  61.9% (56.0-67.5) 1.51 (1.15-1.98)  1.21 (0.88-1.65)  124, 242 134, 236 218, 384 
 
  
 Table 7-2b: Proportion, unadjusted and adjusted odds ratios for prevalent chlamydia infection, self-reported diagnosis in the last year and 
self-reported testing by sociodemographic and behavioural factors (16-24 year-old sexually-experienced men, Natsal-3) 
 
 
Prevalent chlamydia infection detected in urine 
(n=840) 
Diagnosed with chlamydia in the last year 
(among those tested in the last year) (n=471) 
Tested for chlamydia in the last year 
(n=1,375) 
Denominator 
(weighted, unweighted)
a
 
 
% (95%CI) OR (95%CI) p AOR
b
 (95%CI) p % (95%CI) OR (95%CI) p AOR
b
 (95%CI) p % (95%CI) OR (95%CI) p AORb (95%CI) p Infection Diagnosis Tested 
Age group                            
16-19 0.3% (0.1-1.4) 1.00 - <0.01 1.00 - 0.02 4.7% (2.4-9.0) 1.00 - 0.41 1.00 - 0.61 40.4% (35.9-45.1) 1.00 - <0.01 1.00 - <0.01 234, 343 151, 226 374, 582 
20-24 3.4% (2.2-5.2) 10.6 (2.40-46.3)  7.54 (1.37-41.3)  6.7% (3.9-11.1) 1.46 (0.59-3.58)  0.76 (0.26-2.15)  31.1% (27.8-34.7) 0.67 (0.52-0.86)  0.53 (0.37-0.73)  391, 497 192, 245 629, 793 
Country
c
                            
England 1.9% (1.2-3.0) 1.00 - 0.12 1.00 - 0.27        37.3% (34.3-40.3) 1.00 - <0.01 1.00 - <0.01 532, 719 316, 440 859, 1181 
Scotland 5.7% (2.1-14.3) 3.13 (1.04-9.45)  3.16 (0.78-12.8)         22.2% (14.0-33.5) 0.48 (0.27-0.85)  0.33 (0.16-0.64)  60, 72 20, 22 89, 111 
Wales 1.7% (0.2-12.1) 0.88 (0.11-7.02)  1.20 (0.18-7.63)         12.8% (6.9-22.3) 0.25 (0.13-0.48)  0.19 (0.08-0.40)  33, 49 7, 9 55, 83 
IMD quintile of LSOA of residence
d
                    
2 least deprived  1.3% (0.4-3.6) 1.00 - 0.14 1.00 - 0.04 5.2% (2.5-10.5) 1.00 - 0.85 1.00 - 0.85 34.5% (30.0-39.2) 1.00 - 0.89 1.00 - 0.75 241, 315 127, 180 369, 509 
Middle quintile 1.6% (0.6-4.4) 1.24 (0.26-5.88)  1.01 (0.15-6.68)  5.0% (1.7-13.8) 0.96 (0.26-3.58)  0.68 (0.15-2.97)  33.3% (27.4-39.9) 0.95 (0.67-1.35)  1.04 (0.70-1.52)  114, 164 60, 86 183, 263 
2 most deprived 3.4% (2.1-5.6) 2.71 (0.83-8.82)  3.75 (1.11-12.5)  6.5% (3.6-11.4) 1.26 (0.48-3.33)  1.06 (0.42-2.64)  35.2% (31.1-39.5) 1.03 (0.78-1.36)  1.13 (0.82-1.53)  269, 361 155, 205 450, 603 
Age left school
e
                            
17+ 1.6% (0.9-2.7) 1.00 - 0.01    5.3% (3.1-9.0) 1.00 - 0.49    33.6% (30.4-37.1) 1.00 - 0.21    439, 568 233, 304 703, 927 
16 5.0% (2.7-9.2) 3.28 (1.38-7.82)     7.2% (3.6-13.8) 1.38 (0.55-3.45)     37.8% (32.3-43.5) 1.20 (0.91-1.58)     143, 206 87, 134 230, 334 
Frequency of binge drinking                  
Never / <monthly 1.1% (0.4-2.7) 1.00 - 0.08 1.00 - 0.62 3.5% (1.6-7.7) 1.00 - 0.07 1.00 - 0.46 28.1% (24.6-32.0) 1.00 - <0.01 1.00 - 0.04 322, 421 146, 204 527, 715 
Monthly 3.0% (1.4-6.2) 2.79 (0.85-9.18)  1.47 (0.33-6.48)  4.0% (1.5-10.3) 1.15 (0.31-4.18)  0.60 (0.13-2.67)  39.9% (33.4-46.7) 1.69 (1.21-2.37)  1.48 (1.01-2.16)  125, 177 80, 113 202, 289 
>weekly  3.8% (2.0-7.0) 3.58 (1.17-11.0)  2.03 (0.49-8.38)  9.8% (5.6-16.6) 2.98 (1.07-8.34)  1.23 (0.48-3.14)  43.2% (37.5-49.1) 1.94 (1.44-2.62)  1.50 (1.04-2.15)  177, 241 117, 154 273, 370 
Age at first heterosexual sex                      
17+ 1.0% (0.3-2.8) 1.00 - 0.03 1.00 - 0.67 2.8% (0.7-9.9) 1.00 - 0.26 1.00 - 0.74 25.6% (21.4-30.3) 1.00 - <0.01 1.00 - 0.05 210, 245 87, 112 340, 431 
16 1.5% (0.5-4.6) 1.49 (0.31-7.15)  1.14 (0.27-4.74)  4.7% (1.8-11.8) 1.75 (0.33-9.27)  1.14 (0.24-5.30)  33.4% (27.9-39.4) 1.46 (1.03-2.06)  1.13 (0.75-1.67)  148, 205 84, 108 253, 351 
<16 4.0% (2.4-6.5) 4.18 (1.31-13.3)  1.65 (0.55-4.90)  7.8% (4.7-12.6) 2.99 (0.70-12.7)  1.58 (0.37-6.62)  45.3% (40.7-49.9) 2.40 (1.78-3.23)  1.53 (1.07-2.19)  238, 352 167, 243 376, 539 
Condom used for most recent sex with most recent partner                   
Yes 0.7% (0.2-2.0) 1.00 - <0.01 1.00 - 0.10 4.3% (2.0-8.9) 1.00 - 0.22 1.00 - 0.91 33.5% (29.7-37.6) 1.00 - 0.13 1.00 - 0.87 301, 391 163, 221 491, 671 
No 4.1% (2.6-6.4) 6.03 (1.87-19.4)  3.59 (0.77-16.6)  7.4% (4.5-12.0) 1.79 (0.70-4.59)  1.06 (0.35-3.21)  38.0% (33.9-42.4) 1.22 (0.95-1.56)  0.97 (0.70-1.34)  283, 398 172, 237 458, 621 
Number of sexual partners in the last year                    
0 or 1 1.5% (0.7-3.0) 1.00 - 0.01    3.4% (1.5-7.8) 1.00 - <0.01    26.0% (22.6-29.7) 1.00 - <0.01    359, 466 145, 196 568, 768 
2 1.3% (0.4-4.2) 0.86 (0.21-3.56)     0.9% (0.2-3.9) 0.27 (0.05-1.41)     40.3% (33.2-47.7) 1.92 (1.34-2.75)     123, 159 74, 99 185, 251 
3 to 4 3.1% (1.1-8.5) 2.16 (0.60-7.78)     1.5% (0.4-6.2) 0.44 (0.08-2.30)     43.0% (35.5-50.9) 2.15 (1.49-3.10)     70, 110 57, 83 134, 194 
5+ 7.5% (3.7-14.6) 5.47 (1.89-15.9)     21.2% (12.9-32.7) 7.54 (2.66-21.3)     60.9% (51.8-69.3) 4.42 (2.93-6.67)     67, 100 63, 89 103, 146 
 
  
 Table 7-2b continued.  
 
Number of new sexual partners in the last year                    
0 1.8% (0.9-3.8) 1.00 - 0.01 1.00 - 0.49 5.5% (2.3-12.6) 1.00 - 0.37 1.00 - 0.31 26.0% (22.0-30.5) 1.00 - <0.01 1.00 - 0.37 263, 335 108, 136 416, 540 
1 0.8% (0.2-2.5) 0.42 (0.10-1.72)  0.33 (0.05-2.06)  4.0% (1.7-9.0) 0.71 (0.21-2.47)  1.13 (0.09-13.9)  36.7% (31.8-41.8) 1.64 (1.21-2.24)  1.28 (0.88-1.85)  203, 270 115, 161 323, 452 
2+ 5.1% (2.9-8.8) 2.87 (1.08-7.63)  0.47 (0.09-2.45)  8.0% (4.5-13.7) 1.48 (0.50-4.35)  2.87 (0.26-30.7)  46.3% (40.7-52.0) 2.45 (1.78-3.37)  1.06 (0.67-1.68)  152, 229 115, 170 251, 366 
Number of sexual partners in the last year without a condom                  
0 0.3% (0.1-1.3) 1.00 - <0.01 1.00 - 0.09 1.8% (0.4-8.4) 1.00 - 0.04 1.00 - 0.45 27.0% (22.4-32.1) 1.00 - <0.01 1.00 - 0.49 205, 248 88, 115 331, 450 
1 1.7% (0.8-3.6) 5.26 (1.05-26.2)  1.23 (0.09-15.2)  4.9% (2.6-8.9) 2.75 (0.50-15.0)  0.78 (0.19-3.15)  34.3% (30.2-38.7) 1.41 (1.02-1.96)  1.12 (0.72-1.71)  287, 396 160, 222 475, 640 
2+ 6.5% (3.9-10.9) 21.3 (4.67-97.2)  4.95 (0.42-57.9)  10.9% (6.0-19.0) 6.51 (1.19-35.6)  0.46 (0.11-1.83)  48.8% (42.3-55.4) 2.59 (1.81-3.70)  1.37 (0.80-2.34)  130, 194 95, 134 194, 281 
Concurrent partnerships in last year
f
                   
No 2.6% (1.6-4.2) 1.00 - 0.74 1.00 - 0.05 6.7% (4.1-10.8) 1.00 - 0.10 1.00 - 0.07 32.9% (29.6-36.3) 1.00 - <0.01 1.00 - 0.24 418, 557 219, 298 676, 916 
Yes 2.0% (0.7-5.4) 0.75 (0.24-2.37)  0.18 (0.04-0.71)  6.5% (2.7-14.8) 0.96 (0.34-2.72)  0.60 (0.19-1.79)  49.7% (41.0-58.4) 2.02 (1.37-2.96)  1.52 (0.92-2.50)  82, 121 67, 92 136, 188 
Unknown 1.7% (0.5-5.6) 0.64 (0.17-2.37)  0.60 (0.11-3.00)  1.3% (0.3-5.5) 0.19 (0.04-0.88)  0.06 (0.00-0.71)  38.5% (30.9-46.7) 1.28 (0.88-1.86)  1.18 (0.77-1.80)  92, 122 52, 75 137, 193 
Number of lifetime sexual partners                  
1 to 4 0.4% (0.1-1.5) 1.00 - <0.01 1.00 - 0.03 1.0% (0.3-3.1) 1.00 - <0.01 1.00 - <0.01 25.3% (21.8-29.2) 1.00 - <0.01 1.00 - <0.01 332, 412 133, 176 524, 706 
5 to 9 1.2% (0.3-4.0) 3.21 (0.47-21.9)  1.78 (0.20-15.5)  3.8% (1.3-10.8) 4.15 (0.82-21.0)  4.87 (0.58-40.2)  39.6% (33.6-45.9) 1.93 (1.39-2.69)  1.50 (1.01-2.21)  141, 200 84, 123 222, 314 
10+ 7.6% (4.8-11.7) 22.6 (4.92-104)  8.69 (1.21-62.0)  12.3% (7.6-19.2) 14.6 (3.89-54.5)  19.80 (3.03-129.)  49.2% (43.2-55.2) 2.86 (2.09-3.92)  2.23 (1.45-3.42)  148, 224 121, 167 247, 342 
Ever had any same sex experience/contact                  
No 2.3% (1.5-3.5) 1.00 - 0.89 1.00 - 0.37 5.8% (3.8-8.9) 1.00 - 0.87 1.00 - 0.82 33.9% (31.1-36.8) 1.00 - 0.11 1.00 - 0.02 577, 762 311, 427 922, 1260 
Yes 2.0% (0.4-9.0) 0.90 (0.18-4.48)  0.31 (0.02-4.16)  5.1% (1.0-22.0) 0.87 (0.17-4.54)  0.79 (0.10-6.09)  42.4% (32.2-53.4) 1.44 (0.92-2.26)  2.08 (1.12-3.84)  47, 78 31, 44 80, 115 
a
N in column headings shows unweighted denominators. Total denominators by characteristic and in multivariable models vary due to item-missingness. 
b
AOR: 
Adjusted odds ratios, adjusted for all variables shown. 
c
Results for recent diagnosis are not reported due to small sample size in Scotland and Wales when limited to 
those tested.  
d
IMD: Index of multiple deprivation of LSOA (lower super output area) of residence. IMD scores for England, Scotland and Wales were adjusted before 
being combined and assigned to quintiles, using the method described by Payne and Abel
264
. 
 e
Excludes 16 year-olds. 
f
Among those with >1 sexual partner in last 
year.  
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Figure 7-2 shows the unadjusted OR for prevalent infection and for recent 
testing by sociodemographic and behavioural factors. Groups in the upper right 
hand quadrant are those where both the odds of prevalent infection and of 
testing were higher than the reference group. Groups in the upper left hand 
quadrant show those where the odds of prevalent infection were higher, but 
odds of testing were lower than the reference group. The demographic and 
behavioural factors associated with recent testing were broadly similar to those 
associated with prevalent infection and with recent diagnosis, with some 
exceptions. Notably, whereas women living in one of the two most deprived IMD 
quintiles had almost a four-fold increase in the odds of prevalent infection 
compared to those living in less deprived areas (OR 3.82, 95%CI 1.35-10.79), 
the odds of recent testing did not differ by deprivation (OR 0.99, 95%CI 0.77-
1.27). Among men, the odds of prevalent infection were higher among 20 to 24 
versus 16 to 19 year-olds (OR 10.6, 95%CI 2.40-46.3), but odds of recent 
testing were lower in the older age group (OR 0.67, 0.44-0.84). In men, not 
having used a condom at last sex was associated with a six-fold increase in the 
odds of prevalent infection (OR 6.03, 95%CI 1.87-19.42), but was not 
associated with recent testing (OR 1.22, 95%CI 0.95-1.56). Similar patterns 
were seen when comparing adjusted ORs from multivariable models (Table 3). 
Although the proportion recently tested was generally higher in those reporting 
risk factors for chlamydia, recent testing remained well below 100% in all 
sociodemographic and behavioural subgroups. For example, 25% (95%CI 20%-
31%) of women and 47% (95%CI 41%-53%) of men with two or more new 
sexual partners in the last year, and 20% (95%CI 16%-27%) and 45% (95%CI 
38%-51%) with two or more sexual partners without a condom in the last year 
had not been either recently tested or offered a test. There was evidence of 
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both repeat (or persistent) and incident infections. Among individuals with a 
prevalent chlamydia infection, 14% (95%CI 7%-14%) had ever been diagnosed 
with chlamydia and 5% (95%CI 2%-17%) reported a diagnosis in the last year 
(indicating either repeat or persistent infections). Fifty percent (95%CI 35%-
64%) of those with a prevalent infection reported a recent chlamydia test (89% 
of whom did not report a recent diagnosis, thus indicating incident rather than 
repeat/persistent infections within the last year).
 Figure 7-2a: Bubble plot showing unadjusted odds ratios for prevalent chlamydia infection versus recent testing by sociodemographic and 
behavioural factors, and percentage of prevalent infections in each group (sexually-experienced 16-24 year-old women)  
 
The area of the bubble represents the 
percentage of those with a prevalent 
infection in each group (percentage shown in 
parentheses). Factors in the upper right hand 
quadrant are those where both the odds of 
prevalent infection and of testing were higher 
than the reference group. Factors in the 
upper left hand quadrant show those where 
the odds of prevalent infection were higher, 
but odds of testing were lower than the 
reference group. 
 
Letters indicate reference groups: [a] 16-19 years old; [b] Resident in lower super output area in the 2 least deprived quintiles, as measured by Index of Multiple 
Deprivation (IMD); [c] Left school at 17+ (among those aged >16); [d] 17+ years at first heterosexual sex; [e] 0 or 1 sexual partners in the last year; [f] 0 new sexual 
partners in the last year; [g] 0 sexual partners in the last year without a condom; [h] 1 to 9 lifetime sexual partners; [i] Condom used at last sex; [j] No concurrent 
partnership in last year (among those with 1+ more sexual partners in last year); [k] Reports binge drinking never or less than monthly; [l] Never had same sex 
contact/experience.   
 Figure 7-2b: Bubble plot showing unadjusted odds ratios for prevalent chlamydia infection versus recent testing by sociodemographic and 
behavioural factors, and percentage of prevalent infections in each group (sexually-experienced 16-24 year-old men) 
 
The area of the bubble represents the 
percentage of those with a prevalent 
infection in each group (percentage shown 
in parentheses). Factors in the upper right 
hand quadrant are those where both the 
odds of prevalent infection and of testing 
were higher than the reference group. 
Factors in the upper left hand quadrant 
show those where the odds of prevalent 
infection were higher, but odds of testing 
were lower than the reference group. 
 
Letters indicate reference groups: [a] 16-19 years old; [b] Resident in lower super output area in the 2 least deprived quintiles, as measured by Index of Multiple 
Deprivation (IMD); [c] Left school at 17+ (among those aged >16); [d] 17+ years at first heterosexual sex; [e] 0 or 1 sexual partners in the last year; [f] 0 new sexual 
partners in the last year; [g] 0 sexual partners in the last year without a condom; [h] 1 to 9 lifetime sexual partners; [i] Condom used at last sex; [j] No concurrent 
partnership in last year (among those with 1+ more sexual partners in last year); [k] Reports binge drinking never or less than monthly; [l] Never had same sex 
contact/experience. 
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7.4.1.3 Distribution of infections by demographic and behavioural 
characteristics 
Table 7-3 shows the distribution of demographic and behavioural characteristics 
among individuals with a prevalent infection, those with a recent diagnosis and 
the sexually-experienced population. Among both women and men, prevalent 
infections were detected in those reporting no new sexual partners in the last 
year, and those reporting no condomless sexual partners in the last year. 
Infections in women tended to be more evenly distributed according to numbers 
of sexual partners and other risk factors than in men. For example, among the 
62 individuals (37 women, 25 men) with a prevalent infection 38% of women 
and 55% of men reported two or more new sexual partners in the last year 
(versus 21% and 25% of the sexually-experienced population); 37% of women 
and 61% of men reported two or more condomless sexual partners in the last 
year (versus 18% and 19% of the population). Living in one of the 40% most 
deprived LSOA accounted for 73% and 65% of prevalent infections in women 
and men respectively. This difference in distribution of infections by sex is also 
illustrated in Figure 7-2, where the size of the markers indicates the proportion 
of prevalent infections found in that risk group. Reporting that no condom had 
been used at last sex was common among this age group (63% of sexually-
experienced women and 48% of men), and among both women and men with a 
prevalent infection (69% in women and 85% in men).  
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Table 7-3a: Distribution of demographic and behavioural characteristics among 
a) individuals with a prevalent chlamydia infection, b) individuals with a recent 
chlamydia diagnosis and c) the sexually-experienced population (16-24 year-old 
sexually-experienced women, Natsal-3). 
 
(a) Prevalent infection 
detected in urine (n=37) 
(b) Diagnosed with chlamydia in 
the last year (n=54) 
(c) Sexually-experienced 
population (n=1,740) 
 Percent 95%CI Percent 95%CI Percent 95%CI 
Age group 
      16-19 43.6% (26.7-62.1) 40.5% (26.6-56.2) 35.6% (33.2-38.0) 
20-24 56.4% (37.9-73.3) 59.5% (43.8-73.4) 64.4% (62.0-66.8) 
Country 
      England 79.8% (62.5-90.3) 92.1% (80.8-97.0) 85.1% (83.1-86.9)
Scotland 9.5% (3.3-24.5) 3.4% (0.7-14.3) 9.5% (8.0-11.2) 
Wales 10.8% (3.8-27.0) 4.5% (1.3-14.3) 5.4% (4.4-6.7) 
IMD quintile of LSOA of residencea 
    2 least deprived 
quintiles 15.6% (5.9-35.2) 30.9% (18.4-46.9) 35.1% (32.3-38.0) 
middle quintile 11.0% (4.5-24.7) 12.5% (5.6-25.4) 19.5% (17.3-21.9) 
2 most deprived 
quintiles 73.4% (54.9-86.3) 56.7% (40.8-71.3) 45.4% (42.5-48.4) 
Age left schoolb 
     17+ 77.9% (62.0-88.3) 74.9% (60.2-85.4) 78.5% (76.3-80.6)
16 22.1% (11.7-38.0) 25.1% (14.6-39.8) 21.5% (19.4-23.7) 
Age at first heterosexual sex   
   17+ 16.0% (6.5-34.3) 19.5% (8.9-37.7) 33.6% (31.0-36.3)
16 37.3% (21.0-57.1) 27.0% (15.1-43.3) 29.5% (27.0-32.0) 
<16 46.8% (28.8-65.6) 53.5% (38.0-68.4) 36.9% (34.3-39.6) 
Number of sexual partners in the last year 
    0 or 1 52.1% (33.7-69.9) 31.10% (18.2-47.9) 65.3% (62.7-67.9)
2 19.4% (8.6-38.0) 21.70% (12.3-35.5) 15.0% (13.3-17.0) 
3 to 4 6.4% (2.1-17.5) 23.60% (13.6-37.7) 11.6% (10.1-13.2) 
5+ 22.2% (9.8-42.7) 23.60% (12.2-40.6) 8.1% (6.6-9.9) 
Number of new sexual partners in the last year 
    0 38.0% (22.4-56.6) 21.9% (12.0-36.7) 51.8% (49.0-54.5)
1 24.4% (10.9-46.0) 26.1% (13.9-43.7) 27.6% (25.2-30.1) 
2+ 37.6% (21.7-56.6) 51.9% (36.4-67.1) 20.6% (18.4-23.1) 
Number of sexual partners in the last year without a condom 
   0 18.9% (7.5-40.1) 11.4% (3.9-28.6) 21.8% (19.7-24.1)
1 44.1% (26.9-62.9) 43.0% (28.6-58.6) 60.6% (58.0-63.2) 
2+ 36.9% (20.6-57.0) 45.7% (31.5-60.6) 17.5% (15.6-19.6) 
Number of sexual partners over the lifetime 
    1 to 4 42.2% (25.1-61.4) 16.1% (8.3-28.8) 52.6% (49.9-55.3)
5 to 9 22.6% (11.3-40.1) 35.0% (21.6-51.2) 26.3% (24.0-28.8) 
10+ 35.2% (19.2-55.3) 48.9% (33.5-64.5) 21.1% (19.0-23.4) 
Condom used for most recent sex with most recent partner 
   Yes 31.1% (16.6-50.5) 21.9% (10.7-39.7) 36.8% (34.2-39.6)
No 68.9% (49.5-83.4) 78.1% (60.3-89.3) 63.2% (60.4-65.8) 
Concurrent partnerships in last year c 
   No 65.0% (45.4-80.6) 56.0% (40.5-70.4) 76.2% (73.9-78.3)
Yes 22.6% (10.0-43.5) 22.8% (11.8-39.5) 11.3% (9.7-13.1) 
Unknown 12.4% (5.0-27.6) 21.2% (11.7-35.4) 12.6% (10.9-14.4) 
Frequency of binge drinking 
   never / less 
than monthly 50.5% (32.4-68.6) 41.2% (27.0-57.0) 62.3% (59.7-64.9) 
monthly 8.7% (3.0-22.9) 26.4% (14.7-43.0) 22.1% (19.9-24.5) 
weekly or more 
often 40.7% (24.2-59.6) 32.4% (18.8-49.8) 15.6% (13.7-17.6) 
Ever had any same sex experience/contact 
   Yes 21.6% (9.4-42.2) 28.1% (16.5-43.6) 22.5% (20.3-24.8)
No 78.4% (57.8-90.6) 71.9% (56.4-83.5) 77.5% (75.2-79.7) 
Bases (wt, 
unwt)  18, 37  28, 54  968, 1740 
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Table 7-3b: Distribution of demographic and behavioural characteristics among 
a) individuals with a prevalent chlamydia infection, b) individuals with a recent 
chlamydia diagnosis and c) the sexually-experienced population (16-24 year-old 
sexually-experienced men, Natsal-3). 
 
(a) Prevalent infection 
detected in urine (n=25) 
(b) Diagnosed with 
chlamydia in the last year 
(n=27) 
(c) Sexually-experienced 
population (n=1,375) 
 
% 95%CI % 95%CI % 95%CI 
Age group 
      16-19 5.5% (1.2-22.5) 35.6% (17.9-58.3) 37.3% (34.4-40.2) 
20-24 94.5% (77.5-98.8) 64.4% (41.7-82.1) 62.7% (59.8-65.6) 
Country 
      England 71.8% (47.3-87.9) 78.8% (55.5-91.7) 85.7% (82.7-88.2) 
Scotland 24.2% (9.5-49.3) 19.2% (7.0-43.1) 8.8% (6.8-11.4) 
Wales 3.9% (0.5-26.9) 2.0% (0.2-14.5) 5.5% (4.0-7.5) 
IMD quintile of LSOA of 
residencea 
      2 least deprived quintiles 22.0% (7.3-50.1) 33.7% (16.4-56.7) 36.9% (33.6-40.2) 
middle quintile 12.9% (4.1-34.1) 15.3% (5.1-38.0) 18.2% (15.9-20.7) 
2 most deprived quintiles 65.1% (41.5-83.1) 51.0% (29.9-71.8) 44.9% (41.4-48.5) 
Age left schoolb 
      17+ 49.3% (27.7-71.1) 66.5% (43.5-83.6) 75.4% (72.6-77.9) 
16 50.7% (28.9-72.3) 33.5% (16.4-56.5) 24.6% (22.1-27.4) 
Age at first heterosexual sex   
      17+ 15.1% (4.9-37.9) 12.3% (3.1-38.4) 35.1% (32.1-38.2) 
16 15.7% (4.5-42.3) 20.6% (7.7-44.7) 26.1% (23.5-28.8) 
<16 69.2% (44.9-86.1) 67.1% (43.1-84.6) 38.8% (35.8-41.8) 
Number of sexual partners in 
the last year 
      0 or 1 37.4% (18.2-61.6) 25.2% (10.7-48.7) 57.30% (54.3-60.3) 
2 11.0% (3.0-33.3) 3.5% (0.7-15.0) 18.70% (16.5-21.2) 
3 to 4 15.6% (5.1-38.5) 4.4% (1.0-18.0) 13.60% (11.7-15.7) 
5+ 36.1% (17.6-59.8) 66.9% (44.4-83.6) 10.40% (8.8-12.2) 
Number of new sexual partners 
in the last year 
      0 34.1% (16.0-58.5) 30.3% (13.1-55.4) 42.1% (39.0-45.2) 
1 11.1% (3.0-33.2) 23.3% (9.8-45.9) 32.6% (29.7-35.6) 
2+ 54.8% (32.0-75.7) 46.5% (26.3-67.9) 25.3% (22.8-28.0) 
Number of sexual partners in 
the last year without a condom 
      0 4.8% (1.0-19.9) 8.2% (1.6-33.0) 33.1% (30.2-36.1) 
1 34.7% (16.1-59.5) 39.7% (21.1-61.8) 47.5% (44.4-50.5) 
2+ 60.5% (36.7-80.2) 52.1% (30.7-72.8) 19.4% (17.2-21.8) 
Number of sexual partners 
over the lifetime 
      1 to 4 8.50% (1.8-32.5) 6.5% (1.8-21.3) 52.70% (49.8-55.7) 
5 to 9 11.60% (3.0-35.8) 16.7% (5.5-41.1) 22.40% (20.0-25.0) 
10+ 79.90% (55.8-92.6) 76.7% (53.8-90.3) 24.90% (22.5-27.4) 
Condom used for most recent 
sex with most recent partner 
      Yes 15.5% (4.9-39.3) 35.3% (17.2-58.9) 51.7% (48.6-54.8) 
No 84.5% (60.7-95.1) 64.7% (41.1-82.8) 48.3% (45.2-51.4) 
Concurrent partnerships in last 
yearc 
      No 77.6% (55.8-90.5) 74.5% (52.3-88.7) 71.2% (68.4-74.0) 
Yes 11.4% (3.7-30.3) 22.0% (9.0-44.6) 14.3% (12.3-16.6) 
Unknown 11.0% (3.0-33.3) 3.5% (0.7-15.0) 14.5% (12.5-16.7) 
Frequency of binge drinking 
      never / less than monthly 25.1% (9.9-50.6) 25.9% (11.2-49.1) 52.6% (49.6-55.5) 
monthly 26.7% (12.0-49.5) 16.2% (5.8-37.7) 20.2% (17.9-22.6) 
weekly or more often 48.2% (26.6-70.4) 57.9% (35.8-77.3) 27.3% (24.7-30.0) 
Ever had any same sex 
experience/contact 
      Yes 6.8% (1.3-29.3) 8.2% (1.6-33.0) 8.0% (6.5-9.8) 
No 93.2% (70.7-98.7) 91.8% (67.0-98.4) 92.0% (90.2-93.5) 
Bases (wt, unwt) 
 
14, 25 
 
20, 27 
 
1003, 1375 
a
IMD: Index of multiple deprivation of LSOA (lower super output area) of residence. IMD scores for England, Scotland 
and Wales were adjusted before being combined and assigned to quintiles, using the method described by Payne and 
Abel
39
; 
b
Excludes 16 year-olds;
c
Among those with 1+ more sexual partners in last year 
  
196 
7.4.1.4 England versus Scotland/Wales 
Women and men living in England were significantly more likely to have been 
recently tested than those living in Scotland or Wales (OR: 2.25, 95%CI 1.66-
3.05 in women; 2.60, 1.64-4.12 in men, Figure 7-3). There was no significant 
difference in the prevalence of infection or proportion recently diagnosed by 
country of residence.  When limiting to participants resident in England, there 
were no notable differences in either the factors associated with prevalent 
infection, recent diagnosis or recent testing, or in the relationships between 
these factors (Appendix 3).  
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Figure 7-3: Percentage with a prevalent chlamydia infection, ever diagnosed with 
chlamydia, recent diagnosis of chlamydia and recently tested for chlamydia by 
country of residence (sexually-experienced 16-24 year-olds, Natsal-3) 
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7.5 Discussion 
7.5.1 Key findings 
In 2010-12 chlamydia was a common, and commonly diagnosed, infection 
among young adults in Britain. Prevalent infections in women were more evenly 
distributed according to numbers of sexual partners than in men. Diagnoses 
had arisen following both opportunistic screening and clinically-indicated testing 
in roughly equal numbers. Living in more deprived areas was significantly 
associated with prevalent infection after adjusting for sociodemographic and 
behavioural factors. The proportion reporting chlamydia testing was generally 
greater among those reporting factors associated with chlamydia. However, 
substantial proportions of young adults reporting risk factors for chlamydia had 
not been recently tested and incident infections in the last year were evident. 
7.5.2 Strengths and limitations 
The major strength of this analysis is that it used individual-level data from a 
nationally-representative sample. Behavioural and biological data were linked to 
examine a range of risk factors for different outcomes within the same survey. 
Investigations using the Natsal-3 data were reliant on the questions asked in the 
survey. For example the survey asked about the location of the most recent 
test, but not of the most recent diagnosis. The finding that the vast majority of 
those recently diagnosed had last been tested in clinical settings may therefore 
reflect re-testing patterns with follow up tests done in sexual health settings, 
rather than low diagnosis rates among non-clinical settings. However this is 
likely to have minimal impact on these findings as routine re-testing before one 
year after a positive test was not recommended in England until 2013.119  
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Despite the size of Natsal-3 and oversampling of younger people,172 the number 
of participants aged under 25 limited statistical power to explore all associations 
of potential interest including local area and ethnicity. Given the relatively small 
absolute numbers of prevalent infections (n=62), the proportions in specific sub-
groups should be interpreted with caution. These findings may be affected by 
who agreed to take part in the survey or provide a urine sample. Survey weights 
were used to minimise bias but unmeasured bias remains feasible.  
Comparisons between risk factors for prevalent infection and recent testing may 
have been affected by the estimation of outcomes among different 
denominators. This was explored further in a sensitivity analysis, which showed 
no notable difference between ORs for testing when estimated in sexually-
experienced participants versus urine study participants (data not shown). A 
further limitation is the accuracy of self-reporting. Detailed questions were 
answered via self-completion, which are expected to have minimised social 
desirability bias.  
7.5.3 Comparison to other studies/data  
Recent testing was not associated with area-level deprivation in this analysis. 
This is contrary to an analysis of data from the South East of England, which 
found higher rates of chlamydia screening in more deprived areas in 2008.265 
This difference in findings may reflect the different study period, when screening 
coverage was lower, or regional variation in screening patterns.  
National surveillance data on chlamydia tests and diagnoses among 15 to 24 
year-olds are available for England for the period covered by Natsal-3. The 
average coverage of chlamydia testing in England in 2010-12 among 15 to 24 
year-olds was 40% in women and 20% in men.189,266 This is lower than the 57% 
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of women and 37% of men resident in England estimated to have been test in 
the last year in Natsal-3. Differences between denominators (all versus 
sexually-experienced only) and age ranges (surveillance data for this period use 
partly aggregated data and are not available for 16 to 24 year-olds) may partly 
explain these differences. Applying the proportion of 16 to 24 year-olds with one 
or more sexual partner estimated in Natsal-3 (80%235) to surveillance data 
results in an estimated coverage per year of 51% and 25% among sexually-
experienced women and men respectively. This is more comparable, but still 
somewhat lower than the estimates presented in this chapter, especially since 
surveillance data may include repeat tests among from the same individual 
within one year.120 This may indicate some residual bias arising from who took 
part in Natsal-3. The findings on location of last test among those recently 
diagnosed are consistent with 2011 surveillance data, where 42% of diagnoses 
among 15 to 24 year-olds were reported from GUM clinics, 15% from family 
planning services, 7% GPs, 2% from education and 33% from other/unknown 
settings.189 The proportion of diagnoses from GPs was higher in Natsal-3 (27%) 
than in surveillance data. This may reflect the partially- aggregate nature of 
surveillance data as a large proportion of diagnoses made in other/unknown 
settings are likely to be from GPs. 
7.5.4 Implications for evaluation of chlamydia control 
Those reporting risk factors for chlamydia were generally more likely to report 
having been recently tested. This is contrary to uptake patterns often seen in 
public health interventions, where those in most need are often least likely to 
access care.267 However, at least one quarter of women and around half of men 
reporting a risk factor associated with prevalent infection had not been recently 
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tested. This presents a clear potential for ongoing transmission of chlamydia 
from high risk but untested individuals. Almost all prevalent infections in men 
were among 20 to 24 year-olds, less than a third of whom reported recent 
testing. As young women tend to have slightly older male partners,268 sexual 
mixing patterns by age may play a key role in transmission.  
These findings also suggest that the likelihood of having an infection diagnosed 
and treated varies by deprivation, as although screening coverage was uniform 
by area-level deprivation, chlamydia prevalence was higher in those living in 
more deprived areas. This raises the question as to whether efforts to expand 
or intensify chlamydia screening should prioritise those living in more deprived 
areas to address this potential inequality. A high proportion of infections were 
found in those who had not used a condom at last sex, and around one fifth of 
recent diagnoses were made following a test prompted by a partner having 
chlamydia, which emphasises the importance of condom use and partner 
notification in chlamydia prevention and control. 
7.5.5 Summary 
Comparison of factors associated with prevalent infection and with diagnosis 
and testing showed that those with risk factors for chlamydia were more likely to 
have accessed a chlamydia test in the last year. While this alignment between 
need and uptake of the intervention suggests the NCSP may be reaching those 
at risk of infection, this analysis demonstrated substantial opportunities for 
ongoing transmission of infection, and incident infections were evident. Given 
that comparisons between chlamydia prevalence in Natsal-2 and Natsal-3 did 
not provide any strong evidence for chlamydia prevalence to have decreased in 
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the decade up to 2010-12, these opportunities for transmission present a 
possible explanation for an absence of a decrease in prevalence.  
The findings presented up to this point in the thesis still leave us in a position of 
considerable uncertainty as to whether there has or has not been any change in 
the incidence or prevalence of chlamydia during a time of widespread screening 
among under 25-year-olds. In the next chapter I therefore move to investigation 
of a third outcome measure, that of antibody seroprevalence as a marker of 
age-specific cumulative incidence. 
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8 Trends in C. trachomatis antibody seroprevalence, as a 
marker of age-specific cumulative incidence, measured 
using stored sera from participants in the Health Survey 
for England (HSE) (1994 to 2012) 
In previous chapters, my analysis of surveillance data showed that there was a 
decrease in percentage testing positive for chlamydia between 2008 and 2011 that 
remained after adjusting for known confounders, but that unmeasured confounding 
could not be ruled out. My comparison of data from the second and third Natsal 
surveys did not provide evidence to support there having been a decrease in 
chlamydia prevalence in the decade between the two surveys, which were conducted 
before and after the implementation of the NCSP.  Evidence from Natsal-3 
highlighted important opportunities for transmission of infection in 2010-12. In this 
chapter I present a study that applied a novel C. trachomatis antibody assay to stored 
sera from participants in a series of nationally-representative health surveys to 
investigate whether these data support there having been a change in age-specific 
cumulative incidence following the implementation of widespread screening. 
8.1 Background 
As well as being resource-intensive and hard to achieve, population-based 
estimates of chlamydia prevalence using NAATs measure only current 
infections. Such studies are therefore unable to estimate the proportion of the 
population who have ever been infected and who are therefore at risk of 
chlamydia-related sequelae. Serology has therefore been proposed as an 
alternative approach for evaluating the impact of chlamydia control 
programmes.99 Chlamydia antibodies persist and thus provide a longer-term 
marker of past infection.100,269 Using blood samples collected for a purpose 
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other than chlamydia testing can also avoid the bias associated with data from 
populations accessing chlamydia testing. 
As set out in Chapter 3, chlamydia seroepidemiology has been previously 
hampered by the lack of a suitable assay.99 Commercially available assays to 
detect C. trachomatis antibodies suffered from poor sensitivity and specificity 
with several subject to cross-reactive with other species of Chlamydia. Assays 
also lacked robust validation against panels of sera from individuals with known 
previous infection and negative controls. In recent years tests with better 
specificity - not so affected by inter-species cross-reaction - have become 
available.209,269 
The analysis presented in this chapter used data and stored sera from a 
nationally-representative household survey, the Health Survey for England 
(HSE), to explore sociodemographic and behavioural factors associated with 
serological evidence of a previous infection and to evaluate the impact of 
widespread opportunistic chlamydia screening on age-specific cumulative 
incidence of chlamydia in England up to 2012. 
8.2 Aims & objectives 
The aims of this analysis were firstly, to explore the utility of chlamydia 
seroprevalence as an epidemiological tool for the evaluation of chlamydia 
control and secondly, to investigate trends in age-specific chlamydia incidence 
among 16 to 24 year-old women in England between before and after the 
implementation of the National Chlamydia Screening Programme. This aim was 
addressed through the following objectives: 
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 To describe the association between sociodemographic variables and self-
reported health and sexual behaviours and the presence of chlamydia and 
antibodies in serum among HSE2010 and HSE2012 participants. 
 To compare age-specific Pgp3 seroprevalence (defined as the prevalence of 
Pgp3 antibodies detected in serum) at selected years (1994 to 2012) during 
a period of increased chlamydia screening. 
 To compare age-specific Pgp3 seroprevalence between birth cohorts 
exposed to differing levels of chlamydia screening. 
8.3 Methods 
8.3.1 Participants 
HSE is a series of nationally-representative surveys carried out annually since 
1991. Participants are invited to provide a blood sample for laboratory analyses 
and storage for future research. Details of HSE methodology are reported 
elsewhere.7,270 In summary, each annual survey used a multi-stage stratified 
probability sampling design. In each year a random sample of postcode sectors 
was selected from the Postcode Address File, from which a random sample of 
postal addresses was drawn. All adults aged 16 years and over at each 
selected household were selected for interview. Information on participants’ 
health and wellbeing, along with detailed sociodemographic information, was 
collected using a combination of face to face interviews and self-completed 
questionnaire booklets and a nurse visit.7 HSE2010 and HSE2012 also included 
questions on sexual behaviours and chlamydia diagnosis history, which were 
collected using the self-completed booklet. Other household members could be 
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present during interviews and questionnaire completion but did not see others’ 
booklets.7 
Sera were obtained from HSE participants who provided consent for their blood 
sample to be stored and used in future anonymous analyses (Figure 8-1). Sera 
were obtained from a) 16 to 44 year-old HSE2010/12 participants to explore 
factors associated with testing positive for anti-Pgp3 antibodies in serum 
(hereafter ‘Pgp3 seropositive’) and b) female participants aged 16 to 24 who 
took part in HSE years when stored sera were available (1994-1996, 2001-02 
and each year from 2008-2012), to examine trends in the prevalence of anti-
Pgp3 antibodies in serum (hereafter ‘Pgp3 seroprevalence’) in the age group 
targeted by the NCSP. Trends over time among men were not investigated as 
lower assay sensitivity209,269 complicates interpretation of trends and as 
monitoring chlamydia infections in women is of greater public health value given 
that most chlamydia-related complications are among women. 
  
207 
Figure 8-1: Flow chart showing selection of stored sera from Health Survey for 
England (HSE) participants 
 
 
 
Key
Note: analysis groups are not mutually exclusive, therefore sum of number in each group is 
greater than total number tested (n=5,618). 
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HSE2010/12 & 16-24 year-old female 
participants in selected years  
(1994-2012) (n=14,762) 
Provided consent for use of stored 
serum sample 
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or insufficient volume  
(n=1,264) 
16-44 year-olds in HSE2010 or 
HSE2012 
(n=2,521: 1,402 women; 1,119 
men) 
16-24 year-old women in 
selected HSE years (1994-2012) 
(n=3,361, 565 seropositive) 
Blood sample/consent 
not provided 
(n=7,880) 
Pgp3 antibodies detected 
(seropositive)  
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(n=1,975) 
Study population: stored sera available 
with sufficient volume for testing 
(n=5,618) 
Included in analysis of age-
specific Pgp3 seroprevalence 
over time 
Included in analysis of factors 
associated with seroprevalence 
Included in description of 
reported chlamydia diagnoses 
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8.3.2 Laboratory testing 
After collection, samples had been posted to the Royal Victoria Infirmary, 
Newcastle and stored in the HSE serum bank at -40oC. Specimens were sent to 
PHE Colindale where they were aliquoted, relabelled with the study ID and 
stored at -20○C. Specimens were transported frozen to Imperial College London 
and stored at -20○C until testing.  
8.3.2.1 Pgp3 assay 
Pgp3 is a C. trachomatis-specific protein. Pgp3 is considered a useful 
immunogen for serological tests as it is highly conserved between strains and is 
rarely found in C.pneumoniae isolates.209 In 2009, Wills et al developed an “in-
house” indirect immunoglobulin G (IgG) enzyme-linked immunosorbent assay 
(ELISA) based on the Pgp3 antigen (hereafter ‘indirect Pgp3 ELISA’). Sensitivity 
was measured among adult patients attending GUM clinics with a known, 
previously diagnosed chlamydia infection and was estimated at 73.8% (95%CI 
66.5%-79.9%) in women and 44.2% (95%CI 37.3%-51.3%) in men. Specificity 
was estimated using microimmunfluourescence (MIF)-negative paediatric sera 
to reduce likelihood of a previous sexually-acquired C. trachomatis infection, 
and was found to be 97.6% (95%CI 96.2%-98.6%).209 
The sensitivity and specificity of the indirect Pgp3 ELISA has been compared to 
other commercially available assays, and found to be at least 14% more 
sensitive in women than any of the comparator tests (Table 8-1). Sensitivity of 
the indirect Pgp3 ELISA is equivalent to the comparator commercial tests in 
men. No evidence was found of cross-reactivity with C. pneumoniae. 
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Table 8-1: Comparative sensitivities and specificities (and 95%CI) of the Indirect 
Pgp3 ELISA, double-antigen sandwich ELISA and commercial ELISAs 
Adapted from Wills et al
209
 and Horner et al
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Assay Sensitivity 
 
Specificity (women & 
men combined) 
 Women Men 
Double-antigen Pgp3 ELISA 82.9% (76.3-88.0) 54.4% (47.1-61.5) 97.8% (96.1-98.7) 
Indirect Pgp3 ELISA 73.8% (66.5-79.9) 44.2% (37.3-51.3) 97.6% (96.2-98.6) 
Ani Labsystems 59.8% (52.1-67.0) 40.5% (33.8-47.6) 99.0% (97.7-99.6) 
SeroCT 55.5% (47.8-62.9) 40.0% (33.3-47.1) 97.2% (95.7-98.2) 
Medac 45.7% (38.3-53.4) 43.7% (36.8–50.8) 96.0% (94.3-97.2) 
Since the publication of the original performance of the indirect Pgp3 ELISA, 
investigators at Imperial College London and University of Bristol have 
developed a double-antigen sandwich ELISA for the detection of anti-Pgp3 
antibody (hereafter ‘double-antigen Pgp3 ELISA’. This assay has demonstrated 
equivalent specificity (97.8%, 95%CI 96.1%–98.7%) and higher sensitivity 
(82.9%, 95%CI 76.3%-88.0% in women; 54.4%, 95%CI 47.1%-61.5% in 
men)269. 
Although the double-antigen Pgp3 ELISA has demonstrated higher sensitivity 
than the indirect Pgp3 ELISA to detect a previous known infection in both 
women and men, the double-antigen Pgp3 ELISA requires around a 25-fold 
higher volume of sera. A study of female participants in a cohort study in New 
Zealand tested sera using both the indirect and double-antigen Pgp3 ELISA.269 
Comparison of results from the two assays showed that the indirect Pgp3 
ELISA has good agreement with the double-antigen Pgp3 ELISA at low (<0.1) 
and high (>1.0) absorbance values (Table 8-2). Imperial College London 
therefore recommend the use of the indirect Pgp3 ELISA for initial screening, 
with subsequent testing of sera with absorbance values between 0.1 and 1.0 
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using the double-antigen Pgp3 ELISA to resolve ‘equivocal’ specimens 
(personal communication, Myra McClure, Gillian Wills, Imperial College 
London).  
In the study presented in this chapter, all specimens were tested for C. 
trachomatis anti-Pgp3 antibody using the indirect Pgp3 ELISA.209 Specimens 
with an optical density between 0.1 and 1.0 on the indirect Pgp3 ELISA were re-
tested using the double-antigen Pgp3 ELISA. Specimens which were positive 
on both assays (cut-off values were determined by the testing laboratory), 
positive on the double-antigen Pgp3 ELISA only, or which were above the cut-
off value for re-testing (i.e. absorbance value over 1.0) were considered Pgp3 
seropositive. Those which were negative on both assays, were positive on the 
Indirect Pgp3 ELISA but negative on the double-antigen Pgp3 ELISA, or were 
below the cut-off value for re-testing (i.e. absorbance value less than 0.1) were 
considered Pgp3 seronegative. This testing strategy represents a 98.0% 
sensitivity, and 99.8% specificity compared to the results that would have been 
achieved had all samples been tested on the double-antigen Pgp3 ELISA 
(Table 8-2). 
Table 8-2: Comparison of indirect Pgp3 ELISA and double-antigen Pgp3 ELISA 
by absorbance values on indirect Pgp3 ELISA. 
Data are from a study of female participants in a cohort study in New Zealand where all sera 
were tested with both the indirect Pgp3 ELISA and the double-antigen Pgp3 ELISA (n=2,641 
sera).
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 (Personal communication, M McClure & G Wills, Imperial College London) 
 
 
Double-antigen Pgp3 ELISA 
Negative Positive 
Indirect 
Pgp3 ELISA 
(Absorbance 
range) 
Negative (<0.1) 1817 10 
Negative (0.1-0.4731)* 302 233 
Positive (0.4731-1.0) 15 96 
Positive (>1.0) 4 164 
*An absorbance (450-620nm) value of 0.473 is the cut-off for the indirect assay. 
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8.3.3  Statistical analyses 
Data were analysed in Stata 12.1 accounting for weighting, clustering and 
stratification. Weights were applied in line with HSE analysis guidelines and 
included weights to correct for uneven probability of selection and - from 
HSE2003 onwards - non-response weights to ensure the sample is 
representative with regard to age, sex and region and to adjust for differential 
participation in blood specimen collection by sociodemographic and general 
health variables.271  
Pgp3 seroprevalence among HSE2010/12 participants was estimated by sex, 
number of lifetime sexual partners and reporting of a previous chlamydia 
diagnosis, regardless of reported sexual activity. Associations between being 
Pgp3 seropositive and sociodemographic and behavioural factors among 
sexually-experienced HSE2010/12 participants were investigated using 
univariable and multivariable logistic regression. Associations with deprivation 
were explored using a residence-based measure, the IMD quintile of the LSOA 
of residence. Sexual behaviour variables reflecting exposure over the lifetime 
(years since first heterosexual sex, number of lifetime sexual partners) and 
more recent exposures (number of sexual partners in the last year, condom 
used at last sex) were included. Odds ratios (ORs) adjusted for number of 
lifetime sexual partners were calculated to reduce confounding of the 
association between predictors and being Pgp3 seropositive. Pgp3 
seroprevalence among individuals ever diagnosed with chlamydia was 
estimated to explore sensitivity of serological testing to detect a previous known 
infection in this population. Pgp3 seroprevalence in those reporting no lifetime 
sexual partners was also estimated to explore test specificity and validity of 
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reporting of sexual activity. Analyses were conducted on those with non-missing 
data on the variable(s) of interest. 
Pgp3 seroprevalence was estimated among 16 to 24 year-old women for each 
year with available sera from 1994 to 2012. The trend in Pgp3 seroprevalence 
was estimated from 2008 (the first year when the NCSP was nationally-
available) to 2012 using a generalised linear model with year entered as a 
continuous variable.  
Pgp3 seroprevalence by birth cohort was explored among women aged 16 to 
24, with birth cohorts grouped to reflect their relative exposure to widespread 
chlamydia screening. The median age at first sex reported among 16 to 24 
year-olds in Natsal-3 (16 years)235 was used as a proxy age of sexual debut for 
the purposes of categorisation by birth cohort. Women who were ≤16 years in 
2008 (the first year of national implementation of the NCSP) were defined as 
having high exposure. Women aged 17 to 24 in 2008 were defined as having 
partial exposure as they would have had some of their years post sexual debut 
before the NCSP was nationally-implemented but would have still been within 
the target age group when national implementation occurred. Women aged over 
24 years in 2008 were defined as having ‘limited’ exposure as they would have 
been outside the NCSP target age group when the programme was nationally 
implemented. The numbers in each group by year of age are set out in Table 
8-3 below. 
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Table 8-3: Numbers of women aged 16 to 24 contributing to seroprevalence 
estimates by birth cohort, by year of age 
Exposure to widespread screening 
Year 
born 
Year 
turned 
16 
Number of women by year of age 
16 17 18 19 20 21 22 23 24 16-24 
Limited (born 1966-1975) 1970 1986 
        
66 66 
25 or older in 2008 1971 1987 
       
61 81 142 
 
1972 1988 
      
63 76 87 226 
 
1973 1989 
     
47 66 70 
 
183 
 
1974 1990 
    
52 50 69 
  
171 
 
1975 1991 
   
40 46 55 
   
141 
Total   0 0 0 40 98 152 198 207 234 929 
Limited (born 1976-1983) 1976 1992 
   
52 56 
    
108 
25 or older in 2008 1977 1993 
 
51 41 44 
    
45 181 
 
1978 1994 40 54 55 
    
46 76 271 
 
1979 1995 68 61 
    
40 87 
 
256 
 
1980 1996 65 
    
31 87 
  
183 
 
1981 1997 
    
48 82 
   
130 
 
1982 1998 
   
39 75 
    
114 
 
1983 1999 
  
37 69 
     
106 
Total   173 166 133 204 179 113 127 133 121 1349 
Partial (born 1984-1991) 1984 2000 
 
29 74 
     
36 139 
17 to 24 in 2008 1985 2001 37 107 
     
27 9 180 
 
1986 2002 88 
     
23 11 21 143 
 
1987 2003 
     
21 9 17 19 66 
 
1988 2004 
    
26 7 15 24 21 93 
 
1989 2005 
   
16 8 15 11 20 
 
70 
 
1990 2006 
  
22 6 10 20 20 
  
78 
 
1991 2007 
 
28 14 13 12 17 
   
84 
Total   125 164 110 35 56 80 78 99 106 853 
High (born 1992-1996) 1992 2008 27 5 14 15 6 
    
67 
16 or younger in 2008 1993 2009 8 17 13 18 
     
56 
 
1994 2010 9 12 10 
      
31 
 
1995 2011 16 11 
       
27 
 
1996 2012 10 
        
10 
Total   70 45 37 33 6* 0 0 0 0 185 
*Not included in Figure 8-7 due to small group size. 
8.3.4 Regulatory approval 
HSE is approved by an NHS research ethics committee each year. The use of 
stored sera from HSE participants for this study was approved by the Yorkshire 
and the Humber–South Yorkshire research ethics committee (ref: 13/YH/0304). 
All analyses were carried out anonymously and Pgp3 results were not linked to 
any identifiable information.  
8.4 Results 
A flow chart of included participants is shown in Figure 8-1. Of 14,762 eligible 
participants 6,882 (46.6%) provided a sample with consent for future testing. Of 
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these, samples for 1,264 were unavailable due to a missing sample or 
insufficient residual volume. Overall, 1,111/5,618 eligible participants with a 
valid chlamydia antibody test result were Pgp3 seropositive. Among 
HSE2010/12 participants, 546/2,521 were seropositive. Among 16 to 24 year-
old women in selected HSE years from 1994 to 2012, 565/3,361 were 
seropositive. HSE2010/12 participants included in the analysis were 
comparable to the overall HSE population on a range of sociodemographic and 
behavioural variables (Table 8-4).  
Table 8-4: Comparison of reported sociodemographic and behavioural variables 
between HSE participants and the study population by sex and age group (16-44 
year-olds, HSE2010 & HSE2012) 
  Women Men 
  16-24 years 25-44 years 16-24 years 25-44 years 
 
HSE 
participants 
Study 
population 
Difference 
HSE 
participants 
Study 
population 
Difference 
HSE 
participants 
Study 
population 
Difference 
HSE 
participants 
Study 
population 
Difference 
IMD quintile of LSOA 
area of residence
*
 
            Least deprived 18.2% 16.6% -1.6% 18.5% 17.8% -0.7% 18.7% 17.8% -0.9% 17.2% 16.1% -1.0% 
2 18.9% 19.6% 0.8% 18.9% 19.4% 0.5% 18.1% 19.2% 1.1% 19.7% 19.5% -0.1% 
3 21.0% 21.4% 0.3% 21.6% 21.4% -0.2% 21.0% 19.9% -1.1% 21.0% 21.8% 0.8% 
4 21.2% 21.4% 0.2% 19.5% 19.3% -0.1% 18.1% 17.6% -0.5% 21.1% 21.5% 0.4% 
Most deprived 20.6% 21.0% 0.4% 21.6% 22.1% 0.5% 24.2% 25.6% 1.5% 21.1% 21.0% -0.1% 
Ethnicity 
            White 84.9% 85.5% 0.6% 84.5% 86.0% 1.5% 81.2% 82.2% 1.0% 86.2% 86.6% 0.4% 
Black or Black British 4.0% 3.0% -1.1% 3.6% 3.1% -0.5% 2.3% 2.5% 0.2% 2.8% 2.8% 0.0% 
Asian or Asian British 5.7% 5.3% -0.4% 8.5% 7.8% -0.7% 10.4% 9.7% -0.6% 7.7% 7.6% -0.1% 
Mixed 1.7% 1.9% 0.2% 1.3% 1.2% -0.1% 4.8% 4.0% -0.8% 1.5% 1.4% 0.0% 
Other ethnic groups 3.8% 4.4% 0.5% 2.0% 1.9% -0.1% 1.3% 1.5% 0.2% 1.8% 1.6% -0.2% 
Marital status 
            Single 78.5% 77.9% -0.7% 18.5% 18.5% -0.1% 86.7% 86.6% -0.1% 22.7% 22.1% -0.6% 
Married 2.8% 2.5% -0.2% 52.7% 52.0% -0.7% 1.5% 1.7% 0.3% 48.6% 50.0% 1.4% 
Separated 0.2% 0.3% 0.0% 8.2% 8.6% 0.4% 0.0% 0.0% 0.0% 5.2% 5.1% -0.1% 
Cohabiting 18.5% 19.3% 0.8% 20.6% 20.9% 0.3% 11.8% 11.7% -0.2% 23.5% 22.8% -0.7% 
Ever had sex 80.4% 80.2% -0.2% 98.4% 98.5% 0.0% 73.7% 76.5% 2.8% 97.3% 97.2% -0.1% 
Ever diagnosed with 
chlamydia 
5.8% 4.2% -1.5% 6.5% 6.7% 0.2% 2.1% 2.4% 0.4% 5.1% 5.5% 0.4% 
Ever been tested for 
chlamydia 
47.6% 47.7% 0.1% 33.5% 33.2% -0.4% 39.1% 39.9% 0.9% 18.0% 17.7% -0.4% 
*IMD: index of multiple deprivation; LSOA: Lower super output area 
 
 
8.4.1 Pgp3 seroprevalence in HSE2010 & HSE2012 
The overall Pgp3 seroprevalence among 16 to 44 year-olds in HSE2010/12 was 
24.4% (95%CI 22.0%-27.1%) in women and 13.9% (95%CI 11.8%-16.2%) in 
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men. A further 2.1% of women and 2.6% of men aged 16 to 44 reported having 
been diagnosed with chlamydia but were Pgp3 seronegative. Among individuals 
who reported a previous chlamydia diagnosis, 64.7% (95%CI 51.9%-75.6%) of 
women and 43.9% (95%CI 26.5%-63.0%) of men were Pgp3 seropositive.  
Among sexually-experienced participants, Pgp3 seroprevalence increased with 
age (Figure 8-2), years since first sex (Figure 8-3) and with increasing numbers 
of lifetime sexual partners (Figure 8-4). Peak Pgp3 seroprevalence was seen in 
women aged 30 to 34 (33.5%) and in men aged 35 to 39 (18.7%).  
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Figure 8-2: Pgp3 seroprevalence by age group (sexually-experienced 16 to 44 
year-olds, HSE2010 & HSE2012) 
Solid lines show point estimates; dashed lines show 95% confidence intervals. N shows 
unweighted denominator. 
 
Women  Men 
  
N=1,194 N=948 
 
Figure 8-3: Pgp3 seroprevalence by years since first heterosexual sex, (sexually-
experienced 16 to 44 year-olds, HSE2010 & HSE2012) 
Solid lines show point estimates; dashed lines show 95% confidence intervals. 
 
Women Men  
  
N=1,188 N=936 
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Figure 8-4: Pgp3 seroprevalence by reported numbers of lifetime sexual partners 
(16 to 44 year-olds, HSE2010 & HSE2012) 
 
Table 8-5 presents Pgp3 seroprevalence by selected sociodemographic and 
behavioural factors among sexually-experienced women and men. In women, 
those reporting >10 lifetime sexual partners had almost four-fold higher odds of 
being Pgp3 seropositive than those with 1-4 partners (OR 3.84, 95%CI 2.68-
5.51). Being Pgp3 seropositive was also significantly associated with living in 
more deprived areas, younger age at first sex, non-condom use in the last year 
and reporting a previous chlamydia diagnosis. All variables associated with 
being Pgp3 seropositive in univariable analyses remained statistically significant 
after adjusting for number of lifetime sexual partners. The lifetime sexual 
partner-adjusted odds ratio (AOR) of being seropositive was 1.68 (95%CI 1.18-
2.39) in women aged less than 16 at first heterosexual sex versus those aged 
16 or over. Women who reported non-condom use in the last 4 weeks had two-
fold higher odds of being seropositive (AOR 2.17, 95%CI 1.41-3.35).   
In sexually-experienced men, similar factors were associated with being 
seropositive as seen in women in univariable analyses although age group and 
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deprivation of residence were not statistically significant. After adjusting for 
number of lifetime sexual partners, only reporting a previous diagnosis of 
chlamydia remained a significant predictor of being seropositive in men (AOR 
3.55, 95%CI 1.53-8.25).  
Among Pgp3 seropositive individuals, 84.7% (80.3%-88.3%) of 16 to 44 year-
olds did not report a previous chlamydia diagnosis. This proportion varied by 
age group, whereby 76.7% of 16 to 24 year-olds, 79.0% of 25 to 34 year-olds 
and 92.9% of 35-44 year-olds did not report a previous diagnosis. Furthermore, 
among 16 to 24 year-olds 36.3% of seropositive individuals reported having 
been tested for chlamydia, but had never been diagnosed. Among those aged 
16 to 24 years who had any evidence of a previous C. trachomatis infection (i.e. 
those who were Pgp3 seropositive or who reported a previous chlamydia 
diagnosis), 75.5% (95%CI 70.8%-79.7%) did not report a previous diagnosis. 
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Table 8-5a: Percentage Pgp3 seropositive by sociodemographic and sexual 
behavioural variables, and unadjusted and lifetime sexual partners-adjusted 
odds ratios for detection of Pgp3 antibody in serum (sexually-experienced 16 to 
44 year-old women, HSE2010 & HSE2012)  
  
Percent Pgp3 
positive (95%CI) 
Unadjusted OR 
(95%CI) 
p(uOR) 
Lifetime SP-
adjusted OR 
(95%CI) 
p 
(aOR) 
Bases 
(W,UW)
a
 
Overall 25.8%  (23.1-28.6)       1423, 1194 
          
Age group   
       
  
16-19 6.3% (2.3-16.4) 1.00 - 0.002 1.00 - 0.009 114, 55 
20-24 21.4%  (15.3-29.2) 4.05  (1.29-12.78)  3.70 (1.17-11.71)  255, 139 
25-29 23.3%  (17.1-30.8) 4.50  (1.44-14.07)  3.92 (1.26-12.16)  229, 166 
30-34 33.5%  (27.5-40.2) 7.50  (2.50-22.54)  6.34 (2.11-19.04)  284, 224 
35-39 29.5%  (24.2-35.6) 6.23  (2.08-18.65)  5.07 (1.71-15.06)  240, 278 
40-44 28.5%  (23.2-34.3) 5.91  (1.99-17.60)  5.47 (1.84-16.26)  302, 332 
IMD quintile of LSOA of 
residence
b
   
       
  
Least deprived 22.7% (17.1-29.5) 1.00 Ref 0.033 1.00 Ref 0.037 256, 238 
2 25.8%  (20.3-32.2) 1.18  (0.74-1.89) 
 
1.08  (0.67-1.73) 
 
292, 248 
3 19.6%  (15.1-25.2) 0.83  (0.51-1.35) 
 
0.83  (0.50-1.38) 
 
309, 256 
4 32.1%  (26.1-38.8) 1.61  (1.02-2.53) 
 
1.61  (1.00-2.61) 
 
290, 230 
Most deprived 28.9%  (22.7-36.0) 1.38  (0.86-2.24) 
 
1.46  (0.87-2.43) 
 
276, 222 
Age at first heterosexual sex   
       
  
16+ at first intercourse 22.5% (19.6-25.7) 1.00 Ref 0.000 1.00 Ref 0.004 1080, 911 
<16 at first intercourse 39.6%  (33.0-46.6) 2.26  (1.61-3.16) 
 
1.68  (1.18-2.39) 
 
304, 246 
Years since first heterosexual 
sex   
       
  
0 to 4 8.1% (3.8-16.7) 1.00 - <0.001 1.00 Ref <0.001 184, 90 
5 to 9 18.5%  (13.1-25.4) 2.56  (1.01-6.49) 
 
2.05  (0.80-5.20) 
 
289, 174 
10 to 14 25.9%  (20.1-32.8) 3.95  (1.61-9.69) 
 
2.79  (1.14-6.79) 
 
256, 199 
15 to 19 38.2%  (32.0-44.7) 6.96  (2.98-16.26) 
 
5.40  (2.31-12.62) 
 
271, 264 
20+ 31.1%  (26.5-36.0) 5.08  (2.19-11.77) 
 
3.61  (1.55-8.37) 
 
415, 461 
Number of partners of the 
opposite sex in last year   
       
  
0 19.2% (11.7-30.0) 1.00 Ref 0.370 1.00 Ref 0.028 91, 81 
1 26.8%  (23.8-30.0) 1.53  (0.84-2.79) 
 
1.58  (0.80-3.12) 
 
1159, 993 
2+ 25.7%  (17.9-35.4) 1.45  (0.69-3.06) 
 
0.89  (0.41-1.94) 
 
149, 103 
Number of lifetime sexual 
partners
c
   
       
  
1 to 4 16.5% (13.2-20.3) 1 - <0.001  
5 to 9 30.0%  (25.0-35.6) 2.18  (1.51-3.14) 
 
    
10+ 43.1%  (36.6-49.8) 3.84  (2.68-5.51) 
 
    
Condom use in last 4 weeks   
       
  
Used on every occasion 15.8% (11.4-21.6) 1.00 Ref 0.001 1.00 Ref 0.001 262, 207 
Used on some occasions 19.4%  (12.7-28.5) 1.28  (0.68-2.41) 
 
1.09  (0.57-2.09) 
 
133, 95 
Not used in last 4 weeks 30.1%  (26.4-34.1) 2.30  (1.49-3.53) 
 
2.17  (1.41-3.35) 
 
735, 630 
Not had vaginal or anal sex in 
last 4 weeks 26.8%  (20.5-34.3) 1.95  (1.15-3.31) 
 
1.79  (1.03-3.11) 
 
239, 209 
Ever diagnosed with 
chlamydia?            
No 23.6%  (20.9-26.7) 1.00 - <0.001 1.00  Ref <0.001 1145, 960 
Yes 65.5%  (52.7-76.3) 6.12  (3.57-10.51)  5.08  (2.79-9.23)  76, 68 
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Table 8-5b: Percentage Pgp3 seropositive by sociodemographic and sexual 
behavioural variables, and unadjusted and lifetime sexual partners-adjusted 
odds ratios for detection of Pgp3 antibody in serum (sexually-experienced 16 to 
44 year-old men, HSE2010 & HSE2012)  
  
Percent Pgp3 
positive (95%CI) 
Unadjusted OR 
(95%CI) 
p(uOR) 
Lifetime SP-
adjusted OR 
(95%CI) 
p 
(aOR) 
Bases 
(W,UW)
a
 
Overall  14.6%  (12.3-17.1)       1424, 948 
          
Age group           
16-19 4.1%  (1.0-15.0) 1.00 - 0.113 1.00 - 0.385 142, 66 
20-24 10.1%  (5.8-17.0) 2.66  (0.57-12.40)  1.74  (0.35-8.61)  220, 114 
25-29 14.3%  (9.2-21.5) 3.94  (0.88-17.68)  2.32  (0.48-11.20)  255, 139 
30-34 18.1%  (12.6-25.3) 5.22  (1.19-23.00)  3.21  (0.70-14.76)  251, 165 
35-39 18.7%  (13.4-25.6) 5.45  (1.24-23.96)  3.22  (0.70-14.76)  242, 214 
40-44 16.7%  (12.4-22.1) 4.74  (1.09-20.65)  2.74  (0.60-12.62)  314, 250 
IMD quintile of LSOA of 
residence
b
           
Least deprived 13.7%  (8.9-20.5) 1.00  Ref 0.680 1.00  Ref 0.795 241, 184 
2 12.4%  (8.5-17.8) 0.90  (0.47-1.72)  0.98  (0.50-1.92)  283, 195 
3 14.8%  (10.0-21.3) 1.10  (0.56-2.14)  1.31  (0.65-2.61)  304, 199 
4 13.8%  (9.5-19.6) 1.01  (0.54-1.88)  0.90  (0.44-1.82)  285, 179 
Most deprived 17.7%  (12.7-24.0) 1.36  (0.73-2.52)  1.22  (0.61-2.45)  310, 191 
Age at first heterosexual sex           
16+ at first intercourse 12.0%  (9.6-15.0) 1.00 Ref 0.002 1.00 Ref 0.233 980, 658 
<16 at first intercourse 22.6%  (17.5-28.8) 2.14  (1.41-3.24)  1.50  (0.94-02.38)  357, 231 
Years since first heterosexual 
sex           
0 to 4 3.5%  (1.1-10.5) 1.00  Ref 0.003 1.00 - 0.077 230, 109 
5 to 9 10.1%  (6.2-16.2) 3.11  (0.86-11.18)  1.78  (0.47-6.82)  283, 154 
10 to 14 16.3%  (10.7-24.0) 5.36  (1.51-19.03)  3.12  (0.85-11.42)  236, 148 
15 to 19 22.3%  (16.2-29.8) 7.91  (2.31-27.02)  4.10  (1.15-14.66)  249, 186 
20+ 18.0%  (14.1-22.6) 6.03  (1.84-19.76)  3.04  (0.90-10.33)  409, 339 
Number of partners of the 
opposite sex in last year           
0 10.4%  (3.8-25.5) 1.00  Ref 0.741 1.00 - 0.687 100, 59 
1 14.5%  (12.1-17.4) 1.46  (0.49-4.35)  1.52  (0.43-5.38)  1059, 745 
2+ 15.6%  (10.2-23.1) 1.59  (0.49-5.16)  1.28  (0.32-5.06)  215, 115 
Total number of lifetime sexual 
partners
c
           
1 to 4 5.9%  (3.7-9.2) 1.00  Ref <0.001    575, 361 
5 to 9 9.9%  (6.6-14.4) 1.74  (0.90-3.33)     322, 223 
10+ 27.2%  (22.1-33.1) 5.95  (3.41-10.35)     446, 306 
Condom use in last 4 weeks           
Used on every occasion 10.8%  (7.0-16.3) 1.00  Ref 0.046 1.00 - 0.272 285, 181 
Used on some occasions 13.0%  (7.6-21.2) 1.23  (0.58-2.61)  1.24  (0.54-2.82)  173, 98 
Not used in last 4 weeks 17.6%  (14.3-21.4) 1.76  (1.04-3.00)  1.51  (0.83-2.72)  657, 479 
Not had vaginal or anal sex in 
last 4 weeks 9.7%  (5.7-15.8) 0.88  (0.43-1.81)  0.86  (0.39-1.90)  246, 151 
Ever diagnosed with 
chlamydia?          
No 12.8%  (10.6-15.4) 1.00  Ref <0.001 1.00  Ref 0.003 1145, 776 
Yes 44.6%  (26.9-63.8) 5.47  (2.47-12.15)  3.55  (1.53-8.25)  62, 35 
a
Denominator totals vary due to item-missingness & include individuals where the specified 
characteristic is unknown 
b
IMD: index of multiple deprivation; LSOA: Lower super output area 
c
Includes partners of both the opposite and of the same gender. 
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8.4.2 Pgp3 seroprevalence over time among 16 to 24 year-old women 
Figure 8-5 shows Pgp3 seroprevalence among 16 to 24 year-old women in 
each year sampled. There was no significant difference in Pgp3 seroprevalence 
between the first (1994 to 1996) and second (2001 to 2002) time-periods 
sampled. Between 2008 and 2012, there was a non-significant decline in Pgp3 
seroprevalence among 16 to 24 year-old women (prevalence ratio per year: 
0.94, 95%CI 0.84-1.05; p=0.26). After stratifying by age group, there was no 
notable trend among 16 to 19 year-olds (prevalence ratio: 0.96, 95%CI 0.74-
1.24; p=0·76), and a non-significant decline in Pgp3 seroprevalence among 20 
to 24 year-olds (prevalence ratio: 0.92, 95%CI: 0.83-1.04; p=0.18, (Figure 8-6). 
Figure 8-5: Pgp3 seroprevalence by year (16 to 24 year-old women, HSE 1994 to 
2012) 
Solid lines show point estimates; dashed lines show 95% confidence intervals. Unweighted 
denominators: 1994-1996, n=1,555; 2001-2002, n=1097 2008-2012, n=709. 
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Figure 8-6: Pgp3 seroprevalence by year and age group (16 to 24 year-old 
women, HSE 2008 to 2012) 
Solid lines show point estimates; dashed lines show 95% confidence intervals. Unweighted 
denominators: 16-19 year-olds, n=284; 20-24 year-olds, n=425. 
 
Figure 8-7 shows Pgp3 seroprevalence by year of age and birth cohort defined 
by exposure to widespread chlamydia screening. Although data were only 
available on those aged up to 19 years in the group who had high exposure to 
screening (due to the number of HSE survey years available since 2008), there 
was no indication of a difference in the age-specific seroprevalence by birth 
cohort, with similar age curves seen in each group.  
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Figure 8-7: Pgp3 seroprevalence by birth cohort and year of age (16 to 24 year-
old women, HSE 1994 to 2012)* 
 
*Unweighted denominators: High (born 1992-1996), n=185; Partial (born 1984-1991), n=853; 
Limited (born 1976-1983), n=1349; Limited (born 1966-1975), n=929. See Table 8-3 for details 
of denominators by year of age. 
 
8.5 Discussion 
8.5.1 Key findings 
In 2010/12, one quarter of 16 to 44 year-old and one in three 30 to 34 year-old 
women had evidence of a previous chlamydia infection as indicated by the 
presence of detectable Pgp3 antibodies in serum. Being Pgp3 seropositive was 
strongly associated with increasing age, years since first sex and numbers of 
lifetime sexual partners, as would be expected from a marker of previous 
infection with a sexually-transmitted infection. Three quarters of under-25 year-
olds with evidence of previous infection did not report a previous chlamydia 
diagnosis, suggesting a high level of undiagnosed infections. There was no 
0%
10%
20%
30%
40%
16 17 18 19 20 21 22 23 24
P
g
p
3
 s
e
ro
p
re
v
a
le
n
c
e
 
Age in years 
High (born 1992-1996) Partial (born 1984-1991)
Limited (born 1976-1983) Limited (born 1966-1975)
Birth cohort defined by exposure to widespread 
opportunistic chlamydia screening: 
224 
significant trend in age-specific Pgp3 seroprevalence over time or between birth 
cohorts exposed to different levels of opportunistic chlamydia screening.  
The proportion of the population who acquire chlamydia infection by their mid-
40s is much greater than suggested by prevalence studies of current infection 
as measured by NAATs. For example in Natsal-3, which was conducted at a 
similar time, the prevalence of current chlamydia infection was estimated to be 
1.5% in women and 1.1% in men aged 16 to 44 years.23 Studies that focus on 
current infection underestimate the lifetime risk of chlamydia infection.  
8.5.2 Strengths and limitations 
The major strengths of this analysis are that it used data and stored sera from a 
series of nationally-representative samples and applied novel serological tests 
to investigate age-specific cumulative incidence of chlamydia. For HSE2010/12 
participants Pgp3 seroprevalence could be investigated by sociodemographic 
and behavioural factors at an individual level. The assays used in the testing 
strategy have demonstrated higher sensitivity than commercially-available 
assays.209,269 
There were some limitations. The findings may be affected by who agreed to 
take part in the survey or provide a blood sample. Non-response weights were 
applied to account for non-participation in the overall survey and provision of a 
blood sample. HSE2010/12 participants who contributed to this study were 
comparable to the overall HSE population on a range of sociodemographic and 
variables, however unmeasured bias remains feasible. A further limitation is that 
all behavioural data were self-reported. Sensitive items were collected using the 
self-completion booklet to minimise social desirability bias. However, as 
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questions were completed using a booklet rather than the best-practice of 
computer-assisted self-interview and as household members could be present 
during booklet completion, underreporting remains possible.272  
Estimated sensitivity of both the indirect and the double-antigen ELISAs to 
detect a previous chlamydia infection is less than 100% (e.g. 74% and 83% 
respectively in women). The percent Pgp3 seropositive among individuals who 
had ever been diagnosed with chlamydia was comparable to the reported 
sensitivity of the indirect, but slightly lower than that of the double-antigen 
ELISA. Pgp3 seroprevalence will therefore be a biased estimator of age-specific 
cumulative incidence of C. trachomatis due to misclassification arising from test 
performance (i.e. misclassification of presence/absence of antibodies) or 
patterns of seroconversion and subsequent loss of antibodies (i.e. absence of 
antibodies does not always reflect an absence of previous infection). Evidence 
from a study by Horner et al suggests that anti-Pgp3 antibodies are more likely 
to be detectable in the first few weeks/months of an infection and are more 
likely to remain detectable in women with repeat versus those with first 
infections.100 In that study, sera from women attending two GUM clinics with at 
least one known previous chlamydia diagnosis were tested using the indirect 
Pgp3 ELISA. The percentage Pgp3 seropositive declined with increasing time 
since last detection up to ~6 months and remained relatively stable thereafter. 
The percent seropositive in women with more than one known previous 
chlamydia diagnosis remained higher for a longer period than in women with 
only one previous diagnosis. Thus interpreting Pgp3 seroprevalence as a 
measure of age-specific cumulative incidence of C. trachomatis infection will be 
complicated by test performance, time since infection and patterns of re-
infection. Nevertheless, Pgp3 seroprevalence represents a lower bound of age-
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specific cumulative incidence; the proportion of the population ever infected with 
C. trachomatis would be even higher than estimated Pgp3 seroprevalence 
presented in this chapter. While this misclassification error is important to 
understand and ideally quantify, measurement of Pgp3 seroprevalence is a 
promising approach for surveillance and for impact evaluation of chlamydia 
control programmes given the ability to measure minimum age-specific 
cumulative incidence.  
Pgp3 antibodies were detected among people who had never had sexual 
intercourse. This may be due to under-reporting of sexual experience or to false 
positives that would be expected from low prevalence populations. Interestingly, 
the percentage Pgp3 seropositive among those with no lifetime sexual partners 
when measured on the indirect ELISA only was higher than when estimated 
using the testing strategy of combined indirect and double-antigen Pgp3 ELISAs 
(5.7% versus 4.0%). This may suggest a higher specificity of the double-antigen 
ELISA and supports its use within the testing strategy.  
Interpreting Pgp3 seroprevalence patterns among men is complicated by lower 
test sensitivity to detect a previous infection, which may reflect differences in 
immune response following infection by gender and site of infection.209 The 
lower Pgp3 seroprevalence also limits the power to investigate risk factors for 
Pgp3 seropositivity given the smaller number of men with detectable antibodies. 
The more gradual increase in Pgp3 seroprevalence with age in men may partly 
reflect age-mixing patterns whereby women tend to have older male sexual 
partners. Thus as the prevalence of infection in men is higher in those aged 20 
to 24 than in 16 to 19 year-olds,23 women may be at higher risk of incident 
infection at sexual debut than men. However, the more gradual increase in men 
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might also reflect the importance of repeated exposure in developing a 
persistent, detectable Pgp3 antibody response. 
8.5.3 Comparison to other studies 
STI incidence is thought to have been low in the early 1990s following changes 
in sexual risk-taking behaviour after sexual health campaigns aimed at HIV 
prevention in the early- to mid-1980s.273 From the mid-1990s there were 
increases in reports of bacterial STI273 and sexual risk behaviours increased 
between 1990 and 2000,235 suggesting a likely rise in STIs. It might therefore be 
expected that Pgp3 seroprevalence would have increased between the mid-
1990s and early 2000s, but there was no significant difference between these 
periods. One possible explanation for this is that STI incidence had already 
started to increase by the mid-1990s. Chlamydia incidence may also have been 
less affected by changes in sexual behaviour over the period as it is more 
widely distributed in the population than STI such as gonorrhoea or syphilis23. It 
is also feasible that participation bias not reflected in the survey weights 
changed over this period.  
More interestingly for the evaluation of chlamydia screening is that no significant 
change was found in age-specific seroprevalence between 2008 and 2010 and 
there was no difference between birth cohorts exposed to different levels of 
opportunistic chlamydia screening. This is perhaps surprising given the increase 
in chlamydia control efforts over the last decade. Possible reasons for this and 
comparisons with findings from other studies are discussed in detail in the 
following chapter.  
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In this analysis, women with greater numbers of sexual partners and who 
reported younger age at first sex were more likely to have evidence of a 
previous infection. This is consistent with findings from a cohort study of women 
in New Zealand whose sera were tested using the double-antigen ELISA, 
among whom lifetime sexual partners and age at first sex were both associated 
with being seropositive.269 The steep increase in seroprevalence from age 16 to 
age 25 also suggests a particularly high rate of infection among young women 
soon after commencing sexual debut. Based on the observed seroprevalence at 
10-11 years after first heterosexual sex (31%), the average annual incidence of 
chlamydia infection in women can be estimated to be at least 3% per year in the 
ten years following sexual debut. This will be an underestimate of the overall 
rate of transmission, as repeat infections are common48-57 but cannot be 
quantified from seroprevalence data. This emphasises the importance of 
adolescence and young adulthood as periods when chlamydia prevention and 
screening activities are needed to prevent development of adverse 
consequences. 
Pgp3 seroprevalence estimated among HSE participants was higher than that 
reported from a recent population-based study in the Netherlands reported by 
Van Aar et al, which used the Medac CT IgG ELISA (9.8% in women and 5.7% 
in men aged 15 to 39132). Van Aar et al also found a less marked relationship 
with age. This may be due to the difference in assay sensitivity (Medac: 46·2% 
versus double-antigen ELISA: 82·9%),269 or to country differences in the 
epidemiology of chlamydia. 
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8.5.4 Implications for evaluation of chlamydia control 
The clear relationship between Pgp3 seroprevalence and number of lifetime 
sexual partners, especially among women, further supports the use of age-
specific seroprevalence as a marker of previous infection. The insight gained 
from these results demonstrates the strengths of this approach to outcome 
measurement.  
The findings from this analysis do not support there having been a decrease in 
age-specific cumulative incidence among 16 to 24 year-old women following the 
implementation and national roll-out of the NCSP. As discussed in more detail 
in the next section, the evidence for high lifetime cumulative incidence and 
suggestion of high fraction of undiagnosed infections may offer a partial 
explanation for the absence of a decline in age-specific cumulative incidence.  
8.5.5 Summary 
A decrease in age-specific cumulative incidence of chlamydia following the 
national implementation of opportunistic chlamydia screening has not yet been 
demonstrated. The implications of these findings and possible reasons for an 
apparent absence of any decline are explored in detail in the next chapter.   
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9 Summary and discussion 
In the previous five chapters I examined four different approaches to outcome 
measurement for the evaluation of chlamydia screening. In this chapter I discuss the 
meaning of my findings in the context of the original aims of the thesis, which were: 
1. to identify and appraise outcome measures, and methods of their measurement, for 
the purpose of evaluating the impact of opportunistic chlamydia screening on the 
incidence and prevalence of infection (or related measures); and 
2. using the outcome measures and methods identified in (1), to examine whether 
widespread opportunistic chlamydia screening, as it has been delivered in practice, 
has led to a reduction in the incidence or prevalence of chlamydia among young 
adults in England up to 2012 that would otherwise have been seen in the absence of 
opportunistic chlamydia screening.   
I make recommendations about whether and how this range of methods should be 
incorporated into ongoing evaluation of chlamydia screening and discuss the 
implications of my findings for the future development of chlamydia control policies 
in England. Finally, I set out suggestions for future research given the questions 
raised by my research that, as yet, remain unanswered. 
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9.1 Critical appraisal of outcome measures for the evaluation of the 
impact of chlamydia screening on incidence and prevalence of 
infection 
9.1.1 Trends in percentage testing positive for chlamydia using 
surveillance data 
As discussed in Chapter 3, it is well established that, as a large proportion of 
chlamydia infections are asymptomatic10,11,20 the number of chlamydia 
diagnoses reported and proportion of tests which are positive are highly 
dependent on the population tested. Thus reported diagnoses do not represent 
the true burden of incident infections and percentage testing positive does not 
equate to population prevalence.201 
My analysis using surveillance data from populations accessing chlamydia 
testing showed that the percentage testing positive varies according to testing 
venue type, and that significant differences between venues in the odds of 
testing positive remained even after adjustment for sexual behaviour variables. 
This suggests that the sexual behaviour and demographic data items that were 
available in the NCSP dataset could not fully explain the difference in risk of 
having a current chlamydia infection between populations attending different 
services. Given that the available sexual and behavioural variables were not 
sufficient to capture the difference in risk of infection between people attending 
different venues, it is also possible that these variables would be insufficient to 
capture difference in risk arising from a different profile of people accessing 
testing over time, even in analyses stratified by testing venue type. This 
potential for unmeasured confounding would be especially true in the presence 
of changes in testing policy, for example if a venue were to move from universal 
to targeted testing. Thus trends in percentage testing positive from populations 
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accessing chlamydia testing do not provide definitive measures of change in the 
underlying population prevalence of infection.  
As NAATs have been widely available since at least 2006 in the UK,128 then 
there will have been minimal measurement error in the trends in percentage 
testing positive introduced by detection strategies used. However it is important 
to remain vigilant to changes in test technology that might affect surveillance 
data as changes in tests used have repeatedly been shown to affect observed 
trends in percentage testing positive for chlamydia.192,200,203,204,274  Future 
developments in test technologies and testing pathways including point of care 
testing275 and remote testing via mobile devices276 are on the horizon and may 
in the future present a shift in test performance that would be reflected in cases 
reported and estimates of percentage testing positive. Maintaining consistency 
in test technologies is beneficial to permit comparisons over time, but the need 
to deliver the best diagnostic services means that changes will likely occur. 
Future analysis of longitudinal trends should therefore consider changes in test 
sensitivity and specificity. As with changes in testing strategies within the Natsal 
surveys (Chapter 6), head to head comparisons of different test technologies 
used in routine practice as developments occur will be useful to provide data for 
comparisons over time. 
It was not possible to measure uptake of testing (i.e. the percentage of eligible 
individuals attending services who were tested) among those attending all 
venues. This would have been possible with data from GUM clinics as a clinic-
attending denominator is available. However as the offer and uptake of a 
chlamydia test is less likely to vary in GUM settings this was not investigated in 
the analysis presented in Chapter 4. Developments in the GUMCADv2 
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surveillance system, whereby comparable information to that collected in GUM 
clinics is now collected for all commissioned ‘level 2’ (i.e. non-GUM) sexual 
health services, mean that a measure of uptake of testing within sexual and 
reproductive health services and some GP clinics will be available in coming 
years. The extent to which percentage testing positive varies with test uptake 
within a setting would be useful to explore in future analyses.  
Some of the issues of using surveillance data may be addressed if chlamydia 
screening were to be delivered as a register-based screening programme, 
where a defined population were invited to participate. By standardising the 
offer of screening, this might make the resulting data less susceptible to 
confounding arising from differences in who is offered a test. However, even 
register-based screening programmes face challenges in reliable outcome 
measurement. As described in Chapter 3, the CSI project in the Netherlands 
was a register-based programme and invited all 16 to 29 year-olds resident in 
three areas of the Netherlands to be tested for chlamydia once a year for three 
years. In their write-up of findings from the CSI project, van den Broek et al 
noted that the population tested each year appeared to be at higher risk, on 
average, in each subsequent year.88 Thus even in the context of a RCT of 
register-based screening the study’s findings remain open to question due to 
the potential for unmeasured confounding. In another (ongoing) RCT in 
Australia, the Australian Chlamydia Control Effectiveness Pilot ‘ACCEPt’ aims 
to assess the feasibility, acceptability and effectiveness of chlamydia testing in 
GP settings.277 The primary outcome of the trial is chlamydia ‘prevalence’ 
measured among women and men attending GP services. However, as this is 
based on a clinic-attending population this would be more akin to percentage 
testing positive according to the definitions applied throughout this thesis. 
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Prevalence will be compared between clinics in the intervention arm where 
clinics have been asked to offer chlamydia testing to all sexually active under-
30 year-olds to that measured in control clinics. While the baseline prevalence 
survey achieved high response rate (69.7%),278 participants were provided with 
their results. It is therefore feasible that follow up collections might be affected 
by previous offers of testing meaning that participation bias may vary between 
the intervention and control arms. While the results of this study are not yet 
available, this further illustrates the potential limitations of using percentage 
testing positive as an outcome measure even when utilised as part of a RCT.  
In summary, trends in percentage testing positive should not be interpreted as 
trend in underlying burden of disease without first ruling out or addressing 
sources of selection bias and confounders affecting trends over time.  
9.1.2 Repeat cross-sectional anonymous postal surveys of chlamydia 
prevalence 
As described in Chapter 4, the pilot of a postal survey of young women with 
anonymous testing for chlamydia resulted in low participation rates. Both 
provision of a home sampling kit and offering a small financial incentive 
increased participation, and reduced the cost per sample received. Although the 
sample size in the pilot was not sufficient to provide strong evidence for, or to 
rule out selection bias, given the low participation rates achieved, future surveys 
using this methodology would be open to substantial and potentially varying 
selection bias. There was some indication that demographic characteristics 
varied between the groups, suggesting the very real potential for selection bias 
using this methodology. The piloted approach is therefore not feasible or 
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suitable for population-based monitoring of chlamydia prevalence among young 
women in England. 
The maximum achieved participation rate of 14% (in the group with the 
voucher) was comparable with other population based approaches using postal 
invitation for chlamydia testing. In a pilot of a postal offer of chlamydia 
screening, Bracebridge et al achieved a participation rate of 13% among 
women aged 18 to 24.158 In the Netherlands, the CSI project achieved a 21% 
participation rate among 15 to 29 year-old women in year one, which fell to 13% 
in year 3.88 Studies such as Natsal and NHANES, which invited participants to 
provide a sample during a face to face interview, have achieved response rates 
of upwards of 50%.141,172 This suggests that high response rates can be 
achieved, but that a far more resource-intensive recruitment approach would be 
needed. Additionally, surveys with a broader focus than chlamydia prevalence 
may be of more interest to the eligible participants meaning a larger and 
potentially more representative population could be recruited.  
9.1.3 Repeat cross-sectional surveys of chlamydia prevalence 
embedded within sexual behaviour or general health  surveys  
The Natsal surveys have achieved much higher response rates than were 
observed in my pilot of a chlamydia-specific postal survey of chlamydia 
prevalence.172 As with other probability surveys among general population 
samples,7,135,141 participation in Natsal is far from universal and there therefore 
remains some, theoretical, potential for non-participation bias. However these 
surveys are far more robust than postal surveys for chlamydia with regard to 
representativeness of the population.  
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My analyses presented in chapter 6 showed that, while changing approaches to 
prevalence measurement pose challenges for comparisons over time, 
adjustments can be made to allow for differences in diagnostic tests used in 
each survey where the relative sensitivity and specificity of tests is known. The 
adjustments for detection strategy were made using data from two separate 
studies where the tests and specimen collection devices used in Natsal-2 had 
been compared to those used in Natsal-3. As estimated sensitivity and 
specificity are dependent on the gold standard used, such head to head 
comparisons are invaluable. Given ongoing technological developments it is 
possible that tests for chlamydia (and other infections) used in any subsequent 
Natsal survey may differ from those in Natsal-3. In anticipation of this, 
maintaining a panel of residual biological samples for the purposes of validating 
using any future tests will be useful to strengthen the possibility for future 
comparisons.  
While adjustments for different detection strategies could be made, the 
comparisons between age- and gender-specific measures of chlamydia 
prevalence were ultimately limited by the sample size available in each survey. 
The Natsal-2 and Natsal-3 surveys were not powered to detect changes in 
chlamydia prevalence, so it is not perhaps surprising that these comparisons 
were limited by the number of participants in specific groups. Other surveys 
have also been limited by the sample size available. In NHANES in the US, 
estimates by age, gender and race/ethnicity become somewhat unstable due to 
the small denominators in some cases, and small numerators in groups with 
very low measured prevalences.141  
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Given the limitations in sample size and survey methodologies, the real strength 
of the Natsal surveys for understanding effectiveness of chlamydia screening 
was in providing a source of data where chlamydia infection, testing and 
diagnoses within the same population could be investigated incorporating 
individual-level data on both outcomes and demographic and behavioural 
details. The implications of these findings for chlamydia control are discussed 
below (section 0). In summary, the combination of data available made it 
possible to investigate how chlamydia screening was being implemented in 
relation to risk, to identify potentially unmet need and to hypothesise why 
chlamydia screening up to 2012 may not have had a substantial impact on 
chlamydia incidence or prevalence. I therefore propose that future use of 
prevalence surveys should continue to assess prevalence but do so in the 
context of screening and sexual behaviours rather than focus on direct 
comparisons of prevalence alone. 
Natsal has been conducted decennially since 1990. HSE is conducted every 
year, and therefore presents an opportunity for more regular monitoring of 
chlamydia-related outcomes. As described in Chapter 8 HSE successfully 
collected data on sexual behaviour in 2010 and 2012. To date, it has not 
collected data on prevalent chlamydia infections. However this may be feasible, 
as several biological measures are taken, including an array of tests using urine 
specimens.7 Prah et al have shown that some sexual risk behaviours and STI-
related factors were less-commonly reported in HSE2010 than in Natsal-3. This 
is likely due to differences in the administration of the surveys (household 
versus personal interviews) and to differences in participation in general health 
versus sexual attitude and lifestyle-specific surveys.272 However survey-derived 
estimates are broadly consistent, which supports the use of both sources for 
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future monitoring of sexual health parameters including chlamydia prevalence, 
history of chlamydia testing and diagnosis and uptake of chlamydia screening. 
Given the major limitations due to available sample size in comparisons 
between Natsal-2 and Natsal-3, future surveys would also benefit from a larger 
sample size to allow sufficient power for comparison of outcomes across 
repeated surveys. 
9.1.4 C. trachomatis antibody seroprevalence as a marker of age-
specific cumulative incidence 
The use of C. trachomatis antibody seroprevalence as an outcome measure for 
evaluating chlamydia screening faces some of the same challenges as surveys 
that measure prevalence of current infection and surveillance data, in that bias 
may arise from the population sampled and changes in the population who 
contribute serum samples for testing may lead to confounding of the 
relationship between testing antibody seropositive and time. The analysis 
presented in Chapter 8 used data from a nationally-representative probability 
survey with standardised data collection over time in order to minimise the 
impact of these potential problems. However separating the effects of sexual 
behaviour from those of increased access to chlamydia screening remains an 
issue when looking at antibody seroprevalence. Sexual behaviour data were not 
available in all years in the Health Survey for England thus it was not possible to 
adjust for sexual behaviour as a potential confounder of the relationship 
between seroprevalence and exposure to chlamydia screening, which remains 
a limitation of this analysis. Future serum collections should prioritise the 
collection of sexual behaviour data to allow more detailed analysis of trends 
over time in relation to factors that may influence cumulative incidence of 
infection.  
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Another problem in common with surveys of chlamydia prevalence is that of 
power. Although antibody seroprevalence is several-fold higher than that of 
prevalence of current chlamydia infection, the analysis presented in Chapter 
8was restricted to the number of serum samples that were available from 
previous HSE surveys and may have limited the ability of the analysis to detect 
a significant decline in Pgp3 seroprevalence among 16 to 24 year-olds. This is 
explored further in Table 9-1 below, which shows the significance of the 
prevalence ratio that would have been observed had the same point estimates 
been observed in each year, but a larger sample size had been recruited. This 
suggests that a sample size between two to three times larger in each year may 
have resulted in a conclusion of there having been a statistically significant (at 
p<0.05 level) decline in Pgp3 seroprevalence among 16 to 24 year-old women 
between 2008 and 2012. However, although power may be an issue, it is 
important to note that a larger sample would not necessarily have achieved the 
same point estimates and that the downward (non-significant) trend in 
seroprevalence measured in HSE participants was especially driven by 
seroprevalence among 20 to 24 year-olds in 2012 (Figure 8-6). This may be an 
early indication of falling seroprevalence, but additional years of data would be 
needed to investigate this further. 
Table 9-1: Hypothetical scenario showing point estimates, 95%CI and p values 
for prevalence ratio of Pgp3 seroprevalence achieved with different sample sizes 
(16 to 24 year-old women, HSE2008 to HSE2012) 
Prevalence ratios, p values and 95%CI are based on the actual sample size available (as 
presented in section 8.4.2) and three hypothetical scenarios based on two to four times the 
number of participants recruited (maintaining the balance of positive and negative results).  
 
Point estimate 
(prevalence ratio 
per year) 
Sample size 95%CI P value 
In relation to 
actual 
Total N 
0.94 Actual size 707 0.85-1.04 0.250 
0.94 x 2 1414 0.87-1.01 0.103 
0.94 x 3  2121 0.88-1.00 0.046 
0.94 x 4 2828 0.89-0.99 0.021 
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Data from the analysis of HSE participants presented in this paper, and the two 
other analyses using the Pgp3 indirect ELISA among residual sera from women 
attending GUM clinics214 and those submitting sera for routine investigations213 
now provide a wealth of data to indicate the seroprevalence that would be 
expected in future studies in different settings, which can be used to power 
future surveys or collections of residual sera. 
Measurement error remains a major limitation for using C. trachomatis antibody 
seroprevalence as an outcome measure for evaluating chlamydia control 
programmes. While the double-antigen Pgp3 ELISA demonstrates higher 
sensitivity in women than the indirect Pgp3 ELISA and other commercial 
assays, estimated sensitivity to detect a previous known infection remains well 
under 100% at 82.9%.269 Thus Pgp3 seroprevalence remains an imperfect 
measure of cumulative incidence of infection by any given age. It is unclear 
whether this imperfect sensitivity is due in part to some women not developing 
serum antibodies following genital infection with C. trachomatis, or only to 
waning of antibodies over time and/or assay performance, although a 
combination of these factors is likely. Waning of antibodies has been 
demonstrated using the indirect Pgp3 ELISA100 and other commercial 
assays.210  The ability of the double-antigen Pgp3 ELISA to detect antibodies 
appears to be less affected by time since infection.269 However, further work is 
needed to better quantify the relationship between having detectable antibodies 
and time since infection, to allow future estimates using C. trachomatis antibody 
assays to adjust for this measurement error. 
A further limitation with C. trachomatis antibody seroprevalence assays is that 
repeat infections cannot be distinguished from first infections. As is discussed in 
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more detail below, re-infection may play an important part in preventing 
chlamydia screening from having a substantial impact on chlamydia prevalence. 
Being able to measure rates of re-infection among the general population would 
therefore be informative. However it is not yet possible to use serological 
studies to measure rates of re-infection.  
Among men, my analysis of HSE2010/12 participants demonstrated that the 
percentage Pgp3 seropositive correlated with numbers of sexual partners, as 
would be expected as a marker of previous infection with a STI. However, the 
lower sensitivity of the assay to detect a previous infection among men limits 
the use of Pgp3 seroprevalence as an outcome measure for the evaluation of 
chlamydia control. The extent to which this lower sensitivity reflects a difference 
in the immune response to C. trachomatis infection between women and men or 
by anatomical site of infection or differences in antibody waning by sex is 
unclear. However, as discussed in section 9.3 below, as men have an important 
part to play in the transmission of infection and in understanding the challenge 
of controlling the incidence and prevalence of chlamydia, a more detailed 
understanding of the relationship between C. trachomatis infection, antibody 
response and protective immunity in men is warranted.  
Despite these limitations, the application of the Pgp3 indirect and double 
antigen ELISAs present a powerful tool for the evaluation of chlamydia 
screening programmes in England and elsewhere. As with data from Natsal-3, 
the analysis of Pgp3 seroprevalence among HSE2010/12 participants provided 
important insights into the epidemiology of chlamydia in relation to testing 
patterns. Specifically, my analysis showed that chlamydia is widespread 
through the population among women and that a high percentage of infections 
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had, up to 2012, gone undiagnosed. The use of C. trachomatis antibody tests 
combined with information on history of diagnoses provides a valuable and 
novel outcome measure, as a high level of undiagnosed infections represents 
both opportunities for transmission and potential development of complications 
arising from untreated infections. Future serum collections should incorporate 
data on history of chlamydia diagnoses wherever feasible. 
9.2 Summary of recommendations for future evaluation of the impact 
of chlamydia control programmes in England 
In summary, I propose the following recommendations for the ongoing and 
future evaluation of the impact of chlamydia screening on chlamydia incidence, 
prevalence and related measures: 
 Repeat cross-sectional postal surveys of chlamydia prevalence in the 
general population are open to bias and are unlikely to provide value for 
money. They should not be pursued as a means to monitor chlamydia 
prevalence in England. 
 Surveys such as Natsal, which are nationally representative, have relatively 
high response rates and collect data on a range of topics, will present better 
value for money than cross-sectional, chlamydia prevalence-specific postal 
surveys. Analysis of such surveys should focus on assessing prevalence in 
the context of reported screening and diagnoses and sexual behaviours 
rather than on direct comparisons of prevalence alone. 
 The potential to incorporate the following measures into the HSE on a 
routine basis should be considered: current chlamydia infections (as 
measured using NAAT tests of urogenital specimens); previous infection 
with C. trachomatis (as measured using antibody tests of serum specimens); 
sexual behaviour and reported chlamydia testing and diagnosis history.  
 Boosting the available sample size among young adults in both future 
rounds of the HSE and Natsal surveys would increase the power available 
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for comparative analyses and should be considered, using available data to 
determine the sample size required. 
 Trends over time in percentage testing positive for chlamydia among 
populations accessing testing should not be interpreted as trends in the 
underlying burden of disease without first ruling out or addressing sources of 
selection bias and confounders. Future analyses should also consider any 
changes in test technology that may affect the sensitivity and specificity of 
tests used.  
 Estimates of Pgp3 seroprevalence by birth cohort should be extended. In 
addition to continued use of sera from HSE participants, routine collections 
of residual sera from sentinel groups should be pursued, with appropriate 
consideration of the potential bias in each  (e.g. sera collected for routine 
microbiological investigations, GUM clinic attenders, antenatal populations, 
blood donors). 
 Future serum collections should incorporate measures of previous 
chlamydia diagnoses and sexual behaviour where possible to allow the 
measurement of the undiagnosed fraction of C. trachomatis infections and to 
reduce reduce confounding of the relationship between chlamydia control 
interventions and antibody seroprevalence arising from changes in sexual 
behaviour over time.  
9.3 Has chlamydia screening effected a reduction in the incidence or 
prevalence of chlamydia infection? 
I turn now to the second aim of the PhD, which was to address whether 
chlamydia screening as it has been delivered in practice in England has led to a 
reduction in the incidence or prevalence of chlamydia among young adults.  
There is some evidence from analyses presented in this thesis and from other 
sources to support there having been a decrease in the transmission of 
chlamydia infection since the national implementation of the NCSP in 2008. 
Specifically, my analysis of surveillance data (Chapter 7) showed a consistent 
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pattern of a declining trend in percentage testing positive in most subgroups 
(with the exception of tests among MSM). There remained a declining trend 
over time even after adjusting known confounders. This is consistent with the 
hypothesis that chlamydia prevalence among heterosexual young adults has 
declined in recent years. However, as discussed above, there was the potential 
- and some evidence - for unmeasured confounding. It is not, therefore, 
possible to reach a definitive conclusion of declining prevalence using these 
data alone. The second piece of supporting evidence comes from the study by 
Horner et al, which estimated Pgp3 seroprevalence (using the indirect Pgp3 
ELISA) among 17 to 24 year-old women in England using residual sera 
submitted for routine microbiological or biochemical investigations,213 which 
found a significant decrease in Pgp3 seroprevalence from 20% in 2007 to 15% 
in 2010 (p<0.001).213 This observed decline is consistent with there having been 
a decrease in age-specific cumulative incidence in the years following the 
national implementation of the NCSP.  
However, other analyses from population-based probability samples presented 
in this thesis do not support there having been a decrease in incidence or 
prevalence of infection following the national implementation of the NCSP. 
Firstly, comparisons between population prevalence as measured in Natsal-2 
and Natsal-3 (Chapter 6) did not provide evidence to support there having been 
a decrease in prevalence in the decade between the surveys. There was no 
significant difference between prevalence in Natsal-3 compared to Natsal-2, 
although the utility of direct comparisons of age-specific prevalence was 
ultimately limited by the sample size available. Adjustments to correct for 
differences between the surveys suggested a trend towards there having been 
an increase, rather than a decrease in prevalence over the last decade. My 
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analysis of Natsal-3 data (Chapter 7) also showed evidence of ongoing 
transmission in 2010-12 as incident infections were found among those recently 
tested. 
Secondly, my analysis using stored sera from participants in the Health Survey 
for England (Chapter 8) showed that Pgp3 seroprevalence among 16 to 24 
year-old women decreased between 2008 and 2012, but that this observed 
decrease was not statistically significant. Importantly, there was no notable 
difference in age-specific Pgp3 seroprevalence between birth cohorts exposed 
to high levels of opportunistic screening and those who became sexually active 
before widespread screening. This absence of a decline in seroprevalence is in 
contrast to Horner et al’s study mentioned above, where a significant decrease 
in Pgp3 seroprevalence between 2007 and 2010 was found.213 The difference 
between my findings from HSE participants and those of Horner et al may be 
due to the slightly different time-periods investigated or the sources of sera. 
Horner et al used residual sera submitted to laboratories for routine 
investigations rather than a probability sample. While such sera are considered 
broadly representative of the general population with respect to relatively 
common infections, it is not known whether the data are representative with 
respect to STI.213 It is feasible that some bias may have arisen due to possible 
oversampling of antenatal sera in women of childbearing age and changes in 
the way that samples from GUM clinics were recorded (and thus excluded) may 
have affected the trends that were observed, as it is possible that not all GUM 
samples were excluded from the earlier panels. Another possible reason for 
difference in results is that my analysis may have been limited by the number of 
residual sera available. Horner et al had a sample size of 2,519 between 2007 
and 2011 versus the 707 available from 16 to 24 year-old female HSE 
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participants between 2008 and 2012. Thus a larger sample size may have 
resulted in the observed trend being statistically significant.  
In summary, based on my analyses and the available literature there is no 
strong empirical evidence to support the hypothesis that chlamydia screening, 
as delivered in practice, has led to a reduction in either the incidence or 
prevalence of chlamydia infection among young adults up to 2012.  
Given the increases in screening over the last decade (Chapter 2), this lack of 
empirical evidence is perhaps surprising. Screening has certainly led to a large 
number of diagnoses among young adults. Among Natsal-3 participants, around 
a half of 16 to 24 year-olds diagnosed in the last year were considered to be 
‘screen-detected’ infections as defined by the given reason for test (section 
7.4.1.1) Surveillance data show large increases in testing and diagnoses over 
the decade up to 2012 (Figure 2-5; Figure 2-6). These data also show that 
~60% of diagnoses made in 2010 to 2012 among 15-24 year-olds were 
reported from non-specialist GUM settings,279showing the expansion of 
chlamydia screening in recent years. So long as the detected infections were 
adequately treated, this increase in detection of chlamydia infections should 
have reduced their duration (relative to the counterfactual of there having been 
no national screening programme). As set out in section 2.2, reducing the 
average duration of infection is expected to reduce the number of transmission 
events (given the relationship R0=βcD) and also decrease the prevalence of 
infection (given prevalence=incidence x duration). The absence of evidence for 
any such reductions may be due to the limitations of the specific outcome 
measures used, as described above (section 9.1). In particular, my analyses 
using population-based samples may not have had sufficient power to detect 
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changes over time in the outcome measures of interest. However, if the 
opportunistic chlamydia screening efforts among young adults had really not 
effected a reduction in the incidence or prevalence of infection by 2012, this 
begs the question ‘Why not?’  
9.3.1 Insufficient time since implementation of screening 
One possible explanation is that screening might not have been in place for 
long enough to have had a meaningful effect on transmission dynamics of 
infection in the population. As described in Chapter 2, opportunistic screening 
efforts increased substantially between in the first few years after the NCSP had 
achieved national implementation. Between 2008 and 2010 the estimated 
percentage of 15 to 24 year-olds tested in each year (assuming one test is 
equivalent to one person) increased from 26% to 44% in women and 11% to 
24% in men.189 Data up to 2012 therefore represent only three years of 
opportunistic screening at levels of the current programme. The mathematical 
model reported by Turner et al that explored the potential impact of chlamydia 
screening in England on the prevalence of infection demonstrated a reduction 
could be achieved over ten years after introducing screening (Figure 2-1),81 so it 
is perhaps unreasonable to expect there to have been a notable impact on 
prevalence by 2012. However it should be noted that Turner et al’s model 
predicted the greatest declines to be in the first two to three years following 
screening. The implications of my findings for mathematical modelling are 
discussed in more detail below. 
My analysis of age-specific Pgp3 seroprevalence is perhaps more limited by the 
available time between national implementation of screening and measurement. 
The presence or absence of antibodies to infection will depend on the full 
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history of chlamydia infection up to the time of antibody measurement. Thus 
exposure to chlamydia screening should be considered from the time of sexual 
debut. Women who have turned 16 since the national implementation of the 
NCSP were a maximum of age 20 in the analysis using data up to HSE2012, 
which limited the comparison of age-specific Pgp3 seroprevalence by birth 
cohort. Additional years of data are needed to extend these analyses to 
maintain robust monitoring of chlamydia in coming years.  
9.3.2 Opportunities for transmission arising from undiagnosed 
infections and untested groups 
An alternative hypothesis is that chlamydia screening up to 2012 was not 
diagnosing a high enough proportion of infections to lead to substantial 
interruptions in transmission. My findings from the Pgp3 seroprevalence study 
showed that the proportion of the population ever infected with chlamydia was 
much greater than suggested by studies that have measured prevalence of 
current infection. Additionally, screening patterns up to 2012 had left a high 
proportion of infections undiagnosed, as shown by the high proportion of 
women and men with evidence of a previous infection who did not report a 
previous diagnosis (75.5% of 16 to 24 year-old, see section 8.4.1). 
Comparative analysis of factors associated with testing and with prevalent 
infection presented in Chapter 6 also highlighted gaps in testing coverage that 
present opportunities for ongoing transmission among young adults.  Although 
testing rates were generally higher in those reporting risk factors for chlamydia, 
in Natsal-3 at least one quarter of women and around half of men reporting a 
risk factor associated with prevalent infection had not been recently tested. 
Testing rates were relatively low in men, especially among 20-24 year-olds who 
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contributed the majority of prevalent infections and diagnoses. Therefore the 
interpretation of existing testing strategies also leaves room for transmission, for 
example, from men to their (often younger)268,280 partners and from people with 
multiple sexual partners who are not accessing testing.  
9.3.3 Frequency and timing of screening 
Testing frequency in relation to time since infection and rate of partner change 
may also have been insufficient to meaningfully interrupt transmission. The 
impact of screening on incidence will be diminished if onward transmission has 
already occurred before being tested, for example if someone has had one or 
more new sexual partners between the time of infection and testing. Given that 
in some cases untreated chlamydia infections persist for over a year,18 if testing 
is not accessed soon in the course of infection then this presents a potentially 
long time for an infected individual to be at risk of passing the infection on. This 
would be especially relevant in those groups reporting high rates of partner 
change or frequency of non-condom use. This has been explored in the context 
of partner notification by Althaus et al, who used a mathematical model to 
explore the effect of notifying partners on reducing transmission, comparing 
current to previous sexual partners.117 They found that the longer the look-back 
period, the more likely it was that infections would already have been passed 
on, thus models predicted testing of non-current partners to have negligible 
effect on transmission. This highlights that the timing of testing in relation to 
time since infection could substantially affect the expected benefits of screening 
in terms of interrupting transmission.  
The NCSP recommends that young adults be screened on change of sexual 
partner, with the aim of reducing the period between time of infection and time 
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of treatment. The extent to which this recommendation is emphasised in health 
promotion activities is unclear, as is our understanding of whether clinicians and 
young adults interpret this recommendation as a need to test at the end of a 
relationship or to test soon after having a new sexual partner. However, data 
from Natsal-3 suggests there is substantial room for improvement. Among 
sexually-experienced 16 to 24 year-olds in Natsal-3 36% of women and 59% of 
men with at least one new sexual partner in the last year had not been tested 
for chlamydia in the last year. Again, this points towards gaps between 
screening activity and infection risk such that ongoing transmission would be 
expected. 
9.3.4 Re-infection, partner notification and treatment 
The precise relationship between chlamydia infection and subsequent immunity 
is unclear, although studies to date suggest that a previous infection with 
chlamydia confers, at best, only partial immunity.47 In a modelling study using 
data from case rates in British Columbia, Brunham et al hypothesised that high 
levels of testing would lead to higher rates of repeat infections, if treatment 
prevents development of protective immune response. This notion of ‘abrogated 
immunity’ is a contested hypothesis,47 and immunological evidence for this is 
yet to be provided.  
However, even if treatment does not affect the development of protective 
immunity, repeat infections may partially account for high diagnosis rates 
without a corresponding reduction in prevalence. Returning to the relationship 
between prevalence and incidence, if the average duration of infection has been 
reduced (by screening and treatment of infection) but the prevalence has 
remained the same, then mathematically the rate of new infections must have 
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increased, given the relationship prevalence=incidence x duration. However, 
this does not necessarily mean new infections in previously uninfected 
individuals. Instead, re-infection of an individual may counteract any reduction in 
duration, which in turn would limit the impact of screening on the prevalence of 
infection. Given the acknowledged risk of re-infection, in 2013 the NCSP 
introduced a recommendation that young adults who test positive for chlamydia 
be re-tested around three months after treatment.119  
My analyses and other previously published studies48-57 demonstrate that re-
infection is common. In my analysis of surveillance data presented in Chapter 4, 
the odds of testing positive were higher in people with a known chlamydia 
diagnosis in the last year compared to those without, even after adjusting for 
other available demographic and sexual behavioural variables (AOR 1.13/1.04; 
1.27/1.15 for women and men respectively in the NCSP/GUMCAD datasets, 
section 4.4.2). In a complementary analysis of surveillance data from 2010, I 
have previously shown that 10% of chlamydia diagnoses made in GUM clinics 
in 15 to 24 year-olds were among individuals with at least one known previous 
diagnosis that calendar year.120  
Re-infection may occur due to incomplete treatment of sexual partner(s) or re-
infection due to continuing risk behaviour. Although my analysis did not 
incorporate trends over time in partner notification rates (Chapter 4), available 
data suggest that, on average, fewer than 0.5 partners per index case are 
tested,281,282 leaving a high proportion of those diagnosed with chlamydia 
exposed to re-infection. Opportunities for re-infection from new partners are 
also indicated by the high rates of partner change in the age group targeted for 
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screening, with one fifth of sexually-experienced 16 to 24 year-old women and 
one quarter of men reporting two or more new sexual partners in the last year.  
While these data indicate that re-infection is common and demonstrate 
opportunities for re-infection, they do not provide definitive evidence of there 
having been a change in re-infection rates over time that might counteract any 
reduction in the duration of infection. Thus, while re-infection is likely to be 
important, the relative contribution of repeat infections to overall annual 
incidence rates is not known.  
Incomplete treatment of the index case would also reduce the expected impact 
of screening on incidence and prevalence. Infections that are diagnosed but not 
treated would not contribute to a reduction in the average duration of infection. 
Data on treatment rates are also limited, such that trends in treatment rates 
could not be incorporated into my analyses. However, data from clinical audits 
suggest that around 5% to 10% of diagnoses go untreated.89,283  
While data on re-infection rates, partner notification and treatment are not 
sufficient to allow a quantitative analyses of their impact in the context of my 
findings, I hypothesise that reductions in incidence and prevalence that could be 
expected by high diagnosis rates will have been attenuated by re-infections due 
to incomplete treatment of sexual partner(s) and new sexual partners and by 
incomplete treatment of a proportion of those diagnosed with chlamydia.  
9.3.5 Underlying changes in sexual behaviour 
Another possible explanation for an absence of change in chlamydia prevalence 
or age-specific cumulative incidence is that the underlying risk of transmission 
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due to sexual behaviour may have changed over the period of expansion of 
chlamydia screening. My analyses of data from the Natsal-2 and Natsal-3 
surveys (Chapter 6) present a mixed picture. There was no notable increase in 
reported numbers of sexual partners among women or men between the 
surveys. However, the proportion reporting sexual debut before age 16 
increased with subsequent birth cohorts which may suggest increased sexual 
activity or opportunities for transmission over the last decade. In their 
comparison of sexual behaviours between Natsal surveys, Mercer et al reported 
an increase in proportion of participants reporting heterosexual oral and 
particularly anal sex235 between Natsal-2 and Natsal-3. Although not necessarily 
a risk factor for transmission, this may indicate some increase in higher risk 
sexual behaviours and practices. However, if the underlying risk of STI has 
changed, this was not reflected in differences in the prevalence of non-vaccine 
HPV types, which did not differ between surveys. In summary, there is no 
strong evidence to support or to rule out there having been an increase in 
underlying transmission risk in recent years. It remains possible that in the 
absence of widespread chlamydia screening, incidence and prevalence may 
have been even higher.  
In summary, there are several features of the relationship between chlamydia 
infection and approaches to screening that provide possible explanations as to 
why high rates of testing might not have resulted in a fall in transmission. It 
remains to be seen whether additional years will have a more dramatic and 
lasting effect. I now turn to consideration of my findings in relation to how 
chlamydia control efforts might be improved and developed in future years. 
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9.4 Implications for chlamydia control policies 
9.4.1 Targeted versus universal screening strategies 
The extent to which public health interventions are targeted among specific 
groups is an important question for policymakers. Different approaches have 
implications for costs, effectiveness and equity of potential benefit.267,284,285 
Current chlamydia screening recommendations in England strike a balance 
between universal and targeted approaches. Screening is recommended to all 
sexually-active under 25 year-olds. However, from a cost efficiency perspective, 
it might be tempting to pursue a more targeted approach. Since 2012 the Health 
Protection Agency, and then Public Health England, have prioritised the 
detection of infections over testing volumes by recommending that local 
authorities aim to achieve a diagnosis rate of at least 2,300 diagnoses per 
100,000 population.121 This placed an implicit emphasis on testing among 
populations likely to be infected. Shifting screening activity to higher risk 
populations where infections are more likely to be detected might therefore be 
appealing in terms of detecting as many infections as possible for the fewest 
number of tests. One way to achieve this would be through the use of selective 
screening criteria using a combination of behavioural and demographic 
characteristics to determine an individual’s eligibility for screening. Such criteria 
have been suggested and used elsewhere88,286,287 and data from Natsal-3 could 
theoretically be used to develop such a scoring system for use in England.  
However there are some fundamental disadvantages to such an approach for 
chlamydia screening. Selective screening criteria would be unlikely to reduce 
the eligible population by a substantial amount, as infections – at least among 
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women - are relatively widespread. Data from Natsal-3 show that 52% of 
prevalent infections and 31% of reported diagnoses in the last year were among 
women who reported fewer than two sexual partners in the last year (Table 
7-3a). Selective screening may be more appropriate in men where infections 
are more concentrated (e.g. 80% of prevalent infections and 77% of reported 
diagnoses in the last year were in men with ten or more sexual partners by the 
time of the interview, Table 7-3b). Possibilities for different screening 
approaches by gender are discussed in the next section. However, even if a 
scoring system could be developed, there would likely be substantial challenges 
in implementing individual risk-based criteria. Risk-scores based on sexual 
behaviour would require accurate sexual history taking that may go beyond that 
usually provided, or that would be easily obtained, in normal practice. 
Furthermore, targeted interventions in sexual health have been shown to have 
adverse consequences by increasing the stigmatisation of those targeted.91 It is 
also important to note that restricting screening to high risk groups would not 
necessarily achieve full coverage in those groups, so would not in itself improve 
diagnosis rates or reduce the opportunities for transmission presented by 
undiagnosed infections in relatively under-tested groups.  
A further argument against selective screening criteria is that they would limit 
the proportion of all infections that could be diagnosed as infections are not 
restricted to high risk populations. This would restrict the potential direct benefit 
of screening – i.e. the potential reduction in the risk of developing complications 
– to the target population. In the interests of achieving an equitable approach, 
an alternative would be to implement screening so that the chance of having an 
infection diagnosed is balanced across different groups. This would support the 
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distribution of screening according to the risk of infection without restricting 
screening to high risk groups.  
My analysis of Natsal-3 data showed that in 2010-12, screening distributions 
were broadly aligned to risk, but that more could be done to align these 
distributions (Chapter 6). Specifically, under the screening distributions in 2010-
12 women and men with a chlamydia infection living in deprived areas would 
have less of a chance of having their infection diagnosed than those with an 
infection living in less deprived areas. Strategies that achieve higher testing in 
women living in more deprived areas - but not to the exclusion of those living in 
low risk areas - or those at higher risk due to other behavioural factors would 
provide a more equitable approach to diagnosing chlamydial infections and 
should be considered.  
9.4.2 Screening in men 
In contrast to many other countries with recommendations for asymptomatic 
chlamydia testing, the NCSP does not have separate screening 
recommendations for women and men. As set out in Chapter 2, in the late 
1990s when screening policies were under development in England, men were 
not considered to be part of the target population. However when the NCSP 
was implemented in 2003 men were included, partly to prevent stigmatisation of 
women and in recognition of men’s role in transmitting infection to their female 
sexual partners.79 As the majority of chlamydia-related complications are 
thought to occur in women, the suitability of asymptomatic screening in men has 
been questioned.288  
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The research presented in this thesis did not aim to address the question of 
screening in men, but my findings raise some important issues that warrant 
consideration. Firstly, in Natsal-3, peak prevalence in men was among 20 to 24 
year-olds, with no prevalent infections detected among <19 year-olds. However, 
testing rates in this age group were lower than among 16 to 19 year-old men. 
Low levels of testing in men may, therefore, be contributing to ongoing 
transmission to women. Secondly, my analysis showed that chlamydia 
infections in men appeared to be more focussed among those with higher 
numbers of sexual partners, whereas in women infections were more evenly 
distributed in the population. Non-condom use was an important risk factor for 
infection among men, but low testing rates were also seen in those who 
reported recent non-condom use. Therefore focussing screening and prevention 
efforts on 20 to 24 year-old men and those with higher numbers of sexual 
partners may be warranted.  
The optimum means of achieving this is not clear. Achieving high rates of 
screening in men is notoriously challenging79 and increased dedication of 
resources would not necessarily achieve higher testing.289 As chlamydia 
appears to be more focussed in those with more sexual partners, risk-based 
screening criteria may be a way to focus resources more appropriately in men. 
However, these would still face the difficulties of operationalising such scoring 
systems as discussed above. An alternative would be to place more emphasis 
on the control of chlamydia at a partnership level, rather than an individual level. 
Turner et al have proposed focussing on partner notification as a more cost-
efficient alternative to increasing screening in men with regard to the cost per 
diagnosis. This is attractive in terms of preventing re-infection and in the 
potential to identify partners of the partner.290 However, Turner et al did not take 
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into account the potential benefit of identifying infections in women who may not 
have accessed testing themselves so there remains a question about 
comparative cost effectiveness of different approaches. In times of limited 
resources it is also difficult to argue for increased screening in men when the 
majority of chlamydia-related complications are thought to be among women. 
Determining the optimum approach to screening in men is beyond the remit for 
this PhD, but it is perhaps time for some of these questions to be revisited to 
consider screening at the partnership level.  
In the previous section I described how inadequate treatment and partner 
notification can attenuate the potential benefit of screening in terms of 
transmission and that re-infection is an important feature to consider in the 
transmission dynamics of chlamydia. Therefore, independent of the distribution 
or level of chlamydia screening implemented, robust case management of 
individuals diagnosed with infection is needed to maximise the potential benefit 
afforded by each diagnosis. Timely and effective treatment, partner notification 
and re-testing should remain priorities for service delivery.  
9.5 Future research 
The research presented in this thesis raises a number of questions that warrant 
further consideration.  
9.5.1 Validation of the relationship between chlamydia infection and the 
development and persistence of detectable antibodies 
Given the challenges of chlamydia seroepidemiology set out in section 9.1.4, 
further work is needed to develop serological assays so that they can 
distinguish between first and repeat infections. This would in turn allow future 
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studies to investigate the relative contributions of first infections, re-infections 
and treatment to C. trachomatis antibody seroprevalence over time. The 
relationship between antibody-inducing chlamydia infection and complications 
also requires further elucidation to understand the meaning of serological 
findings for understanding the impact of chlamydia screening on long-term 
morbidity. Future outcome monitoring could feasibly comprise monitoring of 
first, repeat and complication-causing infections. A study using clinical samples 
characterised by previous diagnosis history is now ongoing and aims to develop 
the use of the indirect and double-antigen Pgp3 ELISAs in this way.291 
9.5.2 Implications for mathematical modelling 
The most recently published mathematical modelling study to have examined 
the potential impact of chlamydia in England is that by Turner et al.80,81 The 
model results suggested that opportunistic chlamydia screening in GP practices 
of women or women and men aged <25 years could at least halve the 
prevalence of chlamydia within ten years (with substantial reductions seen in 
the first few years after screening implementation as shown in Figure 2-1), 
providing screening is offered to the entire eligible population when they attend 
a GP, that 50% of those offered screening accept the invitation and that 20% of 
partners are treated.81 As Turner et al point out, the predictions derived from the 
model do not represent the truth, but instead present “the likely outcome, if our 
description of reality is accurate”.81 Findings from Natsal-3 showed that 62.5% 
of sexually-experienced women and 43.2% of sexually-experienced men 
reported having a chlamydia test in the last year and surveillance data suggest 
similar levels of testing were in place between 2009 and 2012 (Figure 2-5; 
Figure 2-6). However the dramatic reductions in prevalence predicted by the 
260 
model do not yet appear to have been borne out, thus raising some queries 
about the model predictions. There are a number of infection- and testing- 
related parameters in the model that are challenged by my findings. 
The model was fitted to chlamydia prevalence among women estimated from a 
meta-analysis of studies among GP attenders or those registered with a GP123. 
The resulting baseline prevalence is substantially higher than that estimated in 
Natsal-2 and suggests the baseline prevalence in the model may have been 
high. For example in 16 to 19 year-old women, chlamydia prevalence estimated 
in Natsal-2 was 3.9% (Table 6-4), but the model baseline prevalence was over 
6%. My analysis of Natsal-3 data also shows that the age distribution of 
infection and diagnoses varies by gender, and that screening patterns vary by 
age, gender and, sexual behaviour (Chapter 6). However, the Turner model 
assumed the same distribution of infection and diagnosis in both women and 
men and assumed that acceptance of screening was not associated with age, 
gender or numbers of sexual partners. Given interactions between model 
parameters, the full impact of these departures between the model assumptions 
and empirical data are unclear without further runs of an amended model.  
Findings from the serological study presented in Chapter 8 provide new 
parameters which may be useful either for fitting or validation of mathematical 
models. C. trachomatis antibody seroprevalence by age can be used as a 
marker of minimum age-specific cumulative incidence and the prevalence of 
reporting a chlamydia diagnosis among seropositive individuals represents a 
proportion of those ever infected who have ever been diagnosed.  
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While increasing the complexity of mathematical models may not always result 
in an improvement in their explanatory or predictive capability,292 the impact of 
varying infection and testing by age, gender and sexual behaviour 
simultaneously and the use of newly available parameters should be considered 
in future mathematical models of chlamydia screening in England and 
elsewhere.  
9.5.3 Screening early in the course of infection. 
I have hypothesised that timing of testing in relation to time since infection may 
have been insufficient to prevent transmission. As well as potentially reducing 
onward transmission, testing early in the course of infection has the potential to 
reduce an individual’s risk of developing complications.39 Increasing testing 
rates either at the end of a sexual partnership or following change of sexual 
partner therefore warrants attention. Specifically, future research to examine 
current adherence to recommendations of testing on change of sexual partner 
should be considered. This could include both quantitative analyses among 
those accessing testing and qualitative work in young adults to understand 
attitudes towards current recommendations. This work could contribute to 
developing and evaluating an intervention to increase testing soon after partner 
change with the aim of reducing both onward transmission and the risk of 
developing complications in those with chlamydia.  
9.6 Concluding statement 
In summary, there is some evidence from my analysis of trends in the 
percentage testing positive for chlamydia using surveillance data and Horner et 
al’s analysis of C. trachomatis antibody seroprevalence to support there having 
262 
been a decrease in chlamydia incidence and prevalence in recent years. 
However, findings from population–based studies using probability sampling do 
not support there having been such a decline. Thus, taken together there is no 
strong empirical evidence that chlamydia screening, as it has been delivered in 
practice in England, has had an effect on the incidence or prevalence of 
chlamydia infection among under 25 year-olds.  
This absence of any such evidence may be due to insufficient power to detect 
changes in the outcome measures investigated due to available sample size or 
to insufficient time since the national implementation of the NCSP in 2008. 
Alternatively, a combination of high lifetime risk of infection, high proportion of 
infections that go undiagnosed, insufficient testing levels or frequency among 
high risk groups and – potentially – re-infection due to incomplete treatment of 
sexual partners may have limited the impact of chlamydia control efforts.  
Future evaluation of the impact of chlamydia control programmes should focus 
on applying C. trachomatis antibody assays to population-based serum samples 
and the use of existing population-based surveys to monitor chlamydia 
screening in relation to the risk of infection.  
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APPENDIX 1: Study paperwork used in pilot postal survey to 
measure the population prevalence of chlamydia among young 
women 
Relevant to Chapter 5 
The following documents are available in the printed version of the thesis: 
 Patient Information leaflet (Leaflets varied by group. The leaflet for group A 
is provided as an example) 
 Study questionnaire
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APPENDIX 2: Comparison of maximal and parsimonious 
multivariable models of prevalent chlamydia infection, recent 
diagnosis and recent testing 
Relevant to Chapter 7 
As set out in Chapter 7, two approaches to multivariable modelling to 
investigate associations between sociodemographic and behavioural variables 
and prevalent chlamydia infection, recent diagnosis and recent testing were 
explored: maximal and parsimonious models were constructed for prevalent 
chlamydia infection, self-reported chlamydia diagnosis in the last year and self-
reported chlamydia test in in the last year.  
To fit parsimonious models, variables found significant at p<0.1 in univariable 
analyses were entered into a multivariable model selection process based on 
backwards selection whereby variables were removed from the model if the 
statistical significance of their association with the outcome had an associated p 
value of >0.05. Only those variables significantly associated with the outcome 
were retained in the final parsimonious models. With two exceptions, all 
variables included in univariable models were included in multivariable maximal 
models: number of sexual partners in the last year was not included due to 
collinearity with other sexual partnership variables; age left school was not 
included as data were unavailable for 16 year-olds. 
Table 9-2below shows results from univariable models along with maximal 
(Multivariable model 1) and parsimonious (Multivariable model 2) multivariable 
models for women for the three outcomes of interest (prevalent infection, recent 
diagnosis, recent testing). Table 9-3 shows results for men.  
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Adjusted ORs in the maximal models tended to be closer to 1 than those in 
parsimonious models, reflecting some confounding of associations between 
predictor and outcome variables. Factors which remained statistically significant 
were largely comparable between models, with some exceptions. Firstly, in men 
the maximal model found deprivation of area of residence to be significantly 
associated with prevalent infection and non-condom use was not, whereas in 
the parsimonious model non-condom use remained a significant predictor in the 
model whereas deprivation did not. Age group and number of lifetime sexual 
partners were significant in both models. The adjusted odds ratio (OR) for 
prevalent infection among those reporting non-condom use was similar between 
the models (3.59 versus 4.43 in the maximal and parsimonious models 
respectively). The difference between the models likely reflects, in part, the 
sample size available meaning that maximal models would have reduced power 
to detect associations after adjusting for multiple confounders. In the maximal 
models, no factors were statistically significant predictors of recent diagnosis 
among those tested, reflecting the smaller sample size available when limiting 
to those recently tested and when entering several covariates into the model.  
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Table 9-2: Percentage with a) prevalent chlamydia infection, b) self-reported 
diagnosis in the last year and c) self-reported testing and unadjusted and 
adjusted odds ratios for prevalent chlamydia infection by sociodemographic and 
behavioural variables (16-24 year-old sexually-experienced women)   
1a) Prevalent infection detected in urine (n=992) 
 % (95%CI) Univariable Multivariable model 1 Multivariable model 
2 
Denominator 
(wt, unwt) 
 
 
OR (95%CI) p AOR
b
 (95%CI) p AORb (95%CI) p 
Age group            
16-19 3.8% (2.2-6.3) 1.00 - 0.36 1.00 - 0.50    214, 395 
20-24 2.7% (1.7-4.3) 0.71 (0.35-1.46)  0.71 (0.27-1.87)     383, 597 
Country
c
             
England 2.9% (2.0-4.3) 1.00 - 0.53 1.00 - 0.48    504, 817 
Scotland 3.1% (1.1-8.6) 1.08 (0.35-3.33)  1.34 (0.43-4.14)     56, 103 
Wales 5.3% (1.9-13.8) 1.87 (0.63-5.60)  1.88 (0.63-5.54)     37, 72 
IMD quintile of LSOA of residence
d
         
2 least deprived  1.3% (0.5-3.4) 1.00 - 0.01 1.00 - 0.01 1.00 - <0.01 213, 355 
Middle quintile 1.8% (0.8-4.2) 1.37 (0.38-4.90)  1.40 (0.39-4.98)  1.45 (0.40-5.20)  111, 174 
2 most deprived 4.9% (3.3-7.3) 3.82 (1.35-10.8)  4.23 (1.53-11.6)  4.11 (1.45-11.7)  273, 463 
Age left school
e
             
17+ 3.2% (2.1-4.8) 1.00 - 0.88       445, 700 
16 3.4% (1.9-6.0) 1.06 (0.50-2.22)        120, 229 
Age at first heterosexual sex             
17+ 1.6% (0.7-3.7) 1.00 - 0.15 1.00 - 0.42    188, 246 
16 3.9% (2.1-6.9) 2.52 (0.86-7.36)  2.20 (0.67-7.17)     178, 304 
<16 4.0% (2.4-6.6) 2.65 (0.95-7.36)  1.82 (0.60-5.42)     213, 415 
Number of sexual partners in the last year          
0 or 1 2.5% (1.5-4.0) 1.00 - 0.03       387, 600 
2 3.9% (1.8-8.5) 1.62 (0.63-4.15)        90, 161 
3 to 4 1.9% (0.7-5.1) 0.75 (0.24-2.33)        63, 127 
5+ 8.3% (3.9-16.8) 3.57 (1.39-9.17)        49, 93 
Number of new sexual partners in the last year         
0 2.2% (1.3-3.7) 1.00 - 0.03 1.00 - 0.70    313, 495 
1 2.8% (1.2-6.3) 1.26 (0.47-3.41)  1.17 (0.38-3.52)     160, 263 
2+ 5.9% (3.5-9.8) 2.73 (1.26-5.93)  1.65 (0.50-5.39)     118, 225 
Number of sexual partners in the last year without a condom       
0 2.9% (1.2-7.1) 1.00 - 0.03 1.00 - 0.18    120, 173 
1 2.2% (1.4-3.6) 0.76 (0.26-2.17)  0.34 (0.10-1.10)     368, 606 
2+ 6.3% (3.5-11.2) 2.25 (0.73-6.93)  0.49 (0.12-1.83)     108, 212 
Number of lifetime sexual partners         
1 to 4 2.4% (1.4-4.2) 1.00 - 0.14 1.00 - 0.67    321, 482 
5 to 9 2.8% (1.4-5.2) 1.15 (0.48-2.75)  0.87 (0.32-2.32)     150, 267 
10+ 5.4% (2.9-9.7) 2.29 (0.97-5.39)  1.39 (0.45-4.18)     121, 234 
Condom used for most recent sex with most recent partner       
Yes 2.8% (1.5-5.3) 1.00 - 0.53 1.00 - 0.29    202, 314 
No 3.6% (2.4-5.4) 1.28 (0.59-2.80)  1.59 (0.67-3.74)     352, 613 
Concurrent partnerships in last year
f
        
No 2.7% (1.8-4.2) 1.00 - 0.19 1.00 - 0.85    439, 706 
Yes 6.3% (2.9-13.4) 2.40 (0.94-6.15)  1.34 (0.48-3.70)     66, 134 
Unknown 3.1% (1.3-7.2) 1.14 (0.43-3.04)  1.13 (0.38-3.31)     73, 127 
Frequency of binge drinking         
never / <monthly 2.5% (1.5-4.1) 1.00 - <0.01 1.00 - 0.01 1.00 - <0.01 373, 598 
monthly 1.2% (0.5-3.3) 0.49 (0.16-1.52)  0.46 (0.13-1.51)  0.54 (0.17-1.68)  130, 226 
>weekly  7.9% (4.7-13.1) 3.35 (1.55-7.25)  2.51 (1.08-5.76)  3.73 (1.73-8.08)  95, 168 
Ever had any same sex experience/contact         
No 3.1% (2.1-4.4) 1.00 - 0.92 1.00 - 0.49    473, 750 
Yes 3.2% (1.4-7.1) 1.05 (0.42-2.63)  0.74 (0.30-1.76)     124, 242 
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Table 9-2 continued. 
 
1b) Diagnosed with chlamydia in the last year 
(among those tested in the last year) (n=471) 
 
 
% (95%CI) Univariable Multivariable model 1 Multivariable model 2 Denominator 
(wt, unwt) 
OR (95%CI) p AOR
b
 (95%CI) p AORb (95%CI) p 
Age group             
16-19 6.0% (3.8-9.2) 1.00 - 0.62 1.00 - 0.58    193, 375 
20-24 5.1% (3.4-7.6) 0.86 (0.46-1.60)  0.80 (0.35-1.78)     329, 565 
Country
c
             
England           469, 832 
Scotland           30, 58 
Wales           24, 50 
IMD quintile of LSOA of residence
d
         
2 least deprived  4.8% (2.8-8.1) 1.00 - 0.23 1.00 - 0.36    183, 319 
Middle quintile 3.5% (1.6-7.3) 0.71 (0.27-1.86)  1.06 (0.37-3.04)     102, 176 
2 most deprived 6.8% (4.6-10.0) 1.46 (0.73-2.93)  1.70 (0.73-3.91)     236, 445 
Age left school
e
             
17+ 5.2% (3.6-7.5) 1.00 - 0.58       387, 658 
16 6.2% (3.7-10.5) 1.21 (0.62-2.37)        109, 228 
Age at first heterosexual sex          
17+ 4.1% (1.8-8.9) 1.00 - 0.37 1.00 - 0.93    137, 215 
16 5.0% (2.8-8.9) 1.24 (0.44-3.55)  0.80 (0.26-2.42)     154, 272 
<16 6.9% (4.8-9.9) 1.76 (0.70-4.41)  0.89 (0.35-2.25)     220, 429 
Number of sexual partners in the last year        
0 or 1 3.0% (1.7-5.4) 1.00 - 0.01       291, 507 
2 6.6% (3.7-11.6) 2.25 (0.98-5.18)        93, 178 
3 to 4 8.8% (5.2-14.6) 3.08 (1.34-7.05)        76, 146 
5+ 11.6% (6.2-20.8) 4.19 (1.69-10.4)        58, 101 
Number of new sexual partners in the last year        
0 2.8% (1.5-5.0) 1.00 - <0.01 1.00 - 0.11 1.00 - 0.02 226, 397 
1 4.8% (2.5-9.1) 1.76 (0.71-4.38)  1.89 (0.69-5.16)  1.82 (0.74-4.50)  156, 287 
2+ 10.7% (7.3-15.6) 4.23 (2.04-8.79)  3.09 (1.07-8.86)  3.07 (1.41-6.67)  137, 249 
Number of sexual partners in the last year without a condom       
0 4.2% (1.5-11.6) 1.00 - <0.01 1.00 - 0.84    76, 130 
1 3.8% (2.4-6.1) 0.90 (0.27-2.94)  0.72 (0.15-3.21)     319, 567 
2+ 10.3% (7.0-15.0) 2.60 (0.80-8.46)  0.90 (0.18-4.49)     126, 241 
Number of lifetime sexual partners      
1 to 4 2.1% (1.1-4.0) 1.00 - <0.01 1.00 - 0.08 1.00 - <0.01 218, 391 
5 to 9 6.2% (3.7-10.3) 3.07 (1.33-7.07)  2.40 (0.90-6.37)  2.54 (1.06-6.12)  161, 289 
10+ 9.9% (6.5-14.7) 5.12 (2.31-11.3)  3.76 (1.19-11.8)  3.81 (1.67-8.68)  141, 254 
Condom used for most recent sex with most recent partner      
Yes 3.4% (1.6-7.0) 1.00 - 0.14 1.00 - 0.14    170, 303 
No 6.3% (4.4-8.9) 1.90 (0.81-4.49)  1.88 (0.81-4.32)     328, 592 
Concurrent partnerships in last year
f
        
No 4.3% (2.9-6.4) 1.00 - 0.13 1.00 - 0.46    361, 639 
Yes 8.1% (4.1-15.3) 1.95 (0.84-4.54)  0.75 (0.27-2.00)     78, 146 
Unknown 7.8% (4.3-13.9) 1.88 (0.90-3.94)  1.46 (0.62-3.38)     76, 144 
Frequency of binge drinking         
never / <monthly 3.7% (2.4-5.7) 1.00 - 0.03 1.00 - 0.28    312, 561 
monthly 6.6% (3.6-11.8) 1.85 (0.85-4.01)  1.91 (0.74-4.89)     112, 200 
>weekly  9.4% (5.2-16.3) 2.69 (1.25-5.80)  2.06 (0.75-5.61)     97, 177 
Ever had any same sex experience/contact       
No 5.3% (3.7-7.5) 1.00 - 0.72 1.00 - 0.44    388, 704 
Yes 5.9% (3.5-10.0) 1.13 (0.57-2.24)  0.71 (0.30-1.68)     134, 236 
  
294 
Table 9-2 continued. 
1c) Tested for chlamydia in the last year (n=1,375) 
 
 
% (95%CI) 
Univariable Multivariable model 1 
Multivariable model 
2 Denominator 
(wt, unwt) 
OR (95%CI) p AOR
b
 (95%CI) p AORb (95%CI) p 
Age group             
16-19 56.6% (52.5-60.6) 1.00 - 0.16 1.00 - 0.15    343, 672 
20-24 52.8% (49.2-56.4) 0.86 (0.69-1.06)  0.82 (0.62-1.07)     623, 1064 
Country
c
             
England 57.1% (54.1-60.1) 1.00 - <0.01 1.00 - <0.01 1.00 - <0.01 823, 1452 
Scotland 32.4% (24.4-41.5) 0.36 (0.24-0.54)  0.29 (0.18-0.45)  0.31 (0.21-0.47)  91, 178 
Wales 45.6% (36.2-55.4) 0.63 (0.42-0.94)  0.53 (0.32-0.85)  0.54 (0.34-0.86)  52, 106 
IMD quintile of LSOA of residence
d
        
2 least deprived  54.2% (49.5-58.8) 1.00 - 0.99 1.00 - 0.94    338, 595 
Middle quintile 54.4% (48.0-60.7) 1.01 (0.74-1.38)  1.03 (0.71-1.48)     189, 324 
2 most deprived 54.0% (49.8-58.2) 0.99 (0.77-1.27)  0.97 (0.73-1.29)     439, 817 
Age left school
e
             
17+ 54.3% (51.0-57.6) 1.00 - 0.70       715, 1217 
16 55.5% (50.1-60.8) 1.05 (0.82-1.35)        196, 405 
Age at first heterosexual sex          
17+ 43.9% (38.7-49.1) 1.00 - <0.01 1.00 - 0.05 1.00 - <0.01 313, 489 
16 56.4% (51.6-61.1) 1.66 (1.25-2.20)  1.39 (0.99-1.92)  1.48 (1.09-2.01)  273, 503 
<16 63.9% (59.8-67.9) 2.27 (1.75-2.94)  1.44 (1.05-1.97)  1.66 (1.24-2.21)  344, 680 
Number of sexual partners in the last year        
0 or 1 46.6% (43.3-50.0) 1.00 - <0.01       624, 1096 
2 65.2% (58.8-71.1) 2.15 (1.59-2.89)        143, 275 
3 to 4 69.7% (62.0-76.4) 2.63 (1.82-3.80)        111, 210 
5+ 74.8% (64.4-83.0) 3.40 (2.05-5.65)        77, 135 
Number of new sexual partners in the last year        
0 45.6% (41.9-49.3) 1.00 - <0.01 1.00 - <0.01 1.00 - <0.01 495, 873 
1 59.2% (54.0-64.2) 1.73 (1.34-2.23)  1.69 (1.25-2.27)  1.94 (1.48-2.54)  264, 485 
2+ 70.0% (63.8-75.6) 2.79 (2.03-3.84)  1.46 (0.95-2.21)  2.03 (1.40-2.94)  197, 359 
Number of sexual partners in the last year without a condom      
0 36.4% (30.8-42.3) 1.00 - <0.01   0.05 1.00 - <0.01 210, 361 
1 54.7% (51.4-58.0) 2.11 (1.61-2.78)  1.52 (1.03-2.24)  1.74 (1.29-2.35)  585, 1049 
2+ 74.2% (68.3-79.4) 5.04 (3.47-7.32)  1.86 (1.09-3.15)  2.19 (1.43-3.36)  169, 322 
Number of lifetime sexual partners       
1 to 4 43.5% (40.0-47.1) 1.00 - <0.01 1.00 - <0.01 1.00 - <0.01 503, 894 
5 to 9 63.8% (58.5-68.7) 2.29 (1.76-2.96)  1.96 (1.43-2.69)  1.90 (1.43-2.54)  252, 453 
10+ 69.6% (63.9-74.7) 2.97 (2.22-3.98)  2.11 (1.41-3.13)  2.00 (1.42-2.82)  202, 373 
Condom used for most recent sex with most recent partner       
Yes 51.6% (46.9-56.3) 1.00 - 0.03 1.00 - 0.97    330, 586 
No 58.0% (54.6-61.3) 1.30 (1.03-1.63)  1.01 (0.74-1.35)     567, 1027 
Concurrent partnerships in last year
f
         
No 51.0% (47.8-54.2) 1.00 - <0.01 1.00 - 0.05    710, 1256 
Yes 74.6% (67.1-80.8) 2.81 (1.93-4.09)  1.46 (0.93-2.28)     105, 196 
Unknown 64.6% (57.5-71.2) 1.76 (1.27-2.42)  1.53 (1.02-2.28)     117, 226 
Frequency of binge drinking         
never / <monthly 52.1% (48.7-55.5) 1.00 - 0.01 1.00 - 0.08    601, 1085 
monthly 52.4% (46.6-58.2) 1.01 (0.78-1.32)  0.75 (0.54-1.02)     214, 375 
>weekly  64.4% (57.6-70.7) 1.66 (1.22-2.27)  1.16 (0.81-1.64)     151, 274 
Ever had any same sex experience/contact      
No 51.9% (48.8-55.0) 1.00 - <0.01 1.00 - 0.24    749, 1352 
Yes 61.9% (56.0-67.5) 1.51 (1.15-1.98)  1.21 (0.88-1.65)     218, 384 
a
N in column headings shows unweighted denominators. Total denominators by characteristic 
and in multivariable models vary due to item-missingness. 
b
AOR: Adjusted odds ratios, adjusted 
for all variables shown. 
c
Results for recent diagnosis are not reported due to small sample size 
in Scotland and Wales when limited to those tested. 
d
IMD: Index of multiple deprivation of LSOA 
(lower super output area) of residence. IMD scores for England, Scotland and Wales were 
adjusted before being combined and assigned to quintiles, using the method described by 
Payne and Abel
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. 
e
Excludes 16 year-olds. 
f
Among those with at least 1 sexual partner in last 
year.  
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Table 9-3: Percentage with a) prevalent chlamydia infection, b) self-reported 
diagnosis in the last year and c) self-reported testing and unadjusted and 
adjusted odds ratios for prevalent chlamydia infection by sociodemographic and 
behavioural variables (16-24 year-old sexually-experienced men)   
2a) Prevalent infection detected in urine (n=840) 
 
% (95%CI) 
Univariable Multivariable model 1 
Multivariable model 
2 Denominator 
(wt, unwt)  
 
OR (95%CI) p AOR
b
 (95%CI) p AORb (95%CI) p 
Age group           
16-19 0.3% (0.1-1.4) 1.00 - <0.01 1.00 - 0.02 1.00 - 0.03 234, 343 
20-24 3.4% (2.2-5.2) 10.6 (2.40-46.3)  7.54 (1.37-41.3)  5.71 (1.23-26.6)  391, 497 
Country
c
             
England 1.9% (1.2-3.0) 1.00 - 0.12 1.00 - 0.27    532, 719 
Scotland 5.7% (2.1-14.3) 3.13 (1.04-9.45)  3.16 (0.78-12.8)     60, 72 
Wales 1.7% (0.2-12.1) 0.88 (0.11-7.02)  1.20 (0.18-7.63)     33, 49 
IMD quintile of LSOA of residence
d
        
2 least deprived  1.3% (0.4-3.6) 1.00 - 0.14 1.00 - 0.04    241, 315 
Middle quintile 1.6% (0.6-4.4) 1.24 (0.26-5.88)  1.01 (0.15-6.68)     114, 164 
2 most deprived 3.4% (2.1-5.6) 2.71 (0.83-8.82)  3.75 (1.11-12.5)     269, 361 
Age left school
e
             
17+ 1.6% (0.9-2.7) 1.00 - 0.01       439, 568 
16 5.0% (2.7-9.2) 3.28 (1.38-7.82)        143, 206 
Age at first heterosexual sex          
17+ 1.0% (0.3-2.8) 1.00 - 0.03 1.00 - 0.67    210, 245 
16 1.5% (0.5-4.6) 1.49 (0.31-7.15)  1.14 (0.27-4.74)     148, 205 
<16 4.0% (2.4-6.5) 4.18 (1.31-13.3)  1.65 (0.55-4.90)     238, 352 
Number of sexual partners in the last year        
0 or 1 1.5% (0.7-3.0) 1.00 - 0.01      359, 466 
2 1.3% (0.4-4.2) 0.86 (0.21-3.56)       123, 159 
3 to 4 3.1% (1.1-8.5) 2.16 (0.60-7.78)       70, 110 
5+ 7.5% (3.7-14.6) 5.47 (1.89-15.9)       67, 100 
Number of new sexual partners in the last year       
0 1.8% (0.9-3.8) 1.00 - 0.01 1.00 - 0.49    263, 335 
1 0.8% (0.2-2.5) 0.42 (0.10-1.72)  0.33 (0.05-2.06)     203, 270 
2+ 5.1% (2.9-8.8) 2.87 (1.08-7.63)  0.47 (0.09-2.45)     152, 229 
Number of sexual partners in the last year without a condom       
0 0.3% (0.1-1.3) 1.00 - <0.01 1.00 - 0.09    205, 248 
1 1.7% (0.8-3.6) 5.26 (1.05-26.2)  1.23 (0.09-15.2)     287, 396 
2+ 6.5% (3.9-10.9) 21.3 (4.67-97.2)  4.95 (0.42-57.9)     130, 194 
Number of lifetime sexual partners       
1 to 4 0.4% (0.1-1.5) 1.00 - <0.01 1.00 - 0.03 1.00 - <0.01 332, 412 
5 to 9 1.2% (0.3-4.0) 3.21 (0.47-21.9)  1.78 (0.20-15.5)  2.21 (0.31-15.9)  141, 200 
10+ 7.6% (4.8-11.7) 22.6 (4.92-104)  8.69 (1.21-62.0)  14.2 (3.02-66.7)  148, 224 
Condom used for most recent sex with most recent partner       
Yes 0.7% (0.2-2.0) 1.00 - <0.01 1.00 - 0.10 1.00 - <0.01 301, 391 
No 4.1% (2.6-6.4) 6.03 (1.87-19.4)  3.59 (0.77-16.6)  4.43 (1.32-14.9)  283, 398 
Concurrent partnerships in last year
f
         
No 2.6% (1.6-4.2) 1.00 - 0.74 1.00 - 0.05    418, 557 
Yes 2.0% (0.7-5.4) 0.75 (0.24-2.37)  0.18 (0.04-0.71)     82, 121 
Unknown 1.7% (0.5-5.6) 0.64 (0.17-2.37)  0.60 (0.11-3.00)     92, 122 
Frequency of binge drinking         
never / <monthly 1.1% (0.4-2.7) 1.00 - 0.08 1.00 - 0.62    322, 421 
monthly 3.0% (1.4-6.2) 2.79 (0.85-9.18)  1.47 (0.33-6.48)     125, 177 
>weekly  3.8% (2.0-7.0) 3.58 (1.17-11.0)  2.03 (0.49-8.38)     177, 241 
Ever had any same sex experience/contact        
No 2.3% (1.5-3.5) 1.00 - 0.89 1.00 - 0.37    577, 762 
Yes 2.0% (0.4-9.0) 0.90 (0.18-4.48)  0.31 (0.02-4.16)    47, 78 
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Table 9-3 continued 
 
2b) Diagnosed with chlamydia in the last year 
(among those tested in the last year) (n=940) 
 
 
% (95%CI) 
Univariable Multivariable model 1 
Multivariable model 
2 
Denomina
tor (wt, 
unwt) OR (95%CI) p AOR
b
 (95%CI) p 
AOR
b
 
(95%CI) p 
Age group          
16-19 4.7% (2.4-9.0) 1.00 - 0.41 1.00 - 0.61    151, 226 
20-24 6.7% (3.9-11.1) 1.46 (0.59-3.58)  0.76 (0.26-2.15)     192, 245 
Country
c
             
England           316, 440 
Scotland           20, 22 
Wales           7, 9 
IMD quintile of LSOA of residence
d
        
2 least deprived  5.2% (2.5-10.5) 1.00 - 0.85 1.00 - 0.85    127, 180 
Middle quintile 5.0% (1.7-13.8) 0.96 (0.26-3.58)  0.68 (0.15-2.97)     60, 86 
2 most deprived 6.5% (3.6-11.4) 1.26 (0.48-3.33)  1.06 (0.42-2.64)     155, 205 
Age left school
e
             
17+ 5.3% (3.1-9.0) 1.00 - 0.49       233, 304 
16 7.2% (3.6-13.8) 1.38 (0.55-3.45)        87, 134 
Age at first heterosexual sex           
17+ 2.8% (0.7-9.9) 1.00 - 0.26 1.00 - 0.74    87, 112 
16 4.7% (1.8-11.8) 1.75 (0.33-9.27)  1.14 (0.24-5.30)     84, 108 
<16 7.8% (4.7-12.6) 2.99 (0.70-12.7)  1.58 (0.37-6.62)     167, 243 
Number of sexual partners in the last year         
0 or 1 3.4% (1.5-7.8) 1.00 - <0.01    1.00 - <0.01 145, 196 
2 0.9% (0.2-3.9) 0.27 (0.05-1.41)     0.18 (0.03-1.17)  74, 99 
3 to 4 1.5% (0.4-6.2) 0.44 (0.08-2.30)     0.23 (0.04-1.31)  57, 83 
5+ 21.2% (12.9-32.7) 7.54 (2.66-21.3)     2.67 (0.88-8.08)  63, 89 
Number of new sexual partners in the last year         
0 5.5% (2.3-12.6) 1.00 - 0.37 1.00 - 0.31    108, 136 
1 4.0% (1.7-9.0) 0.71 (0.21-2.47)  1.13 (0.09-13.9)     115, 161 
2+ 8.0% (4.5-13.7) 1.48 (0.50-4.35)  2.87 (0.26-30.7)     115, 170 
Number of sexual partners in the last year without a condom      
0 1.8% (0.4-8.4) 1.00 - 0.04 1.00 - 0.45    88, 115 
1 4.9% (2.6-8.9) 2.75 (0.50-15.0)  0.78 (0.19-3.15)     160, 222 
2+ 10.9% (6.0-19.0) 6.51 (1.19-35.6)  0.46 (0.11-1.83)     95, 134 
Number of lifetime sexual partners         
1 to 4 1.0% (0.3-3.1) 1.00 - <0.01 1.00 - <0.01 1.00 - 0.01 133, 176 
5 to 9 3.8% (1.3-10.8) 4.15 (0.82-21.0)  4.87 (0.58-40.2)  4.25 (0.61-29.7)  84, 123 
10+ 12.3% (7.6-19.2) 14.6 (3.89-54.5)  19.80 (3.03-129.)  8.30 (1.77-38.8)  121, 167 
Condom used for most recent sex with most recent partner      
Yes 4.3% (2.0-8.9) 1.00 - 0.22 1.00 - 0.91    163, 221 
No 7.4% (4.5-12.0) 1.79 (0.70-4.59)  1.06 (0.35-3.21)     172, 237 
Concurrent partnerships in last year
f
        
No 6.7% (4.1-10.8) 1.00 - 0.10 1.00 - 0.07    219, 298 
Yes 6.5% (2.7-14.8) 0.96 (0.34-2.72)  0.60 (0.19-1.79)     67, 92 
Unknown 1.3% (0.3-5.5) 0.19 (0.04-0.88)  0.06 (0.00-0.71)     52, 75 
Frequency of binge drinking         
never / <monthly 3.5% (1.6-7.7) 1.00 - 0.07 1.00 - 0.46    146, 204 
monthly 4.0% (1.5-10.3) 1.15 (0.31-4.18)  0.60 (0.13-2.67)     80, 113 
>weekly  9.8% (5.6-16.6) 2.98 (1.07-8.34)  1.23 (0.48-3.14)     117, 154 
Ever had any same sex experience/contact        
No 5.8% (3.8-8.9) 1.00 - 0.87 1.00 - 0.82    311, 427 
Yes 5.1% (1.0-22.0) 0.87 (0.17-4.54)  0.79 (0.10-6.09)     31, 44 
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Table 9-3 continued 
 
2c) Tested for chlamydia in the last year (n=1,736) 
 
 
% (95%CI) 
Univariable Multivariable model 1 
Multivariable model 
2 Denominator 
(wt, unwt) 
OR (95%CI) p AOR
b
 (95%CI) p AORb (95%CI) p 
Age group          
16-19 40.4% (35.9-45.1) 1.00 - <0.01 1.00 - <0.01 1.00 - <0.01 374, 582 
20-24 31.1% (27.8-34.7) 0.67 (0.52-0.86)  0.53 (0.37-0.73)  0.55 (0.40-0.77)  629, 793 
Country
c
             
England 37.3% (34.3-40.3) 1.00 - <0.01 1.00 - <0.01 1.00 - <0.01 859, 1181 
Scotland 22.2% (14.0-33.5) 0.48 (0.27-0.85)  0.33 (0.16-0.64)  0.37 (0.19-0.73)  89, 111 
Wales 12.8% (6.9-22.3) 0.25 (0.13-0.48) 
 0.19 (0.08-0.40)  
0.22 
(0.09- 
0.50) 
 
55, 83 
IMD quintile of LSOA of residence
d
        
2 least deprived  34.5% (30.0-39.2) 1.00 - 0.89 1.00 - 0.75    369, 509 
Middle quintile 33.3% (27.4-39.9) 0.95 (0.67-1.35)  1.04 (0.70-1.52)     183, 263 
2 most deprived 35.2% (31.1-39.5) 1.03 (0.78-1.36)  1.13 (0.82-1.53)     450, 603 
Age left school
e
             
17+ 33.6% (30.4-37.1) 1.00 - 0.21       703, 927 
16 37.8% (32.3-43.5) 1.20 (0.91-1.58)        230, 334 
Age at first heterosexual sex          
17+ 25.6% (21.4-30.3) 1.00 - <0.01 1.00 - 0.05 1.00 - 0.045 340, 431 
16 33.4% (27.9-39.4) 1.46 (1.03-2.06)  1.13 (0.75-1.67)  1.10 (0.75-1.62)  253, 351 
<16 45.3% (40.7-49.9) 2.40 (1.78-3.23)  1.53 (1.07-2.19)  1.52 (1.06-2.16)  376, 539 
Number of sexual partners in the last year        
0 or 1 26.0% (22.6-29.7) 1.00 - <0.01    1.00 - <0.01 568, 768 
2 40.3% (33.2-47.7) 1.92 (1.34-2.75)     1.63 (1.11-2.39)  185, 251 
3 to 4 43.0% (35.5-50.9) 2.15 (1.49-3.10)     1.44 (0.93-2.22)  134, 194 
5+ 60.9% (51.8-69.3) 4.42 (2.93-6.67)     2.43 (1.49-3.98)  103, 146 
Number of new sexual partners in the last year        
0 26.0% (22.0-30.5) 1.00 - <0.01 1.00 - 0.37   416, 540 
1 36.7% (31.8-41.8) 1.64 (1.21-2.24)  1.28 (0.88-1.85)    323, 452 
2+ 46.3% (40.7-52.0) 2.45 (1.78-3.37)  1.06 (0.67-1.68)    251, 366 
Number of sexual partners in the last year without a condom       
0 27.0% (22.4-32.1) 1.00 - <0.01 1.00 - 0.49   331, 450 
1 34.3% (30.2-38.7) 1.41 (1.02-1.96)  1.12 (0.72-1.71)    475, 640 
2+ 48.8% (42.3-55.4) 2.59 (1.81-3.70)  1.37 (0.80-2.34)    194, 281 
Number of lifetime sexual partners         
1 to 4 25.3% (21.8-29.2) 1.00 - <0.01 1.00 - <0.01 1.00 - <0.01 524, 706 
5 to 9 39.6% (33.6-45.9) 1.93 (1.39-2.69)  1.50 (1.01-2.21)  1.49 (1.01-2.20)  222, 314 
10+ 49.2% (43.2-55.2) 2.86 (2.09-3.92)  2.23 (1.45-3.42)  2.03 (1.31-3.13)  247, 342 
Condom used for most recent sex with most recent partner      
Yes 33.5% (29.7-37.6) 1.00 - 0.13 1.00 - 0.87    491, 671 
No 38.0% (33.9-42.4) 1.22 (0.95-1.56)  0.97 (0.70-1.34)     458, 621 
Concurrent partnerships in last year
f
       
No 32.9% (29.6-36.3) 1.00 - <0.01 1.00 - 0.24    676, 916 
Yes 49.7% (41.0-58.4) 2.02 (1.37-2.96)  1.52 (0.92-2.50)     136, 188 
Unknown 38.5% (30.9-46.7) 1.28 (0.88-1.86)  1.18 (0.77-1.80)     137, 193 
Frequency of binge drinking         
never / <monthly 28.1% (24.6-32.0) 1.00 - <0.01 1.00 - 0.04 1.00 - 0.04 527, 715 
monthly 39.9% (33.4-46.7) 1.69 (1.21-2.37)  1.48 (1.01-2.16)  1.51 (1.05-2.19)  202, 289 
>weekly  43.2% (37.5-49.1) 1.94 (1.44-2.62)  1.50 (1.04-2.15)  1.42 (1.00-2.00)  273, 370 
Ever had any same sex experience/contact      
No 33.9% (31.1-36.8) 1.00 - 0.11 1.00 - 0.02    922, 1260 
Yes 42.4% (32.2-53.4) 1.44 (0.92-2.26)  2.08 (1.12-3.84)     80, 115 
a
N in column headings shows unweighted denominators. Total denominators by characteristic 
and in multivariable models vary due to item-missingness..
b
AOR: Adjusted odds ratios, adjusted 
for all variables shown. 
c
Results for recent diagnosis are not reported due to small sample size 
in Scotland and Wales when limited to those tested.  
d
IMD: Index of multiple deprivation of 
LSOA (lower super output area) of residence. IMD scores for England, Scotland and Wales 
were adjusted before being combined and assigned to quintiles, using the method described by 
Payne and Abel
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 e
Excludes 16 year-olds. 
f
Among those with >1 sexual partner in last year.  
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Appendix 3: Factors associated with prevalent infection, recent 
diagnosis or recent testing among 16 to 24 year-olds resident 
in England (Natsal-3)  
 
Relevant to Chapter 7 
Table 9-4a and Table 9-4b overleaf present equivalent tables to those 
presented in Table 7-2a and Table 7-2b with the population restricted to 
participants resident in England as opposed to the population resident in Britain.  
 
 Table 9-4a: Percentage, unadjusted and adjusted odds (OR/AOR) ratios for prevalent chlamydia infection, self-reported diagnosis in the 
last year and self-reported testing by sociodemographic and behavioural factors (16-24 year-old sexually-experienced women resident in 
England Natsal-3) 
 
Prevalent chlamydia infection detected in urine 
(n=992) 
Diagnosed with chlamydia in the last year 
(among those tested in the last year) (n=940) 
Tested for chlamydia in the last year 
(n=1,736) 
Denominator  
(weighted, unweighted)
 a
 
 
% (95%CI) OR (95%CI) AOR
b
 (95%CI) p % (95%CI) OR (95%CI) AOR
b
 (95%CI) p % (95%CI) OR (95%CI) AOR
b
 (95%CI) p Infection Diagnosis Tested 
Age group                         
16-19 3.6% (2.0-6.5) 1.00 -   0.35 5.8% (3.6-9.2) 1.00 - 1.00 - 0.62 61.2% (56.7-65.5) 1.00 - 1.00  - 0.07 181, 332 177, 341 291, 566 
20-24 2.5% (1.5-4.2) 0.68 (0.30-1.53) 0.61 (0.21-1.74)  5.5% (3.6-8.2) 0.94 (0.49-1.81) 0.80 (0.34-1.89)  54.9% (50.9-58.8) 0.77 (0.61-0.98) 0.76 (0.56-1.02)  323, 485 292, 491 532, 886 
IMD quintile of LSOA of residence                  
2 least deprived  1.2% (0.4-3.6) 1.00 - 1.00  - 0.01 4.7% (2.6-8.2) 1.00 - 1.00 - 0.23 56.9% (51.9-61.8) 1.00 - 1.00  - 0.660 179, 296 166, 289 292, 510 
Middle quintile 1.3% (0.5-3.4) 1.02 (0.23-4.44) 0.95 (0.21-4.13)  3.2% (1.3-7.5) 0.66 (0.22-1.96) 0.92 (0.28-3.00)  58.0% (50.9-64.7) 1.04 (0.74-1.48) 1.20 (0.80-1.79)  92, 140 92, 154 159, 267 
2 most deprived 4.9% (3.1-7.5) 4.08 (1.26-13.3) 4.40 (1.32-14.6)  7.4% (4.9-10.9) 1.61 (0.77-3.36) 1.83 (0.77-4.31)  56.9% (52.2-61.5) 1.00 (0.76-1.32) 1.03 (0.75-1.39)  233, 381 210, 389 371, 675 
Age at first heterosexual sex                   
17+ 1.3% (0.4-3.8) 1.00 - 1.00  - 0.51 4.4% (1.9-9.6) 1.00 - 1.00 - 0.94 47.8% (42.1-53.6) 1.00 - 1.00  - 0.13 156, 198 127, 195 267, 406 
16 3.7% (1.9-7.1) 3.00 (0.82-11.0) 2.38 (0.54-10.3)  5.8% (3.2-10.2) 1.34 (0.47-3.83) 0.93 (0.30-2.79)  57.7% (52.4-62.8) 1.49 (1.09-2.04) 1.21 (0.85-1.71)  152, 245 133, 230 231, 413 
<16 3.9% (2.2-6.8) 3.11 (0.89-10.9) 1.79 (0.48-6.66)  6.5% (4.4-9.7) 1.53 (0.60-3.89) 0.85 (0.32-2.24)  67.4% (63.0-71.5) 2.26 (1.70-3.01) 1.42 (1.01-2.00)  181, 351 198, 385 295, 579 
Number of sexual partners in the last year without a condom               
0 2.3% (0.7-7.7) 1.00 - 1.00  - 0.26 4.5% (1.6-12.1) 1.00 - 1.00 - 0.79 40.3% (34.1-46.8) 1.00 - 1.00  - 0.160 101, 143 72, 121 181, 306 
1 2.0% (1.1-3.5) 0.85 (0.22-3.33) 0.41 (0.09-1.78)  3.8% (2.2-6.3) 0.83 (0.25-2.79) 0.79 (0.17-3.60)  57.2% (53.5-60.7) 1.98 (1.48-2.65) 1.41 (0.92-2.14)  309, 492 282, 494 495, 869 
2+ 6.6% (3.5-12.0) 2.93 (0.72-11.9) 0.81 (0.18-3.63)  10.9% (7.3-16.1) 2.62 (0.80-8.65) 1.12 (0.22-5.63)  77.7% (71.5-83.0) 5.18 (3.42-7.85) 1.73 (0.96-3.10)  94, 181 113, 215 146, 274 
Number of new sexual partners in the last year                 
0 2.2% (1.2-3.9) 1.00 - 1.00  - 0.99 2.9% (1.6-5.4) 1.00 - 1.00 - 0.22 47.8% (43.8-51.9) 1.00 - 1.00  - 0.003 263, 400 201, 348 421, 727 
1 2.6% (1.0-6.7) 1.22 (0.39-3.81) 1.06 (0.28-3.89)  5.2% (2.7-9.9) 1.83 (0.72-4.62) 2.04 (0.71-5.80)  62.5% (56.9-67.8) 1.82 (1.38-2.41) 1.71 (1.23-2.36)  140, 225 143, 257 229, 411 
2+ 5.4% (3.0-9.7) 2.60 (1.08-6.27) 1.06 (0.28-3.98)  10.5% (6.9-15.7) 3.91 (1.82-8.42) 2.76 (0.86-8.82)  74.1% (67.2-80.0) 3.12 (2.16-4.51) 1.74 (1.09-2.79)  97, 186 122, 222 166, 301 
Number of lifetime sexual partners                 
1 to 4 2.1% (1.1-4.1) 1.00 - 1.00  - 0.48 2.3% (1.2-4.3) 1.00 - 1.00 - 0.08 47.3% (43.4-51.3) 1.00 - 1.00  - 0.000
9 
274, 401 203, 357 430, 751 
5 to 9 2.2% (1.0-4.7) 1.03 (0.36-2.92) 0.87 (0.28-2.72)  6.8% (4.0-11.4) 3.16 (1.36-7.34) 2.60 (0.96-6.98)  66.3% (60.6-71.7) 2.19 (1.64-2.93) 1.81 (1.28-2.55)  126, 217 142, 251 214, 376 
10+ 6.1% (3.2-11.3) 3.02 (1.17-7.81) 1.71 (0.54-5.39)  9.8% (6.2-15.1) 4.70 (2.07-10.7) 3.71 (1.12-12.2)  71.5% (65.2-77.1) 2.80 (2.01-3.89) 1.92 (1.24-2.95)  100, 191 122, 219 170, 310 
Condom used for most recent sex with most recent partner                 
Yes 2.3% (1.0-5.1) 1.00 - 1.00  - 0.36 3.7% (1.8-7.6) 1.00 - 1.00 - 0.24 55.1% (49.9-60.2) 1.00 - 1.00  - 0.920 173, 262 156, 273 284, 494 
No 3.6% (2.3-5.5) 1.54 (0.60-3.93) 1.49 (0.63-3.50)  6.5% (4.4-9.3) 1.80 (0.76-4.31) 1.67 (0.70-3.94)  60.9% (57.2-64.5) 1.27 (0.99-1.63) 1.02 (0.73-1.40)  298, 505 293, 521 482, 858 
 
 Table 9-4a continued. 
 
Concurrent partnerships in last year
f
                  
No 2.6% (1.6-4.2) 1.00 - 1.00  - 0.46 4.5% (2.9-6.8) 1.00 - 1.00 - 0.56 54.0% (50.5-57.5) 1.00 - 1.00  - 0.12 369, 574 325, 564 603, 1045 
Yes 7.2% (3.3-15.1) 2.92 (1.10-7.75) 1.60 (0.55-4.64)  8.6% (4.2-16.6) 2.00 (0.83-4.86) 0.72 (0.25-2.02)  77.5% (69.6-83.7) 2.92 (1.92-4.44) 1.47 (0.90-2.39)  58, 117 70, 131 90, 169 
Unknown 1.6% (0.5-5.2) 0.63 (0.18-2.24) 0.66 (0.15-2.75)  7.4% (3.8-14.0) 1.72 (0.78-3.81) 1.34 (0.55-3.25)  67.3% (59.5-74.3) 1.75 (1.23-2.51) 1.46 (0.93-2.29)  60, 105 67, 126 99, 190 
Frequency of binge 
drinking 
                     
Never / <monthly 2.3% (1.3-4.1) 1.00 - 1.00  - 0.02 3.9% (2.5-6.0) 1.00 - 1.00 - 0.27 55.1% (51.4-58.7) 1.00 - 1.00  - 0.01 321, 502 289, 512 527, 934 
Monthly 1.1% (0.3-3.3) 0.46 (0.12-1.70) 0.43 (0.11-1.67)  6.8% (3.5-12.8) 1.80 (0.78-4.12) 2.08 (0.75-5.72)  53.4% (46.8-59.8) 0.93 (0.70-1.25) 0.66 (0.47-0.93)  108, 181 95, 165 178, 302 
>weekly  8.2% (4.6-14.1) 3.80 (1.60-9.04) 2.39 (0.97-5.89)  9.7% (5.2-17.6) 2.66 (1.18-5.99) 2.15 (0.74-6.22)  71.7% (64.0-78.3) 2.06 (1.42-2.99) 1.35 (0.89-2.04)  76, 134 84, 153 117, 214 
Ever had any same 
sex experience/contact 
                     
No 2.7% (1.7-4.2) 1.00 - 1.00  - 0.64 5.5% (3.7-7.9) 1.00 - 1.00 - 0.36 54.9% (51.4-58.3) 1.00 - 1.00  - 0.33 397, 609 346, 618 633, 1120 
Yes 3.7% (1.6-8.2) 1.39 (0.53-3.60) 0.80 (0.31-2.04)  6.0% (3.4-10.4) 1.10 (0.54-2.27) 0.65  64.6% (58.2-70.6) 1.50 (1.11-2.03) 1.19 (0.83-1.68)  107, 208 122, 214 190, 332 
 
 
  
 Table 9-4b: Proportion, unadjusted and adjusted odds ratios for prevalent chlamydia infection, self-reported diagnosis in the last year and 
self-reported testing by sociodemographic and behavioural factors (16-24 year-old sexually-experienced men resident in England, Natsal-
3) 
 
 
Prevalent chlamydia infection detected in urine 
(n=992) 
Diagnosed with chlamydia in the last year 
(among those tested in the last year) (n=940) 
Tested for chlamydia in the last year 
(n=1,736) 
Denominator  
(weighted, unweighted)
 a
 
 
% (95%CI) OR (95%CI) AOR
b
 (95%CI) p % (95%CI) OR (95%CI) AOR
b
 (95%CI) p % (95%CI) OR (95%CI) AOR
b
 (95%CI) p Infection Diagnosis Tested 
Age group                         
16-19 0.2% (0.0-1.5) 1.00 - 1.00  - 0.06 3.7% (1.8-7.8) 1.00 - 1.00  - 0.91 44.3% (39.6-49.2) 1.00 - 1.00 - 0.0001 202, 303 141, 218 319, 511 
20-24 2.9% (1.8-4.8) 13.85 (1.80-106) 9.72 (0.92-102)  5.9% (3.3-10.6) 1.63 (0.60-4.44) 0.93 (0.27-3.12)  33.1% (29.4-37.1) 0.62 (0.48-0.81) 0.50 (0.35-0.70)  330, 416 175, 222 540, 670 
IMD quintile of LSOA of residence             
2 least deprived  0.9% (0.3-3.1) 1.00 - 1.00  - 0.04 4.7% (2.1-10.3) 1.00 - 1.00 - 0.54 37.1% (32.3-42.1) 1.00 - 1.00 - 0.64 214, 284 121, 171 327, 457 
Middle quintile 0.8% (0.2-3.5) 0.92 (0.14-6.04) 0.78 (0.06-9.66)  3.4% (1.0-10.4) 0.70 (0.17-2.96) 0.47 (0.11-1.94)  35.3% (28.6-42.6) 0.92 (0.63-1.34) 0.97 (0.64-1.45)  95, 137 53, 77 151, 217 
2 most deprived 3.3% (1.9-5.7) 3.69 (0.96-14.2) 4.13 (0.91-18.5)  5.7% (3.0-10.7) 1.22 (0.41-3.58) 0.97 (0.35-2.67)  38.2% (33.8-42.8) 1.05 (0.79-1.39) 1.13 (0.81-1.56)  222, 298 142, 192 381, 507 
Age at first heterosexual sex               
17+ 0.9% (0.3-2.9) 1.00 - 1.00  - 0.64 3.1% (0.8-11.0) 1.00 - 1.00 - 0.86 26.9% (22.5-31.9) 1.00 - 1.00 - 0.02 173, 207 78, 105 291, 371 
16 1.7% (0.5-5.3) 1.93 (0.35-10.5) 2.13 (0.43-10.5)  4.5% (1.6-12.2) 1.48 (0.27-8.27) 1.01 (0.18-5.60)  36.2% (30.2-42.6) 1.54 (1.07-2.20) 1.17 (0.78-1.74)  129, 179 80, 103 221, 308 
<16 3.0% (1.7-5.3) 3.47 (0.89-13.5) 1.21 (0.32-4.50)  6.3% (3.6-10.8) 2.11 (0.48-9.22) 1.38 (0.28-6.66)  49.4% (44.3-54.4) 2.64 (1.94-3.60) 1.64 (1.14-2.35)  205, 301 154, 225 318, 458 
Number of sexual partners in the last year without a condom            
0 0.4% (0.1-1.6) 1.00 - 1.00  - 0.12 0.0% -    28.3% (23.4-33.7) 1.00 - 1.00 - 0.08 167, 207 77, 107 276, 382 
1 1.3% (0.5-3.1) 3.20 (0.59-17.2) 0.41 (0.03-4.64)  3.8% (1.9-7.4) 0.31 (0.11-0.83)   36.4% (31.9-41.1) 1.45 (1.03-2.04) 1.25 (0.79-1.97)  259, 356 152, 209 424, 568 
2+ 5.9% (3.3-10.5) 15.56 (3.32-73.0) 1.82 (0.12-26.4)  11.3% (6.1-20.0) 1.00 -   56.2% (48.8-63.3) 3.26 (2.20-4.81) 1.86 (1.06-3.25)  104, 154 88, 124 156, 227 
Number of new sexual partners in the last year             
0 1.2% (0.5-3.1) 1.00 - 1.00  - 0.99 4.5% (1.7-11.3) 1.00 - 1.00 - 0.99 28.3% (24.0-33.1) 1.00 - 1.00 - 0.77 234, 298 105, 132 371, 477 
1 0.9% (0.3-3.0) 0.75 (0.16-3.49) 0.94 (0.15-5.80)  3.0% (1.2-7.8) 0.67 (0.16-2.71) 1.12 (0.24-5.21)  38.2% (32.8-43.8) 1.56 (1.13-2.16) 1.14 (0.77-1.66)  167, 226 99, 145 269, 381 
2+ 4.5% (2.4-8.2) 3.74 (1.18-11.9) 0.92 (0.16-5.18)  7.3% (3.9-13.4) 1.67 (0.50-5.51) 1.11 (0.29-4.12)  52.1% (46.0-58.1) 2.75 (1.97-3.84) 1.17 (0.72-1.87)  127, 190 108, 159 208, 309 
Number of lifetime sexual partners             
1 to 4 0.4% (0.1-1.8) 1.00 - 1.00  - 0.03 0.7% (0.2-3.1) 1.00  - 1.00 - 0.00 27.1% (23.4-31.2) 1.00 - 1.00 - 0.004 281, 357 122, 167 451, 616 
5 to 9 0.3% (0.0-2.2) 0.72 (0.06-8.26) 0.30 (0.02-3.45)  2.0% (0.5-8.3) 2.86 (0.35-23.2) 2.31 (0.22-23.3)  43.2% (36.6-50.1) 2.04 (1.44-2.89) 1.52 (1.01-2.26)  125, 173 80, 118 193, 270 
10+ 6.9% (4.1-11.3) 17.25 (3.68-80.8) 6.27 (0.88-44.2)  12.0% (7.2-19.3) 19.23 (3.87-95.5) 14.44 (2.19-94.9)  53.4% (46.8-59.9) 3.08 (2.21-4.31) 2.15 (1.36-3.38)  124, 186 110, 151 206, 284 
Condom used for most recent sex with most recent partner             
Yes 0.3% (0.1-1.4) 1.00 -   0.04 2.8% (1.1-7.0) 1.00 - 1.00 - 0.14 36.1% (32.1-40.4) 1.00 - 1.00 - 0.59 252, 330 149, 209 417, 576 
No 3.6% (2.2-6.0) 10.99 (2.45-49.3) 9.41 (1.06-82.9)  7.2% (4.2-12.1) 2.73 (0.88-8.50) 2.47 (0.75-8.12)  40.8% (36.3-45.6) 1.22 (0.94-1.59) 0.91 (0.64-1.28)  245, 343 160, 218 395, 532 
 
  
 Table 9-4b continued. 
 
Concurrent partnerships in last year
f
              
No 2.0% (1.1-3.6) 1.00 - 1.00  - 0.09 6.1% (3.6-10.2) 1.00 -  0.05 36.0% (32.4-39.8) 1.00 - 1.00 - 0.72 357, 475 207, 281 582, 789 
Yes 2.6% (0.9-7.0) 1.27 (0.39-4.21) 0.18 (0.03-0.84)  5.0% (1.8-13.5) 0.81 (0.24-2.71) 1.00 -  51.5% (42.4-60.5) 1.89 (1.26-2.82) 1.11 (0.69-1.78)  62, 97 55, 80 106, 152 
Unknown 1.4% (0.3-6.0) 0.70 (0.15-3.37) 0.62 (0.09-4.05)  0.6% (0.1-4.2) 0.09 (0.01-0.73) 0.07 (0.00-0.70)  41.6% (33.4-50.3) 1.26 (0.86-1.87) 1.20 (0.76-1.86)  83, 111 50, 73 123, 173 
Frequency of binge drinking             
Never / <monthly 0.8% (0.3-2.5) 1.00 - 1.00  - 0.49 2.8% (1.2-6.5) 1.00 - 1.00 - 0.18 30.3% (26.4-34.5) 1.00 - 1.00 - 0.06 279, 363 138, 194 463, 624 
Monthly 2.9% (1.3-6.2) 3.56 (0.88-14.5) 1.89 (0.31-11.4)  2.1% (0.7-6.7) 0.76 (0.17-3.27) 0.48 (0.09-2.36)  44.0% (36.8-51.5) 1.81 (1.27-2.59) 1.52 (1.01-2.28)  108, 154 75, 106 171, 246 
>weekly  3.3% (1.6-6.6) 4.13 (1.07-16.1) 2.73 (0.51-14.3)  9.8% (5.3-17.5) 3.78 (1.25-11.4) 1.78 (0.61-5.16)  46.6% (40.5-52.8) 2.01 (1.46-2.75) 1.41 (0.97-2.04)  143, 201 103, 140 224, 310 
Ever had any same sex experience/contact            
No 2.0% (1.2-3.2) 1.00 -    5.4% (3.4-8.5)    36.4% (33.4-39.6) 1.00 - 1.00 - 0.02 499, 661 289, 401 799, 1093 
Yes 0.9% (0.1-6.5) 0.44 (0.06-3.44)    0.0% -    48.4% (36.7-60.3) 1.64 (1.01-2.68) 2.22 (1.11-4.42)  33, 58 27, 39 60, 88 
a
N in column headings shows unweighted denominators. Total denominators by characteristic and in multivariable models vary due to item-missingness. 
b
AOR: 
Adjusted odds ratios, adjusted for all variables shown. 
c
Results for recent diagnosis are not reported due to small sample size in Scotland and Wales when limited to 
those tested.  
d
IMD: Index of multiple deprivation of LSOA (lower super output area) of residence. IMD scores for England, Scotland and Wales were adjusted before 
being combined and assigned to quintiles, using the method described by Payne and Abel
264
. 
 e
Excludes 16 year-olds. 
f
Among those with >1 sexual partner in last 
year. Shaded areas indicate variables that were not entered into univariable or multivariable logistic regression due to small sample sizes.  
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